LIST OF CONTRIBUTORS
. ..............289 . .................205 . ................... 12 . ................236 . ...
17 downloads
1919 Views
20MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
LIST OF CONTRIBUTORS
. ..............289 . .................205 . ................... 12 . ................236 . ............... 99 . ................. 99 . .................247 . ................... 30 . ............... 1 . ................. 67 . .................213 ...................247 . ...............136 . .................331 . ..................109 . ..................324 . ................. 40 . .........129 ...................331 . .................331
Anderson. G W Babock. J C Biel. J H Bloom. B M Bolhofer. W A Brodie. D A Buyske. D A Cain. C K Childress. S J Cragoe. E J Diassi. P A Dvornik. D Elslager. E F Finger. K F Flynn. E H Foye. W 0 Harris. L S Herrmann. E C., Jr Higuchi. T Higuchi. W I
. .................... 150 ..................... 277 . ...............191 ............... 78 . ................ 59 . .. .................. 129 ..................213 . ............... 92 ..................... 164 . .................... 51 . ................299 . ................ 224 . ................118 . ............... 314 . ................... 267 . ................. 67 . ................... 85 . ..................311 . ................178 .................... 233
off, D R Horita. A Jorgensen. E C Kennedy. P., Jr Kornfeld. E C Kucera L S Lerner. L J Moreland. W T Pinson. R Poos. G I Schaeffer. H J Scherrer. R A Shepherd. R G Smissman. E E Smith. C G Sprague. J M Tam. R D Taylor. W I Ursprung. J 3 Weiner. M
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, 1965 Sponsored by the Division of Medicinal Chemistry of tbe American Chemical Society Editor-in-Chief: CORNELIUS K, CAIN McNElL LABORATORIES, INC. FORT WASHINGTON, PENNSYLVANIA
SECTION EDITORS JOHN BlEL 0 SYDNEY ARCHER 0 EDWlN FLYNN RICHARD HEINZELMAN 0 IRVING TABACHNICK 0 EDWARD SMISSMAN
@
ACADEMIC PRESS
New York and London 1966
B Y ACADEMIC PRESSI NC. ALL RIGHTS RESERVED. NO PART OF THIS BOOK MAY BE REPRODUCED I N A N Y FORM, BY PHOTOSTAT, MICROFILM, OR ANY OTHER MEANS, WITHOUT WRITTEN PERMISSION FROM THE PUBLISHERS.
COPYRIGHT 0 1966,
ACADEMIC PRESS INC. 111 Fifth Avenue, New
York, New York 10003
United Kingdom Edition fiublished by ACADEMIC PRESS INC. (LONDON) LTD. Berkeley Square House, London W:1
LIBRARY OF
CONGkESS CATALOG CARD
NUMBER: 66-26843
PRINTED I N T H E UNITED STATES OF AMERICA
Preface While excellent reviews in depth covering selected fields of medicinal chemistry a r e available, no publication outlines the c u r r e n t developments and trends in the whole a r e a . The p r e s e n t volume is the f i r s t of a planned annual publication in which m o r e than thirty authors p r e s e n t a c r i t i c a l summary of new and significant contributions appearing in the l i t e r a t u r e of the p a s t year concerning various fields of medicinal chemistry. Its main purpose is to enable r e a d e r s to "catch up" in fields of t h e i r p e r i pheral i n t e r e s t s and, perhaps, to find some different views in fields of their major i n t e r e s t s . The breadth of the subject and limitations of space presented to the authors a very difficult task of selection of m a t e r i a l and condensation of discussion. Recent reviews and leading r e f e r e n c e s a r e cited to guide r e a d e r s to further information if desired. Topics were chosen to achieve reasonable coverage, but a few chapters initially listed had to be postponed to future volumes. Organization of the m a t e r i a l is p r i m a r i l y by pharmacological action, although some chapter titles r e p r e s e n t concepts, chemical c l a s s e s , methods, etc. The manner of presentation v a r i e s , a s is to be expected from the various disciplines of the authors, the nature of the subjects and the lack of a previous volume to s e r v e a s a model.
1 know of no adequate way to e x p r e s s my thanks for the cheerful, enthusiastic and dedicated efforts of a l l who were involved in this undertaking. Especially to be mentioned a r e the section editors and the chapter authors, but s e c r e t a r i e s , proof-readers, a s s i s t a n t s and a l l who supplied m o r a l support and encouragement should not be forgotten. Comments, c r i t i c i s m s , suggestions and, hopefully, p r a i s e will be welcomed by authors and editors.
F o r t Washington, P a . June, 1966
Cornelius K . Cain
V
Section I - CNS Agents Editor: John H. Biel, Aldrich Chemical Co., Milwaukee, Wisconsin Chapter 1. Antipsychotic and Anti-anxiety Agents Scott J. Childress, Wyeth Laboratories, Inc., Radnor, Pennsylvania Most basic biological work concerned with CNS agents that was reported in 1965 falls into the biochemical area. The belief that the antipsychotic drugs function through some interference with adrenergic processes in the brain is widely accepted. Reserpine, for example, is known to deplete the brain of its stores of catecholamines whereas chlorpromazine has a central adrenolytic action. Although the antipsychotic agents can be shown to interfere with the brain amines, the causal relationship between the changes and the behavioral effects is less clear. The mode of action of the anti-anxiety drugs remains unknown.
A symposium on catecholamines held in Milan in 1965 and recently published1 does much to clarify present views of their role in the central nervous system. Other reviews on the biochemical effects of drugs acting on the central nervous system and on the pharmacology of the central nervous system were prepared by Decsi2 and by Bradley.3 More detailed reviews on serotonin4 and y -aminobutyric acid5 appeared. These papers provide excellent background for any fundamental consideration of the CNS drugs. If the brain amines are conceded to play a crucial part in the functioning of the central nervous system, some disorder in the supply, action or disposal of these agents might be responsible for abnormal behavior. ~ellhorn6,for example, has hypothesized that a disturbance in the noradrenalindadrenaline ratio forms a neurophysiological basis for fear and anxiety. The suggestion that toxic substances in the brain might be responsible for schizophrenia is an old one and the search for a faulty metabolic process in schizophrenics has remained a popular pursuit. Bourdillon7 has recently reEmphasized the finding of a "pink spot," probably 3 4-dimethoxyphenethylamine, in the urine of schizophrenics. Work by Ernsd supports the possibility of an abnormal metabolism of dopamine to 3,4-dimethoxyphenethylamine in schizophrenia. He studied the structure-activity relationships of a group of methoxylated phenethylamines in the production of catatonia in cats. He found the presence of a E-methoxy group and the absence of m-hydroxy group to be required with the duration of action determined by the number of methoxy groups in the molecule. Prior treatment with iprpniazid eliminated the requirement for the absence of a m-hydroxy group. The blocking of the aminooxidase resulted in g-methylation by 0-methyltransferase. A behavioral study' of this compound in the dog and cat also indicates some relationship to schizophrenia. Woolley and Gommi'' have detected in the blood of schizophrenics a substance that is synergistic with serotonin in its action on the rat uterus and are studying the possibility of a causal relationship to the mental disorder. An excellent review" on biochemistry and mental function has been published by Kety who has also republished his 1959 review12 criticizing some
2
Sect. 1 - CNS Agents
B i e l , Ed.
of the methodology involved in finding the "needle-in-the-haystack"that might explain the causes of schizophrenia. Six rejoinders from other scientists are included. Most of the compounds cited below were tested by two general methods: 1) the study of animal behavior following drug treatment in experimental models designed to mimic a clinical situation (conflict, avoidance, etc.) and 2) the measurement of classical pharmacological reactions caused or modified by the agent under test (anticonvulsant, antiemetic, etc.). These methods have been collected in a recent Hahnemann symposium volume.13 The testing of the antipsychotic compounds has been reviewed by Janssen, e t &.,I4 who rely strongly upon the production of catalepsy and the antagonism of the emetic effect of apomorphine for predicting the clinical response. In fresh work on test methods, Marriott and Spencer15 have observed that the anti-anxiety agents increase exploratory behavior in inexperienced rats whereas the antipsychotic compounds reduce such activity. The use of a treadmill in approach and avoidance studies of anti-anxiety compounds has been described by Gluckman.16 A criticism of some of the behavioral tests used for evaluating anxiety in animals has been made by Ray.17 The electronencephalographic effects of the psychotropic agents have been reviewed. 18 Methods of clinical study of psychotropic drugs have also been discussed and criticized.l9,zo Phenothiazines and Analogs - Chemical work directed toward modification of the phenothiazine drugs is presently characterized by the preparation of novel tricyclic systems to which the common basic side chains can be attached. Variation of the central ring is most frequent but the peripheral rings are attracting some attention. A group of compounds having a seven-membered central ring has been described by Stille, et a1.21,22 The synthesis of the intermediate lactams was accomplished by ring closure of the appropriate isocyanates.23 The most active of these compounds is the oxazepine (I) which is approximately equipotent with haloperidol in cataleptic and antiapomorphine effects. In a more extensive study of the thiazepine analog (11, clothiapine) an intense antiserotonin effect was measured in the paw-edema test, thus differentiating it from chlorpromazine. It is noteworthy that opening of the piperazine ring as in compound I11 practically eliminates activity.
The Czech group led by Protiva prepared a host of compounds containing seven-membered rings. Two of these having good central depressant effects are IV (octoclothepine) and V.24 Compound IV which has antiserotonin and antihistamine activities as well, is about three times as strong in its central depressant effects as its unchlorinated analog. The compounds were prepared conventionally from the corresponding dibenzothiepinone which, in turn, resulted from ring closure of the requisite 2-phenylthiophenylacetic acid.25 Reports ha e been made on several thioxanthene derivatives: VI (thiothixene), 2& 27 VII (SKF 10812), 28, 29 and VIII (N-7009). 3' Each was indicated to be effective in the treatment of psychotic states. 6iothixene was said to cause only a low incidence of extrapyramidal symptoms.
Chap. 1
Antip sychotic s, Anti -Anxiety Agents
Childres s
3 -
CHC%C%R
XI:
%= - C F 3 j
R10= -(CH
NI
3
II
A
CHCH CH N 2 2
NCH3
u
XI I XI11
\NC%C%OH
v
v
4
Sect. 1 ’
- CNS Agents
Propericiazine (IX)3 1 has been tried in psychopathic patients severe behavioral disorders with fair success and dixyrazine (X)32 found effective in anxiety associated with autonomic disturbances. ~1,33available in Europe, is a homolog of fluphenazine. Although catalepsy it does not have antiemetic properties.
B ’ i e l , .Ed. having has been Compound it produces
Neuroleptic activity has been reported for X d 4 which has a novel ring system. A metabolite of thioridazine has been identified as XIlIand shown to have a much lower neuroleptic potency than its parent.35 Since there was some suggestion of activating properties (suppression of the tetrabenazine syndrome in rabbits, potentiation of serotonin fever and central anticholinergic it was tested clinically as antidepressant agent with negative ~~~~~~~~6 However the activity in schizophrenia seems to be good.
In the continuing study of the metabolism of chlorprmazine, 2-chlorophenothiazine and 2-chlorophenothiazine 5-oxide have now been identified in human urine.37 Butyrophenones - None of the fluorobutyrophenone compounds is at present in use in the United States although they are extensively used in Europe. The recent review by Haase and Janssen is a useful summary of these comp0unds.3~ A n extension from thekr use in ps chiatry to use in surgical procedures for producinf analgesia is underway.3 j40 The appearance of several .clinical studies4 on the psychiatric use of trifluperidol indicates the prospect of its future availability for treatment of schizophrenia. There are some reports of its especial value in paranoid schizophrenia.42
B
Pharmacological and clinical data on compound XI$3 show it to resemble haloperidol except for the addition of an antireserpine effect. A homolog of XIV (XV)44 has also been studied but was found to have troublesome sideeffects. Both of these products are somewhat related to mI45 which, although having an effective antipsychotic action, caused cataracts and disturbances of cholesterol balance. A group of fluorobutyrophenones derived from 4-aminopiperidines has been described.46 The treatment of l-benzyl-4-~-aminopiperidine-4-nitriles with Grignard reagents effected displacement of the cyano group whereas organolithium reagents reacted with the cyano function to afford ketones. Subsequent debenzylation and alkylation gave the corresponding fluorobutyrophenones. These compounds are less active than haloperidol in apomorphine antagonism but are more potent in countering morphine-induced mania in cats. The most potent of these preparations is XVII. A strong neuroleptic of long duration related to the butyrophenones has recently been reported.47 Compound X a I I antagonizes the effect of apomorphine for as long as 100 hours.
Chap. 1
Antipsychotics, Anti -Anxiety Agents
-5
Child re s s
XVIII
Carbamates - A new carbamate, tybamate (XIX)48 closely resembling meprobamate in structure and in activity was marketed during 1965. Its potency is comparable to meprobamate in many tests, yet it has only one-third the potency of meprobamate in the antipentylenetetrazole test. However, in contrast to meprobamate, it antagonises the effect of LSD on the electroencephalogram and has an antiserotonin action. Convulsions are not seen in dogs receiving tybamate upon abrupt withdrawal of the drug, whereas convulsions do result upon withdrawal of meprobamate.49 In the dog tybamate is metabolized by hydroxylation and/or N-dealkylation.50 Hydroxytybamate is the principal metabolite found in the urine. Several clinical studies have appeared demonstrating effectiveness against anxiety. 51,52 One report53 suggested mild stimulant properties, but in a study with alcoholics no separation from placebo could be made.54 A series of meprobamate analogs was prepared containing silicon in place of the quaternary carbon atom.55 Each silicon compound is approximately
equivalent to its carbon analog in the rotarod test and in acute toxicity. monothiol analog (rOr) of meprobamate is also comparable to meprobamate in potency and toxicity.56
A
A chemical review of the carbamates has been written by Adams and Baron57 with some attention to biological activity.
Sect. 1 - CNS Agents
Biel, Ed.
%NOCOC%CC%OCONHC4Hg
I
cH3 XIX
H NOCOCH~CCH~SCONH~ 2
I
CH
3
Benzodiazepines - The introduction of oxazepam in 1965 brought to three the number of 1,4-benzodiazepines comycially available in the United States. ~ particularly the anticonvulsant The animal studies of oxazepam (XXI)' 3 5 8 59 and conflict tests, suggested its use as an anti-anxiety agent and clinical studies60r61 indicated its efficacy for this purpose. Its potency appears to lie between chlordiazepoxide and diazepam. The compound has also been examined as a water-soluble hemisuccinate ester, sodium salt.& In the form of its glucuronide, oxazepam is the principal excretion product in the dog and man of diazep which is also hydroxylated to some extent without N-demethylation. In the circulating serum, the most prominent metabolite of diazepam is the unhydroxylated compound XXIII. There is an indication of the presence of further phenolic metabolites whose precise structures are unknown. The metabolism of chlordiazepoxide in the dog and man results principally in the production of 7-chloro-1,3-dihydro-5-phenyl2g-1,4-benzodiazepin-2-one 4-oxide, but in the rat basic compounds as yet unidentified are produced.65 Some opening of the lactam ring was observed, but no alteration of the aromatic rings or reduction of the N-oxide function was detected. Nitrazepam (XXIV)66,67 has been introduced in Europe and is being promoted as a hypnotic but its activity profile suggests it woul be cffective against anxiety. A clinical report on a related compound (XXV)g8 indicates a resemblance to diazepam. Some additions to the list of benzodiazepinones having functional substituents have been made. French workers succeeded in preparing 3-carboalkoxybenzodiazepinones, e.g. XXVI, 69 by transimidation of the appropriate 2aminobenzophenone imines with a-aminomalonic esters followed by cyclization. The benzodiazepine esters so obtained were converted to amides and also hydrolyzed to salts of the corresponding carboxylic acids. The ease of decarboxylation upon acidification of these salts suggests that the decarboxylation products may be responsible for the high biological activity. Although the esters and amides have typical benzodiazepine profiles they are not so potent as the carboxylic acid salts which compare favorably with diazepam.
Chap. 1
Antipsychotic s, Anti -Anxiety Agents
R
XXI:
R3
-N
9
R5
H
H
CH
H
c6H5 g-FC&
XXVI:
H
C%C%N
C02Et
H
(c@5)2
‘SH5
@ ‘SH5
xxx
02
0
XXXII
c@5
XXV:
c1
‘SH5
H
c6H5
XXIX
K2
c@5
H
‘SH5
c1
R5
OH
H H
XXVII:
XXVIII
3
XXIII: XXIV:
3
I
‘SH5
XXXIII
-7
Child re s s
c6H5 “-FC&
9
c1 c1 c1
N02 C1
c1 C1
8 -
Sect. 1 - CNS Agents
Biel, Ed.
3-Acetamidobenzodiazepines were prepared by cyclization of 2-(2-acetamido2-aminoa~etamido)benzophenones.7~ A novel elimination of acetic acid from the appropriate 2-(N-acetoxyacetamid0)acetamidobenzophenone afforded the intermediate. It was possible to hydrolyze the acetamidobenzodiazepines to the corresponding 3-amino compounds and convert these products into 3-hydroxy compounds by treatment with nitrou acid. The amino and acetamido compounds are merely reported to be active.7
Stempel, et a1.,72 achieved a direct synthesis of a 3-chlorobenzodiazepinone 4-oxide by base treatment of 6-chloro-~-dichloromethyl-4-phenylquinazoline 3-oxide. The course of this ring enlargement, which was responsible for the original discovery of chlordiazepoxide, was clarified by the isolation of an intermediate, ~-dichloroacetamido-5-chlorobenzophenone oxime (ant), which slowly cyclized. Cyclization of the monochloroacetyl analog is too fast to permit its isolation. The 3-chloro substituent of the benzodiazepine product reacted conventionally with nucleophiles following removal of the N-oxide function. A number of benzodiazepinones with functional substituents in the 1position has been published along with test data.73 The general structureactivity requirements already described for the benzodiazepines obtain for the 1-aminoalkyl types. The importance of an 2-fluoro substituent on the 5phenyl ring in increasing the potency of the compounds is clear. Compound XXVII is one of the most potent of the group, but it is slightly less potent than diazepam. The activity of the related 1-aminobenzodiazepinesprepared by use of chloramine was not given.74
Compounds containing a fused naphthalene ring (XXVIII)75 and a fused pyridine ring (xxIX)76 have been disclosed. The former types are inactive and the latter are less active than diazepam. Further examples of compounds related to active benzodiazepines, but for which test data are missing, include XXXR , xw[I,78 XXXII79 and XXXIII.80 Miscellaneous Compounds - Investigations on several compounds that do not fall into the above groups were reported. The pharmacology of trimetozine (XXXIV)81 indicates it to be a tranquillizer without hypnotic or anticonvulsant properties. Compound XXXV82 has sedative properties approximating chlorpromazine but does not produce catalepsy and ataxia. A disruptive effect on conditioned behavior at very low dosage is seen with the adrenolytic compound XXXVr.83 Compound XXXVII84 is less effective than meprobamate against anxiety and it has been shown that poor absorption is not the explanation.85 The tranquillizing potency of XXXVII186 is approximately equivalent to meprobamate. Taborsky, et al.,87 have studied the effect of 1-methylation on a group of psychoactive indoles. In general, the effects on behavior of the methylated and unmethylated pairs are similar. Compound XXXIX, 88 which resembles tetrabenazine in structure, has both stimulant and depressant properties. It blocks conditioned avoidance in rats but the required dose is at least five times that of chlorpromazine. Replacement of the 2-chlorophenyl groups by an alkyl or aralkyl group leads to inactive products. A good clinical response in schizophrenics has been noted. A group of 17-haloyohimbanes89 was examined by observation of the effects on
A n t i p s y c h oti c s , A n t i - A n x i e t y A g e n t s
Chap. 1
Childress
-9
t h e behavior of untamed r h e s u s monkeys. Although 17-CT-bromoyohimbane i s approximately a s p o t e n t a s r e s e r p i n e i n a l t e r i n g behavior i t has u n d e s i r a b l e cardiovascular properties.
XXXVIII
C H -2-Cl 6 4
XXXIX References
1. 2.
3. 4. 5.
6.
7. 8. 9.
10. 11. 12.
13. 14. 15.
16.
G. H. Acheson,
Ed., "Second Symposium on Catecholamines, ' I Pharmacol. 1, P t . 1 (1966). L. Decsi i n E. Jucker, Ed., Progress i n Drug Research, Vol. 8, Birkhauser Verlag, Basel, 1965, p. 53. P.B. Bradley, Ed., "Pharmacology of t h e C e n t r a l Nervous System," Brit. Med. Bull., NO. 1 (1965). s. M r a t t i n i and L. V a l z e l l i , "Serotonin", E l s e v i e r , New York, 1965, p. 199. D.R. C u r t i s and J . C . Watkins, Pharmacol. Rev., E. Gellhorn, P e r s p e c t i v e s Biol. Med., 8, 488 (1 R . E . Bourdillon, C.A. Clarke, A.P. RiGes, P.M. Sheppard, P. Harper and S.A. L e s l i e , Nature, 208 453 (1965). A.M. Ernst, Psychopharmacologia, 383, 391 (1965). Arch. I n t e r n . Pharmacodyn., 12, M.L. Brown, W.J.. Lang and S. 439 (1965). D.W. Woolley and B.W. Gomi, Science, 1 % 670 (1965). S.S. Kety, Nature, 208, 1252 (1965). S.S. Kety, I n t e r n . r P s y c h i a t . , 409 (1965). J . H . Nodine and P.E. S i e g l e r , Eds., "Pharmacologic Techniques i n Drug Evaluation, I' Year Book Medical P u b l i s h e r s , Chicago, 1964. P.A. J. Janssen, C. J . E . Niemegeers, and K.H.L. Schellekens, A r z n e i m i t t e l Forsch., hc' 1 5 104, 1196 (1965); l& 339 (1966). A.S. M a r r i o t t and P.S.J. Spencer, B r i t . J. Pharmacol., 25 432 (1965). wd M . I . Gluckman, Current Therap. Res., 7, 721 (1965).
&., 2, No.
2,
-'
A,
cu,
S e c t . 1 - CNS Agents
10 -
B i e l , Ed.
17. O.S. Ray, Arch. I n t e r n . Pharmacodyn., 1 3 , 49 (1965). 18. 19. 20. 21. 22.
2324. 25. 26. 27. 28. 29. 30.
31.
32-
33-
34. 35.
36. 37. 38
-
39 * 40. 41. 42. 43. 44. 45. 46. 4748. 49. 50.
224 (1965). H.F. Mtfller and A.K. Mtfller, I n t e r n . J. Neuropsychiatry, L.E. H o l l i s t e r and J . E . Overall, J . New Drugs, 286 (1965). M. Ostow, J. New Drugs, 5, 3 (1965). G. S t i l l e , H. Lauener, ET Eichenberger, F. Hunziker and J. Schmutz, 841 (1965). Arzneimittel-Forsch, G. S t i l l e . H. Ackermann, E. Eichenberger and H. Lauener, I n t e r n . J. Neuropharkacol., $, 375- (1965). J. Schmutz, F. K k z l e , F. Hunziker and A . Bcrki, Helv. Chim. Acta, _336 (1965)-. J . O . J i l e k . V. Seidlova, E. Svatek, M. F'rotiva, J. Pomykacek and Z. Sedivy, Mohatsh., 96, 182 (1965). M. P r o t i v a , J.O. J;\iek, J. Metysova, V. Seidlova, I. Jirkovsky, J. Metys, E. Adlerova, I. Ernest, K. Pelz and J. Pomykacek, Farmaco, Ed. Sci., 721 (1965). A.A. Sugerman, H. S t o l b e r g and J. Herrmann, Current Therap. Res., 7, N 310 (1965). G.M. Simpson and J. Iqbal, Current Therap. Res., 7, 697 (1965). D.M. Gallant, M.P. Bishop and W. Shelton, C u r r e n t y h e r a p . Res., 7, h 415 (1965). A.A. Sugerman and F.J. L i c h t i g f e l d , Current Therap. Res., 7, 707 (1965). Y B. Holst, Acta Psychiat. Scand., 40, 415 (1965). D. Turns, H. C. B. Denber and D.N. T e l l e r , J. New Drugs, 5, 90 (1965). T . Fokstuen, I n t e r n . J. Neuropsychiatrp, 1, 294 (1965).* T.M. Itil, Arzneirnittel-Forsch, 2, 817 (y965). Sandoz, Neth. Pat. 6,507,469 (1965). D.M. G a l l a n t , M.P. Bishop and D. Sprehe, Current Therap. R e s . , 7, v 102 (1965). D.M. Gallant, M.P. Bishop and C. S t e e l e , Current Therap. k., 7, N 783 (1965). D . E . Johnson, C.F. Rodriguez and H. P. Burchf i e l d , Biochem. Pharmacol., cvv' 14 1453 (1965). H.J. Haase and P.A.J. Janssen, Eds., "The Action of Neuroleptic Drugs," Year Book Medical Publishers, Chicago, 1965. L. T o r e l l i and F. Schiavi, Aggressologie, 6, 327 (1965). N.W. Shephard, "The A p p l i c a t i o n of Neuro1e;tanalgesia i n Anesthetic and Other P r a c t i c e , Pergamon Press, Oxford, 1965. A.A. Sugerman and B.H. W i l l i a m s , J. New Drugs, 5 318 (1965). L . E . H o l l i s t e r , J . E . Overall, J . L . Bennett, I. 4 K m b e l l , Jr. and J. Shelton, Am. J. Psvchiat., 13, 9 6 (1965). J . A . Christensen, S. Hernestam, J . B . Lassen and N. S t e r n e r , Acts Pharmacol. Toxicol., 23 109 (1965). -' G.M. Simpson, E. Kunz and T.P.S. Watts, Psychopharmacologia, 5 223 (1965). G.M. Simpson, T . Farkas and J . C. Saunders, Psychopharmacologia, 306 ( 1 9 a ) . B. Hermans, P. Van Daele, C . Van De Westeringh, C. Van Der Eycken, J . Boey and P . A . J . Janssen, J . Med. Chem., 5 851 (1965). P.A.J. Janssen, Fr. P a t . 3695M (1965). F.M. Berger, M. Kletzkin and S. Margolin, Med. E x p t l . , fi 327 (1964). S. Margolin, O.J. Plekss and F.M. Berger, Pharmacoloqist, 143 (1965). J.F. Douglas, J. Edelson, A. Schlosser, B. J. Ludwig and F.M. Berger, Federation Proc. No. 1, P t . 1, 489 (1964).
3
9,
45,
a
3
2,
3,
Chap. 1 51. 52. 53 * 54. 55. 56. 57. 58. 59.
Antipsychotics, Anti-Anxiety Agents
11 -
Childress
M. C h i e f f i , Diseases Nervous System, 2 6 369 (1965).
I. Slaughter, J. New Drugs, 177 (lpbs). E . Raab, K. Rickels and E. Moore, Am. J. Psychiat., H.B. Mooney and K.S. Ditman, J. New Drugs, 233 (1 R . J . Fessenden and M.D. Coon, J. Med. Chem., 604 (1965). M.A Leaffer, W.A. Skinner and B . J . Ludwig, J. Med. Chem., 5 208 (1965). P. Adams and F.A. Baron, Chem. Rev., c 5 , 567 (1965). H. Klupp and J. G h l i n g , Arzneimittel-Forsch., 359 (1965). L.O. Randall, C.L. Scheckel and R.F. Banziger, Current Therap. Res., 590 (1965). €3. S c a s s e r r a , Diseases Nervous Sys tem, 2J_6, 511 (1965). 60. 61. W. Janke and K. -D. Stoll, Arzneimittel-Forsch., 15, 366 (1965). 62. S.N. Steen and L.R. Martinez, Anesthesia A n a l g e s g , Current Res., 44, 358 (1965). 63 H.W. -Ruelius, J.M. Lee and H.E. Alburn, Arch. Biochem. Biophys., 1,1-_1, 376 (1965). 64. M.A. Schwartz, B.A. Koechlin, E. Postma, S. Palmer and G. Krol, 2. Phannacol. E x p t l . Therap., lA8, 423 (1965). 65. B.A. Koechlin, M.A. Schwartz, G. Krol and W. Oberhansli, J. Pharmacol. Exptl. Therap., lk8, 399 (1965). 66. L.O. Randall, W. Schallek, C. Scheckel, R . E . Bagdon and J. Rieder, Schweiz. Med. Wochschr., %, 334 (1965). 67- W. F. Borck, Arzneimittel-Forsch., 9, 1155 (1965). 68. H.O. Gerz, Am. J. Psychiat., 121, 495 (1964). 69. Etab. Clin-Byla, Belg. P a t . 6 K 4 0 1 (1965). 70- S . C. Bell, R. J. McCaully and S . J. Childress, Tetrahedron L e t t e r s , 2889 (1965). 71- S. C. Bell, U . S . Pat. 3,198,789 (1965). 4267 (1965). 72- A. Stempel, E. Reeder and L.H. Sternbach, J. Org. Chem., 73. L. H. Sternbach, G.A. Archer, J .V. Earley, R. I. Fryer, E. Reeder, N. Wasilyw, L.O. Randall and R. Banziger, J . Med. Chem., 4, 815 (1965). 74. W. Metlesics, R.F. Tavares and L.H. Sternbach, J. Org. Chem., 30, 1311 (1965). R. L i t t e l l and D.S. Allen, Jr., J. Med. Chem., 5 892 (1965). 75 76. R. L i t t e l l and D . S . Allen, Jr., J. Med. Chem., 5 722 (1965). 77. E. T e s t a and L. Fontanella, Farmaco, Pavia, Ed. Sci., 20, 323 (1965). 78 * P. H.L. Wei, U. S . Pat. 3,185,680 (1965). 79. L.H. Sternbach, H. Lehr, E. Reeder, T . Hayes and N. S t e i g e r , J. Or&. Chem., 0 2812 (1965). icolaus, E. B e l l a s i o , G. Pagani, L. Mariani and E. Testa, 80. B . J . R . a i m . Acta., 1867 (1965). 81. J . - R . B o i s s i e r , P. Simon and J. Fichelle-Pagny, Therapie, 2 3 401 (1965). 82. H. Fujimori and D.P. Cobb, J . Pharmacol. Exptl. Therap., lA8, 151 (1965). V.G. Longo and V. Rosnati, Psychophannacologia, 145 (1965). 83 84. J. Janacek, B . C . Schiele, T.P. B e l l v i l l e , N.D. Vestre and 0. Raths, 2. New Drugs, 5 51 (1965). 85. B.M. P h i l l i p s , C. E. P i l k v i s t and P. J. Kraus, Arch. I n t e r n . Pharmacodyn., 156, 358 (1965). 704 (1965). 86. L.M. Rice and C. H. Grogan, J Med. Chem., 87 * R . G . Taborsky, P. Delvigs, I . H . Page and N. Crawford, J. Med. Chem., fL 460 (1965). 88. C.R. Ganellin and R.G.W. S p i c k e t t , J. Med. Chem., 619 (1965). 89. M. von Strandtmann, G. Bobowski and J. Shavel, Jr., J. Med. Chem., 338 (1965).
3
2,
12,
4.,
-
p
w.
s,
-
3
w1
2,
2,
2,
12 -
Sect. I
- CNS Agents
Biel, Ed.
f
Chapter 2. Antidepressants, Stimulants, Hallucino ens J. H. Biel, Aldrich Chemical Company, Milwaukee, W 8 .
I.
The Antidepressants A. Introduction There were no spectacular break-throughs in the treatment of mental depression durin 1965. However, the development of drugs that displayed a select ve type of antidepressant activity underscored the very complexity of mental depressive illness and afforded a greater understanding of the fact that mental depression is not a single disease entity but requires individualized therapy and the availability of drugs capable of coping with the various facets of this mosaic disease syndrome. Other major developments demonstrated the influence of the antidepressant drugs on catecholamine metabolism, uptake, storage, and intracellular binding. These findings shed new light on the mechanism of action of these drugs pointing to a possible etiology of a breakdown in central chemical homeostasis. Well-controlled clinical investigations brou ht into sharper focus the need for both stimulant and tranquiliz ng antidepressant agents, particularly where depressant symptoms were an overt expression of an underlying psychotic illness which wa exacerbated by the "stimulantT1 type of antidepressant. introduction of monodemethylated imipramine and amitriptyline derivatives was a ste in the direction of achieving greater selectivity of action.g,4,5,6 B. The MA0 Inhibitors 1. New Structures
f
'f
8 , sft;;e
CH3 I $CH2CH(CH3 )N-CH2CECH
ArC O( C H 2)
(IV)
( IVa)
R;R .R -lower '-alkyl groups (VI)
p a H
N-C OR #-R
(V) Ar = phenyl or substituted phenyl R = alkyl, cycloalkyl, heterocyclic amfne
Chap. 2
Stimulants
Biel
13 -
Structures I and I1 are modifications of pargyline (Eutonylm). Knoll et a1.8 d e s c r i b e s t r u c t u r e I1 as being ?'an acute psychostimulant" and ? ? achronic psychic energizer". I t s MA0 i n h i b i t o r y potency i n v i t r o i s s a i d t o be 200 times t h a t of NiamidTM. Unlike pargynn-is agent is a potent c e n t r a l stimulant comparable t o amphetamine i n potency. S t r u c t u r e 111, a phenoxy analog of tranylcypromine w a s o et h i r d a s potent a s the l a t t e r drug and twice a s long-lasting?*g I n r a t s , I11 displayed moderate anorexigenic and increased locomotor a c t i v i t i e s . As an MA0 i n h i b i t o r , compound I V was approximately onehundredth as potent a s pheniprazine (a-methylphenethylhydrazine). As a group, these compounds displayed a v a r i e t y of pharmacologic e f f e c t s : CNS stimulation, tryptamine and nfEotine antagonism The d a t a presented and suppression o f f i g h t i n g mouse behavitvr. do not allow a conclusion concerning t h e i r p o t e n t i a l a s a "lead" i n the a r e a of antidepressants o r CNS s t i m u l a n t s . The s e r i e s is i n t e r e s t i n , however, because of t h e d u a l i s t i c type of psychot r o p i c a c t on ( e x c i t a n t and t r a n q u i l i z i n g ) and bears f u r t h e r watching. Compound V i s another s t r u c t u r e displaying a multitude of pharmacologfc a c t i o n s Both n e u r o l e p t f c and Tfpotenttti n v i t r o MA0 i n h i b i t o r y p r o p e r t i e s a r e ascribed t o t h i s s e r i e s . mec l i n i c a l u t i l i t y of t h i s s t r u c t u r a l group i n mental depression remains i n doubt. Structure i l l u s t r a t e s v a r i a t i o n s on t h e theme of Monasem (etryptam n e ) . Compound V I I has been i n v e s t i g a t e d c l i n i c a l l y by Azirnal3 who found it t o be an e f f e c t i v e a n t i d e p r e s s a n t . The 7-methyl-a-ethyltryptamine ( V I I I ) is s a i d t o be s u p e r i o r a s an MA0 i n h i b i t o r t o etryptamine, both i n v i t r o ( t e n times) and vivo ( t w o t o f o u r t i m e s ) . l 4 The c l s i c a l t i l i t y o f t h i s agent E n t i d e p r e s s a n t therapy has n o t been revealed.
f
B
(VII) MP-809 (VIII) 2 . New Developments on Older MA0 I n h i b i t o r s The hypertensive c r i s e s produced by t r a n lcypromine i n t h e presence of tyramine-rich foods 15915a9 15b, has r e s t r i c t e d the a p p l i c a t i o n of t h i s valuable agent t o h o s p i t a l use. While o t h e r MA0 i n h i b i t o r s evoke s i m i l a r responses i n tyramfnet r e a t e d r a t s , 16 the i n t r i n s i c sympathomimetic a c t i v i t i e s of tranylcypromine presumably enhance i t s potency i n t h i s regard .I7 E f f o r t s t o overcome t h e p e r i p h e r a l s i d e e f f e c t s of t h e MA0 i n h i b i t o r s have taken t w o d i r e c t i o n s : (1) Masking o f t h e f r e e amino group of tranylcypromine by a s u i t a b l e a c y l radical18, 19
Sect. I
14 -
- CNS Agents
B ' i e l , Ed.
(structures I X and X I which would not impede the d r u g ' s passage
( 1x1
(XI across the blood-brain b a r r i e r nor form so s t a b l e an amide linkage as t o preclude enzymatic cleavage t o the f r e e d n e a t the t a r g e t s i t e . ( 2 ) Blockade of the e r i heral c e l l receptors of MA0 by a reversible MA0 i n h i b i t o r w t h greater receptor a f f i n i t y than the therapeutically active MA0 inhibitor and an i n a b i l i t y t o penetrate the blood-brain barrier. I n t h i s way, the therapeutic MA0 i n h i b i t o r Will be forced i n t o the c e n t r a l nervous system r metabolized t o an e a s i l y excretable metabolite. HoritaS8 has succeeded i n demonstrating the u t i l i t y of t h i s concept. Wemedication of the r a t with a reversible MA0 i n h i b i t o r , BW 392C60 ( X I ) , followed by treatment with pheniprazine blocked brain MA0 completely, but maintained h i h MA0 a c t i v i t y i n the l i v e r and other peripheral organs. Phen prazine and pargyline could be e f f e c t i v e l y antagonized, but n o t tranylcypromine o r iproniazid. Compound MO 1255 ( X I 1 1 has been claimed t o be an acgfve antidepressant devoid of cardiovascular side effects. NCH3
?
f
O-CI~~H~NH!!-NHCH~
( X I ) BW 392C60 ( X I I ) MO 1255 (encyprate) neTM (2-piperidino-3-methylpyrazine) has been shown by Rider t o produce g a s t r i c antisecretory e f f e c t s comparable t o atropine. The drug has properties common t o both MA0 inhibit o r s and the imipramine-type agents. A s an MA0 inhibitor, it is f o u r t o s i x t b e s as potent as phenelzine, but unlike the l a t t e r , produces r a t h e r severe o r t h o s t a t i c hypotension i n man.22a 3. Mechanism of Antidepressant Action of MA0 Inhibitors A t the present s t a t e of our knowledge, the mechanism of the antidepressant action of the MA0 i n h i b i t o r s i s thou h t t o be intimately t i e d t o brain catecholamine levels. Sch ldkraut 23 has summarized the evidence favoring the involvement of catecholamine In transmitting the e f f e c t s of the MA0 inhibitors. Spector 28 showed t h a t during selective depletion of norepinephrine and dopamine, the MA0 inhibitor, pargyline, was unable t o reverse reserpine o r tetrabenazine depression u n t i l brain catecholamine levels had stached 50% of pre-dru levels. Recently, Ingvarsson has reported dramat c remissions of long-standing drug r e s i s t a n t depressions following the administ r a t i o n of 50 mg. of DOPA every other day. Marked improvement
a
s9, !da
M
f
f
Chap. 2
Stimulants
Biel
15 -
was seen within a few hours. P a t i e n t s a l s o a f f l i c t e d with asthma and Parkinsonism experienced complete r e l i e f of t h e i r symptoms from the DOPA treatment. Relapse occurred on discontinuance of DOPA therapy. The i n h i b i t i o n of NE biosynthesis by blocking t h e r a t e l i m i t i n g s t e p with a-methyltyrosine r e s u l t e d i airment of motor a c t i v € t y and s e d a t i o n i n animals and man Clinical improvement i n t h e depres9Bd a t i e n t c o r r e l a t e d w e l l with t h e degree of MA0 i n h i b i t i o n . 9 28 Recently, Pletscher30 has presented evidence t h a t the MA0 i n h i b i t o r s may block the uptake of r e l e a s e d NE i n t o s t o r a g e granules, thereby producing an increased concentration of NE around t h e adrenergic synapses. 4. Conclusions a. P o t e n t , i r r e v e r s i b l e i n h i b i t i o n of b r a i n MA0 i s a primary p r e - r e q u i s i t e f o r e f f e c t i v e a n t i d e p r e s s a n t therapy. b. The c l o s e temporal r e l a t i o n s h i p between t h e onset of MA0 i n h i b i t i o n and a n t i d e p r e s s a n t e f f e c t s lends f u r t h e r support t o t h e hypothesis t h a t "free" NE, p r o t e c t e d from o x i d a t i v e metabolism, may be implicated i n mediating t h e a n t i depressant e f f e c t s of the MA0 i n h i b i t o r s . c. C l i n i c a l l y , t h e MA0 i n h i b i t o r s e x e r t optimum a n t i d e p r e s s a n t e f f e c t s i n r e a c t i v e and n e u r o t i c depressions. Activated, psychotic o r endogenous depressions were l e s s s u s c e p t i b l e t o MA0 i n h i b i t o r y therapy.25731 d. The "False Neurochemical Transmitter" theory promulgated by Kopin e t a1.32 t o e x p l a i n t h e sympathetic blocking p r o p e r t i e s of t h e MA0 i n h i b i t o r s , must be s e r i o u s l y considered a l s o w i t h r e s p e c t t o the c e n t r a l p r o p e r t i e s of t h e s e agents. I n essence, t h i s hypothesis proposes t h a t MA0 i n h i b i t i o n w i l l produce an accumulation of sympathomimetic m e t a b o l i t e s which a r e normally n o t present i n t h e body, but have s u f f i c i e n t a f f i n i t y f o r t h e adrenergic r e c e p t o r s i t e s t o d i s p l a c e the r e g u l a r l y p r e s e n t n e u r o t r a n s m i t t e r s (e.g., norepinephrine, dopamine) from sympathetic nerve endings. Furthermore, sympathetic nerve s t i m u l a t i o n w i l l r e l e a s e these agents i n t h e same manner a s it does NE; however, the r e s u l t a n t e f f e c t w i l l be g r e a t l y d i l u t e d , since t h e f a l s e n e u r o t r a n s m i t t e r s have d i s t i n c t l y weaker adrenergic p r o p e r t i e s than NE o r dopamine. Normally, tyramfne is r a p i d l y metabolized by MA0 so t h a t l i t t l e , i f any, octopamine is formed. I n t h e presence of MA0 i n h i b i t o r s , however, s i g n i f i c a n t amounts of octopamine a r e produced.
Ss:B -
H
O
D 2H4NH2
(XIII) Tyramine
H O o C H ( OH )CH2NH2
(XIV) Octo m i n e 0-1
transmitter
5. Review A r t i c l e s t a i l e d information regarding ad For f u r t h s i d e e f f e c t s , 45, comparative c l i n i c a l e f f i c a c y Y$:J!,
!l%
al sb,iysc and
Sect. I - CNS Agents
16 -
B i e l , Ed.
p o s s i b l e mechanism of a c t i o n 3 8 7 3 9 9 4 0 of t h e MA0 i n h i b i t o r s , t h e r e a d e r i s r e f e r r e d t o the c i t e d review a r t i c l e s . S t r u c t u r e- ac t i v i t y , biochemical , pharmacological and c 1i n i c a l pharmacological d a t a on both hydrazine 39, 40 and non-hydrazine MA0 i n h i b i t o r s 41 have been covered extensively i n the respect i v e references. S c h i l d k r a u t ' s paper 38 i s of s p e c i a l i n t e r e s t , s i n c e it provides much of t h e supporting evidence f o r the "Catecholamine Theory" of the antidepressant drug a c t i o n . C. The Thymoleptic Agents ( T r i c y c l i c Antidepressant Drugs) 1. Introduction Listed below a r e t h e s t r u c t u r e s of the t r i c y c l i c antidepress a n t s which a r e e i t h e r commercially a v a i l a b l e o r In advanced
(XV)
I m i ramine
R=CH3: R=H :
h
l ~
(XVI) R=CH3: Amitriptgline R=H : Nortrm
N / e I CH2CH(CH3)CH2N(CH3>2
i
N
(XVII 1
Protriptyline
/
(h,3 N 3 1 C $ € 4 0 H
(XVIII) (XIXI Trimipramine Opipramol Kuhn's discovery42 of t h e antidepressant e f f e c t s of imipramine c o n s t i t u t e d a major break-through i n t h e treatment of mental depression. A e x c e l l e n t and comprehensive review by H'etfliger and BurckhardtQ3 covers t h e chemistry, pharmacology, and c l i n i c a l e f f e c t s of t h i s drug group u n t i l 1963. 2. Evidence f o r Enhancement of Adrenergic Responses by t h e Thymoleptic Drugs The o r i g i n a l pharmacolo i c spectrum of imipramine ave no h i n t of i t s p o t e n t i a l a c t i v t y a s a novel c l i n i c a l a n t depressant; rath the drug behaved l i k e a mild t r a n q u i l i z e r i n animals. S i gEg7w a s t h e f i r s t t o d i s c e r n pharmacologic d i f f e r e n c e s between i m pramine and chlorpromazine on t h e b a s i s of enhancement of c e r t a i n adrenergic responses t o exogenously administered NE by t h e former drug. Sigg ascribed t h i s a c t i o n of the drug t o a I * s e n s i t i z a t i o n of EQe adrenergic r e c e p t o r s Kaumann e t a l . demonstrated an increase i n c a r d i a c r a t e and f o r c e of c o n t r a c t i o n w i t h desipramine which would be blocked by D C I . U r s i l l o and Jacobsen46 working with the i s o l a t e d
f
f
f
Stimulants
Chap. 2
17 -
Biel
v a s deferens achieved marked q u a n t i t a t i v e d i f f e r e n c e s between m x o r and major a n t i d e p r e s s a n t s . Thus, desipramine had 50 100 times t h e potency of methylphenidate. Amitriptyline, chlorprothixene, chlorpromazine produced only i n h i b i t i o n of NE i n t h i s t e s t . Catecholami -induced h erthermia i n r a t s was p o t e n t i a t e d by imipramine.gq Imipram+a-n ne an e s pramhe, i n small doses, enhanced amphetamine stimulant and hyperthermic e f f e c t s . Opipramol produced only a s l i g h t p o t e n t i a t i o n and c l i n i c a l l y , t h i s drug i s l e s s of an a n t i d e p r e s s a n t than an a n x i o l y t i c agent. 3 . Mechanism of NE P o t e n t i a t i o n by t h e Thymoleptic Agents One of t h e major r o u t e s of i n a c t i v a t i o n of f r e s h l y r e l e a s e d (from c e l l u l a r binding s i t e s ) NE i s re-uptake by t h e cell.48a Glowinski and Axelrod 49 devised a technique capable of d e t e r mining b r a i n l e v e l s of exogenously administered (by i n t r a v e n t r i c u l a r i n j e c t i o n ) t r i t i a t e d NE. The exogenous NE i s taken up and r e t a i n e d by the sympathetic nerve endings i n the brain and behaves biochemically l i k e the endogenous neurotransmitter. These i n v e s t i g a t o r s were a b l e t o show t h a t only c l i n i c a l l a c t i v e antidepressant drugs ( h i p r a m i n e , desipramine an am tr p t y m were capable of reducing t h e uptake of t r i t i a t e d NE i n t h e r a t brain. A c l o s e s t r u c t u r a l analog of imipramine, i n a c t i v e a s an antidepressant, was devoid of any a c t i v i t y on NE uptake. The authors suggest t h a t t h e a b i l i t y of c l i n i c a l l y a c t i v e antidepress a n t s t o block t h e re-uptake of f r e s h l y r e l e a s e d "free" ( a c t i v e ) NE by t h e c e r e b r a l t i s s u e s may accoun f o r t h e mechanism of t h e i r antidepressant a c t i o n . Iversent0 working with the i s o l a t e d r a t h e a r t , found desipramine t o be 100 times more potent a s an i n h i b i t o r of NE uptake than chlorpromazine. I n the i s o l a t e d perfused c a t spleen, Thoenen e t &.51 showed t h a t NE output r e s u l t i n g from sympathetic s t f m u l a a o n was increased and t h e i n a c t i v a t i o n of exogenously administered NE delayed i n t h e presence of prev ously administered imipramine o r p r o t r f p t y l i n e . Haefely e t a l . 53 concluded from t h e i r s t u d i e s w i t h t h e , a c t i v e thymoleptic drugs, t h a t such a n t i d e p r e s s a n t s exerted a t l e a s t t h r e e types of a c t i v i t y a t t h e p e r i p h e r a l adrenergfc synapses: (1) a sympathomimetic e f f e c t , presumably due t o r e l e a s e of a c t i v e NE from i t s binding s i t e s , ( 2 ) i n h i b i t i o n of re-uptake of "E by the storage s i t e s of sympathetic nerve endings, and (3) a sympathicolytic or noradrenolytic e f f e c t i n higher doses. The desmethyl d e r i v a t i v e s were uniformly more potent i n i n n s i f y i n g t h e sympathetic e f f e c t s of neuronally r e l e a s e d NE. f
-
4
f
I n t e r a c t i o n of Thymoleptics with Reserpine, Tctrabenazine, o r Benzoquinolizlnes The thymoleptfc agents respond s i m i l a r l y t o t h e bove t h r e e catecholamine "releasing" drugs. S u l s e r and SorokoS3 have shown t h a t the r e v e r s a l of r e s e r p i n e sedation depends on the a v a i l a b i l i t y of NE s t o r e s and t h e r a t e of r e l e a s e of NE from i t s binding 4.
18
Sect. I
-
CNS Agents
B i e l , Ed.
s i t e s . I n animals, s e l e c t i v e l y depleted of t h e i r NE by a - M , the thymoleptic drugs were unable t o r e v e r s e the r e s e r p i n e induced depression. There was a d e f i n i t e temporal r e l a t i o n s h i p between b r a i n l e v e l s of desipramine and r e v e r s a l of the s e d a t i v e response of the benzoquinolizines .54 Hence, t h e authors concluded t h a t t h e r e v e r s a l of r e s e r p i n e s t u p o r by t h e thymolept i c drugs is dependent on r a p i d and copious r e l e a s e of b r a i n catecholamines. 5. A n t i c h o l i n e r g i c E f f e c t s of Thymoleptic Drugs An a l t e r n a t e o r a d d i t i o n a l mechanism of a n t i d e p r e s s a n t drug a c t i o n which would implicate blockade of c e n t r a l cholfgergic responses had been proposed o r i g i n a l l y by B i e l et a l . as imipramine and desipramEe have been Thymoleptic drugs , shown by S u l s e r e t :??6 t o antagonize a l l t h e c e n t r a l parasympathomimetic e f f e c t s of r e s e r p i n e (increased s a l i v a t i o n , muscular r i g i d i t y , hunchback posture and blepharospasms), even i n catecholamine-depleted animals. The c e n t r a l a n t i c h o l i n e r g i c a c t i v i t y of oxygen i s o s t e r e s o g 7 a m i t r i p t y l i n e and n o r t r i p t y l i n e <xX and XXI) w a s demonstrated . by t h e i r antagonism t o t h e c h o l i n e s t e r a s e i n h i b i t o r , d i e t h y l p-nitrophenyl phosphate (Paraoxon) and emetic e f f e c t i n pigeons. Increased p e r i p h e r a l a n t i c h o l i n e r g i c e f f e c t s were displayed by t h e c e n t r a l l y more potent diastereoisomer (B) of s t r u c t u r e X X I I . Diastereofsomer (A) w a s considerabfg l e s s a c t i v e a s an a n t i c h o l i n e r g i c and c e n t r a l stimulant.
Monro e t &.” i n v e s t i g a t e d a s e r i e s of t r i c y c l i c a n t i d e p r e s s a n t a r u g s and found a p o s i t i v e c o r r e l a t i o n between potent CNS p r o p e r t i e s and a n t c h o l i n e r g i c potency i n animals. Giarman and Pepau6& demonstrated t h a t only c e n t r a l l y a c t i v e (animals and man) b a s i c g l y c o l a t e e s t e r s caused a reduction i n b r a i n a c e t y l c h o l i n e (AcCh) l e v e l s of t h e r a t . The authors suggested as a l i k e l y mechanism, i n t e r f e r e n c e of the psychotropic g l y c o l a t e s with s t o r a g e of b r a i n acetylchoF2ne r e s u l t i n g i n reduced uptake of newly synthesized AcGh. Conclusion. On t h e basis of p r e s e n t l y a v a i l a b l e experimental evidence, one would have t o conclude t h a t t h e mechanism of a c t i o n of t h e t r i c y c l i c a n t i d e p r e s s a n t drugs may be due (1) t o an i n t e r ference with c e l l u l a r binding of b r a i n catecholamines, presumably NET thereby producing increased concentrations of catecholamines a t t h e c e n t r a l adrenergic synapses, and (2) a lowering of b r a i n AcCh l e v e l s which would tend t o enhance the o v e r a l l antidepressant effect.
Chap. 2
Stimulants
Biel
19 -
D. Newer Antidepressant Drugs Two drugs which represent structural departures from the currently marketed antidepressants are shown below (XXII1,XXIV):
QcsJ
2H4NMe2
8;
(XXIV) IN 1060
Compound XXIII displayed activity only in "septat;;; rats by suppressing the rage reaction and hyperirritability. Unlike other antidepressants, XXIII did not produce a reserpine reversal. In man, prelim nary data i n E a t e it to be a rapidly acting antidepressant drug. 62 As to compound IN 1060, Sletten et ,1.62 concluded a that the pharmacologic profile of this compous resembles that of imipramine with respect to (1) activation of psychotic processes, ( 2 ) increase in spontaneous motor activity in mice, (3) reversal of reserpine-induced ptos.is and depression in rats, (4) antagoni s m to Ditran-induced behavior in dogs,and ( 5 ) potentiation of epinephrine and NE pressor response of systolic blood pressure in man. E. The Significance of Imipramfne Metabolites K ~ h has n ~ tried ~ to correlate the urinary excretion of imipramine metabolites with clinical improvement. Imipramine Metabolites
(XXVII) desipramine n
(CH ) 3-NHCH3
(XXVIII) While a strict correlation proved difficult, clinical improvement normally became evldent following the maximum urinary excretion of metabolite XXVIII which usually occurred between the sixth and fifteenth day of therapy and was preceded by accumulation of
20 -
Sect. 1
-
CNS Agents
B , i e l , Ed.
metabolite X X V I I , desipramine. Kuhn suggests t h a t t h e formation of metabolite XXVIII i s dependent on t h e presence of s i g n i f i c a n t q u a n t i t i e s of X X V I I whose formation may be t h e r a t e - l i m i t i n g s t e p i n generating metabolite X X V I I I . The p a r a l l e l i s m i n t h e temporal r e l a t i o n s h i p between the o n s e t of t h e a n t i d e p r e s s a n t e f f e c t following imipramine and t h e appearance of maximal amounts of XXVIII i n the u r i n e would e x p l a i n gbe more r a p i d on t of a c t i o n S u l s e r et al.3g have shown (two t o f o u r days) of desipramine. t h a t animal s p e c i e s which a r e unable t o convert s i p r a m i n e t o desipramine a r e a l s o incapable of counteracting r e s e r p i n e o r benzoquinolizine-induced s e d a t i o n w i t h imipramine. F . C l i n i c a l P r o p e r t i e s of Antidepressant Drugs A number of review papers have appeared concerning t h e c l i n i c a l pharmacologic23 1 i 1 r o e i e s of t h e MA0 i n h i b i t o r y and thymoleptic agents. and6g, gy, 68,68,% Ayd has published a compilation of h i s c l i n i c a l experiences w i t h a m i t r i p t y l i n e during a Fix-year p e r i o d . Space permits only a summary of t h e general conclusions which have been reached by t h e s e authors: 1. Mental depression i s a multifaceted d i s e a s e syndrome w i t h varying types of e t i o l o g y . I t may be primary o r secondary ( i . e . , r e s u l t i n g from o t h e r mental disturbances such a s severe a n x i e t y o r an underlying psychosis). It may be r e a c t i v e ( i . e . , i n response t o an environmental s t r e s s ) o r a r i s i n g from within the p a t i e n t due t o a I t i s o f t e n s u b j e c t t o a spontaneous remission. make-up). 2 . W i t h r e s p e c t t o t h e comparative e f f i c a c i e s of t h e a n t i d e p r e s s a n t s , t h e r e c e n t review paper by Wechsler 5 al.69 i s probably most p e r t i n e n t . The a u t h o r s ' conclusion may-6e summarized as follows: a. V a r i a b i l i t Reported e f f e c t i v e n e s s f o r h i p r a m i n e , amit-EST, i p r o n i a z i d , phenelzine, i s o c a r boxazid and nialamide o f t e n ranged from 0 t o 100%. Amitriptyline had t h e l e a s t v a r i a b i l i t y (32 t o 79%). b. Improvement Rate - Average improvement r a t e f o r p a t i e n t s on imipramine, a m i t r i p t y l i n e , and isocarboxazid was 65%, whereas the range f o r i p r o n i a z i d , phenelzine, and nialamide was 40 t o 49%. ECT ranked t h e highest w i t h 72% improvement i n depressive symptoms and placebo therapy the lowest (23%). c . R e l a t i v e Chronicity of Depression Depressions of r e c e n t o r i g i n afforded a much higher improvement r a t e than chronic depressions. For phenelzine, the r a t e decreased from 56 t o 8%, and f o r imipramine and a m i t r i p t y l i n e from 69 t o 45% and 66 t o 32%, r e s p e c t i v e l y . 3. Anergic ( l e t h a r g i c ) depressions responded best t o the "stimulanttt type of a n t i d e p r e s s a n t (imipramine, desipramine, p r o t r i p t y l i n e ) , whereas a g i t a t e d o r anxiety depressions improved most with t h e "sedativet7 type of a n t i d e p r e s s a n t drug ( a m i t r i p t y l i n e , n o r t r l p t y l i n e ) . A l l t h e a n t i d e p r e s s a n t s exacerbated psychotic symptoms; however, a m i t r i p t y l i n e , having a t h e r a p e u t i c spectrum i n between chlorpromazine and imipramine, was t h e s m a l l e s t offender i n t h i s regard. The r e c e n t combination ( T r i a v i l m , E t r a f o n m ) of a potent a n t i d e p r e s s a n t ( a m i t r i p t y l i n e )
kt,
-
-
Chap. 2
Stimulants
Biel
21 -
with a p o t e n t t r a n q u i l i z e r (perphenazine, T r i l a f o n m ) r e p r e s e n t s an attempt t o d e a l more e f f e c t i v e l y with d e p r e s s i o n s accompanied by a n x i e t y , a g i t a t i o n o r schizophrenic s y p t o m a t o l o g y . The p r e l i m i n a r y r e p o r t s appear f a v o r a b l e . 72, 3 ~ 7 4 4. The desmeth 1 d e r i v a t i v e s o f hi ramine (desipramine, , Norpraminm, P e r d ) and a m i t r i p t yl-iptyline A v e n t y l m ) provided a f a s t e r o n s e t of a c t i o n (two t o f o u r days) and a l e s s e n e i n t e n s i t y of parasympatholytic and a d r e n o l y t i c s i d e e f f e c t s . 9 5 , 76977 N o r t r i p t y l i n e proved t o be a valuable adjunct i n t h e treatment of g a s t r o - i n t e s t i n a l disturbances.78 G . C l i n i c a l P r o p e r t i e s of Some Newer Antidepressant Agents More r a d i c a l s t r u c t u r a l d e p a r t u r e s from t h e imipramine and a m i t r i p t g l i n e - t y p e of a n t i d e p r e s s a n t agent a r e shown below: Newer Antidepressant Structures YH2CH2N(CH3l2
(XXX) ID-22
CH3
( X X X I I I ~P-4599
(=I)
(N
HF 1927 o G r m )
(XXXII) SKF 10810
(XXXV) IN 1060
Preliminary c l i n i c a l d a t a i n d i c a t e t h a t ID-22 is a s a t i s f a c t o r y a n t i d e p r e s s a n t endowed w i t h both s t i m u l a n t and t r a n q u i l i z i n g p r o p e r t i e s (dependin on t h e p a t i e n t ) ; s i d e e f f e c t s included o r t h o s t a t i c hypote f o n , dry mouth, c o n f u s i o n a l symptoms, and nocturnal anxiety Compound HF-1927 w a s e f f e c t i v e i n t h e treatment o f i n h i b i t e d and a g i t a t e d endogenous d e p r e s s i o n s ; t h e incidence of psychotomimetic and c a r d i o v a s c u l a r s i d e e f f e c t s w a s high. 807817 82 Freeman e t al.83 have described t h e r a p i d ( t h r e e days) o n s e t of thiazesim, n t e r two weeks' t r e a t m e n t with t h i s agent, 70% of t h e p a t i e n t s could be discharged. Unfortunately, t h e d i s char e r a t e w a s q u i t e comparable i n t h e placebo-treated group. The mipramine-like p r o p e r t i e s of I N 1060 i n animals and man In preliminary c l i n i c a l have been discussed i n S e c t i o n I - D . s t u d i e s , t h e drug e x e r t e d b e n e f i c i a l e f f e c t s i n a n e r g i c schizophrenics and a s m a l l number of depressed p a t i e n t s .84
.
f
22 -
Sect. I
-
CNS Agents
B i e l , Ed.
H. The Anticholinergic Antidepressants The clinical psychotomimetic and Rytidepressant properties A more recent study by of Ditran have been reviewed by Biel. Davis et a1.86 found this drug a "worthwhile, safe, and effective" antidepressant when tested in 78 patients over a period of two and one half years. Improvement became apparent after fi.ve to six treatments spaced two to three days apart. Tachyphylaxis to the psychotomimetic effects were quite pronounced in all patients. Prolonged remissions of illness appeared possible. Reactive, psychotic, and schizo-affective depressions responded best to Ditran, whereas schizophrenic and psychoneurotic depressions proved quite resistant to this type of therap In a well-controlled study by Fink et a1.87 the addition of an anticho1inergic-antiparkinsonism agent, procyclidine, to chlorpromazine produced an antidepressant effect comparable to imipramine . Centrally active anticholinergic agents, either alone or in combination with a tranquilizer, de$erve further evaluation as potential antidepressant drugs. Final Conclusions The principal developments in the field of antidepressant drugs during 1965 may be summed up as follows: 1. An increased understanding of the possible mechanisms of antidepressant drug action was gained through the study of their effects on central adrenergic and cholinergic neurotransmitters. 2. The availability of several drugs with differential types of useful antidepressant activity served to demonstrate that "mental depression'' is a "catch-allf7phrase which encompasses several disease syndromes of varying etiologies and requiring antidepressant drugs with either stimulant, tranquilizing, or antipsychotic properties. 3 . Some progress was made toward achieving a faster onset (two to four days) of action and a lessening of side effects with the desmethyl derivatives of active thymoleptics. 4. Advances in methodology of animal testing for antidepressant activity revealed definite qualitative differences between the antidepressant and tranquilizing agents. 5. On the basis of the mechanism of action of various effective antidepressant drugs, one could conceive of a biochemical etiology for mental depressive illness founded on the inability of the central nervous system to (a) elaborate sufficient amounts of neurotransmitter substance (possibly norepinephrine) (b) release adequate quantities of "active" neurotransmitters from cellular binding sites to the adrenergic synapses or (c) prevent a too rapid metabolic destruction of the critical neurotransmitter substance(s). 6. Clinical evaluation of antidepressant drugs still poses a major problem due to the complex nature of the disease, the hi h incidence of favorable placebo responses and spontaneous remiss ons.
f
Chap. 2
Stimulants
Biel
23 -
C e n t r a l Stimulants The c e n t r a l mechanism of a c t i o n of amphetamine s t i l l remains i n d i s p u t e . Since c e n t r a l catecholamine d e p l e t o r s ( r e s e r p i n e , a - W ) f a i l e d t o block amphetamine-induced motor s t i m u l a t i o n , f e l t t h a t amphetamine a c t s i r e c t l y on t h e CNS. s e v a r ~ 8 8 ~ ~ ~ $ o bO ~na t8h e~ ~ o t~ h e~r dhand, Stein8$ p o i n t s o u t t h a t amphetamine's f a c i l i t a t i n g e f f e c t on i n t r a c r a n i a l s e l f stimulation i n rats blocked by r e s e r p i n e and p o t e n t i a t e d by MA0 i n h i b i t o r s . Hence, he concluded t h a t t h e c e n t r a l stimulant e f f e c t s of amphetamine were mediated by catecholamine r e l e a s e . A novel mechanism h a s now been proposed by Weissman e t al.89a which is based on t h e experimental f i n d i n g t h a t t y r o s i n e T y c o x y l a s e i n h i b i t o r s ( e . g . , a-methyltyrosine) which block t h e biosynt h e s i s of dopamine and NE, a l s o i n h i b i t a l l t h e CNS e f f e c t s e x e r t e d by a m hetamine and amphetamine-like drugs (methamphetamine, Hence, t h e authors conclude t h a t t h e c e n t r a l phenmetrazine? responses induced by amphetamine r e q u i r e a ' ' c r i t i c a l l e v e l of NE a t t h e receptor" and " t h a t t h i s l e v e l d e r i v e s from a f u n c t i o n a l pool of norepinephrine i n t h e CNS h i g h l y s u s c e p t i b l e t o blockade of norepinephrine b i o s y n t h e s i s a t t h e t y r o s i n e hydroxylase s t e which is t h e r a t e - l i m i t i n g s t e p i n catecholamine b i o s y n t h e s i s . %b On t h e o t h e r hand, a-MMT which is a p o t e n t catecholamine-depleting agent, but does n o t i n t e r f e r e with NE b i o s y n t h e s i s , f a i l s t o antagonize t h e c e n t r a l e f f e c t s of amphetamine. I n essence, amphetamine may r e q u i r e t h e presence of f r e s h l y synthesized, r e a d i l y a v a i l a b l e NE t o produce i t s c h a r a c t e r i s t i c CNS e f f e c t s . C l i n i c a l s t u d i e s on a novel sympathomimetic ketone (F-1983) revealed t h a t t h i s substance was capable of i n c r e a s i n g d r i v e and spontaneous a c t h z i t y i n a group of c h r o n i c a l l y depressed and psychotic p a t i e n t s . 11.
=
.
CH3
yHC2H4CH3
("7
(XXXVI) F-1983 C e n t r a l s t i m u l a n t and a n t i t r e m o r i n e e f f e t s were d i s p l a y e d i n animals by a diphenylthiocarbamate (XXXVII). 81 A mild c e n t r a l stimulant (XXXVIII) was shown by Glasky and Simong2 romo t e ~ ~ ' t h e b i o s y n t h e s i s of RNA i n r a t b r a i n and by P l ~ t n i k o ~t o f a c i l i t a t e l e a r n i n g by i n c r e a s i n g memory and r e t e n t i o n of l e a r n e d behavior. This p r o p e r t y was n o t shared by o t h e r c e n t r a l s t i m u l a n t s . jd2NC OSC2H4NEt2
(XXXVII) (XXXVIII 1 (XXXIX) A s t r u c t u r a l l y s i m i l a r cgtpound (XXXIX) has been i n v e s t i g a t e d by G r e e n b l a t t and Osterberg. The pharmacologic spectrum of XXXIX l i e s between amphetamine and imipramine. The compound is
Sect. I
24 -
-
B i e l , Ed.
CNS Agents
a c e n t r a l e x c i t a n t with anorexigenic p r o p e r t i e s . The l a t t e r a r e more pronounced and longer l a s t i n g than those of amphetamine. Tolerance did n o t develop t o e i t h e r e f f e c t . The drug displayed only minimal cardiovascular e f f e c t s and w a s devoid of a n a l e p t i c p r o p e r t i e s . Like imipramine, it delayed t h e onset of r e s e r p i n e depression and i n h i b i t e d tetrabenazine depression. I t protected mice from maximum s e i z u r e s and prolonged b a r b i t u r a t e hypnosis. The Hallucinogens Most d r u s capable of p e n e t r a t i n g t h e CNS have s t r u c t u r a l r e l a t i v e s wh ch w i l l produce psychotomimetic e f f e c t s . T h i s a p p l i e s t o the a n a l g e t i c , antidepressant, a n t i c h o l i n e r g i c , a n e s t h e t i c , sympathomimetic, serotonergic and t r a n q u i l i z i n g drugs. It i l l u s t r a t e s perhaps more than anything e l s e the f i n e l i n e which we a r e s t r a d d l i n g between normal and pathologic emotional behavior and underscores t h e s e n s i t i v e chemical balance necessary f o r t h e maintenance of c e n t r a l homeostasis and presumably ttnormallt behavior. For back round materi reader is r e f e r r e d t o t h e following r e v ew a r t i c l e s . 9gy7 A m t comprehensive review on LSD has been published by Hoffer The s o c i a l and t h e r a p e u t i c fmplications conGQrning the use of LSD2 have been discussed by Cole an Savage and S t o l a r o f f , 200 and McGlothlin and S. Cohen. f 0 f a t z , S t r u c t u r e - a c t i v i t y r e l a t i o n s h i p s with regard t o the c e n t r a l stimulant and psychotomimetic p r o p e r t i e s of the basic g l y c o l a t e e s t e r have been presented by B i e l e t a1.102 and Abood and B i e l . 803 A . Analgetics Psychotomimetic p r o p e r t i e s have been reported f o r dexoxadrol Io4 and cyclazocine 05 i n man. In animals, both drugs were devoid of a n a l g e t i c a c t i v i t y but displayed morphine antagonism. I1I .
f
‘si
.!%;
.88
(XL) Dexoxadrol
( X L I ) Cyclazocine
Anesthetics A s an a n e s t h e t i c , phencyclidine (SernylTM) is q u i t e unique from t h e standpoint of high potency, lack of r e s p i r a t o r y and circulafBgy depresfhqn o r disturbance of c a r d i a c rhythm both i n animals . I t s ps chotomimetic p r o p e r t i e s have been and man reviewed by Davles and Beech. 15s The s i m i l a r i t y i n sympathomimetic p r o p e r t i e s phencyclidine, desoxyephedrine and cocaine prompted Chen e t al. t o speculate on a c e n t r a l adrenergic mechanism of a c t i o n , even though the i n s e r t i o n of a methylene group between t h e phenyl and cyclohexyl B.
188
Chap. 2
Stimulants
Biel
25 -
r i n g t o simulate a P-phenethylamine abolished a l l a c t i v i t y . A simple, s p e c i f i c and q u a n t i t a t i v e t e s t f o r t h e assessment of c a t a l e p t i c a c t i v i t y of phen l i d i n e - t y p e compounds i n pigeons The c a t a l e p t i c e f f e c t i s has been developed by Chen. a s c e r t a i n e d by t h e loss of r i g h t i n g r e f l e x without "head drop" over a wide range of dosage A s t r u c t u r e - a c t i v i t y s t u d y was conducted by Maddox e t a l . The most p o t e n t c a t a l e p t i c a g e n t s were those where R = H , ? i i e t h y l o r methoxy and N ( R , R ' ) was p i p e r i d i n o , p y r r o l i d i n o , 3-methylpiperidino, P-methoxyethylamino, methylamino o r ethylamino.
ErB
(XLII
Phenc c l i d i n e
(s e e +
(XLIII) Phencyclidine Derivat i v e s
Adrenergic Agents The proponents of an abnormal m i n e metabolism i n schizophrenic p a t i e n t s received f u r t h e r support f o r t h e i r s p e c u l a t i o n from t h e experimental f i n d i n g of Friedhoff and Van Winkle 11* t h a t 3,4-dimethoxyphenethylamine (DMPEA) was excreted i n t h e u r i n e of schizophrenic p a t i e n t s , but could never be i s o l a t e d t h e u r i n e of normal p a t i e n t s . Bourdillon e t &.I were a b l e t o demonstrate t h a t when t h e schizophrenic population was f u r t h e r subdivided, c e r t a i n groups showed high c o n c e n t r a t i o n s o f t h i s amine i n t h e u r i n e . For an up-to-date l i s t of r e f e r e n c e s on t h i s c o n t r o v e r s i a l s u b j e c t , t h e r e a d e r i s r e f e r r e d t o an E d i t o r i a l . 1 l 4 Friedhoff and Van Winkle115 f u r t h e r found t h a t l i v e r homogenates obtained from b i o p s i e s of schizophrenic p a t i e n t s were capable of 0-methylating both 'OH' groups of dopamine, whereas those obtained from normal s u b j e c t s were unable t o convert dopamine t o DMPEA. I n c a t s , DMPEA produced a c a t a t o n i c e f f e c t s i m i l a r t o t h a t of mescaline. 116,117 D . The C e n t r a l A n t i c h o l i n e r g i c s I t had p r e v i o u s l y been concluded by Bie1118 t h a t p o t e n t a n t i c h o l i n e r g i c a c t i v i t y w a s a p r i m a r y p r e - r e q u i s i t e f o r inducing psychotomimetic e f f e c t s both i n animals and man, but t h a t n o t every potent a n t i c h o l i n e r g i c d r need n e c e s s a r i l y be a psychotogenic agent. Giarman and PepeuBg r e p o r t e d t h a t r a t b r a i n l e v e l s o f a c e t y l c h o l i n e were reduced by t h e psychotomimetic g l y c o l a t e e s t e r s , but n o t by non-psychotogenic a n t i c h o l i n e r g i c s of s i m i l a r s t r u c t u r e . A s i n g l e i n j e c t i o n of 0.5 mg/kg of scopolamine t o r a t s which had been t r a i n e d f o r a s h o r t p e r i o d , produced an amnesic e f f e c t of learned performance which elated well with Both e f f e c t s t h e decrease i n t o t a l r a t b r a i n AcCh l e v e l s . were abolished by e s e r i n e and amphetamine. On t h e o t h e r hand, C.
€30"
€SF
26
Sect.
I
-
CNS Agents
Bi
e l , Ed.
overtrained r a t s experienced no amnesic e f f e c t s , even though b r a i n AcCh l e v e l s were decreased t o t h e same e x t e n t . The authors concluded t h a t only r e c e n t memory may be c h o l i n e r g i c a l l y mediated. I n adequate doses, scopolamine disrupted s e v e r e l y both the s i t i o n and r e t e n t i o n of passive avoidance response in r a t s . I n a r e c e n t paper by Deutsch e t a1.122 t h e i n j e c t i o n of t h e a n t i c h o l i n e s t e r a s e drug, diisopropyl fluorophosphate, i n t o t h e hippocampi of r a t s , 30 minutes a f t e r escape l e a r n i n g , produced a p a r t i a l amnesia l a s t i n g f o r f i v e days. C e n t r a l l y , scopolamine had t e n times t h e a c t i v i t y of a t r o p i n e , whereas i n t h periphery, t h e r a t i o was c l o s e r t o t w o t o one, r e s e c t i v e l y . The compound (Ro 3-1172) was reported by Parkes lq3t o have 50 times t h e CNS a c t i v i t y of a t r o p i n e .
88Yui-
123
3I
Id2C(OH)C02C2H,N
(XLIV) RO 3-1172 S h o r t - l a s t i n g psychotomimetic e f f e c t s (two hours) were induced i n humans by N-allylnoratropine ( 5 mg/man). I n the periphery compound only had 1/16 the autonomic a c t i v i t y o f a t r o p i n e . i2thiS The i n t e r a c t i o n between phenothiazine t r a n q u i l i z e r s i n small doses and the c e n t r a l a n t i c h o l i n e r g i c s , a t r o p i n e , scopolamine, and Ditran (JB-329) was studied by Gershon e t al.125 Chlorpromazine, a t a dose of 0.1 mg/kgtpotentiated t h e e f f e c t s of 0.05 mg/kg of Ditran producing a comatose-like s t a t e i n human s u b j e c t s . Imipramine d i d not p o t e n t i a t e t h e a c t i o n of Ditran. Hence, t h i s t e s t could be applied i n dogs t o d i f f e r e n t i a t e an a n t i d e p r e s s a n t from a t r a n q u i l i z i n g drug. Buehler et a l . l 2 6 synthesized a number of t h i o l analogs of basic g l v c o l a t e e s t e r s which were considerablv weaker a s psychotomimet i c agents than t h e corresponding- oxygen analogs.
= $, cycloalkyl Rl= CH3, C2H5 R
The influence of stereochemical f a c t o r s on a n t i c h o l i n e r g i c p i p e r i d y l g l y c o l a t e s have been psychotomimetic a c t i v i t y of so d i s c w s e d by Gabel and Abood. 137 Summary Present evidence suggests t h a t mental depression may be the cauee o r consequence of a breakdown i n c e n t r a l chemical homeos t a s i s , i . e . , an imbalance between two mutually a n t a g o n i s t i c c e n t r a l neurotransmitter systems, which may possibly be adrenerg i c - l i k e and cholitlergic-like In c h a r a c t e r . Chemical c o r r e c t i o n of t h i s imbalance through drug treatment has afforded a means of accornplisAing remissions i n acute, nonpsychotic depressions.
Chap. 2
Stimulants
27 -
Biel
References L. Klerman and J . 0. Cole, Pharmacol. Rev., lJ-, 101 (1965). L. E . H o l l i s t e r , C l i n . Pharmacol. Therap., 555 (1965). 3 . J. R . Markette and Y. H. H a r r i s , Dis. Nerv. S y s t . , 3.42 (1965). 4. D. M. G a l l a n t , M. P. Bishop, W. Nesselhof and T. E. Fulmer, Curr. Therap. R e s . , 6, 69 ( 1 9 6 4 ) . 5. H. B r i c k , W. H. Doub, and W. C . Perdue, I n t e r n . J. Neuropsychiat., 1,325 ( 1 9 6 5 ) . 6. A. M. Kasich, Cum. Therap. R e s . , 1,542 (1965). 7. B r i t i s h P a t e n t 1,003,686. 8. J. Knoll, Z. E c s e r i , K. Kelcnen, J . Nievel and B. K n o l l , Arch. i n t . Pharmacodyn., 154 (19651. 9. J. F i n k e l s t e i n , E. Chang and J. Lee, J. Med. Chem., 8. 432 (1965). 10. G. A. Youngdale, D. G. Anger, W. C. Anthony, J. P. DaVanzo, M. E. G r e i g , R . V. Heinzelman, H. H. Keasling and J. Szmuszkovicz, J . Med. Chem., 1,,415 (1964). 11. P. A. M. J a n s s e n , U. S. P a t e n t 3,161,637 (1964). 1 2 . The Upjohn Co., French P a t e n t 329lM. 573 (19621. 13. H. Azima, D . A r t h u r s , A. S i l v e r and F. J. Azima, Am. J. P s y c h i a t . , 2. 14. J . B. H e s t e r , M. E. Greig, W. C. Anthony, R . V. Heinzelman and J. Szmuszkovicz, J. Med. Chern., 1, 274 ( 1 9 6 4 ) . 456 (1964). 15. L. I. Goldberg, J. Am. Med. Assoc., 15a. J. M. C u t h i l l , A. B. G r i f f i t h s and D. E. B. Powell, L a n c e t , L. 1076 ( 1 9 6 4 ) . 763 ( 1 9 6 4 ) . 15b. Council on Drugs, J. Am. Med. Assoc., 945 , (1965). 1 5 ~ . E d i t o r i a l , L a n c e t , I16. D. M. Tedeschi and E. J. Fel-lows, S c i e n c e , %, 1225 ( 1 9 6 4 ) . 456 (1964). 17 * L. I . Goldberg, J. Am. Med. Assoc., 18. J. H. B i e l , J. S p o e r l and E. S p r e n g e l e r , B r i t i s h P a t e n t 961,313 ( 1 9 6 4 ) . 19- C. L. Z i r k l e and C. K a i s e r , i n Psychopharmacological Agents, Vol. I , e d . M. Gordon, Academic Press, New York-London, 1964, 445. 20. A . H o r i t a , I n t . J. Neuropharmacol.,.lC, 337 (1965). G. M. E v e r e t t , Second Catecholamine Symposium, Milan, I t a l y , J u l y , 1965, p u b l i s h e d i n 21. (1966). Pharm. Revs., 22. J. A. R i d e r , H. C. Moeller and E . A. DeFelice. T o x i c o l . & Appl. Pharmacol., 1,438 ( 1 9 6 5 ) . 22a. H. Freeman, I . Karacan, W . E. Waterman, A. U. Khan, F. L. Zimmer, A . F e l d s t e i n , C . 0. Tedeschi and E. A. DeFelice. I n t e r n . J. N e u r o p s y c h i a t r y , 1 c5], 513 (19651. J. J. S c h i l d k r a u t , Am. J. P s y c h i a t . . 112, 509 (1965). 23. 856 (1963). 24. S. S p e c t o r , N . Y. Acad. S c i . , 25. C . G. I n g v a r s s o n , A r z n e i m i t t e l F o r s c h . , 3,849 (1965). 86 (1965). 26. S. S p e c t o r , A . Sjoerdsma and S. Udenfriend, J . Pharmacol. E x p t l . Therap.. A. Sjoerdsma, Pharm. Revs., 673 ( 1 9 6 6 ) . 27. '28. A. F e l d s t e i n , H. IIoagland. M. R. Oktem and H. Freeman, I n t . J. N e u r o p s y c h i a t . , L, 384 ( 1 9 6 5 ) . 29 * A. F e l d s t e i n and H. Freeman, C l i n . Pharmacol. T h e r a p . , 6 , 470 (19651. A. P l e t s c h e r , Pharm. Revs., 1 2 1 (1966). 30. 31. R . M. Atkinson and K. S. Ditman, C l i n . Pharmacol. Therap.. 6. 631 (1965). 32. I . J . Kopin, J. E . F i s c h e r , J. M. Musacchio, W. D. Horst and V. K. Weise, J . Pharmacol. E x p t l . Therap., 186 (1965). 33. L. I. Goldberg, J. Am. Med. Assoc., E, 456 (1964). 448 (1964). 34. J . 0. Cole, J . Am. Med. Assoc., 35. G. L. Klerman and J. 0. Cole, Pharmacol. Rev., Q, 101 (1965). 36. L. E. H o l l i s t e r , C l i n . Pharmacol. Therap., 6. 555 (1965). 37 * N. K l i n e , J. Am. Med. Assoc.. E,732 (1964). 38. J. J. S c h i l d k r a n t , Am. J. P s y c h i a t . . 112, 509 (1965). A. P l e t s c h e r . K. F. Gey and P. Z e l l e r , Progr. Drug R e s . , 2, 417 (1960) I I n t e r s c i e n c e ] . 39. J. H. B i e l , A. H o r i t a and A. E. Drukker, i n Psychopharmacological Agents, Vol. I , e d . M. Gordon, 40. Academic P r e s s , New York-London. 1964, 359. 41. C. L. Z i r k l e and C. K a i s e r , i n Psychopharmacological Agents, Vol. I , ed. M. Gordon, Academic P r e s s , New York-London, 1964, 445. 42. R . Kuhn, Schweiz. Med. Wochsch., Q, 1135 (1957). 43. F. H P f l i g e r and V. Burckhardt, i n Psychopharmacological Agents, Vol. I , ed. M. Gordon, Academic P r e s s , New York-London, 1964, 35. 1. 2.
G.
6,
a,
=,
.
a,
s,
2
m,
9.
9,
m,
z,
m,
Sect. I
28 -
-
CNS Agents
B i e l , Ed.
48a. 49. 50 * 51. 52: 53. 54. 55.
E. B. Sigg, Can. Psychiat. Assoc. J., 4. Spec. Suppl.. 7 5 (1959). A. Kaumann. N. Basso and P. Armendia, J. Pharmacol. Exptl. Therap., 54 (1965). R. C. Ursillo and J. Jacobsen, J. Pharmacol. Exptl. Therap.. 247 (1965). A. Jori and S. Garattini, J. Pharm. Pharmacol., lJ, 480 (1565). W. Theobald, 0. &ch, H. A. Kunz, C. Morpurgo, E. G. Stenger and G. Wilhelml, Arch. int. Pharmacodyn., 560 (1964). J. Axelrod. G. Hertting and L. Potter, Nature, Lond.. 297 (1962). J. Glowinski and J. Axelrod, Nature, 1318 (1964). L. L. Iversen, J. Pharm. Pharmacol., 3, 62 (1965). H. Thoener:, A. Huerlimann and W. Haefely, J. Pharmacol. Exptl. Therap., %, 405 ( 1 9 6 4 ) . W. Haefely, A . Huerlimann and H. Thoenen, Helv. Physiol. Acta, 22, 15 (1964). F. Sulser and F. Soroko. Psychopharmacologia, 8. 191 (1965). F. Sulser, M. H. Bickel and B. B. Brodie, J. Pharmacol. Exptl. Therap., 144, 321 (1964). J. H. Biel. P. A. Nuhfer, W. H. Haya and H. A . Leiser, Ann. N. Y. Acad. Sci., $, 251
5657 * 58 * 59. 60. 61.
F. Sulser, M. H. Bickel and B. B. Brodie, J. Pharmacol. Exptl. Therap., 321 (1964). A. Ribbentrop and W. Schaumann, Arzneimittel-Forsch., 3, 863 (1965). A. Ribbentrop and W. Schaumann, Arzneimittel-Forsch., B,863 (1965). A. M. Monro. R. M. Quinton and T. I. Wrigley, J. Med. Chem., 6, 255 (1963). N. J. Giarman and G. Pepeu, Brit. J. Pharmacol., 9, 123 (1964). Z. P. Horovitz. A. R. Furgiuele, L. J. Brannick, 3. C. Burke and B. N. Craver, Nature,
44. 45. 46. 47 * 48.
62. 62a. 63. 64. 6566. 67. 68. 69 * 70.
-
71.
72 73. 74. 75.
76. 77. 78 * 79. 80. 81. 82. 83.
84. 85. 86. 87 88. 88a. 88b. 88c. 886. 8989a. 89b.
-
148.
B,
a,
N,
z,
(1962).
w,
200, 369 (19631. p.1. S. Mapp. R. Dykyj, C. K. Gorby and J. H. Nodlne, Pharmacologist, 5,
234 (1963). I. W. Sletten, X. Pichardo and S. Gershon, Curr. Therap. Res.. 1. 609 (1965). R. Kuhn. Psychopharmaeologia. 8, 201 (1965). A. Ribbentrop and W. Schaumann, Arzneimittel-Forsch., 863 (1965). J. 0. Cole, J. Am. Med. Assoc.. 448 (1964). J. E. Overall, L. E. Hollister. F. Meyer. I. Kimbell, Jr. and J. Shelton, J. Am. Med. Assoc., 605 (1964). G. L. Klerman and J. 0. Cole, Pharmacol. Rev., lJ-, 101 (1965). L. E. Hollister. Clin. Pharmacol. Therap., 6 . 555 (1965). H. Wechsler. G. H. Grosser and M. Greenblatt, J. Nerv. Ment. Dis., 141,231 (1965). N. Kline, J. Am. Med. Assoc., 732 (1964). F. J. Ayd. Dis. Nerv. Syst., 26. 719 (1965). V. #. Pennington, Am. J . Psychiat.. 120. 115 (1964). T. E. Hanlon. J . New Drugs, k, 52 (1964). E. Incas Smith, J. National Med. Assoc., 284 (1965).
x,
u.
m,
*,
z,
J. H. Nodine, P. E. Siegler. T. Bodi. Y. Mapp and R. Dykyj, Am. J. Med. Sci.,
a,
443 (1965). D. M. Gallant, M. P. Bishop, W. Nesselhof and T. E. Fulmer. Curr. Therap. Res., 6 . 69 (196%). J. R. Markette and Y. H. Harris, Dis. Nerv. Syst., 42 (1964). A. M. Kasich. Curr. Therap. Res., 2 , 542 (1965). E. DePerrot, Psychiat. Neurol., 146,341 (1963b.
a,
D. Bente, M. P. Engelmeier, K. Heinrich, H. Hippius and W. Schmitt. Arzneimlttel-Forsch.,
14,538
(1964). J. Angst acd H. Kind, Schweiz. Med. Wochschr., 2, 759 (1964). 0. H. Arnold, H. Bauer and K. Cmyral. Arzneimittel-Forsch.. 14. 510 (1964). H. Freeman, M. R . Otkem, M. W. Kristofferson and C. K. Gorby, Curr. Therap. R e s . , 1, 655 (1965) * I. W. Sletten, X. Pichardo and S. Gershon, Cum. Therap. Res., 1, 609 (1965). J. H. Biel, in Advances in Chemistry Series, No. 45, ed. F. W. Schueler, American Chemcal Society, Baston, Pa., 1964, 114. H. K. Davis, H. F. Ford, J. P. Tupin and!A; Colvin, Dis. Nerv. Syst., 179 (1964). M. Fink, D. F. Klein and J. C. Kramer, Psychopharmacologia, 5, 27 (1964). H. Brick, W. H. Doub. and W. C. Perdue, Intern. J. Neuropsychiat., 1,325 (1965). A. M. Kasich. Cum. Therap. Res., 1, 542 (1965). J. M. VanRossum. J. B. VanDerSchoot and J. A. Th. M. Hurkmans, Experientia, 18,229 (1962). A . Randrup, I. Munkvad and P. Udsen. Acta Pharm. Tox., 20, 145 (1963). R. M. Quinton and G. Halliwell, Nature, 200, 178 (1963). L. Stein. Fed. Proc.. 836 (1964). A. Weissman, B. K. Koe and S. S. Tenen, J. Pharmacol. Exptl. Therap. s,339 (1966). M. Levit, S. Spector, A. Sjoerdsma and S. Udenfriend, J. Pharmacol. Exptl. Therap., 148, 1 (1965).
a,
a,
Chap. 2 90. 91. 9293. 9&. 95. 96 * 97. 98 * 99.
100. 101. 102.
B iel
Stimulants
a. z,
H. Heimann and K. Vetter, Schweiz. Med. Wochschr., 306 (1965). W. Wirth and R. Gosswald, Arch. int. Pharmacodyn.. 393 (1965). A. J. Glasky and L. N. Simon, Science, 702 (1966). N. Plotnikoff. Science, 703 (1966). E. N. Greenblatt and A. C. Osterberg. Toxicol. Appl. Pharmacol., 1, 566 (1965). Symposium on "Some Biological Aspects of Schizophrenic Behavior.'' ed. D. V. Siva Sankar, Art. 1, 1962, 1. Ann. N. Y. Acad. Sci., 3. F. Downing, Quart. Rev., X V I , 133 (1962). D. F. Downing, in Psychopharmacological Agents, Vol. I. ed. W. Gordon, Academic Press, New York-London. 1964. 555. A. Hoffer, Clin. Pharmacol. Therap., 6 , 183 (1965). 3. 0. Cole and M. M. Katz. J. Am. Mad. Assoc., 8 lJ , 758 (1964). C. Savage and M. J. Stolaroff. J. Nerv. Ment. D i s . , 140, 218 (1965). W. H. McGlothlin and S. Cohen. Am. J. Pkychiat.. 572 (1956). J. H. Biel. P. A. Nuhfer, W. K. Hoya and H. A. Leiser, Ann. N. Y. Acad. Sci., &,
z,
s,
s,
x,
251 (1962).
L. 0. Abood and 3. H. Biel, Intern. Rev. Neurobiol., 4. 217 (1962). 104. L. Lasagna and J. W. Pearson, Proc. SOC. Bxptl. Biol. Med., 118,352 (1965). 105. L. Lasagna, Pharmacol. Rev., 16,47 (1964). 106. G. Chen, Fed. Proc., lJ, 358 (1958). 107. F. E. Greifenstein, M. DeVault. J. Yoshitake and J. E. Gajewski, Anesthesiz Analgesia, Current Res., 283 (1958). 108. B. M. Davies and H. R. Beech, J. Ment. Sci., 912 (1960). 1353 (1965). log. G. Chen, C. R. Ensor and B. Bohner, J. Pharmacol. Exptl. Therap., 110. G. Chen, Arch. int. Pharmacodyn., 193 (1965). 111. V. H. Maddox, E. F. Oodefroi and R. F. Parcell. J. Med. Chem., 8_, 230 (1965). li2. A. J. Friedhoff and E. Vanwinkle. Nature, 897 (1962). 113. R. E. Bourdillon, C. A. Clarke, A. P. Ridges, P. M. Sheppard, P. Harper and S. A. Leslie, Nature, @. 453 (1965). 114. Editorial, Brit. Med. J., 1966, I, 119. 115. A. J. Friedhoff and E. Vanwinkle, Nature, 1pe. 1271 (19631. 178 (1962). 116. A. M. Ernest, Nature, 117. R. Michaux and W. 0 . Verly, Life Sci., 1, 175 (1963). 118. J. H. Biel. in "Advances in Chemistry Series," No. 45, ed. F. W. Schueler. American Chemical Society, Easton, Pa., 1964, 129. 119. N. J. Giarman and G. Pepeu, Brit. J. Pharmacol., 2.123 (1964). 120. A. Pazzagli and G. Pepeu, Int. J. Neuropharmacol., k, 291 (1964). 121. B. Meyers. Psychopharmacologia. g. 111 (1965). 122. J. A. Deutsch. M. D. Hamburg and H. Dahl, Science, 2 2 1 (1966). 123. K. W. Parkes, Psychopharmacologia. 1, 1 (1965). 12&. L. F. Soyka and K. R. Unna. Psychopharmacologia. 6 , 453 (1964). 125. S. Gershon, H. Neubauer and D. M. Sundland, Clin. Pharmacol. Therap., 6, 749 (1965). 126. C. A. Buehler. S. F. Thames, L. G. Abood and J. H. Biel, J. Med. Chem., g, 643 (1965). 127. N. W. Gabel and L. G. Abood, J. Med. Chem., 8. 616 (1965). 103.
x,
106.
x,
m,
m.
x,
z,
30 -
Sect. I Chapter 3 .
-
CNS Agents
B i e l , Ed.
Sedatives, Hypnotics, Anticonvulsants, Muscle Relaxants, Gene r a1 Anesthetics
Cornelius K. Cain, McNeil Laboratories, Inc., F o r t Washington, P a .
-
The classification of a given drug according to the pharmacoIntroduction logical actions listed i n the title (plus tranquilizers discussed in Chapter 1) is recognized as a r b i t r a r y and dependent upon dosage being used. The following discussion is divided m o r e on the basis of established o r projected clinical utility than on the basis of widely different pharmacological proper ties o r chemical s t r u c t u r e .
1 Some y e a r s ago, Chen and P o r t m a n undertook a quantitative approach to the problem. They determined the C D 5 0 1 of ~ a convulsant in mice p r e treated with graded doses of a depressant. Plotting these values gave a graph showing two points of inflection, and t h r e e corresponding straight lines were constructed. The slopes of these lines were interpreted a s r e p resenting the sedative, hypnotic and anesthetic potencies of the depressant. The i n t e r s e c t s represented minimal hypnotic and anesthetic doses. The authors concluded that this approach was useful in indicating that a given d e p r e s s a n t drug might be m o r e useful as a hypnotic, an anesthetic o r as a sedative.
;"8
Sedatives and Hypnotics - Several a r t i c l e s d e s c r i b e the favorable r e s u l t s obtained with nitrazepam, Mogadona, RO 4-5360 (I). The pharmacology was thoroug y investigated by Randall and coThey postulate that the sleepworkers inducing effect is due not to a d i r e c t effect on the a r o u s a l system, but to a reduction of stimuli acting on it. Metabolic studies O2 showed the unchanged drug as well a s i t s 7-amino and 7-acetylamino derivative in human plasma and urine. \ I 3 Clinical studies by Wyss and Mgder in 200 patients gave good r e s u l t s in onset and duration of sleep a t doses of 5 to 10 mg. At higher doses (up to 200 mg.), tolerance was excellent. They state h a t the mechanism of action differs f r o m known hypnotics. Lanoir, Dolce and Chirinos4 found that in a battery of neurophysiological t e s t s in cats, nitrazepam and diazepam showed the s a m e type of activity in many respects, such as action on spontaneous rhythm, evoked responses, etc. Both are potent anti-convulsants. The m a j o r difference is that nitrazepam induces a lasting and profound slee while diazepam a c t s essentially as a relaxant and not as a hypnotic. Borck
7
9.
!?
Chap. 3
Depressants
Gain
31 -
reported that the drug in doses of 5 to 15 mg. was a highly suitable hypnotic in psychiatric patients. E g e r t and Jahn6 found it gave v e r y good to good results in 75% of a wide variety of clinical c a s e s . P a r t i c u l a r l y noteworthy were i t s new type of mechanism of action when compared with b a r biturates, i t s low toxicity and i t s u s e l e s s n e s s f o r suicidal pur o s e s . In 40 children ranging in age f r o m a few days to 11 y e a r s , Matthes 7p induced daytime sleep in 50% of the c a s e s . B e s t results were obtained in infants up to 12 months of age. About 10 y e a r s ago, the hypnotic, anticonvulsant and sedative p r o p e r ties of a s e r i e s of 2-alkyl-3-aryl-4(3H)quinazoloneswere reported by Gujral and co-workers 8~ 9 and confirmed by B o i s s i e r . l 0 Recently, a s e r i e s of 79 compounds of this type was examined by Leszkovszky, Erdely and Tardos" who reported that compound I1 showed the highest o r a l activity. Swift, Dickens and Becker12 published a thorough pharmacological study of this compound in 1960. Clinical studies were published by s e v e r a l investigators 13, 14J15J16,17 who 0 compared methaqualone to glutethimide, chloral hydrate and cyclobarbital. A r e cent l e t t e r to the editor cites four I1 patients who consumed l a r g e amounts of the drug daily f o r extended periods, raising the question of physical dependence. In 1965, compound 11 was marketed a s a hypnotic and sedative in the f o r m of 150 m g . tablets as methaqualone (Quaaludem).
qJ$
Fenimide i s the non-proprietary name recently adopted19 for 3-ethyl-
2-methyl-2-phenylsuccinimide(111) which was described by Chen and BassZO
a s a sedative agent comparable to m e p r o bamate and phenobarbital. It protects against s t r e s s -induced u l c e r s while m e p r o bamate and phenobarbital do not.
Q$ . . f . 2Hc3Hc 111
At the same time, the non-proprietary name trimetozine was adopted for 4-(3, 4, 5-trimethoxybenzoyl)morpholine. This compound (IV) was r e o r t ed e a r l i e r by Vargha and co-workers 8 , 2 2
d3
as being selected f r o m a l a r g e s e r i e s of alkoxybenzamides f o r clinical t r i a l as a neurosedative in Hungary. Of particular 6 7 - C OCH3 i n t e r e s t in their p a p e r s is the r e p o r t of OCH3 the marked influence on pharmacological activity of changes in position and/ o r IV nature of the afkoxy groups. B o i s s i e r and c o - w o r l ~ e r sstated ~ ~ that tests in animals show the compound to be a sedative but not a hypnotic even a t toxic doses.
r
/ \
32
Sect. I - CNS Agents
B i e l , Ed.
Metabolic studies of the optical antipodes of glutethimide (V) (Doriden@)by Keberle, Riess and HoffmannZ3 a r e of especial interest since the authors showed stereospecific metabolism in dogs. The dextrorotatory form of V was hydroxylated in the ring to give mainly V I (isolated a s the glucuronide) and VII, resulting from dehydration. The levorotatory f o r m of V was hydroxylated in the ethyl group to give mainly VIII (isolated a s the glucuronide) and IX, resulting from l o s s of acetaldehyde. Total r e covery of these products was 96% of theory. No products resulting f r o m ring opening were detected. CH2CH3
p CH2CH3 I
k
v
VIII
IX
The sedative and hypnotic properties of thalidomide have been almost forgotten in view of i t s reported embryotoxic effects. Recent metabolic studies of thalidomide in abbits, r a t s , mice and guinea pigs by SchuL macher, Smith and Williams 2 4 showed that up to 12 hydrolysis products appear in the urine. These products a r e the same a s those obtained from thalidomide in aqueous solutions a t pH values above 6, 25 and can be accounted for by initial hydrolysis of the phthalimide ring followed by hydrolys i s of the glutarimide ring. E a r l i e r , the same group of investigatorsz6 had studied the relationship of embryotoxic activity and chemical structure in a s e r i e s of compounds related to thalidomide and had concluded that a phthalimide group was important in determining teratogenic activity; and, in a recent article, 27 suggest that the reactivity of the drug towards certain natural diamines such a s spermidine, putresciae, etc., may be of significance in relation to its biological properties. Anti-convulsants - A s in previous years, many compounds were tested and reported to be active a s anti-convulsants during 1965. No new drugs for this use were marketed in the United States, and none marketed in other countries appear to offer considerable advantages over those in general use. A recent review by Millichap28 discusses clinical and EEG indications, efficacy and toxicity of some 2 0 drugs in current use in this field.
Chap. 3
Depressants
Gain
33 -
Central Muscle Relaxants - No new drugs in this field were introduced in the domestic market during 1965. Several reports were published of clinical t r i a l s of various compounds in severe spastic conditions. Bhargava and S r i ~ a s t a v astudied ~~ the anti-tetanus activity in cats of central muscle relaxants and found 3210220, 3-(q-chloropheny1)-3-hydroxy-2,2-dichloropropyl carbamate (X) to be the most potent and longest-acting of 11 compounds tested. Hendrickse and Sherman30 found CHOHCCSLCHZOCONHZdiazepam (Valium@)an effective muscle relaxant in children suffering from X tetanus, although it was not very effective in controlling convulsive spasms. Marsh31 obtained excellent results in 10 of 26 severely cerebralpalsied children using o r a l doses of diazepam in a controlled study, confirming e a r l i e r reports of effectiveness in adults similarly affected. Encouraged by the results of Berman, Noe and Goodfield3’ using chlorzoxazone in cerebral-palsied patients abandoned to supportive care, Darienzo 33 used a combination of chlorzoxazone and acetaminophen and obtained a change from severe to mild symptoms in 12 of 15 children.
A metabolic study of chlormezanone (Trancopala) in rat, dog and man by McChesney and co-workers34 showed that the compound was excreted as such. A review of benzazoles; chemistry, pharmacology and clinical application a ~ p e a r e d ?SKF ~ 13,436, 3 -amino5-trifluoromethyl- 1H -indazole (XI) was reported by Santella and c o - ~ o r k e r to s~~ be a muscle relaxant in r a t s , cats, dogs, F3C&NH2 rabbits and monkeys.
XI Anesthetics (a) - D a t a from thousands of patients were examined for possible relation between post-operative liver damage and anesthesia. Herber and S p e ~ k reviewed t ~ ~ findings in about 20,000 cases and estimated that one case of hepatic necrosis may be expected in about 800 halothane anesthetics. They suggest that careful selection of patients should minimize liver necrosis in the continued use of this valuable anesthetic. Gingrich and Virtue38 reviewed records of nearly 3800 cases using fluorinated hydrocarbons and over 20,000 cases using other inhalation agents a s well a s 48, 000 non-surgical patients. They doubt that either halogenated hydrocarbons o r other anesthetic agents p e r s e have been of significance in the production of hepatic necrosis.
Sect. I
34 -
-
CNS Agents
B i e l , Ed.
OH3 g
(b) Injection Anesthetics
XI1
XI11
-
McCarthy, Chen, Kaump and E n ~ o studied r ~ ~ the general anesthetic and o t h e r pharmacological p r o p e r t i e s of CI 581 (XI), an analog of phencyclidine (Se rnyl@) (XIII) in eight species of animals and concluded that XI1 showed a l e s s e r d e g r e e of CNS XIII. stimulation However, and of Domino, b r i e f e r Chodoff durationand than Corssen40 found that in humans, XIII, like XI, was hallucinatory and that skeletal muscle tone was increased. They sugg e s t the t e r m "dissociative anesthetic" for this c l a s s of agents.
s ~ ~by G. The earlier r e p o r t s by H. Laborit and c o - ~ o r k e r and Laborit and co-workers4' on the clinical u s e of sodium y -hydroxybutyrate f o r sedation, hypnosis and general anesthesia stimulated s e v e r a l other authors to investi4gte the pharmacology of this compound. 43s44,45 B e s s m a n and Skolnick found that the d e p r e s s a n t action paralleled the concentration in brain of the lactone and not of the anion. Recently, Winters and S p ~ o n e suggest r ~ ~ that a r e - a p p r a i s a l of the clinical usefulness of this drug m a y be in o r d e r , based on the epileptiform EEG patterns and grand ma1 s e i z u r e s in cats after intraperitoneal administration of 0,7 to 1.0 g/kg. Propanidid (XIV) and a few other substituted phenoxyacetamides have been investigated f u r t h e r as very short-acting intravenous anesthetics. Gunner and ~ o - w o r k e r sfound ~ ~ propanidid useful in electroconvulsive therapy in 70 patients. They found the OCHZCON(CzH5)z duration of unconsciousness averaged four minutes a t a dose of 5 mg/Kg. and s i x minutes a t a dose of 7 mg/Kg. They a s c r i b e the brevity of action to hydrolysis of the e s t e r group by e s t e r a s e s . E i s t e r e r and c o - ~ o r k e r found s ~ ~ the drug CH2C OOC 3H very suitable in 96 ambulatory patients r e XIV quiring anesthesia of up to five minutes' duration. Hewitt, Hamilton, O'Donnell and Dundee50 reported that, while propanidid showed a slightly higher incidence of venous thrombosis than thiopentone o r methohexitone, the incidence was not enough to influence clini cal acceptability
6"'". .
Adjuncts to Anesthesia (a) - Lunsford and coworkers5l synthesized a s e r i e s of substituted pyrrolidinones (XV) and
Chap. 3
Depressants
Cain
35 -
studied their pharmacological properties. Some were stimulants of r e s p i ration and the CNS, and m o s t of these showed p r e s s o r activity; o t h e r s were depressants. One of the stimulants (XVI) was selected f o r f u r t h e r study.
xv
R = alkyl, cycloalkyl, benzyl B = basic residue
o & c H 2 cR H2B
XVI B R = morpholino ethyl
Dopram@Doxepram
52 E v e r s , Malik and Dobkin found doxepram to be a s effective a s d-amphetamine in shortening the recovery time in dogs given a standardized dose of thiopental; no untoward effects were observed. They a l s o used the drugs a s an intravenous infusion in 50 healthy female patients and found it effective for stimulating respiration (both tidal volume and r e s p i ration r a t e ) without producing any appreciable circulatory changes.
53
Mauro and co-workers studied 52 patients to whom doxepram was given and 23 controls; all were anesthetized with thiopental. A few seconds after a single injection of 0 . 3 mg/Kg. of doxepram, t h e r e was a marked i n c r e a s e in tidal volume to levels approaching control values. Noe, Borrillo and G r e i f e n ~ t e i n injected ~~ 0. 5 mg/Kg. doses into 20 patients anesthetized with (1) pentobarbital-pentothal, (2) nitrous oxideoxygen o r ( 3 ) halothane -nitrous oxide and found r e s p i r a t o r y stimulation with m o r e o r l e s s arousal in a l l t h r e e groups. Brief E E G changes were observed in five subjects and m o s t c a s e s showed moderate hypertension; otherwise, there were no side effects. (b) - Combinations of neuroleptic agents and narcotic analgesics have been widely used in surgical procedures with o r without inhalation o r injection anesthetics. Such combinations a r e r e f e r r e d to a s neuroleptanalgesics and a r e usually considered a s adjuncts to anesthesia. Proceedings of a Symposium held a t Edinburgh were published. 6 8 During 1965, some 20 to 30 a r t i c l e s appeared concerning clinical studies with Innova@, a combination of the neuroleptic droperidol (XVII) and the analgesic fentanyl (XVIII). Contributions by the m o s t active workers
0
XVII
XVIII
36
Sect. I
-
CNS Agents
B i e l , Ed.
in the field a r e : Israel, Jansen and Dobkin;” Corssen, Chodoff, Domino and Kahn;56 DeCastro, Mundeleer and B a ~ d u i n :Gorodetzky ~~ and Martin; 58 Aubry, Denis, Keeri-Szanto and Parent;59 and Gemperle and Buhler. 60 Pharmacological studies using the combination of the two drugs were reported by Dobkin and co-workers;61, 62 Chodoff and D o m i n 0 ; 6 ~and Canellas, Roquebert and Courtois. 64 A combination of the two d r u s was marketed during 1965 as Innova@-Vet. Yelnosky and Fieldg5 investigated i t s u s e i n s i x species of animals and found it m o s t useful in dogs. Franklin and Reid66 obtained good to excellent r e s u l t s in 564 out of 601 surgical procedures usin various b r e e d s of dogs. Mortelmans, Marsboom and Vercruyssee’ reported highly successful r e s u l t s in 174 t r i a l s using p r i m a t e s and lower monkeys.
Chap. 3
D e p r e s s a n ts
Cain
37 -
References (1) G. Chen and R. P o r t m a n , A.M.A. A r c h . Neurol. P s y c h i a t . 68, 498 (1952). L. 0. Randall, W. Schallek, C. Scheckel, R. E. Bagdon and J. (2) Rieder, Schweiz. Med. Wochschr. 95, 334 (1965). S. W w .zy -ie Med. Wochschr. 2, 338 (1965). (3) J. Lanoir, G. Dolce and E. Chirinos, Compt. Rend. SOC.Biol. (4) 431 (1965). W . F. Borck, A r z n e i m i t t e l - F o r s c h . 1155 (1965). (5) (6) H. E g e r t and 0. Jahn, A r z n e i m i t t e l - F o r s c h . l5, 1159 (1965). (7) A. Matthes, A r z n e i m i t t e l - F o r s c h . l5, 1157 (1965). (8) M. L. Gujral, P . N . Saxena and R. S. Tiwari, Indian J. Med. R e s e a r c h 43, 637 (1955), Chem. A b s t r . E, 6662b (1956). (9) M. L. Gujral, K. N. S a r e e n and R. P. Kohle, Indian J. Med. 51 15787h (1957). R e s e a r c h 45, 20? (1957), C h e m . A b s t r . -’ (10) J. R. B c i s s i e r , T h e r a p i e 2, 30 (1958). (11) C. Leszkovszky, I. E r d e l y and L. T a r d o s , A c t a P h y s i o l . Acad. Sci. Hung. 27, 81 (1965), Chem. A b s t r . 62, 16782g (1965). (12) J. G. Swift, E. A. Dickens and B. A. B e c k e r , A r c h . I n t e r n . 112 (1960). Pharmacodyn. (13) A. Ravina, P r e s s e Med. 3, 891 (1959). (14) R. Neubauer, Med. T i m e s s , 61 (1963). (15) N. Asbell, J. Am. G e r i a t . SOC. lo, 1032 (1962). (16) V , Matthews, H. E. Lehmann and T . A. Bau, Appl. T h e r . 6, 806 (1964). (17) T. W . P a r s o n s and T . J. Thomson, B r i t . Med. J. L, 171 (1961). (18) J. S. Madden, B r i t . Med. J. 1 , 676 (1966). 208 (1966). (19) J. Am. Med. A s s o c . *, (20) G. Chen and P. B a s s , A r c h . I n t e r n . P h a r m a c o d y n . E , 115 (1964). (21) L. Vargha, E . K a s z t r e i n e r , J. B o r s y , L. F a r k a s , J. Kuszmann and B . Dumbovich, Biochem. P h a r m a c o l . g, 639 (1962). (22) E. K a s z t r e i n e r , J. B o r s y and L. Vargha, Biochem. P h a r m a c o l . 651 (1962). (23) H. K e b e r l e , W . R i e s s and K. Hoffmann, A r c h . I n t e r n . P h a r m a c o d y n . 142, 117 (1963). (24) H. Schumacher, R. L. Smith and R. T. W i l l i a m s , B r i t . J. P h a r m a c o l . 25, 338 (1965). (25) H. Schurnacher, R. L. S m i t h and R. T . W i l l i a m s , B r i t . J. P h a r m a c o l . 25, 324 (1965). (26) S. F a b r o , H. Schumacher, R. L. Smith and R. T. W i l l i a m s , Life Sci. 2, 987 (1964). 1208 (1965). (27) S. F a b r o , R. L. Smith and R. T . W i l l i a m s , N a t u r e (28) J. G. Millichap, P o s t g r a d . Med. 37, 22 (1965).
m,
2,
z,
z,
-
m,
38 -
Sect. I
- CNS Agents
B i e l , Ed.
References
P
g,
(29) K . P. B h a r g a v a and R. K. S r i v a s t a v a , B r i t . J. P h a r m a c o l . 74 (1965). (30) R. G. H e n d r i c k s e and P. M. S h e r m a n , Lancet 1965, p. 737. (31) H. 0. M a r s h , J. Am. Med. A s s o c . &, 797 (1965). (32) H. H. B e r m a n , 0. Noe and F. Goodfield, D i s e a s e s Nervous S y s t e m 2!5, 430 (1964). (33) C. Darienzo, D i s e a s e s Nervous S y s t e m 27, 189 (1965). (34) E. W. McChesney, W . F. Banks, J r . , G. A. P o r t m a n a n d A . V . R . Grain, F e d e r a t i o n P r o c . (2), 418 (1966). (35) C. K . C a i n and A. P. Roszkowski in”Psychopharmacologica1 Agents:‘ Vol. I, M. Gordon, E d . , A c a d e m i c Press, New York, N. Y. 1964, Chap. 10. (36) P. J. Santella, D. H. Tedeschi, J. J. Lafferty, C. L. Z i r k l e and E . J. Fellows, P h a r m a c o l o g i s t ‘7, 164 (1965). 266 (1965). (37) R. H e r b e r and N. W. Specht, A r c h . I n t e r n a l Med. (38) T . F. Gingrich and R. W. Virtue, S u r g e r y = , 241 (1965). (39) D. W . McCarthy, G. Chen, D. H. K a u m p a n d C. E n s o r , J. New D r u g s 5, 21 (1965). (40) E. F. Domino, P. Chodoff and G. C o r s s e n , Clin. P h a r m a c o l . T h e r a p h , 279 (1965). (41) H. Laborit, J. M. Jouany, J. G e r a r d and P. Fabiani, P r e s s e Med. 68, 1867 (1960). 1216 (1961). (42) G. Laborit, A. Kind and C. d e L. Regil, Presse Med. (43) A. B. Drakontides, J. A. Schneider and W. H. F u n d e r b u r k , J. P h a r m a c o l . Exp. T h e r a p . 135, 275 (1965). (44) E. H. Jenny, H. B. M u r p h r e e , L. Goldstein and C. C. Pfeiffer, P h a r m a c o l o g i s t 4, 166 (1962). (45) M. J. HOsko, Jr. and M. I. Gluckman, P h a r m a c o l o g i s t ? , 254 (1963). (46) S . P. B e s s m a n and S . J. Skolnick, Science E,1045 (1964). (47) W. D. W i n t e r s and C. F.Spooner, Intern. J. Neuropharmacol. 4, 197 (1965). (48) B. W. Gunner, G. A. H a r r i s o n , W. D. W a l k e r and I. S. Jenkinson, (11), 327 (1965). Med. J. A u s t r a l i a (49) H. Eisterer, G. F r a u n d o r f e r , P. F o r g e s , H. Seidl and K. Stein638 (1965). b e r e i t h n e r , Wien. Med. Wochschr. (50) J. C. Hewitt, R. C. Hamilton, J. F. O’Donnell and J. W. Dundee, B r i t . J. A n a e s t h e s i a 2 , 115 (1966). (51) c. D. Lunsford, A. D. Cale, J r . , J. W. Ward, B. V. F r a n k o and H. Jenkins, J. Med. Chem. 7 ‘ , 302 (1964). (52) W. E v e r s , K. Malik and A. B. Dobkin, Canad. Anaesth. SOC. J. l2, 281 (1965). (53) A. L. Mauro, L. Labartino, E . Mojdehi and B. Reynolds, Am. J. Med. Sci. 269 (1965).
c,
3,
u,
z,
Chap. 3
Depressants
Cain
39 -
References
(54) F. W. Noe, N. B o r r i l l o and F. E. Greifenstein, A n e s t h e s i a Analgesia, C u r r e n t R e s . 44, 206 (1965). (55) J. s. Israel, G. T. J a n s e n and A. B. Dobkin, Anesthesiology 26, 253 (1965). (56) G. C o r s s e n , P. Chodoff, E. F. Domino and D. R. Kahn, J. T h o r a c . 901 (1965). Cardiov. Surg. 2, (57) J. DeCastro, P. Mundeleer and T. Bauduin, S u r v e y of A n e s t h e s i ology (3, 348 (1965). (58) C. W . Gorodetzky and W. R. Martin, Clin. P h a r m a c o l . T h e r a p . 6, 731 (1965). (59) U. Aubry, R. Denis, M. Keeri-Szanto and M. P a r e n t , Canad. Anaesth. SOC. J. l2, 510 (1965). (60) M. G e m p e r l e and J. C. Buhler, Schweiz. Med. Wochschr. 158 (1965). (61) A. B. Dobkin and P . K . Y . Lee, Canad. Anaesth. SOC. J. l2, 34 (1965). (62) A. B. Dobkin, P . K . Y . L e e and P. H. Byles, Canad. Anaesth. SOC. JI, 39 (1965). (63) P. Chodoff and E . F . Domino, A n e s t h e s i a Analgesia 44, 558 (1965) (64) J. Canellas, J. Roquebert and P. Courtois, Compt. Rend. SOC. Biol. 159 1538 (1965). (65) J. Yelnosky and W. E. Field, Am. J. V e t . R e s . 25, 1751 (1964). (66) I. I. F r a n k l i n and J. S. Reid, V e t . Med. / S m a l l Animal Clinician 60, 927 (1965). (67) J. M o r t e l m a n s , R. M a r s b o o m and J. V e r c r u y s s e e , Bull. SOC. Roy. 2001. d ' A n v e r s 36, 13 (1965). (68) N. W. Shephard, Ed., "The Application of Neuroleptanalgesia in Anesthetic and O t h e r Practice", P e r g a m o n Press, Oxford, 1965. (69) J. R. B o i s s i e r , P. Simon and J. Fichelle-Pagny, TherapieAO, 401 (1965). I
s,
-
-J
Sect. I
40 -
- CNS Agents
B i e l , Ed.
Chapter 4. A n a l g e t i c s --Stronf and Weak Louis S . H a r r i s , U n i v e r s i t y of North Carol na, Chapel H i l l , N.C. Introduction The p a s t few y e a r s have witnessed a ferment i n t h e f i e l d of a n a l g e t i c s . S e r i o u s q u e s t i o n s have a r i s e n t o challenge o u r concept of p a i n as a s p e c i a l i z e d sensory system. Indeed we now take a more A r i s t o t e l i a n view of p a i n and speak of t h e " p a i n experience" which encompasses n o t o n l y t h e s e n s a t i o n of p a i n but a s s o c i a t e d s e n s a t i o n s such as touch and h e a t and f e e l i n g s t a t e s such a s f e a r and p l e a s u r e . I t i s n o t s u r p r i s i n g t h e n t h a t more and more drugs a r e becoming a v a i l a b l e f o r t h e t r e a t m e n t of p a i n which appear t o have mechanisms which d i f f e r , sometimes q u i t e markedly, from those of t h e c l a s s i c a l a g e n t s . We now have s t r o n g a n a l g e s i c s which a r e devoid of morphine-like a d d i c t i o n p o t e n t i a l and mild a n a l g e s i c s which a r e i n c r e a s i n g i n t h e i r p a i n r e l i e v i n g potency. I t would appear t h a t we a r e approaching c l s e r and c l o s e r t o t h e i d e a l a n a l g e s i c agent. A r e c e n t monograph P p r e s e n t s an e x c e l l e n t summary of much of t h i s work.
I.
Strong Analgesics Morphine and Morphinans There was l i t t l e a c t i v i t y i n t h i s a r e a i n 1965. P i r k l e and Gates2 prepared t h e hydroaromatic analogs ( I and 11) of t h e p o t e n t a n a l g e s i c s &-3-hydroxy-N-methylmorphinan and t h e c o r r e s ponding isomorphinan. The morphinan ( I ) w i t h a c i s - r i n g f u s i o n was e s s e n t i a l l y i n a c t i v e while t h e isomorphinan
A.
I B/C I1 B/C
cis -
111 B/C
trans HO
cis
I V B/C t r a n s 6 -OF
CH3 6 only a t n e a r t o x i c doses. The secondary a l c o h o l of I showed a c t i v i t y . Thus, r e d u c t i o n of t h e aromatic r i n g depresses a n a l g e s i c a c t i v i t y and lends evidence t o t h e importance o f t h e p l a n a r r i n g f o r bindin$ t o o r f i t on t h e r e c e p t o r . A n i n t e r e s t i n g m o d i f i c a t i o n of t h e morphinan s t r u c t u r e was described by Sawa and h i s colleague^.^^^ They synthesized (-13-hydroxy-6,N-dimethyl-c-nor-morphinan 111 and t h e corresponding 6-oxo-isomorphan I V , t h e compounds w i t h a 5-membered C-ring. The &-fused compound was 1 9 x morphine and t h e trans-compound 1 2 x morphine i n r a t s u s i n g t h e D'Amour-Smith t e s t . I n t h e way of mechanisms, Way5 and h i s co-workers have shown t h a t h e r o i n ( H ) i s r a p i d l y metabolized t o monoacetylmorphine (MAM) and morphine (M). They p o s t u l a t e t h a t t h e major e f f e c t s of H a r e dependent on t h e formation of MAM. Unchanged H e x e r t s only minor e f f e c t s . H i s biotransformed t o MAM which t h e n a c t s
-
Chap. 4
Analg e ti c s
Harris
41 -
a s a c a r r i e r t o f a c i l i t a t e t h e a c c e s s of M t o r e c e p t o r s i t e s i n t h e C.N.S. Krivoy and h i s group have continued i n t h e i r a t t e m p t s t o r e l a t e t h e development of t o l e r a n c e t o morphine with t h e formation of p r o t e i n s o r p e p t i d e s i n t h e C.N.S. which c o u n t e r a c t t h e drug. Cohen e t a l . 6 r e p o r t some i n t r i g u i n g experiments i n which t h e y a r e a b l e t o d e l a y t h e development of t o l e r a n c e t o morphine by p r e t r e a t i n g t h e animals w i t h actinomycin D . Whether t h e i n h i b i t i o n of t o l e r a n c e development i s r e l a t e d t o d e p r e s s i o n of RNA s y n t h e s i s and consequent changes i n p r o t e i n s y n t h e s i s remains t o be shown a s does t h e s p e c i f i c n a t u r e of t h e p r o t e i n o r p e p t i d e involved. The r o l e of p h y s i c a l and psychological s t r e s s on a n a l g e s i c s was a s s e s s e d by Frome17 who found t h a t t h e s e s t r e s s e s prolonged t h e a c t i o n of morphine i n guinea p i g s . B. Benzomorphans May and h i s c o l l e a g u e s continued t h e i r e l e g a n t s t u d i e s i n t h i s a r e a . C h i g n e l l e t a1.8 r e p o r t e d t h e p r e p a r a t i o n a - ( c i s ) and ~-(trans)-2-hydro~-~9-dimethyl-5-propyl-6,7-benzomorphan. Again, a s h a s been p r e v i o u s l y r e p o r t e d f o r o t h e r members of t h i s s e r i e s , t h e trans-isomer i s c o n s i d e r a b l y more p o t e n t t h a n t h e cis-isomer T h e e - c o m p o u n d , l i k e o t h e r cis- and 5-monoalkyl d e r i v a t i v e s i n t h e benzomorphan s e r i e s , has l i t t l e o r no a b i l i t y t o s u b s t i t u t e f o r morphine i n a d d i c t e d monkeys. The t r a n s compound, however, does s y p r e s s withdrawal symptoms i n d i c t e d monkeys. C h i g n e l l and May prepared t h e 9-methylenedesoxy compound (V) which t h e y t h e n reduced s t e r e o s p e c i f i c a l l y t o t h e c i s - ( V I ) and t r a n s - i s o m e r s ( V I I ) . The methylene compound proved
.
-
VI
V
C3H7
VII
t o have about h a l f t h e a n a l g e s i c a c t i v i t y of morphine a s d i d t h e Jacobson and Maylo prepared a v a r i e t y of 2' - n i t r o - , trans-ieomer. 2' -amino-, and 2 ' -halo-5,9-dialkyl-2-methyl-6,7-benzomorphans. Replacement of t h e p h e n o l i c hydroxyl by t h e s e o t h e r f u n c t i o n a l groups l e d t o a diminution of a n a l g e s i c potency and an i n c r e a s e i n t o x i c i t y . As an i n t e r e s t i n g s i d e l i g h t , it was r e p o r t e d t h a t a n a l g e s i c (Hot P l a t e ) ED50 values i n a new type o f Caesarean d e r i v e d g e n e r a l purpose mlce were approximately 1/2 t h o s e It p r e v i o u s l y o b t a i n e d w i t h o t h e r mice a t t h i s i n s t i t u t i o n . would appear t h a t t h e s e h e a l t h i e r , f a s t e r growing mice a r e more s e n s i t i v e t o a n a l g e s i c s . J o s h i e t a l . 1 1 prepared a homologous s e r i e s of 5-alkyl-2~-hydroxy-6,7-benzomorphans,and have compared t h e s e w i t h a s e r i e s of &-2-alkyl-2'-hydroxy-5,9-
Sect. I
42 -
-
CNS Agents
B i e 1, Ed.
I n t h e 5-alkyl s e r i e s t h e r e l a t i v e I n t h e N-alkyl s e r i e s a c t i v i t y was Me<Et = P r = Bu>Am>Hex. they found Hex>Am>Me with t h e E t , P r and B u being i n a c t i v e . I t had e a r l i e r been reported12 t h a t t h e N-propyl compound i s a potent analgesic antagonist. Kametani and h i s colleaguesL3t l4 have r e p o r t e d an i n t e r e s t i n g m o d i f i c a t i o n of t h e benzomorphan nucleus. They prepared 1 , 2 3,4-tetrahydro-6H-l, 5 - ( e ) ( 1 , 4 ) diazocine and 1 , 2 , 3 , 4 , 5 , 6 - h e x a hydro-2,6-methanobenzo ( e ) ( 1 , 4 ) d i a z o c i n e , two azabenzomorphans I t w i l l be i n t e r e s t i n g t o a s c e r t a i n t o what e x t e n t t h e approp r i a t e N-alkyl d e r i v a t i v e s of t h e s e compounds e x h i b i t a n a l g e s i c activity. C Meperidine D e r i v a t i v e s Despite t h e f a c t t h a t over 4000 meperidine d e r i v a t i v e s have been prepared, work i n t h i s a r e a continues unabated. Hardy e t a1 .I5 described s e v e r a l homologous s e r i e s of nor-meperidines z c l u d i n g N-alkyl, a l k a n o l , a l k y l e t h e r , e t c . where t h e N-side chain v a r i e d i n l e n g t h from 3 - 7 atoms. Their r e s u l t s i n d i c a t e t h a t t h e o v e r a l l l e n g t h of t h e s i d e c h a i n i s q u i t e important f o r a n a l g e s i c a c t i v i t y . Peak a c t i v i t y c o n s i s t e n t l y appeared when t h e s i d e chain s k e l e t o n had an o v e r a l l l e n g t h of 7-9 A O . Their r e s u l t s i n d i c a t e t h a t w i t h i n d i f f e r e n t s e r i e s of compounds i n c r e a s i n g t h e Len t h of t h e N-side chain produces t h e same changes i n analges c potency. A s they p o i n t o u t , t h i s may be t h e r e s u l t of e q u i v a l e n t e f f e c t s on r a t e s of t r a n s p o r t t o t h e a c t i v e s i t e o r t o s i m i l a r changes i n a f f i n i t y f o r t h a t s i t e . Casy and Armstrongl6 prepared a s e r i e s of 4-alkoxy- and 4acyloxy-4-arylpiperidines o f t h e type V I I I and I X f o r comparison
dimethyl-6,7-benzomorphans.
.
.
?!
ArGf
VIIIa:
A
VIII
Ar=$ R =@O(CH2)2 R'=H R" =C 2H5
OCOR"
B
IX
IXa:
Ar=$ R =P((CH2I2 R ' =H R" =CH3
w i t h t h e p r e v i o u s l y r e p o r t e d a n a l g e s i c 4-ethoxy-4-(2-furyl)-3me t h y l - 1 -phene t h y l p i p e r i d i n e . They found t h e 4-phenyl-4-alkoxy d e r i v a t i v e s t o be g e n e r a l l y more a c t i v e t h a n t h e corresponding 4-(2-furyl)-4-alkoxy compounds. The h i g h e s t a c t i v i t y i n the alkoxy s e r i e s w a s found w i t h t h e benzoylethyl d e r i v a t i v e ( V I I I a ) ( 4 x meperidine) while among t h e acyloxy compounds t h e phenethyl d e r i v a t i v e ( I X a ) w a s t h e most a c t i v e (5.7 x meperidine). Kugita and h i s colleagues17 continuing t h e i r e a r l i e r work w i t h 3-alkyl-3-phenyl-piperidines prepared a s e r i e s of 3-alkyl-2methyl-3-arylpiperidines of t h e g e n e r a l s t r u c t u r e X . The Nphenacyl d e r i v a t i v e (Xa) was found t o be about as p o t e n t a s CH3 Xa: R=CH3, R'=@OCH2, R"=OH R" &N-R 1 Xb: R=CH3, R'=CH2=CHCH2, R"=OH
U UX
Chap. 4
Analgetics
Harris
43 -
morphine a s an a n a l g e s i c i n mice. The N-ally1 d e r i v a t i v e (Xb) proved t o be an a n t a g o n i s t and was devoid of a n a l g e s i c a c t i v i t y . T h i s is of i n t e r e s t s i n c e t h i s d i f f e r s markedly from t h e meperidine s e r i e s where t h e N-ally1 compound i s a s t r a i g h t forward a n a l g e s i c . A s was p o s t u l a t e d by Archer and H a r r i s , 1 8 a n t a g o n i s t i c a c t i v i t y may be r e l a t e d t o t h e phenethylamine fragment of molecule, a s t r u c t u r a l f e a t u r e which Xb s h a r e s with t h e o t h e r n a r c o t i c a n t a g o n i s t s and which i s l a c k i n g i n Nallylnormeperidine
.
D.
Miscellaneous
Casy and Meyerslg have prepared a s e r i e s of 1 , 2 - d i a r y l - 4 dimethylamino-3-methylbutan-2-ols. S u b s t i t u e n t s i n t h e 1-phenyl r i n g reduced o r a b o l i s h e d a n a l g e s i c a c t i v i t y . Among t h e a c y l e s t e r s , X I was 1.3 x meperidine. An a d d i t i o n a l methylene group CH3 )CH2N( CH3
I2
)CH2N(CH3 )2 C OCH3 X II
XI
XI11
between Cp and t h e C 2 phenyl ( X I I ) d i d n o t a f f e c t a c t i v i t y . However, a methylene group between C 1 and t h e C phenyl ( X I I I ) e s s e n t i a l l y a b o l i s h e d a c t i v i t y . These changes i n a c t i v i t y a r e r e l a t e d t o t h e r e l a t i v e l y r i g i d molecular s t r u c t u r e of X I and X I 1 a s opposed o t h e l e s s crowded more mobile s t r u c t u r e ( X I I I ) . Portoghese2S, I n h i s c o n t i n u i n g s t u d i e s of t h e r e l a t i o n s h i p of s t e r i c f a c t o r s t o b i o l o g i c a l a c t i v i t y has determined t h e a b s o l u t e c o n f i g u r a t i o n of (-1-phenampromide t o be (R)-N-(1-methyl2 - p i p e r i d h o e thy1)propioanilide ( X I V ) . ( R ) -Phenampromide , ( S ) isomethadone, and (2S:3R)-propoxyphene a r e s t e r e o c h e m i c a l l y This r e l a t e d and have g r e a t e r a c t i v i t y t h a n t h e i r enantiomorphs.
xI V i n d i c a t e s a s t e r e o s e l e c t i v e attachment t o a common r e c e p t o r s i t e . I n a l a t e r p a p e r 2 I Portoghese has p u t f o r t h a concept o f t h e mode of i n t e r a c t i o n of n a r c o t i c a n a l g e s i c s w i t h r e c e p t o r s . He p o s t u l a t e s d i f f e r e n t modes of a n a l g e s i c - r e c e p t o r i n t e r a c t i o n s depending on t h e type of s e r i e s of a g e n t . When p a r a l l e l changes i n a c t i v i t y a r e s e e n i n a s e r i e s of compounds w i t h i d e n t i c a l changes i n t h e N - s u b s t i t u e n t , t h i s would suggest s i m i l a r binding
44 -
Sect.
I
-
CNS Agents
B i e l , Ed.
modes. Nonparallel r e l a t i o n s h i p s would then be i n d i c a t i v e of d i s s i m i l a r i n t e r a c t i o n s . He has demonstrated q u a n t i t a t i v e l y , i n a s e r i e s where t h e mode of binding i s s i m i l a r , t h a t a l i n e a r free-energy r e l a t i o n s h i p e x i s t s . He conceives of t h e r e c e p t a r a s having a charged anionic s i t e a s a common p i v o t p o i n t around which the analgesic may be more o r l e s s t i g h t l y bound depending upon i t s s t r u c t u r a l and conformational c h a r a c t e r i s t i c s . I n t h e l i g h t o f t h i s , and o u r t h i ing about t h i s f i e l d over concerning t h e potent the years, t h e note by Axelrod e t ,1.% a n a l g e s i c p r o p e r t i e s of a non-nErogenous s t e r o i d 2CV i s even more s u r p r i s i n g . This compound was r e p o r t e d t o be 40 x morphine i n a modification of the r a t t a i l - f l i c k method when given by the intravenous r o u t e . I n man, t h e compound a d m i n h t e r e d intravenously, was s t a t e d t o r e l i e v e p o s t o p e r a t i v e and chronic cancer p a i n . F'urther d e t a i l s of t h i s work a r e awaited with g r e a t i n t e r e s t . E. Narcotic Antagonists I t i s , perhaps, among t h e group of compounds known a s analgesica n t a g o n i s t s t h a t t h e g r e a t e s t progress has been made i n r e c e n t years i n t h e f i e l d of a n a l g e t i c s . The t o i c has r e c e n t l y been c r i t i c a l l y reviewed by Archer and Harris.y8 The development of pentazocine (XVIa), cyclazocine (XVIb), and cyclorphan (XVII)
has helped t o change our concepts o f drug development i n t h i s a r e a . These agents antagonize t h e a c t i o n s of morphine, a r e g e n e r a l l y i n a c t i v e o r poorly a c t i v e a s analgesics i n animals, yet a r e potent a n a l g e s i c s i n man and have l i t t l e o r no morphinel i k e addiction p o t e n t i a l . 1. Pentazocine I n t h e p a s t year s e v e r a l s t u d i e s 23-27 have confirmed t h e a n a l g e s i c e f f i c a c y of pentazocine. The consensus of opinion i s t h a t 30-40 mg/70 kg is equlvalent t o 10 mg/70 kg of morphine. Side e f f e c t s resembled those seen with morphine and t h e drug was remarkably f r e e of nalorphine-like psychotomimetic p r o p e r t i e s . Like morphine entazocine produces ome degree of r e s p i r a t o r y depression.28'3g Telford and KeatsP8 have shown t h a t t h i s r e s p i r a t o r y depression can r e a d i l y be reversed by t h e a n a l e p t i c , methyl henidate. I n concomitant tilt t a b l e s t u d i e s , I s r a e l e t a1 .so noted hypotensian only r a r e l y with pentazocine. 2 . Cyclazocine This compound i s bout 40 times more potent than morphine a s an a n a l g e s i c i n man.38 A t equianal e s i c doses it produces about the same degree r e s p i r a t o r y depress on as morphine but, l i k e o t h e r analgesic a n t a g o n i s t s , t h e r e is l i t t l e i n c r e a s e i n t h i s
--
f
Chap. 4
Analgetic s
Harris
45 -
depression as t h e dose i s i n c r e a s e d . Cyclazocine produces a high enough incidence of n a l o r p h i n e - l i k e s u b j e c t i v e e f f e c t s t o make it unacc3qtable as a u s e f u l a n a l g e s i c . Martin and h i s group have r e p o r t e d t h a t t o l e r a n c e develops t o t h e s u b j e c t i v e e f f e c t s of t h e drug and t h a t when p a t i e n t s a r e k e p t on high doses f o r prolonged p e r i o d s and a b r u p t l y withdrawn, abstinence s i g n s appear. These withdrawal symptoms a r e r e l a t i v e l y mild and n o t t y p i c a l of those seen w i t h morphiyj. O n t h e b a s i s of t h e s e and o t h e r s t u d i e s , Martin e t a l . have proposed t h e use of cyclazocine i n maintaining n a r c o t i c a d d i c t s f r e e from n a r c o t i c abuse. Under t h e i n f l u e n c e of cyclazocine t h e euphorogenic e f f e c t s of n a r c o t i c s a r e antagonized and t h e development o f p h y s i c a l dependence i s prevented. An o u t p a t i e n t c l i n i c t r i a l of t h i s t h e r a p y i s being c a r r i e d o u t by J a f f e 3 4 and Freedman.35 The i n i t i a l r e p o r t s a r e q u i t e encouraging. 3 . Cyclorphan T h i s drug i s a l s o a p o t e n t a n a l g e s i c i n man. 36 Like cyclazocine, it produces too high an incidence of n a l o r p h i n e - l i k e s u b j e c t i v e e f f e c t s t o be a c l i n i c a l l y u s e i u l a n a l g e s i c . 4. Oripavine D e r i v a t i v e s One of t h e most i n t e r e s t i n g f i n d i n g s i n r s y e n t years has been that ring the o b s e r v a t i o n by Bentley and h i s c o l l e a g u e s expansion of morphine t o t h e s i x - r i n g 6,14-endoethenotetrahydrothebaine o r o r i p a v i n e s t r u c t u r e l e a d s t o agents of s u r p a s s i n g potency. Thus XVIIIa was found t o be n e a r l y 8,000 times more XVII I a: R=CH3,
AN-"
R' =( CH3 ) y2HCH2CH2
XVIIIb: R= v C H 2 , RT=CH3 X V I I I C : R= y 7 C H 2 ,
HO
RT=(CH3)2CHCH2CH2
J
p o t e n t than morphine.38 These compounds have been used extens i v e l y t o immobilize wild animals s i n c e t h e i r high potency makes d a r t i n g q u i t e f e a s i b l e and t h e i r s a f e t y r a t i o i n four-legged animals i s high. Recently Bentley e t G.39 have described t h e s e r i e s . T h i s s i d e chain N-cyclopropylmethyl d e r i v a t i v e s i n has led t o p o t e n t a n t a g o n i s t s i n t h e morphine, morphinan and benzomorphan s e r i e s . I n t h e 6,14-endoethenothebaine s e r i e s when t h e C-alkanol s i d e chain i s isopropanol (XVIIIb) p o t e n t antagonism (35 x n a l o r p h i n e ) i s produced. When R?=isoamyl (XVIIIc) t h e 1000 x compound behaves more l i k e a s t r o n g a n a l g e s i c (250 morphine). There were, however, some q u a l i t a t i v e d i f f e r e n c e s bet een XVIIIc and morphine. Compound XVIIIb has been given t o mango and has been found t o produce a high incidence of n a l o r phine-like s i d e e f f e c t s .
mis
-
46 -
Sect.
I
- CNS Agents
B i e l , Ed.
5. Miscellaneous There has been some q u e s t i o n a s t o whether t h e n a r c o t i c a n t a g o n i s t s a r e competing w i t h t h e n a r c o t i c s f o r a common r e c e p t o r site i n t h e C.N.S. Evidence f a v o r i n g t h i s view f o r nalorphine and l e v a l l o r p h a n w a s p u t f o r t h by Grumbach and Chernov4I in' a c a r e f u l l y c o n t r o l l e d study. They c a r r i e d o u t Gaddum Drug Ratio s t u d i e s i n r a t s w i t h t h e two a n t a g o n i s t s and a v a r i e t y of a n a l g e s i c s . The r a t i o s f o r f o u r p a i r s of drugs were c o n s t a n t over a wide dose range i n d i c a t i n g t h a t t h e antagonism produced i s a tTsurmountable'vone and t h u s t h e drugs a r e competing f o r a common r e c e p t o r s i t e . The s e a r c h f o r a s p e c i f i c animal &qalgesic t e s t f o r t h i s c l a s s of agent has continued. Ward e t a l . compared nalorphine and pentazocine with morphine i n a m o d i m c z i o n of t h e R a n d a l l - S e l l i t o e T e s t . Winter and F l a t a k e r 4 3 described a more complete study encompassing s e v e r a l a n t a g o n i s t s . Nalorphine, pentazocine, cyclazocine, and N-cyclopropylmethylnormorphine r a i s e d t h e t h r e s h o l d of t h e y e a s t inflamed f o o t but had no e f f e c t on t h e c o n t r o l paw. (-)-3-Hydroxy-N-cyclopropylmethylnorisomorphinan was i n a c t i v e . There was l i t t l e r e l a t i o n s h i p between t h e dose necessary t o r a i s e e t h r e s h o l d and t h e g i i n i c a l e f f i c a c y of t h e drugs. Taber e t al.6k and Blumberg et &. report the effect i v e n e s s of t h e a n t a g o n i s t s i n t h e mouse phenylquinone-writhing t e s t . This has been expanded by P e a r l and H a r r i s . 4 6 To d a t e , a c t i v i t y i n t h i s t e s t g i v e s t h e b e s t c o r r e l a t i o n with c l i n i c a l efficacy. 111. Weak Analgesics Much of t h e l a b o r a t o r y work i n t h i s f i e l d has r e c e n t l y been reviewedl a s has t h e c l i n i c a l pharmacology.47 C e r t a i n a s p e c t s o f t h i s drug c l a s s a r e covered i n g r e a t e r d e t a i l i n t h e Chapter on Non-Steroidal Anti-Inflammatory Agents i n t h e p r e s e n t volume. A. New Agents Takamura and h i s colleagues48 have r e p o r t e d a s e r i e s of a n i l i n e d e r i v a t i v e s of t h e type X I X and XX. The compounds X I X a and b were t h e most p o t e n t a n a l g e s i c s . I n an i n t e r e s t i n g study,
--
CH2CH2C0RXIXa: R=N(CH3)2, XIX
--
XIXb: R=N(CH312,
R'=CH2=CHCH20 R'=p-Br
E h r h a r t e t a1.49 have prepared a s e r i e s of P-hydroxybutyrates and a-dimethylamino-P-hydroxybutyrates o f p-phenetidine and N-methyl-p-phenetidine. These compounds e x h i b i t e d a n a l g e s i c a c t i v i t y of about t h e same l e v e l a s phenacetin but appeared t o produce much l e s s methemoglobin formation. This w a s a t t r i b u t e d t o a metabolic breakdown d i f f e r e n t from t h a t of phenacetin. T h a t i s , t h e r e w a s no formation of p-phenetidine. Casadio e t a l . 50 described a s e r i e s of a,a - d i s u b s t i t u t e d p h e n y l a c e t o n i t r n e s , l-naphthylacetonftriles, phenylacetamides, and l-naphthylacetamides, many of which had a n a l g e s i c and a n t i -
Chap. 4
47 -
Harris
Analge tic s
inflammatory p r o p e r t i e s . Most a c t i v e were t h e l-naphthylacetamfdes, i n p a r t i c u l a r , naphthypramide XXgl which is c u r r e n t l y undergoing c l i n i c a l t r i a l . P a l a e t a l . suggested, from s t r u c -
--
c-c-c
\
N-C-C-C
'i""
XXI ' A corn2 XXII t u r e - a c t i v i t y s t u d i e s of t h e whole s e r i e s , t h a t X X I I r e p r e s e n t s t h e optimal s t r u c t u r e f o r a n a l g e s i c a c t i v i t y . Nishino and h i s group,52 i n a continuing study, prepared a s e r i e s of 1 , 4 - b i s ( s u b s t i t u t e d phenoxyacety1)piperazines XXIII, which showed a n a l g e s i c a c t i v i t y . These compounds a l s o appear t o have C .N.S. 0
R-~OCH20C-N7-com20~-R
W
XXIII
XXIV
Olin and Cashinfi3 r e p o r t e d a s e r i e s of cycloalkanespiro-5-hydantoins (XXIV), which were a c t i v e i n t h e mouse w r i t h i n g t e s t when R o r R' was a s m a l l a l i p h a t i c group o r when R ' was a c e t y l . These compounds a l s o had anti-inflammatory p r o p e r t i e s . Meyer e t a1.54 prepared a group of 3-amfno-2,lb e n z i s o t h i a z o l e s X c a l a r g e number of which showed a n t i n o c i c e p t i v e a c t i v i t y i n mice which was n o t c o r r e l a t e d w i t h t h e i r a n t i b r a d y k i n i n a c t i v i t y . Some resembled aminopyrine i n being Rll I XXVIa: R=p-S02CH3, R ' =Rfl=H depressant p r o p e r t i e s .
as
R l e k T R 1 '
R"
RON. R ' XXV
" er-R
XXVIb: R=p-S02CH3, R ' = H , XXVIc: R=p-S02CH3, R1=H Rii= ( CH3 2
~
R1'=NH2
~
~
2
et a1.55 r e p o r t e d a s e r i e s of a c t i v e i n both t e s t s . Almirante imidazol-[ 1 , P - a I p y r i d i n e s of t h e g e n e r a l s t r u c t u r e XXVI. The most i n t e r e s t i n g a c t i v i t y w a s found i n t h e methylsulfonyl analogs (XXVIa, b, and c ) . There have been r e p o r t s s 6 t h a t t h e dimethylaminoethanol s a l t of 2-(4-biphenyl) b u t y r i c a c i d (namoxyrate) i s an e f f e c t i v e a n a l g e s i c . T h drug appears t o be r a p i d l y absorbed a f t e r o r a l a d m i n i ~ t r a t i o nreaching ~~ a m a x i m u m plasma l e v e l a t one hour. Namoxyrate and/or i t s m e t a b o l i t e s a r e e x c r e t e d slowly over s e v e r a l days. The animal pharmacology has n o t , as y e t , been reported. Mefenamic a c i d X X V I I continues i n a c t i v e c l i n i c a l r e s e a r c h while another compound i n t h i s s e r i e s M N I I I has been r e p o r t e d t o be 150 x more p o t e n t than a s p i r i n (1). Bfsse158 r e p o r t e d
48 -
Sect. I
- CNS Agents
B i e l , Ed.
mefenamic acid t o be equivalent t o codeine compound and superior t o partgetamol i n a double blind crossover study. Williams c a r r i e d out a double blind e v a l u a t i o n of a s p i r i n and et al. X X V I I f o r t h e i r a b i l i t y t o a l t e r experimental ischemic arm pain. Both s i g n i f i c a n t l y increased pain threshold w i t h no s i g n i f i c a n t d i f f e r e n c e between medications. No placebo c o n t r o l was run. An Indomethacin XXIX i s now being market d i n t h e U.S.A. e d i t o r i a l i n t h e B r i t i s h Medical .Journal6g sums up r e c e n t experience with t h i s drug. I n general, it has proven t o be an e f f e c t i v e m i l d analgesic, a l b e i t with a r e l a t i v e l y high incidence of s i d e e f f e c t s . These s i d e e f f e c t s , however, a r e considerably lower when t h e drug i s given by capsule and the dose c a r e f u l l y adjusted. Indomethacin i s p a r t i c u l a r l y u s e f u l i n t h e treatment of many of the rheumatic d i s e a s e s . B. Miscellaneous Portoghese61, continuing h i s s t u d i e s of t h e r e l a t i o n s h i p of s t r u c t u r a l conformation tQ a c t i v i t y , prepared t h e enantiomers of N-2 - (p-me thylbenzylme thy1amino)propyl propioanilide and i t s Npropyl analog. The S-(-)-isomers had g r e a t e r a c t i v i t y . There was a l e s s e r potency r a t i o between the isomers of the N-methyl and t h e N-propyl compound. This was a t t r i b u t e d t o a diminution i n t h e s t e r e o s e l e c t i v i t y of the analgesic r e c e p t o r s and might be r e l a t e d t o d i f f e r i n g modes of analgesic-receptor bindin I t has become apparent from the s t u d i e s of GilfoildfS;t h a t inflammation and hyperesthesia a r e n o t a s i n g l e phenomenon. Many agents produce swelling without a t t e n d a n t increase i n pain s e n s i t i v i t y . A f a c t o r o r f a c t o r s which a r e r e l e a s e d by c e r t a i n agents which produce inflammation may be r e l a t e d t o hyperesthesi This f a c t o r i s n o t s e r o t o n i n o r bradykinin. Winter and F l a t a k e r$3 using a v a r i e t y of hyperesthesia-producing agents, have shown t h a t indomethacin and t h e narcotic-antagonists can reduce hyperesthesia a t doses which do not a f f e c t swelling and which do n o t a f f e c t t h e pain threshold of uninflamed t i s s u e . This might r e v e a l a c e n t r a l analgesic a c t i o n i n c e r t a i n mild analgesics unrelated t o t h e i r p e r i p h e r a l a c t i o n . This work appears t o be leading t o a g r e a t e r understanding of inflammatory pain and how the mild analgesics exert t h e i r effects.
.
Analge tic s
Chap. 4
Harris
49 -
References
1. 2. 3. 4. 5. 6.
7. 8. 9.
10. 11* 12.
13. 14. 15. 16. 17. 18.
19. 20. 21. 22. 23. 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34.
G. de Stevens, e d . , A n a l g e t f c s , A c a d e m i c P r e s s , N.Y. and Lond.. 1965. W.H. P i r k l e and M. G a t e s , J. Org. C h e m . , 30, 1769 (1965). Y.K. S a w a , N. T s u j i , K. O k a b e and T. M i y a z t o , Tetrahedron, 21, 1 1 2 1 (1965). T K . S a w a , M. H o r i u c h i and K. Tanaka, i b i d . , 2 1 , 1133 (1965). E . L . Way, J . M . Y o u n g and J . W . Kemp, B u r N a r G t f c s , 27, 25 (1965). M. C o h e n , A . S . K e a t s , W. K r i v o y and G . U n g a r , Proc. SOC. E x p . B i o l . Med., 119, 3 8 1 (1965). E . F r o m m e l , A r z n e i m i t t e l - F o r s c h . , IS, 80 (1965). C . F . C h i g n e l l , J . H . A g e r and E . L . M a y , J. Med. C h e m . , 8, 235 (1965). C . F . C h i g n e l l and E . L . May, i b i d . , 8, 385 (1965). A . E . Jacobson and E . L . M a y , ibid., 8 , 563 (1965). B . C . J o s h i , C . F . C h i g n e l l a n m L . Ray, i b i d . , 8, 694 (1965). S . A r c h e r , N.F. A l b e r t s o n , L.S. H a r r i s , A.K. Pierson and J . G . B i r d , -.' %bid 7, 1 2 5 (1964). T . K a m e t a n i , K. K i g a s a w a , M. H f i r a g i and H . I s h i m a r u , C h e m . Pharm. B u l l . Tokyo, 13, 295 (1965). T . K a m e t a n l , K. K i g a G w a and T. H a y a s a k a , i b i d . , 13, 300 (196 5). D.G. H a r d y , R . E . L i s t e r and E . S . S t e r m , J.m.C h e m . , S, 847 (1965). A . F . C a s y and N.A. A r m s t r o n g , $ b i d . , 8, 57 (1965). H. K u g i t a , 0. T o y a n a r i , H. Inoue and G. H a y a s h i , ibid., 8, 313 (1965). S . A r c h e r and L.S. H a r r i s , Progress i n Drug Research, ed E . Jucker, B k k h g u s e r V e r l a g , B a s e l , V o l . 8 (1965). A . F . C a s y and J . L . Meyers, J. C h e m . S O C . , 4092 (1965). P.S. Portoghese, J. M e d . C h e m . , (1965 1. P . S . Portoghese, P b i d . , 8, 609 (Fb65L1;: L . R . Axelrod, P.N. Rao and D.H. B a e d e r , J. Am. C h e m . SOC -788 856 (1966). M. E n d e , J. Am. G e r . SOC., l3, 775 (1965). R.A. G o r d o n and J . H . Moran, J. C a n . A n e s . SOC., ,2.l 3 3 1 (1956 J . R . H i n s h a w , K . E . K o b l e r , and A.R. B o r j a , Am J. Med. Sci., 251, 57 (1966). M . S . Sadove and R . C . B a l a g o t , J. Am. Med. A s s o c . , 193, 887 (1965). V.K. S t o e l t i n g , A n e s t h e s i a 81 A n a l g e s i a , 44, 769 (1965). J. T e l f o r d and A . S . K e a t s , C l i n . P h a r m . T h e r a p . , 6, 12 (1965) J . W . B e l l v i l l e and J. G r e e n , i b 1965 J . S . I s r a e l , G.T. Jansen and ~ . ~ o ~ i l t ~ ' A ~ e s t h e s i o l o26, p;y, 253 (1965). - - -L. Lasagna, T . J . D e K o r n f e l d and J . W . Pearson, J. Pharmacol.
.
-
.,
@, 12 (1964).
H . F . Fraser, H.C. G o r o d e t z k y and D.E. R o s e n b e r g , J. Pharmacol., 150, 426 (1965). W.R. M a r t i n , C.W. G o r o d e t z k y and T . K . M c C l a n e , Pharmacologist, 7. 163 (1965). ~-~ J. J a f f e and-L. B r i l l , I n t . J. A d d i c t i o n s , 1, 99 (1966). -7
~
-
50 -
Sect. I
- CNS Agents
B i e l , Ed.
35. A.M. Freedman, P e r s o n a l communication. 58, 978 (1965). 36. L. Lasagna, F'roc. Roy. SOC. Med 37. K.W. Bentley, Endeavor, 23, 91 38. R.E. L i s t e r , J. Pharm. Pharmacol., l6, 364 (1964). 39. K.W. B e n t l e y , A.L.A. Boura, A . E . F i t z g e r a l d , D . G . Hardy,
ii9m.
A . McCoubrey, M.L. Aikman and R . E .
(1965).
L i s t e r , Nature,
9,102
40. A . S . Keats, P e r s o n a l communication. 41. L . Grumbach and H . J . Chernov, J. Pharmacol. Exp. Therap., 150, 385 (1965). 42. J . W . Ward, M. Foxwell and W.H. Funderburk, Pharmacologist, 1, 163 (1965). 43. C . A . Winter and L . F l a t a k e r , J . Pharmacol. Exp. Therap., 150, 165 (1965). 44* R.I. Taber, D.D. Greenhouse and S . I r w i n , Nature, 204, 189 (1964). 45. H. Blumberg, P.S. Wolf and D.B. Hyman, P r o c . SOC. Em. B i o l . Med --, 118, 763 (1965). 46. J. P e a r l and L.S. H a r r i s , J. Pharmacol. Exp . Therap., i n p r e s s . 47. W.T. Beaver, Am. J. Med. S c i . , 250, 5//=963). N . Asada, S . Takaku, 48. K. Takamura, A . S h i o y a , i n a m o t o , A . Yoshimitsu and Y . N i t t a , Chem. Pharm. B u l l . Tokyo, 13, 198 and 205 (1965). 49. G . E h r h a r t , E. L i n d e r , and A. KSussler, A r z n e i m i t t e l - F o r s c h . , 15, 727 (1965). 50. S. Casadio, P. Gianfranco, E . C r e s c e n z i , T . Bruzzese, E . Marazzi-Uberti, and G . Coppi, J. Med. Chem., 8, 589 and 594 (1965). 51. G . P a l a , S. Casadio, T . Bruzzese, E. C r e s c e n z i , and V.E. Marazzi, -* i b i d ' 8, 698 (1965). 52. K. NishTno, N. I c h i n o s e k i , K. S h l s h i d o , and T . I r i k u r a , 2. Pharm. S O C . Japan, 85, 715 (1965). 53. W. O l d f i e l d and C.H. Cashin, J. Med. Chem., 8, 239 (1965). 54. R.F. Meyer, B.L. Cummings, P. Bass and H.0.J: C o l l i e r , %bid. 8, 515 (1965). 55. L. Almirante, L. Polo, A. Mugnaini, E . P r o v i n c i a l $ , P. Rugarli, A . B i a n c o t t i , A. Gamba and M . Murmann, i b i d . , 8, 305 (1965). 56. A. Cohen and E.A. DeFelice, J. New Drug-, 153 (1965). 57. 0. Resnick, E.A. D e F e l h e , J . R . Bergen and H . Freeman, C u r r . T H . , 7, 443 (1965). s s e 1, P r a c t i t i o n e r , 194, 817 (1965). 58. 59. M.W. W i l l i a m s , C.S. W i l l i a m s , and M. J. Kartchner, T o x i c o l . A 1. Pharmacol., 7, 45 (1965). 60. Mzd. J., 1329 (1965). 61. T.M. G i l f o i m I. K l a v i n s , Am. J. P h y s i o l , 208, 867 (1965). 62. P.S. Portoghese and T.N. R i l e y , J. Pharm. S c i y z , 1831 (1965).
.-
51 Chapter 5.
Anorexigenic Agents
George I. Poos, McNeil Laboratories, Inc., F o r t Washington, P a .
Introduction - Because of its efficacy and widespread clinical usage, amphetamine has been the standard anorexigenic drug for some time. L 2 , 3 Efforts to reduce the central stimulant and cardiovascular effects of a m phetamine have led to the development o v e r the y e a r s of a number of new products which, hopefully, a r e f r e e of undesirable side effects. Excellent s u m m a r i e s of these developments a r e available. 4, 5* 6~ Along with these new drugs t h e r e has also developed a controversy. A r e t r u e anorexigenic and central stimulant effects s e p a r a b l e ? 6 y Can drug control of a "hunger center" in the l a t e r a l hypothalamus9*"8 11, l2 o r ~ 6 of a "satiety center" i n the ventromedialhypothalamus 13, l4, 1 5 ~ selectively overcome powerful psychological factors that may be associated with obesity? If appetite and hunger a r e effectively drug-controlled in a completely selective manner, w i l l the obese patient be m i s e r a b l e f r o m deprivation without substitution ? Although investigations of anorexigenic agents in 1965 do not s e e m to have provided c l e a r - c u t answers to a l l of these questions, we may well be getting c l o s e r to the truth. Newer Drugs - Both the laboratory and clinical investigation of amphetamine congeners h v e received considerable attention over the p a s t s e v e r a l y e a r s . Of greatest i n t e r e s t s e e m to have been the chloro, trifluoromethyl and alkyl-substituted amphetamine analogs.
-a,a-dimethylphenethylamine)(I), which Chlorphentermine (p-chloro h a s been known f o r some time as an anorectic i n animals' with little CNS stimulant effect, l8 was introduced into g e n e r a l clinical use in April, 1965. At effective anorexigenic dosa e s chlorphentermine seems t o p r o duce little o r no central stimulation 18*2 b , 21 and h a s been reported to c
~
c
I
''
FH3
H - N ~H ~ -
~
CH3 22
produce mild sedation in the f o r m of drowsiness and relaxation. Since chlorphentermine has been shown t inhibit l a t e r a l hypothalamic stimulus induced eating in the satiated c a t as well a s altering the evoked
52 -
Sect. I - CNS Agents
B i e l , Ed.
23
potentials of hypothalamic "appetite centers", answers to the questions mentioned e a r l i e r m a y come f r o m observation of patient and physician acceptance of this new drug. T h e r e a r e a number of r e p o r t s on the investigation of ring-substituted amphetamine analogs (11). A s e r i e s of 4-chloro, 2,4-dichloro and 3,4-dichloro compounds were only of modest i n t e r e s t . 24 An a s s o r t m e n t of analogs monosubstituted at the 2 , 3 and 4 position with methylthio, bensyl-
I1 thio , me thyl s ulf on yl, d imethylami no, isop r opyl, amino s ulf onyl, am in0 , benzoylamino, methylsulfonylamino and trifluoromethyl were examined for anorectic activity in the rat and dog. 25 Only the p-dimethylamino and m - and p-trifluoromethyl derivatives showed m a r g e d activity. The trifluoromGthy1 compounds appear to have little CNS stimulant effect and have been investigated extensively. 2 6 , 2 7 9 289 29* 303 31 The t h r e e i s o m e r i c monofluoro amphetamines a r e a l s o reported to have substantial anorectic activity. 31
-
Recent studies on N-substituted amphetamines have included the n was varied f r o m 2 to 5. In this s e r i e s , N-alicyclic compounds I11 where -
111
IV
V
only the N-cyclop pyl compound was effective in depressing the food consumption of r a t s . 3% Phentermine I V l 7 and Z-phenyl-3-methyl-3-aminobutane (V) 33 a r e recent examples of active amphetamine analogs substituted on the side chain. Multiple substitution such as with the N-methyl-ubenzyl-P-phenethylamine (VI), 34 the N-benzyl-p-chloro compound VII, 35 N -me thyl -E-pentylamphetamine VIII, 6 , and 5 -ethyl -m -trifluoro de riva tive I X (fenfluramine) 38,39,40,41, 42343 has given active compounds of interest. Compounds I, I V , V and I X have been compared with d-amphetamine as to potency and duration of the inhibition of food consumption in r a t s . 4 4 Both chlorphentermine I and fenfluramine IX were l e s s potent d-amphetaa t two hours but of about the same potency a t twelve h o u r s as mine. In a t h r e e day, multiple-dosing experiment, they were clearly superior. 44 Metaboiic studies on chlorphentermine 45 and fenfluramine 42
-
Chap. 5
Anorexigens
53 -
Poos
showed a relatively slow catabolism which undoubtedly contributes to their longer duration of action.
VI
VII
VIII
IX
Research activity with anorexigenic compounds more remotely related in structure to amphetamine continues. In most cases, one can detect a basic nitrogen atom approximately two carbons distant from a benzene ring.
A group of 4 - a m i n o r n o r p h o l i n e ~related ~~ in structure to phenmetrazine were examined f o r their CNS effects.47 The most interesting compound proved to be the N-( 1 -phenyl-2 -propylamino) derivative X, NH II
0-NH - C -NH
A
2
XI
which is an N - N combination of amphetamine and phenmetrazine. Compound X was shown to be an active anorexigenic agent with a behavioral profile different from that of amphetamine. 47 Aralko guanidines have recently been reported to have anorexigenic activity. 4T ' he most active compound, benzyloxyguanidine ( XI), i s about 1/ 5th a s active in inhibiting food consumption in dogs as d-amphetamine. The discovery of anorexigenic activity for certain 2, 5-benzodiazocines 49 provides another new class of potentially useful compounds. The pharmacological 50, 51 reports on 1-(e-chlorophenyl)-l,Z, 3,4, 5,6hexahydro-2,5-benzodiazocine (XII) describe potency in the range of amphetamine with reduced central stimulant and cardiovascular actions. The potent anorexigen Z-amino-5-phenyl-2-oxazoline(MII, aminorex), which was described several y e a r s ago along with a s e r i e s of analogs, 5 2 3 53
54 -
Sect. I
-
CNS Agents
XI11
B i e l , Ed.
XIV
has been reported to be a n effective drug in obese diabetics. 54 In both r a t s and man, aminorex was shown to be rapidly metabolised and eliminated in the urine. 55 The structural1 s i m i l a r 2-dimethylamino-4-phenyl-2-oxazolin-4-one (XIV, thozalinone)x6 is a l s o reported to be an active anorexigen with l e s s acute toxicity and a longer duration of action than amphetamine when compared in mice. 57 Large doses of a-methyl-m-tyrosine have been found to d e c r e a s e the consumption of a sweetened m i l k s o l u t i o n by r a t s . 58 The long-lasting3 dosedependent effect is thought to be due to metabolites of a-methyl-m-tyrosine. 58 Anorexia has been attributed to imipramine. 59 Iproniazid h a s been shown to potentiate the anorexigenic effects of L-E-cocaine in' rats. 6o The anorectic effect of L-n-cocaine is attributed to an amphetamine-like effect i n the CNS r a t h e r t h a n t o i t s local anesthetic activity. 6o Pharmacological Testing Methods - Classical procedures have measured drug effects on food consumption, weight gain o r both. 61, 6 2 * 63 Many r e finements of these methods have been described. 64 One of the m o r e i n t e r e s t ing variations has been the use of obese animals, obtained either by destruction of the ventromedial nuclei 12365 o r by chemical methods such a s the aurothioglucose -obese mou.se. 66s 67 The inhibition of drinking behavior h a s also been used as an index of anorexigenic activity. Effects on the controlled, s h o r t - t e r m consumption of beef broth i n rats have been suggested to m o r e clearly reflect appetite suppression than feeding studies. 53 The u s e of sweetened milk solutions with rats also s e e m s to give satisfactory test r e s u l t s . 58 P e r s p e c t i v e s - Most r e s e a r c h i n the anorexigenic a r e a in the p a s t has concentrated around compounds that a r e either chemically a n d / o r biologically similar to amphetamine. As a result, many drugs a r e known which inhibit food consumption and concommitant weight i n c r e a s e s in a manner s i m i l a r to amphetamine. Available evidence suggests that s e v e r a l of these compounds e x e r t their effect by a r a t h e r specific action in the hypothalamus without producing the central stimulant effects which a r e also associated with amphetamine. We now m u s t wonder i f such a drug alone will provide
Chap. 5
Anorexigens
Po0 s
55 -
adequate and reasonable therapy in obese humans. P e r h a p s a second p h a r macological component will be n e c e s s a r y . Possibly this would be a "psychic stimulant", "psychic energizer" o r anti-anxiety effect n e c e s s a r y to substitute f o r reduced food intake o r relieve the underlying cause of overeating. It has been stated that over 90% of obesity i n humans is psychogenic in origin. 6 Although only centrally acting anorexigenic agents have been considered thus f a r in this review, the possibility should not be overlooked that metabolic, biochemical o r hormonal factors might be drug controlled to combat obesity. Both d-amphetamine68 as well as chlorphentermine, methylphenidate, pipr adol, i m i p r amine, desipramine and a m i t r iptyline show a marked lipid mobilizing activity i n r a t s as shown by i n c r e a s e s in plasma f r e e fatty acids. 69
-
An anorexigenic and faf mobilizing substance (FMS)has been i s o lated f r o m the urine of fasting r a t s . 70 It has been partially fractionated and i s thought to be polypeptide in nature. 71s 72 The function and mechanism of action of F M S remain obscure. Summary - Even though 1965 did not produce any obvious breakthroughs in the a r e a of anorexigenic agents, t h e r e was one significant development. Chlorphentermine was introduced into widespread clinical usage in the United States during 1965. This drug appears to have a d i r e c t amphetaminelike anorectic effect in the hypothalamus with a much lower incidence of CNS stimulation than previous anorexients. Thus, an evaluation of the a c ceptance of chlorphentermine m a y provide an answer a s to whether a "pure anorexigen" is d e s i r a b l e in the t r e a t m e n t of obesity. If i t turns out that some other c e n t r a l effect is a d e s i r a b l e attribute of an anorexigenic agent, then a s u p e r i o r drug may be available f r o m a variety of active compounds that a r e in various stages of development. These v a r y f r o m amphetamine analogs to somewhat different s t r u c t u r e s with a range of both quantitative and qualitative pharmacological differ ences f r o m amphetamine. Research effort continues to be concentrated on amphetamine -like anorexigenic action. The possibility of effective drug control of obesity by a completely different mechanism should not be overlooked.
56 -
Sect. I
- CNS Agents
B i e l , Ed.
References
(1)
E. Davidoff and E. L. Reifenstein, J r . , J. Am. Med. AS'SOC.,
108, 1770 (1937).
H. Nathanson, J. A m . Med. A s s o c . , W 528 (1937) Ulrich, New Eng. J. Med. 696 (1937). A. N u s s b a u m e r and P. B u r i , S-=,, (1965). (5) L. S. Goodman and A. Gilman, "The P h a r m a c o l o g i c a l B a s i s of Therapeutics", T h e Macmillan Company, New York, N. Y . , 1965, pp. 501, 516. (6) W. Modell, "Drugs of Choice", The C. V. Mosby Company, St. Louis, M i s s o u r i , 1964, pp. 313-323. (7) J. R. B o i s s i e r , Therapie,& 803 (1962). (8) S. K. F i n e b e r g , J. Am. Med. A s s o c . , E , 680 (1961). B. K. Anand and J. R. Brobeck, -Y a l e J. Biol. Med., a 1 2 3 (1951). (9) 143 (1955). (10) B. K. Anand, S. Dua and K . Shoenberg, J. Physiol. 248 (1957). (11) S. D. M o r r i s o n and J. M a y e r s , J. P h y s i o l . , e 13,114 (1957). (12) F. R. Stowe, Jr. and A. T. Miller, J r . , E (13) J. R. Brobeck, J. T e p p e r m a n and C.N.H. Long, Y a l e J. Biol. Med., l5, 831 (1943). 358 (14) J. R. Brobeck, S. L a r s s o n and E. Reyes, J. P h y s i o l . , (1956). 89 (1943). (15) A. W . Hetherington, A m e r . J. P h y s i o l . , (16) A. W. Hetherington and S. W. Ranson, A m e r . J. P h y s i o l . , 36, 609 ( 1942). (17) T. Hohn, I. Huus,R. Kopf, I. Moller-Nielsen and P. V. P e t e r s e n , Acta. P h a r m a c o l . Toxicol., l7, 121 (1960). (18) J. A. Gylys, J . J . D . H a r t and M. R. W a r r e n , J. P h a r m a c o l . Exp. T h e r a p . , E,365 (1962). (19) E. I. B o x e r , P r a c t i t i o n e r , 18_7, 214 (1961). (20) L. A. Rudolph and I. MacLachlan, C u r r e n t T h e r a p . R e s . , 4, 629 ( 1 962). (21) H. I. Russek, A m . J. Med. S c i . , 9, 305 (1965). (22) A. Di M a s c i o and D. H. Buie, Clin. P h a r m a c o l . T h e r a p . , 5, 174 (1964). (23) J. F. Emele and M. M. Winbury, Symp. Obesity, Roy. Coll. S u r g . , 22 (1963). (24) J. E. Owen, J r . , J. P h a r m . Sci., 52, 679 (1963). (25) G. F. Holland, C. J. Buck and A . Weissman, J. Med. Chem., 519 (1963). (26) A . W e i s s m a n , F e d e r a t i o n P r o c . , I & 168 (1959). (27) A. W e i s s m a n , J. Exp , g, 271 (1959). (28) A. W e i s s m a n and J. A. Schneider, P h a r m a c o l o g i s t , 2, 71 (1960). (2) N. H. (3) P. (4) 286, 365
217,
,E, E,
-
z,
-
a,
-
Chap. 5
Ano rexig e n s
57 -
Poos
Ref e r ence 8 (29) C. A. Leonard, T. Fujita, D. H. Tedeschi and E. J. Fellows, Pharmacologist, 2, 79 (1961). (30) A. Kandel, R. B. Miller, C. A. Leonard and E. J. Fellows, Pharmacologist, 2, 78 (1961). (31) J. C. LeDouarec and L. Beregi, Conf. Hung. Therap. Invest. P h a r macol. , 2, Budapest (1962), pp. 115-125 [Chem. Abs., 63, 227113 (1965)l. w (32) M. F r e i f e l d e r , J. Med. Chem., &, 813 (1963). (33) W. A. Behrendt and R. Deininger, Arxneimittel-Forsch, 7x1 (1963). (34) V. 0. Nieschutz and G. Schneider, Arxneimittel-Forsch, ,l4, 104 (1964). (35) M. F r e i f e l d e r , Y. H. Ng and F. N. P r e s t o n , J. Med. Chem., 1, 381 (1964). (36) M. Morin-Jomain, J. A b r a h a m and R. Jacquot, Arch. Sci. Physiol., 17, 261 (1963). (37) F r e n c h P a t e n t M2563, June 29, 1964 [Chem. Abs., 6l, P 16014d (1964)); Unlisted Drugs, 17, 62a (1965); Unlisted Drugs, l8, 27c (1966). (38) J. Vague and J. L. Codaccioni, Rev. P r a t i c i e n , l2, 3533 (1962). (39) P. Lambusier, Presse Med., 7 l , 181 (1963). (40) R. S. Alphin, W. H. Funderburk and J. W. Ward, Tox. Appl. P h a r macol. , p, 340 (1964). (41) B. V. Franko, L. J. Honkomp and J. W. W a r d , J. P h a r m . P h a r m a col., l7, 222 (1965). (42) J. Duhault and S. F e n a r d , A r c h . i n t e r . Pharmacodyn., 251 (1965). (43) H. Schmitt and J. C. LeDouarec, Therapie, 20, 111 (1965). (44) V. K. Opitz, F. K e m p e r and A. L o e s e r , A r z n e i m i t t e l - F o r s c h . , s , 278 (1965). (45) B. Dubnick, G. H. Leeson, R. Leverett, D. F. M o r g a n a n d G . E. Phillips, J. P h a r m a c o l . Exp. Therap., E, 85 (1963). 427 (1964). (46) M. J. Kaln, J. Med. Chem., 433 (1964). (47) D. J. Knapp, J. Med. Chem., (48) D. G. Martin, E. L. Schumann, W. Veldkamp and H. Keasling, J. Med. Chem., 8, 456 (1965). (49) T. S . Sulkowski and M. H. W i l l e , A b s t r a c t s 150th A.C.S. Meeting, Atlantic City, N. J., September 13-16, 1965, p . 16P. (50) M. I. Gluckman, Pharmacologist, 1, 146 (1965). (51) T . Baum, Pharmacologist, 1, 147 (1965). (52) G. I. Poos, J. R. C a r s o n , J. D. Rosenau, A. P. Rosxkowski, N. M. Kelley and J. McGowin, J. Med. C h e m . , 9, 266 (1963). (53) A. P. Roszkowski and N. M. Kelley, J. P h a r m a c o l . Exp. Therap. , 367 (1963).
,a
3
-
-
E,
z, z,
s,
58 -
Sect. I
- CNS Agents
B i e l , Ed.
References (54) L. C. Wood and J. H. Owen, J r . , J. New Drugs, 53, 181 (1965). The name "aminoxaphen" was used instead of the c o r r e c t adopted name "aminorex" f o r compound XIII in this article. (55) G. A. Braun, G. I. P o o s and P. C. Johnson, Fed. Proc., 546 (1965). (56) C. F. Howell, N. Q . Quinones and R. A. Hardy, J r . , J. Org. Chem., 27, 1679 (1962). (57) E. N. Greenblatt and H. C. Osterberg, Toxicol. Appl. P h a r m a c o l . , 7, 566 (1965). (58) P. L. Carlton and A. R. Furgiuele, Life Sci., 4, 1099 (1965). (59) H. Chimenes, P r e s s e Med., 72, 1131 (1964). (60) G. Schmidt, Arch. i n t e r . Pharmacodyn., %, 87 (1965). (61) M. L. Tainter, J. Nutr., 27, 89 (1944). (62) W . Sangster, M. I. G r o s s m a n and A. C. Ivy, Am. J. Physiol., 152, 259 (1948). (63) H. Wendel, F. M. Sturtevant and I. Shemano, Pharmacologist, 2, 71 (1960). (64) B. Andersson and S. Larsson, Pharmacol. Rev., l3, 1 (1961). (65) See, f o r example, H. J. Adams and L. C. Greene, J. P h a r m . Sci., 22, 1405 (1964), and G. Stille and H. Lauener, Helv. Physiol. Pharmacol. Acta, 22, C 46 (1964). (66) G. Friedman, L. A. Weingarten and H. D. Janowitz, A m . J. Clin. Nutr., lo, 225 (1962). (67) P. D. Cullen and H. A. Swartz, Canad. P h a r m . J., 97, 33 (1964). (68) R. Santi and G. F a s s i n a , J. P h a r m . Pharmacol., 131 (1964). (69) R. Santi and G. Fassina, J. P h a r m . P h a r m a c o l . , l7, 596 (1965). ( 7 0 ) J. A. F. Stevenson, B. M. B o x a n d A. J. Szlavko, P r o c . SOC. Exp. Biol. Med., 9, 424 (1964). (71) J. R. Beaton, A. 3. Szlavko and J. A. F. Stevenson, Can. J. Physiol. P h a r m a c o l . , 42, 647 (1964). (72) J. R. Beaton, A. J. Szlavko, B. M. Box and J. A. F. Stevenson, Can. J. Physiol. P h a r m a c o l . , 42, 657 (1964). ,
a,
u
-
16,
S e c t i o n I1 Editor:
- Pharmacodynamic A g e n t s
S , Archer, Sterling-Winthrop Research I n s t i t u t e R e n s s e l a e r . N e w York
Chapter 6. E,
C.
A n t i h y p e r t e n s i v e Agents
K o r n f e l d , E l i L i l l y and Company, I n d i a n a p o l i s , I n d .
Of t h e t w e n t y - t h r e e new c h e m i c a l e n t i t i e s i n t r o d u c e d i n t o m e d i c i n e i n t h e U n i t e d S t a t e s i n 1965, none were c o n c e r n e d The y e a r w a s c h a r primarily w i t h antihypertensive therapy,' a c t e r i z e d , t h e r e f o r e , by t h e e x t e n s i o n of e s t a b l i s h e d l e a d s r a t h e r t h a n by r a d i c a l i n n o v a t i o n . The f o l l o w i n g g r o u p s of drugs received a t t e n t i o n :
Diuret i c s The o r a l d i u r e t i c s of t h e t h i a z i d e or r e l a t e d c l a s s c o n t i n u e d t o be t h e one most i m p o r t a n t g r o u p of a g e n t s for u s e e i t h e r a l o n e or, more o f t e n , i n c o m b i n a t i o n w i t h o t h e r hypot e n s i v e drugs. T h i s a r e a i s r e v i e w e d i n d e t a i l i n C h a p t e r 7. Use of t h e t h i a z i d e s w i t h p o t a s s i u m c h l o r i d e t o m a i n t a i n p o t a s s i u m b a l a n c e h a s l e d t o small bowel u l c e r a t i o n p r o b l e m s ; 2 h o w e v e r , a d m i n i s t r a t i o n of p o t a s s i u m i n r e a d i l y d i s p e r s i b l e or slow-release forms a p p e a r s t o o b v i a t e t h i s d i f f i c u l t y O 3 R e s e r p i n e AnaloRs A p p l i c a t i o n of t h e method d e v e l o p e d by R, B. Woodward' f o r t h e t o t a l s y n t h e s i s of r e s e r p i n e h a s been e x t e n d e d t o t h e p r e -
p a r a t i o n of u n n a t u r a l a n a l o g s i n F r a n c e , 5 and o t h e r d e r i v a t i v e s h a v e been s t u d i e d i n t e n s i v e l y i n C z e c h o s l o v a k i a , ' Reearpines w i t h s u b s t i t u e n t s i n r i n g s A , C , and E have been d e v e l o p e d ; however, i t i s u n c e r t a i n a s y e t w h e t h e r t h e s e o f f e r a s i g n i f i cant advantage over t h e n a t u r a l alkaloids. G a n g l i o n i c BlockinR D r u g s The a p p l i c a t i o n of t h e s t e r i c a l l y h i n d e r e d amine g a n g l i o n i c b l o c k i n g d r u g s , s u c h as mecamylamine and p e m p i d i n e , has diminiehed i n favor of a g e n t s w i t h fewer a i d e e f f e c t s . N e v e r t h e l e s s , work on a few r e l a t e d d r u g s h a s been p u b l i s h e d , Workers a t Parke+-Davis l a b o r a t o r i e s h a v e r e p o r t e d on D i b u t a d i a m i n (1)' w h i l e pempidine d e r i v a t i v e s s u c h a s I1 and I11 have been s t u d i e d a t Lakeside.'
60 -
Sect. II
- Pharmacodynamics
A r c h e r , Ed.
I1
I
I11
Amino Acid Enzyme Inhibitors a-Methyl dihydroxyphenylalanine (a-methyl-DOPA) continued to find growing application a s a moderately potent hypotensive agent. Although it i8 still the only drug of this class in wide use, a few related colapounds have been studied. The a-ethyl-DOPA (IV) and the tropone derivative ( V > appear to be
T
hu
IV
.. V
H
decarboxylase inhibitors,"'lo while a,p,@-trimethyl-DOPA is reported to inhibit tryptophane hydroxy1ase.l'
HGrZ
CH3 N TH 2 Cp O O H
(VI)
Ho-Q-cHzEL
80
P
VI
VI I
Still another member o f this group. a-methyl-L-p-tyronine (a-MPT) (VII), inhibits tyrosine hydroxylase. a-MPT has been shown to be effective in the treatment of hypertension caused by pheochromocytoma,l* Hydralizine Analons Although it is one of the oldest hypotensives, hydralizine (VIII) is stiL*l widely used. usually in combination with other agents, A n analogous compound IX, reported from the Lakeside l a b ~ r a t o r i e s .has ~ ~ been shown to lower blood preseure by decreasing peripheral resistance.
Chap. 6
Antihypertensives
Kornfeld
61 -
NkNH2
VIII W.A.O.
I X
Inhibitors
I n t e r e s t i n t h i s g r o u p h a s waned b e c a u s e o f p r o b l e m s a s s o c i a t e d w i t h s i d e e f f e c t s and w i t h h y p e r t e n s i v e c r i s e s f o l l o w i n g c o n c o m i t a n t i n g e s t i o n of t g r a m i n e - c o n t a i n i n g f o o d s i 4 P a r g y l i n e ( X I i s t h e b e s t known of t h e s e a g e n t s .
J3-Receptor
X
Blockers
which was d e v e l o p e d f o l l o w i n g t h e l e a d
Pronethalol ( X I ) ,
XI1
XI
o r i g i n a l l y discovered i n t h e drug D O C - I . ( X I I ) , 1 5 h a s been SUSs t u d i e d i n t h e t r e a t m e n t of a n g i n a and a r r h y t h m i a s . t a i n e d f a l l s i n blood p r e s s u r e have been n o t e d w i t h t h i s d r u g a f t e r o r a l administration f o r several ronths,le Pronethalol was s u b s e q u e n t l y shown t o be c a r c i n o g e n i c i n r o d e n t s , s o t r i a l s have been s h i f t e d t o p r o p r a n o l o l ( X I I I ) , a r e l a t e d member of t h e s e r i e s . l 7 & ~ ! ~ C € I 2 N H C H ~ C H ~ ~ 2 eHC1 \
/
XIII
62
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
G u a n e t h i d i n e Analogs B y f a r t h e most i n t e n s i v e s y n t h e t i c e f f o r t d u r i n g t h e p e r i o d has been d i r e c t e d t o w a r d t h e p r e p a r a t i o n of r e l a t i v e s of g u a n e t h i d i n e ( X I V ) . T h i s d r u g h a s been d e s c r i b e d
XIV
by I. H. Page ae “ t h e most s a t i s f a c t o r y a n t i h y p e r t e n s i v e , . . t o date”18 f o r f a i r l y severe hypertension. Consequently, t h e q u e s t f o r even s u p e r i o r v a r i a n t s h a s been a n a c t i v e one. G u a n e t h i d i n e i e composed of a h e p t a m e t h y l e n i m i n o p o r t i o n ( A ) l i n k e d t h r o u g h a two-carbon c h a i n ( B ) t o a q u a n i d i n e m o i e t y (C), The f o l l o w i n g new a n a l o g s h a v e been d e r i v e d from g u a n e t h i d i n e by v a r i a t i o n of any o r a l l of t h e s e t h r e e structural features, C l i n i c a l r e s u l t s a r e l a c k i n g w i t h some of t h e new compounds; w i t h 0 t h e r 8 , i t a p p e a r s t o o e a r l y t o a s s e s s t h e c l i n i c a l u t i l i t y r e l a t i v e t o t h a t of g u a n e t h i d i n e . I t a p p e a r s l i k e l y t h a t a number of t h e new d r u g 8 w i l l be available. D e b r i s o q u i n (XV)l* and B e t h a n i d i n e (XVI)eo h a v e
xv
XVI
a s h o r t e r d u r a t i o n of a c t i o n t h a n g u a n e t h i d i n e , a f e a t u r e which may make d o s a g e more f l e x i b l e , Each i s l e s s l i k e l y t o produce t h e d i a r r h e a s e e n o f t e n w i t h g u a n e t h i d i n e , Envacar (Guanoxan) ( X V I I ) * l and V a t e n e o l ( X V I I I ) e P h a v e e a c h been
c1
c1 XVII
XVIII
Chap. 6
Antihypertensives
Kornfeld
found t o be e f f e c t i v e i n c e r t a i n g u a n e t h i d i n e - r e s i s t a n t cases. A n o t h e r c l i n i c a l l y e f f e c t i v e a g e n t i s t h e German d r u g , G u a n a c l i n e ( L e r o n ) (XIX);p3 and a f u r t h e r a n a l o g w i t h b o t h h y p o t e n a i v e and a n t i d e p r e s s a n t p r o p e r t i e s is Parke, Davis and Company's Guanoxyfen (XX)." The
XIX g u a n e t h i d i n e i s o m e r s X X I and X X I I h a v e a l s o been p r e p a r e d 2 5 ' 2 e and may o f f e r some q u a n t i t a t i v e a d v a n t a g e o v e r
xx I
XXII
t h e p a r e n t drug, O f i n t e r e s t a l s o from a s t e r e o c h e m i c a l p o i n t of view is t h e o b s e r v a t i o n t h a t t h e o l e f i n i c a n a l o X X I I I i 8 more a c t i v e i n t h e Cis form t h a n i n t h e t r a n s ,
XXIII The o r a l l y a c t i v e Cis form i s more a c t i v e and a l s o of e h o r t e r duration than guanethidine. F i n a l l y , the foilowing a r e l i s t e d t o i l l u s t r a t e o t h e r m o d i f i c a t i o n s which h a v e been reported:
R
P
8 , CHa
(ref. 28)
Guanoctine ( r e f , 29)
63 -
Sect. I1
64 -
CH3
(ref.
30)
(ref.
31)
- Pharmacodynamics
A r c h e r , Ed.
(ref.
24)
32)
(ref.
Miscellaneous AntihjRertensives The p r o s t a g l a n d i n s h a v e shown some h y p o t e n e i v e p r ~ p e r t i e s ,but ~ ~ t h e i r r o l e i n t h i s a r e a is n o t y e t f u l l y elucidated. Among new s y n t h e t i c t y p e s t o ehow a n t i - h y p e r t e n e i v e q r o p e r t i e s a r e t h e Bulgarian d r u g Depreton (XXIV),3 which i s c l a i m e d t o be e f f e c t i v e i n human h y p e r t e n s i o n , and d i a l l y l m e l a m i n e (XXV),35 which i s h y p o t e n s i v e /CH p CH t C H p
“y
f
b
H
2CH r CH 2
by v i r t u e of d i r e c t a c t i o n on v a s c u l a r smooth m u s c l e . REFERENCES d e H a e n , D r U R a n d Cosmet.
Ind.,
s, 27
(1966).
1.
P.
2.
W. B. Ashby, J. Humphreye, and S. J. S m i t h , B r i t . Med. J., 11, 1409.
3.
V.
4.
R. B. Woodward, F. E. B a d e r , H . B i c k e l , A. J. F r e y , and R. W. K i e r s t e a d , J. Am. Cher. SOC., 7A, 2023 (1956).
5.
R o u s s e l l UCLAF, F r . P a t e n t s 1366721, 1366723, 1369956, 1369957 (Derwent 1 3 6 9 0 , 1 3 6 9 1 , 14065, 14066 1.
6.
I. J i r k o v e k y , I. E r n e s t , and M. Chem. C o m m . , 3355 (1956).
Wynn, L a n c e t , l S 5 11, 1241.
x,
P r o t i v a , Coll.
Czech.
Chap. 6
7.
D. K.
Antihypertensives
65 -
Kornf eld
McCarthy, G. M. Chen, D. H. Kaump, D. P o t t e r , K. H o l a p p a and C. E n s o n , Arch. I n t . Pharmacodyn., 154, 263 L1965). A.
4 1 ) 5 .
8.
W. B. S e v e r s , W. Pharm. S c i . ,
9.
R.
10
J. K i n n a r d , and J. P.
2. 859
.
.
J. L e v i n e and A.
lL6, 42 (1964).
Sankyo, Jap.
and 1 0 2 6 ( 1 9 6 5 ) .
S j o e r d e m a , J.
B u c k l e y , J.
Pharm.
EXR. T h e r . ,
P a t e n t 12930/64. Roche, Neth.
P a t e n t 6414247 (Derwent 17316).
11
Hoffmann-La
12.
A. S j o e r d a m a , K. Engelman, S. S p e c t o r , and S. U d e n f r i e n d , L a n c e t I1 ( 7 4 2 2 1 , 1 0 9 2 ( 1 9 6 5 ) . A. I. E d l i n , W. J. B u c k l e y , J. Pharm.
14.
a,
K i n n a r d , E. E. V o g i n , and J. Sci., 2 0 . (1965).
P.
S i m p s o n , and a, 754 ( 1 9 6 4 ) .
F. S. G l a z e n e r , W. M. Morgan, J. M . P. K . J o h n s o n , J. Am. Med. A B B . , C.
E. P o w e l l and I. H. S l a t e r , J. Pharm. EXR. T h e r . ,
E,480
(1958).
16
B. N.
Prichard, B r i t .
17.
J. Hamer, T. G r a n d j e a n , L. M e l a n d d z , and G O Sowton, Brit. Med. J., - 1 720.
18.
A. C. C o r c o r a n , D r u R s of C h o i c e 1966-1967, C. V. Woeby Co., S t . Louis (1966).
19.
M. H. L u r i a and E. 289 (1965).
20
.
21 22 23
24
.
C.
M.
W.
G i f f o r d , J.
W.
S.
P e a r t and M .
398 ( 1 9 6 5 ) .
J.,
The
D. Freis, C u r r e n t Ther. Ree., Am.
Med.
ABB.,
x,901
HcWahon, B r i t .
T.
T. D. V. L a w r i e , A. R. 8. R e i n e r t , B r i t . Med.
Med.
-
(1965).
J.,
1.
L o r i m e r , S. 0 . H c A l p i n e , and 402 ( 1 9 6 4 ) .
J.,A
K. Kuehna, C. J a n o c h a , V. Muench. Med. Wschr.,
--
Hed.
J a n o c h a , and D. (1965).
3, 2599
P a r k e , D a v i s and Co. , U.S. A s s , , 1 9 4 , 1376 ( 1 9 6 5 g .
P a t e n t 3203988
Hagnus,
17.
Am.
Med.
Sect. I1
66 25,
R.
26.
Sandoz Co.,
27.
W. E. B a r r e t t , R. 2 1 , 506 (1965).
G i u d i c e l l i , H.
- Pharmacodynamics
Najer, s, 726 (1965).
23,
a n d 2’.
A r c h e r , Ed.
L e f e v r e , ComVt. Rend.,
Fr. P a t e n t 1413924 ( D e r w e n t 18888). M u l l , a n d A.
P.
J.
Plummer, Exver,,
/ch.
28.
Bager. U . S .
29.
H. J.
P a t e n t 3236859.
G. S c h o e p k e , H. L.
z,
D. BrondyK, L. H. Weimeter, and I n t . Pharmacodyn., 185
S c h m i d t , Arch.
(1965).
30.
D. I. B a r r o n , I. L. N a t o f f , a n d D. J. Pharm., 534 (1965).
31.
C i b a , U.S.
32.
Lab
33.
E. W. H o r t o n , E x p e r , , $ ( 3 ) ,
34.
D. P a s k o v , A. S p a s o v , I. K r u s h k o v , and E. Arch. I n t . P h a r m a c o d y n . , x 7 . 1 3 2 (1965).
35.
W. A . Arch.
2.
K.
V a l l a n c e , Brit.
P a t e n t 3178443.
Lumiere, B r i t .
P a t e n t 973533 ( D e r w e n t 1 4 2 3 7 ) .
113 (1965).
F r e i b u r g e r , J. R. Weeks, a n d D. W. Exa. P a t h . Pharm., 39 (1965).
3,
Golovinsky, Ducharme,
Chapter 7.
Diuretic Agents
Edward J. Cragoe, Jr. and James M. Sprague Merck Sharp & Dohme Research laboratories, West Point, pa.
A perusal of the current l i t e r a t u r e , including the patent literature, leads one t o believe t h a t compounds with d i u r e t i c a c t i v i t y a r e most abundant. However, many of these reports a r e undocumented o r the supporting biological data a r e meager. This review i s r e s t r i c t e d t o selected reports that contain credible biological support o r present chemical novelty. The l i t e r a t u r e coverage includes p a r t of 1964 and extends through April 1966.
Organomercurials. The advent of newer d i u r e t i c s has diminished the ckinical importance of the organomercurial d i u r e t i c s and few new compounds have been r - m r t e d i n recent years. Nevertheless, an active i n t e r e s t continues in the locus of action of t h i s c l a s s of agents i n the kidney nephron and the definition of t h e molecular events involved i n the action of these substances on nephron function, p a r t i c u l a r l y a s it relates t o sodium transport, potassium excretion and e f f e c t s on uric acid and glucose metabolism. Additional important evidence has been reported i n support of the mercuric ion hypothesis1 over the i n t a c t molecule hypothesis* f o r the action of mercurials. The mercuric ion theory1 implies t h e presence i n the kidney of mercuric ion during the period of active diuresis following organomercurial administration; solid evidence of t h i s has been lacking. Using a novel isotope exchange diffusion analysis f o r @3, evidence has been presented t h a t the l e v e l of mercuric ion i n the rat kidney correlated w e l l w i t h the onset and duration of diuresis a f t e r Hgm3-chlormerodrin. Mercuric ion was released a l s o i n kidney t i s s u e of the r a b b i t and the chicken.3 Similar results were obtained i n the rat w i t h p-chloromercuribenzoic acid, 4,5 an organomercurial t h a t i s not d i u r e t i c i n the dog and does not release mercuric ion i n a model i n v i t r o system where other active mercurial d i u r e t i c s readily yield mercuric ion'lTaowever, t h i s substance has been shown t o be rapidly d i u r e t i c i n t h dog when administered by retrograde infusion i n t o t h e renal tubular lumen.
-
%
Important studies on t h e locus of action i n the nephron7 and the e f f e c t of the sodium reabsorption and oxygen consumption8 of these mercurials have been reported. Recently reported data support the concept that mercurial d i u r e t i c s in-
h i b i t active sodium reabsorption & vivo by inhibition of the Na+-@-activated component of the membrane ATPaSe SYSThus, an enzyme system has been
identified t h a t can be correlated w i t h active sodium and potassiumtransport and that i s inhibited i n v i t r o and i n vivo by mercurial diuretics.
--
--
Acylphenoxyacetic Acids. Compounds of t h i s type containing an tY,&unsaturated-acyl group were designed t o react w i t h functionally important sulfhydryl gro s in a manner similar t o t h a t believed t o occur w i t h mercurial diuretics.% Biological data have now appeared indicating t h a t such a react i o n indeed does occur i n v i m as well as i n v i t m . Ethacrynic acid (I) i s
68 -
Sect. I1
c1
- Pharmacodynamics
A r c h e r , Ed.
c1
excreted, in part in t h e dog as the cysteine -uct;d mercurials are known t o b e p r e t e d as the cysteine 5-11 conjugates. The ethacrynic acidc'4! cysteine adduct was shown to be an I active diuretic i n man.13 In the dog, ethacrynic acid caused a decrease in protein-bound sulfhydryl It had no such effec in the groups in kidney c e l l s as do t h e mercurials. rat, a species i n which it is not d i ~ r e ! t i c . l ~ , ~The 5 uptake of G 3 - c h l o r merodrin by s l i c e of renal cortex of t h e dog and the rat was reduced by ethacrynic acid.
-
C H C-!-&-c~~2~
2
Using thirteen cosnpounds of t h i s class ranging from highly active to inactive in the dog diuretic assay, l i t t l e correlation was found between diuret i c a c t i v i t y and reactivity toward sulfhyaryl (cysteine) in an 2 v i t r o model system. Better correlation was found with the a b i l i t y to inhibit m t r o Na+-K?-(membrane)-ATPase from guinea pig kidney. However, the enzyme derived f r o m t h e kidney of the dog and the t was inhibited in v i t r o t o approximately the same extent by ethacrynic 8 c i d . e Also, ATPase from the kidenys of rats t h a t had received e t crynic acid shoved substantial inhibition without resulting in diuresis.
--
3
Substitution on the ammatic nucleus o r on the unsaturated-acyl group markedly influences diuretic a c t i v i t y as measured in the dog. Compounds without nuclear substituents showed only weak activity. Substitution in the 2-position increased a c t i v i t y modestly while substitution in the 3-position o r in t h e 2,3-positions, especially by chlorine o r methyl, gave highly active compounds. Additional substitution in the 5 and/or 6 positions resulted in l o w activity. However, the 1,kaaphthalene analog was quite active. Substireduced activity; the tution on the methylene of the unsaturated-acyl -up mono-methyl campounds showed reduced a c t i v i t y and the dimethyl compounds had only l o w activity. Saturation of t h e double bond of the acyl group yielded compounds w i t h marginal activity.lOil? Detailed documentation of the pharmacology of ethacrynic acid and some of i t s congeners has appeared. I n dogs, they caused a prompt and profound water diuresis and the excretion of nearly equivalent amounts of sodium and chloride when administered either parenterally or orally. There was some increase i n potassium excretion, especially following intravenous administration. They have a steeper dose response curve and a substantially greater maximal saluretic effect than the thiazides, and a t least as great an effect as the organomercurials. Results w i t h combinations indicate a mechanism of action f o r ethacrynic acid different from t h a t of the thiazides, acetazolamide and t h e mercurials. The ascending loop of Henle is a major s i t e of action i n the nephron.ll,lg Numerous reports on ethacrynic acid support i t s c l i n i c a l efficacy.
Aromatic Sulfonamides. Interest continues in derivatives and structural variants of the m-benzenedisuli'oaamides. A number of 4-chloro-5-( substitut e d - a m i n o ) - m - b e n z e n e d i s u d e s and some khydroxy analogs were effective
Chap. 7
Diuretics
Cragoe and Sprague
69 -
diuretics Bd the 4-chloro-5-(2-guanidinoethylamino) compound was weakly hypotensive. Several 5- and 6-hydrazino derivatives were less effective in dogs and rats than dichlorphenamide.21 However, the major recent i n t e r e s t in compounds of t h i s class l i e s i n analogs where one sulf'amyl group has been replaced by other electmn a t t r a c t i n g gmups, such as, alkylsulfonyl, acyl o r carboxyl and i t s functional derivatives. Diuretic a c t i v i t y i n rats mice has been reported f o r several 3-nethylsulfonylbenzenesulfonamides.8Bt23 The carboxylic acid analogs have yielded highly active and useful drugs of current interest. Four campounds of this category have received considerable study. The chemistry and pharmacology of clopamide (11) has appeared earlier, but evidence of i t s c l i n i c a l u t i l i t y continues t o appear.
V
111, R=H; R'=N(CH3)2
Iv, R=R'=CH3 The related acylhydrazine (III)(CI-546) was an effective diuretic, natriuretic and cbloruretic in rats, dogs, monkeys and man. Results in the dog indicated that it exerts its effect on t h e renal tubule and that carbonic anhydrase inhibition becomes significant only a t high doses. In man, kaluresis did not occur t o any marked extent in the effective daily o r a l dose of 20-320 mg. resulting in a favorable sodium-potassium excretion r a t i o . Metabolism studies in several laboratory species, following o r a l administration, indicated rapid absorption and excretion principally i n the urine with recoveries of 80-100$ of the dose. The major urinary excretion products were unchanged drug and a minor amount of the corresponding benzoic The related c a r b p m i d e derivative (IV)$cI-456) was similarly effecacid* The methyl substitu ion on the sulfamoyl group t i v e in t h e same species. of t h i s compound i s noteworthy. The f a t e of t h e methyl group is not reported but, from r e s u l t s with other methylated sulfonamides i n vim, demethylation t o yield an unsubstituted sulfamoyl compound would be anticipated. The action of these compounds and the thiazides on active ion transport and m o t h muscle contractility has been studied i n relation t o the hypotensive a c t i v i t y of the benmthiadiazines .27
ange
Remarkable a c t i v i t y has been found i n a series acids appropriately substituted i n the amino group. was achieved when t h e amlno substituent was arylmethyl o r heterocyclic-methyl.
Sect. I1
70 -
- Pharmacodynamics
A r c h e r , Ed.
One member of t h i s series, furosemide (V)(also designated, f u r e d e , frusemide) had strikingly different properties from t h e sulfonamides of a l l other types. Eowever, the isomeric compounds, the 2 - c h l o r o - 4 - s u b s t i t ~ e d ~ i n o - 5 sulfamoylbenzoic acids, were not saluretic.28 The meximum naturesis, chloruresis and diuresis obtainable with furosemide, following o r a l o r parentera1 administration t o man and t o several species of animals, was several-fold greater than that produced by the most active thiazides.30 &tassim excret i o n increased but, due to the massive sodium excretion, the sodim/potassim r a t i o is favorable. R e n a l studies indicated a s i t e of action in the renal tubule different from the thiazides and mercurials; furosemide a f f e c t s not only proximal and istal tubule sites but a l s o t h e ascending limb of the loop of Henle.3l-3 These properties of furosemide are shared 'by ethacrynic acid, a non-sulfonamide, of entirely unrelated structure. Furthermore, interaction of furosemide w i t h other diuretics i n the dog indicated that the mechaniam of furosemlde is different from that of the t h i a z i es and mercuria l s and i s similar o r identical t o that of ethacrynic acid. 39
P;
Furosemide was excreted largely as unchanged drug i n the urine36 but 2-chloro-5-sulfamoylanthranilic acid, a r i s i n g from loss of the furfury1 group, was identified as a metabolite.37,38 The c l i n i c a l efficacy of t h i s drug i s w e l l s ~ p p o r t e d . 3 9 9 ~m s e m i d e i s reported t o produce t h e same stde e f f e c t s c o m n t o other s onamide diuretics, i e hypokalemia, hyperglycemia and hyperuricemia. 393
.
3
Benzothiadiazines and Analogs. Many new publications on thiazide d i u r e t i c s continue to appear, but no strikingly novel structural variants have been disclosed. Variations of t h e heterocyclic ring have given active compounds. The 3-aza analog of chlorothiazide, 6-chlo1-0-2~-1,2,3, kbenzothiatriazine-7-sulfonamide 1 , l - d i xide, showed a c t i v i t y comparable to hydrochlomthiazide i n rats and rabbits.& 6-chloro thiochrcnnan-7-sulfonamide 1,ldioxide i s reported to be active in r a t ~ . ~ 6-Chloro-3,4-dihydro-2~-1,23 benzothiazine-7-sulfonamide 1,l-dioxide (the isostere of pprochlorothiazide i n which the b N H I s replaced by C%) wa8 active i n dogs. Detailed attention has been given t o the ieoindoline analogs, i.e. the phthalimides ( V I ) and the corresponding 1-oxoisoindolines. h e compound of the latter series, chlorexolone (VII) was suff i tly active t o j u s t i f y c l i n i c a l trial and has received further study.
43-fa
VI
VII
In each series, the nature of the substituent on the ring nitrogen had pronounced e f f e c t s on a c t i v i t y a s measured in the rat. Cycloa-1 groups were
Chap. 7
Diuretic s
Cragoe and Sprague
71 -
most favorable i n each series, and maximum a c t i v i t y wa6 found w i t h cyclohexyl o r substituted-cyclohexyl although, i n the phthalimide series, cyclopentyl, cycloheptyl and cyclo-octyl showed comparable a c t i v i t y . These derivatives were 3-6 times a s a c t i v e as chlomthiazide. Reduction of one carbonyl group t o CHOH and t o Cf4! (VII) increased a c t i v i t y some 10 and 50-fold respectively. Chlorexolone i s 300-450 times as active as chlorothiazide i n the rat and 50-fold i n t h e dog. Conversion of the other carbony1 group t o C+ to give the chlorexolone isomer abolished a c t i v i t y . The sodium, potass um and chloride excretion i n t h i s s e r i e s resembled t h a t of the thiazides.'5 Metabolism studies i n rats and dogs showed chlor olone t o be excreted as monohydroxy derivatives of t h e cyclohexane ring.@ C l i n i c a l r e s u l t s showed c rexolone t o resemble hydroflumethiazide i n its action and t o be e q u i p o t e n t Y t 4 7 O f i n t e r e s t are the 3-(ketoalkyl) derivatives of t h e hydrothiazide series.49,w These a r e formed from the reaction of ketoaldehydes, RCO(CH )nCHO, with t h e appropriate disulfamoyl aniline. With pketoaldehydes fn=l), intermediate a n i l s were isolated when the ortho-sulfamy1 group carried a t least one substituent. These were assigned t h e anil-enol struct u r e (VIII). On f u r t h e r reaction, under acid conditions, IX, R - R k H zides (M)were fomed. Certain of these compounds (e.g. the X=CF3, n-1 or 2; V I I I , R 2 = a l l y l , R3=CH3 o r C6H5, X=C1) exhibited diure&
Yrothia-
VIII
Ix
a c t i v i t y i n the dog comparable t o trichlormethiazide. P a r t i c u l a r i n t e r e s t l i e s i n the hydrazones derived from M and 1-hydrazinophthalazine (hydralazine), an antihypertensivs agent. Some properties two such compo ds have X 4 8 p fi 4 H 3 , R31CH3, n=l, X=CF3)?' and EX-5004 (R !? =HI been reported, E R k H , n=l, ~ 4 1 ) . 59 5 These hydrazones were not active d i u r e t i c s but t ey showea a unique blocking action on t h e d i u r e t i c a c t i v i t y of the thiazides. k9 T h i s blocking action of E X - 4 8 7 has been employed t o analyze the mechanism of action of t h e t h i a ~ i d e s . 5 ~W-48n did not a l t e r the d i u r e t i c response t o acetazolamide but it blocked the d i u r e t i c a c t i v i t y of hydrochlorothiazide. The a c t i v i t y of chlorothiazide was only p a r t i a l l y blocked. Thus, it was concluded t h a t EX-487" i n h i b i t s the "B" (benzothiadiazine) e f f e c t of the thiazides, i.e. both hydrochlorothiazide and chlorothiazide, but leaves the carbonic a drase inhibitor "A" (acetazolamide) response of chlorothiazide unaffect&T1 EX-5004 was reported to be hypotensive in t h e rat and dog, probably by the lowering of eriphexal resistance through a d i r e c t action on vascular smooth muscle.~3
72 -
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
y r i d i n e s (xy. The diuretic properties of triamterene, 2,4,7-triamino- -phenylpteridine, have been known f o r m e time. Some structurea c t i v i t y results have now been published. The nature of the substituents not odiy influence the potency of the compounds, but the qualitative charact e r i s t i c s of water and electrolyte excretion. ~n rats, 2,1C-diaminO-6,7dimetbylpteridine (SKF-371), like
4 X
2-anilino- 4,7-diamino-6-phenyl derivat i v e caused saluresis with lraluresis and no diuresis.55
The 6-cartmmyl derivatives were g e n e m l u more natriuretic than triamterene, especially in dogs. Although these derivatives prpduced l i t t l e kaliuresis, they did not display the antikaliuretic e f f e c t s exhibited by triamterene Thus, 2-phenyl- 4,7-diaminopteridine-6-carboxmide (SKF-6874) in the adrenalectomized rat receiving aldosterone produced natriuresis w i t h no e f f e c t on potassium excretion. In contrast triemterene increased sodium excretion and depressed potassium excreti0n.5~ Substitution on the carbarmy1 nitrogen with o r without simultaneous substitution on the 7-amino nitmgen can lead t o increased a c t i v i t y in rats. In a series of N-R-2phenyl-lcamim-7-NMc-6-pteridinecarboxamides, the most active compound was ~y-5256, where R=2-methoxyethyl. Replacing the 2-phenyl w i t h p-methoxyo r p-chloro-phenyl, 2-thienyl, methylmercapto-, diethylaminoethylamino or hydrogen gave l e k s active compounds as did replacing 7-NHEi w i t h hydroxyl. 56 ~n more detailed studies in rats and dogs, ~y-5256was shown t o have about the same o r a l diuretic a c t i v i t y as hydrochlorothiazide. About equal amounts of sodium and chloride were excreted along w i t h some potassium and, when combined w i t h hydrochlomthiazide, t h e e f f e c t s of t h e two drugs were additive. 57
.
Another substituted-amide, N- (2-mrpholinoethyl) -2-phenyl-4,7-diaminopteridinecarbommide (Vy-3654), i n t h e dog produced marked sodium and chloride excretion w i t h some potassium excretion. From studies on combinations of Wy-3654 w i t h other diuretic agents, it has been concluded that the mode and/or s i t e of action of ~y-3654differs from that of hydrochlorothiazide, acetazolmide and ethacrynic acid but are similar to t h a t of mercaptomerin .58 The metabolism of triamterene in humans results in five products i n unchanged drug, 2,4,7-triamino-6-p-hydroxyphenylpteridine, the corresponding s ic acid ester, a N-glucuronide of triamterene and an unknown m e t e b o l 3 9 From the kidney ti sue of triamterene-treated rats, a pteridine nucleotide has been isolated.& Clinical studies using a combination of triamterene and a thiazide indicated t h a t no levels could be maintained without potassium supplements. t h e urine:
T1
-fk-!N%
Chap. 7
Diuretics
73 -
Cragoe and Sprague
zincs. N - A m i d i n o - 3 - ~ p ~ z i n e c a r b o x a m i d e s(XI) constitute a new class o diuretic agents. They are unique both in structure and in their strong basic character. In norma1 rets, they produced marked diuresis while leaving unaffected o r repressing potassium excretion. They antagonized 6 the renal actions of exogenously administered aldostemne, DOCA o r hydmcorti5 sone in the adrenalectamized rat. N 3 Although the potency in dogs YBS lower, t h e relative a c t i v i t i e s of the various members f the series paralleled those XI in rats. 83
Halogen in the 6-position enhanced activity; the potency was in the order C l > B r > I . The 6-chloro derivative (XII) was more t e n t than triamterene and considerably more active than spironohctone. 630 Introduction of alkyl, substituted-alkyl, alkylideneamino o r a r y l substituents on one o r both of the terminal nitrogens of t h e guanidino moiety gave compounds that generally were l e s s active than XII; however, derivatives of XI1 bearing N-benzyl, N-(2-hydroxyethyl) o r N, N' -dimethyl substituents were equipotent with XII. Derivatives of XI1 having one acyl group on t h e 3-amino o r on one o r both of the termina nitrogens of the guanidine moiety were considerably less active than XII. k2 The introduction of a second amino group, a t position-5, further improved activity. N-Amidino-3-amino-5-dimethylamino-6-chloropyrazinecarboxamide (XIII) was more active than XI1 in rats and dogs with a slower onset and a longer duration of action. When XI11 was administered t o rats dogs In o r humans, it was demethylated stepwise t o the 5-amino analog (XIV).'4 rats, X N was as natriuretic a s hydrochlorothiazide with no kaliuretic effect. S m a l l doses augmented the natriuresis produced by large doses of acetazolamide while decreasing potassium excretion. A synergistic increase i n sodium excretion occurred when X N and hydrochlorothiazi e were coadministered while potassium excretion was considerably reduced. 85
In dogs, XIV was qualitatively similar but less potent than in rats. Small doses of XIV in combination w i t h either hydrochlomthiazide o r ethacrynic acid produced enhanced natriuresis and depressed kaliuresis. Although the mode of action is different from spironolactone and organomercurials, stop-flow studies in icated that X I V i n h i b i t s d i s t a l potassium secretion and sodium r e a b ~ o r p t i o n . ~ 5
I n patients w i t h cirrhosis and ascites, XIV, in doses of 8 to 30 mg./day, produced diuresis and saluresis with some bicarbonate excretion with reduced kaliuresis. In combination w i t h hydrochlorothiazide o r ethacrynic acid, sed t h e excretion of potasXIV enhanced the excretion of sodium and d slum mre effectively than spironolactone.
878
g-Triazines. A recent c r i t i c a l study in rats has confirmed and extended earlier diuretic and natriuretic structure-activity r e l a t ons in a large series of 2-mono-6ubstituted-amino-4-amino-e-triazines.55r L
b
74
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
2-(p-Chlorophenylamino)-4-amino-~-triazhe (Chlorazanil) has received considerable study in man, However, a more recent study indicated that the m-chloro isomer may be significantly more active in rats and dogs and i n I U R In comparison with the present day potent diuretics, campounds of t h i s c l a s s have l i t t l e p r a c t i c a l importance. The principle remaining interest l i e s i n t h e i r modest e f f e c t on potassium excretion and i n the modification of the action of several adrenalocorticoid steroids such as the antagonism of minerslocorticoids and of t h e deposition of hepatic glycogen induced by the g l u c o c o r t i c o i d s . ~ ~A detailed study has shown the influence on potassium excretion i n the rat; a t l e a s t , it is complex and strongly dose related. A t non-toxic doses, most of the compounds can produce kaluresis. Miscellaneous Heterocyclic Compounds. From a s e r i e s of 2-methylene-4thiazolidones ,.(O the d i u r e t i c a c t i v i t y of one member, 2-ethoxycarbonylmethylene-3-methyl-5-piperidino-bthiazolidone(XV), has been re r t e d under the name Etozolin. It was effective in both the rat and dog.7l-B I n the
xv
XVI
XVII
E
rat, it was reported to give a grea er response than chlorothiazide, hydrochlorothiazide and acetazolamide.7 r75 I n t h e dog, however, it was l e s s active than hydrochlorothiazide and meralluride.75 When given t o dogs i n clearance type experiments, it enhanced the maximal diureses of the mercuria l s and of chlorothiazide, indicating a probable mechanism different from these d i u r e t i ~ s . 7 ~ Results i n man a r e not available. Substituted sydnones (XVI) have been shown to increase the excretion of sodium and chloride i n rats.77~78 O f the three compounds reported i n d e t a i l , the 3-butyl-Lethyl derivative showed a c t i v i t y a t lower doses than the 3-sec. -butyl compound and t h e 3-isopropyl-4-carboxylic acid; however, t h e a c t i v i t y was not great, and t h e i r p o t e n t i a l usefulness is limited by t h e i r convulsive properties. A series of 3-(aminoaUryl)-sydnones were not a c t i v e .79
I n a s e r i e s of thirty-nine s-triazoles, only the lead member, 5-(paminophenyl)-5-triazole-3-thiol 7XV I ) showed d i u r e t i c and n a t r i u r e t i c act i v i t y i n rats a t reasonable doses.
80
The intense diuresis produced derivatives was related to i n vivo polyuria was not accompanied by an t h e action bears no resemblance t o
--
i n the rat by a number of ethyleneimine l i b e r a t i o n of ethyleneimine. This marked increase i n electrolyte excretion, hence that of the d i u r e t i c s i n c l i n i c a l use.
~ . ~ ~
Chap. 7
Diuretics
Cragoe and Sprague
75 -
An extrarenal mechanism may be involved, perhaps a t the p i t u i t a r y , since t h e polyuria was similar t o t h a t of diabetes insipidus.81
Aldosterone Antagonists. Although many 17-spirolactones of t h e s t e r o i d type have proven t o be p o t e n t aldosterone antagonists in animals and i n r a m , few new compounds of t h i s type have been reported. However, t h e c l i n i c a l u t i l i t y of these compounds have stimulated the examination of other s t e r o i d s f o r e f f e c t s on e l e c t r o l y t e t i o n i n animals and i n man. Oxygenated derivatives of progesterone@" and testosterone85 showed augmented act i v i t y . The a c i d s corresponding t o c e r t a i n s t e r o d spirolactones exhibited antagonistic a c t i v i t y comparable t o the lactone.& Diuretic a c t i v i t y of some adrenocortical steroids in t h e rat have been compared. Cortisone, hydrocortisone and some of t h e i r 1,2-dehydro and fluorinated analogs have a c t i v i t y exceeding t h a t of chlorothiazide .87 Compounds that are possibly non-steroid aldosterone antagonists have turned up i n a series of 3-substituted-coumarins (e.g. 3-carboq1, 3-acety1, The a c t i v i t y is said t o be confirmed i n man.@ An extensive 3-glyoxyloyl). review of aldosterone antagonists has appeared.@
REFERENCES
2,
1. I.M.
Weiner, R . I . Uvy and G.H. Mudge, J. P h a m c o l . Fxptl. Therap., (1962). 2. R.H. Kessler, R. Zozano and R.F. P i t t s , J. C l i n . Invest., 656 (1957). 3. T.W. Clarkson, A. Rothstein and R. Sutherland, B r i t . J. Pharmacol., 24, 1 (1965 . 1. 4. T.W. Clarkson and M. Greenwood, B r i t . J. Pharmacol., :5O (1966). 5. T.W. Clarkson, Federation P m c . , ' w 6. E.J. Cafruny, N. Y. Acad. Sci. Symp., Mar. 3-5, 1966. 7. E. Littman, M. H. Goldstein, I,. Kasen, M.F. Levitt and R . P . Wedeen, J. Pharmacol. Exptl. Therap., 152, 130 (1966); N. Y. Acad. Sci. Symp., Mar. 3-5, 1966. ,221 8. R.H. Kessler, S.W. Weinstein, F.D. Nash and M. FuJimto, Nephron, 1, (1964); R.H. Kessler, N. Y. Acad. Sci. Symp., Mar. 3-5, 1966. 9. V.D. Jones, G. Zockett a n d h a x m a c o l . Exptl. Therap. 23 - (1965). . _- _ 10. E.M. Schultz, E.J. Cragoe, Jr., J.B. Bicking, U.A. Bolhofer and J.M. Sprague, J. Med. Pharm. Chem., 5, 660 (1962). 11. K.H. Beyer, J.E. Baer, 7.K. Michaelson and H.F. Russo, J. Phaxmacol. Exptl. them^*, 1 (1965). 12. I . M . Weiner and O.H. Muller, J. Pharmacol. Ekptl. Therap., 113, 241 (1955). 13- Y.H. Kong, G.V. Irons, Jr., W.M. G i n n , Jr., G.E. Garrison and E.S. Orgain, Circulation, 32, Suppl. 11, 128 (1965). 14. R.M. Komorn anhE.J. Cafruny, Science, 133 (1964). 15 R.M. Komorn and E.J. Cafruny, J. P h a m c o l . Exptl. Therap., 148, 367 (1965). 16. R.Z. Gussin and E.J. Cafruny, J. Pharmacol. Exptl. Therap., 1 (1965). 17. D.E. Duggan and R.M. Noll, Arch. Biochem. Biophys., log, 3-965). 18. J.B. Hook and H.F. Williamson, Proc. Soc. Exptl. B i o m e d . , 120, 358 (1965). SOC. Exptl. 19- J.E. Baer, J.K. Michaelson, D.N. McKinstry and K.B. Beyer, Biol. Med., 3, 87 (1964).
96
&,
-
26,
-
,
147,
143,
m,
a,
76 -
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
20.
A. Lespagml, D. Bar, C. I&spagnol and A. Anouwtr, Bull. 8oc. chim. France,
21.
A. u-gml,
22.
HFKugita, M. Zbkeda, T. Oine and K. Higaki, Chem. Phaxm. Bull., 10, 1001 to 1008 (1964) J.R. Boissier, C. Dumont, J. Usbms and C. %lea, Thempie, 20, 1 3 5 (1965)D. H. KaW, R.L. F m ~ m y ,LIT. Blouin and D. Williams, J. New Drugs, 21
23. 24. 25. 26. 27.
28.
29. 30.
800 (1965).
D. Bar, A. Robclet, C. Mizon-Capron and J. B i z a r d , Thempie,
-
19, 1423 (1964).
5,
(1964)
R.E. Ober, S.F. Chang, L.T. B l o u i n and G.W. Gymn, Federation Proc., 532 (1966). L.T. B l O ~ i n , D.H. Kaumip, R.L. Fm8-y and D. WiUiamS, J* New D W S ,
302 (1963).
25, 2,
Daniel and C.W. Nash, Arch. Intern. Pharmacodyhamie, 158, 139 (1965). K. Sturm, U. Siedel, R. Weyer and H. Ruschig, Chem. Ber., 99, 328 (1966). W. Siedel, K. Stuxm and W. Scheurich, Chem. B6 3-45 n 9 6 6 ) . R.J. Timuexman, F.R. Springman and R.ii. T h c S9 Current Therap. Res., 88 (1964). J.B. Hook and H.E. Williamson, Pmc. SOC.Exptl. Biol. Med., ll8, 372 (1965). W. Suki, F.C. Rector, Jr. and D.Y. Seldin, J. C l i n . Invest., 1458 (1965). G. Malnic, F.L. Vieria and H. Enokibara, Nature, E.E.
5,
31. 32. 33. 34. A. small and E.J. Cafruny, ~ h a x m a c o l o g i s t - , ~ 6 5 ~ ~ ~ . ~ 35. J.B. Hook and H.E. Yilliemson, J. Pharmacol.Exptl. Therap., 3,88 (1965). 36. J. Gayer, Klin Yochschr., 2,$ 1 5 . 37. A. $ussler and P. J3ajd6, Arznezidz-iorsch., 14, 710 (1964). 38. A. EIaussler and H. Wicha, Arzneimittel-Forsch., 15, 81 (1965). 39. D.E. Hutcheon, D. Mehta and A. Romano, A.M.A. A r x . Internal Med., 9, 542 (1965). b. R.G. Mu*, J. Am. M ed. Assoc., 195, 1066 (1965). 41. L. Bencomo, J. Fyvolent, S. a and L. Knhnlul, Current Therap. Res., 2, 339 (1965). 42. A. Bose, S.K. Bose and D. Chakravarty, Indian J. Pharm., 27, 3 (1965). 43. J.R. Boissier, C. DuWnt, J. Lesbros and C. Malen, Theraps 20, 1305 (1965). 44. Merck & co., Inc., French Pat. M-3136 (g,64, 1 1 2 i , 4 ) 7 450 E.J. Cornish, G.E. Lee and U.R. Wragg, J. PGm. Phannacol., 18, 65 (1966). 46. A.F. Lant, W.I. Baba and G.M. Wilson, Ciin. Phanuacol. Therap: 7, 196 (1966). 47. W.I. Baba, A.F. Iant and G.M. Yilson, Clin. Pharmacol. Therap., 1, 212 (1966). 48. K. Corbett, S.A. Edwards, G.E. Lee and T.L. Threlfa l l , Nature, 208, 286 (1965). 49. J.E. Robertson, D.A. Dusterhoft and T.F. Mitchell, Jr.,'nMed.chem., 8, 9 (1965). 50. H. Inoue, M. Take&, K. H i g s k i and H. Kugita, J. Pham. Soc. Japan, 85, 95
1m.
-
51. 52. 53. 54.
55.
(1965)
C.R.
Ross and E.J.
R.A. Yea-,
C.A.
Cafruny, J. Pharmacol. Exptl. Therap., 140, 125 (1963). Brahm and D.L. Miller, Toxicol. Appl Fhai5=col., 1, 598
.
-
(1965) A.I. E d l i n , W.J. Kinnard, E.E. Vogin and J.P. Buckley, J. Pharm. Sci., 54 20 (196). V.D. Wiebelhaus, J. Weinstock, A.R. Maass, F.T. Breanan, G. Sosnowski and T. larsen, J. Phaxm. Gxptl. Therap., 397 (1965). T.U. S h l a n and F.E. Shidemm, J. Phazm. Exptl. Therap., 148, 356 (1965).
149,
-
Chap. 7
Diuretics
Cragoe and Sprague
77 -
56.
A.A. S a n t i l l i , L.E. McCardle and T.S. Osdene, Abstr. papers, 150th Am. Chem. Soc., Meeting Abstracts, 16~-17~+, September, 1965. 57- M.E. Rosenthale and T.S. Osdene, Pharmacologist, 7, 165 (1965). 58. M.E. Rosenthale, L. Datko, J. Kassarich and F. Sckeider, J. Pham. Exptl. ThemPo, 147, 399 (1965)15 812 (1965). 59- K ~ m > z n e i m i t t e l - F o r s c h . , 60. H. Herken, V - Neuhoff and G. Senft7ki.n. Wochschr., 43, $0 (1965). 61. R.A. Thompson and M.F. Cmwley, Postgrad. Med. J., 41, 706 (1965). 62. J.B. Bicking, J.W. Mason, O.W. Woltersdorf, Jr., J.H. Jones, S.F. Kwong, C.M. Robb and 6. J. Cragoe, Jr., J. M e d . Chem., 8, 638 (1965). 63 M.S. Glitzer and S.L. Steelman, PIVC. Soc. ExptlT Biol. Med., 1x), 364 (1965) 64. C.B. Jones, H.F. RUESO and A. Zacchei, Federation Proc., 25, 197 (1966). 65 J.E. Baer, C.M. Mucha, S.A. Spitzer and H.W. Yee, Federatsn Proc., 25, 197
-
(1966)-
66. N.W. 67. T.B. 68. W.B. 69. K. N. 70.
71 72
73
9
74. 75 76. 77. 7879.
Moulcheibir and W.M. Kirkendall, C l i n . Research, 13, 425 (1965). Repold8 and H.C. Pelle, C l i n . Research, 2, 184719661 McKeon, Jr., Arch. Intern-mie, 151, 225 (1964). Modi, C.V. D e r I n . Pharmacodynamie, 151, 13 - (1964). . - G. Satzinger, Ann. Chem. Uebigs, 150 (1963). 0. Heidenreich and L. Baumeister, Arch. Exptl. Pathol. Pharmakol., 247,
-
665,
-
347,,(1964)*
G. Fulgraff, L. Bauueister and 0. Heidenreich, Arch. Exptl. Pathol. Pharmakol. 3% (1964). 0. Heidenreich, G. Fulgraff, L. Baumeister and K. Schmiz, Arch. Exptl. Pathol. Pharmakol., 249 432 (1964). 0. Heidenreich, G. Gharemani, P. Keller, Y 1 Kook and K. Schmiz, Arzneimittel-Forsch., 1242 (1964). R.J. Girerd, C.L. Rsssaert, G. D i P a s q u a l e and C.R. Smith, Rev. Can Biol., 23, 197 (1964). OFHeidenreich and L. Baumeister, Klin. Wochschr., 42, 1236 (1964). -L.B. K i e r , D. D h a m and M.J. Fregly, J. Pham. S c i z 53, 677 (1964). M.J. Fregly, L.B. Kier and D. Dhawan, Toxicol. Appl. P&mcol., 6, 529
, 247,
-’ 14,
-
(1964)
T. Bruzzese, S. Casadio, E. Marazziuberti and C. Turba, J. Pham. Sci., 54 1041 (1965). 80. H d Yale and J. J. Prala, J. Med. Chem., 2, 42 (1966). 81. R.M.V. James and H. Jackson, Blochem. Pharmacol., 14, 915, 1847 (1965); B r i t . J. Pharmacol., 223 (1965). 82. R.C. %it and C.M. Kagawa, J. Med. Chem., 7, 524 (1964). 83 C.M. Kagawa, Endocrinology, 2, 724 (1964184. J.M. George, G. Saucier and F.C. Bartter, J. Clin. Endocrinol. Metabolism, 25 621 (1965)999 (1964). 85 C.M. Kagaua and R. Pappo, Endocrinology, 86. C.M. Kagawa, D.J. Bouska, M.L. Anderson and W.F. Krol., Arch. Intern. Pharm a c o F , 8 (1964). ’ J 368 , (1965). 87 P.F. D Arcy and E.M. Howard, J. Wsm. Pharmacol., l 88. R. S e l l e r i , 0. Caldini, R. Spano’, G. Cascio and M. Palazzoadriano, Arzneimittel-Forsch., 15, 910 (1965). 89. E.J. Ross, C l i n . ~ r m c o l .Therap., 6, 65 (1965).
-
-
-
25,
-’
2,
149,
-
78 -
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
Chapter &A. Angina P e c t o r i s and Antianginal Agents Paul Kennedy, Jr., Pharmaceutical Division, Geigy Chemical Corp.
, Ardsley,
N.Y.
During t h e last few y e a r s t h e symptom complex of angina p e c t o r i s h a s been t h e s u b j e c t of an i n t e n s e renewal of i n t e r e s t . Angina i t s e l f , by d e f i n i t i o n is pain, t h e e a s i l y described y e t poorly understood c l i n i c a l s i g n of a complex patho-physiological problem which occurs when t h e need €or oxygen and p o s s i b l y o t h e r n u t r i e n t s by myocardial t i s s u e exceeds t h e a v a i l a b l e supply. The need of t h e h e a r t i s governed by t h e work t h e h e a r t must perform and t h e supply i s dependent on an adequate coronary a r t e r i a l system and flow of blood through t h i s system. The oxygen s a t u r a t i o n of blood, t h e s t a t e of t h e c a p i l l a r y bed, t h e a b i l i t y o f myocardial t i s s u e t o u t i l i z e oxygen, and t h e metabolic s t a t u s of t h e h e a r t a r e r e l a t e d f a c t o r s . A t h e r o s c l e r o s i s of t h e coronary vessels i s t h e major e t i o l o g i c f a c t o r y e t i t should be noted t h a t angina p e c t o r i s can o c c a s i o n a l l y occur without evidence of coronary d i s e a s e , a s i n s e v e r e anemia, c o n g e n i t a l h e a r t d i s e a s e and advanced pulmonary d i s e a s e . I n c o n t r a s t , some p a t i e n t s w i t h evidence of coronary a r t e r y d i s e a s e never experience angina. Antianginal drugs have as t h e i r goal t h e a l l e v i a t i o n , a b o l i t i o n o r prevention of t h e symptom, angina p e c t o r i s , without a d v e r s e l y a f f e c t i n g c a r d i a c performance. I n a d d i t i o n , most drugs base t h e i r claim f o r a n t i a n g i n a l e f f i c a c y on p r o p e r t i e s which hopefully w i l l improve t h e b a s i c coronary i n s u f f i c i e n c y . No compound a v a i l a b l e today alters t h e fundamental a t h e r o s c l e r o t i c process. N i t r o g l y c e r i n has been and s t i l l i s t h e most important agent f o r a b o r t i n g t h e a c u t e a t t a c k of angina p e c t o r i s , though as w e s h a l l soon see, i t s e f f i c a c y has been challenged by some very thought-provoking experiments. I n animals n i t r o g l y c e r i n a c t s a s a pure d i l a t o r by i n c r e a s i n g coronary flow, decreasing coronary a r t e r i o v e n o u s d i f f e r e n c e and by e f f e c t i n g no s i g n i f i c a n t change i n c a r d i a c oxygen consumption. The same w a s thought t o be t r u e f o r man. I n 1959, Brachfeldl s t u d i e d f o u r normal and s i x mild c a r d i a c p a t i e n t s b e f o r e and a f t e r n i t r o g l y c e r i n . Following n i t r o g l y c e r i n , myocardial oxygen consumption increased as w e l l a s coronary flow. There w a s no change i n c a r d i a c work and a f a l l i n myocardial e f f i c i e n c y w a s observed. Also noted w e r e decreases i n pulmonary a r t e r y , pulmonary wedge and r i g h t a t r i a l p r e s s u r e s . A t t h e same time, Gorlin2 reported on seventeen p a t i e n t s , f o u r t e e n of whom had angina p e c t o r i s . Following n i t r o g l y c e r i n t h e r e was a decrease i n c a r d i a c output, blood pressure, and l e f t v e n t r i c u l a r work accompanied by f a l l s i n t h e systemic and pulmonary venous pressures. Coronary flow as measured by t h e n i t r o u s oxide flow method w a s e s s e n t i a l l y unchanged and even decreased i n some p a t i e n t s . Gorlin concluded t h a t n i t r o g l y c e r i n a c t e d by temporarily reducing t h e work of t h e h e a r t r a t h e r than by r e l a x i n g t h e coronary v a s c u l a r tree. The time-honored conclusion t h a t n i t r o g l y c e r i n increased coronary flow i n angin a l p a t i e n t s had been challenged using t h e technique of c a r d i a c c a t h e t e r i z a t i o n . Gorlin2 confirmed h i s f i n d i n g s using I 1 3 l serum albumin t o measure transcoronary c i r c u l a t i o n time with a n e x t e r n a l counting technique. Coronary c i r c u l a t i o n time was decreased i n normal i n d i v i d u a l s a f t e r n i t r o g l y c e r i n b u t remained t h e same o r increased i n t h e abnormal group. I n c o n t r a s t , Johnson and Sevelius,3 using r a d i o a c t i v e iodopyrocet, demonstrated i n c r e a s e s i n myocardial blood flow i n
Chap. 8A
Antiang inal
Kennedy
79 -
arteriosclerotic patients followin sublingual nitroglycerin and oral pentaerythritol tetranitrate. While the substances seem to have fallen from favor, a variety of external countin! techniques have been developed for the study of the coronary circulation. Rb 6, Rb84, Na24, Kr42, Kr85 and ~e133,among others, have been employed to measure myocardial blood flow.
,bl
Bing4 has worked with a coincidence counting technique using RbB4, a positron emitter, to determine coronary flow equivalent. With this method, nitroglycerin increased the clearance equivalent of Rb84 in patients without coronary heart disease and caused a decrease in clearance equivalent in patients with coronary disease. Ross5 has measured human myocardial blood flow by determining precordial radioactivity following the injection of solutions of radioactive Kr85 or Xe133 directly into coronary arteries after coronary arteriography. The right and left coronary circulations could be studied separately and comparisons made with anatomical findings. No significant differences in flow at rest were found between normal and coronary artery disease patients. Bernstein6 using Xe133 has studied the effect of nitroglycerin in thirty patients undergoing selective coronary arteriography for the evaluation of chest pain. Nitroglycerin (0.4 mg) sublingually caused a decrease in myocardial blood flow, left ventricular work and no significant decrease in coronary vascular resistance in patients with normal as well as diseased coronaries. Nitroglycerin (0.1 to 0.2 mg) injected directly into the coronary vessel caused an immediate though transient increase in myocardial blood flow and a decrease in coronary vascular resistance in the same patients. This blood level, attained by intracoronary administration, could not be achieved by the sublingual route using accepted dosages. However in attempting to explain the apparent conflict between arteriographic dilation caused by nitroglycerin and other nitrates7 and the failure of these compounds to increase blood flow, Bernstein has presented a hypothesis based on a biphasic action. He suggests that during the first phase there is coronary vasodilation, a drop in coronary vascular resistance and increase in myocardial blood flow. During the second phase of the drug's action, the effects on the systemic circulation predominate and there is a decrease in arterial pressure and cardiac output. The decrease in coronary vascular resistance persists into the second phase, but because of the drop in arterial pressure, the myocardial blood flow falls below control levels. Winbury8 and Conng have presented detailed reviews and critiques of the use of radioactive tracers to which the reader is referred. Ross5 feels that the accurate location and discreet measurement of flow in unperfused areas of heart muscle which result from disease, may prove difficult using external counting techniques. The advent of selective coronary arteriographylo has made it possible to study the pathological anatomy of the diseased coronary artery. Sones7 and Likoffll have demonstrated an increase in the calibre of the main coronary arteries and those branches large enough to be visualized following sublingual administration of nitroglycerin and other nitrates. Not only have presumably sclerotic vessels been seen to dilate, but also previously non-visualized collaterals were visualized following drug administration. However an increase in the calibre of a vessel, "vasodilation", does not imply an increase in myocardial blood flow. Winbury8 has pointed out that smaller vessels which regulate flow cannot be visualized by the approach and questions whether or not the results obtained by
80 -
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
these techniques have any greater significance than those obtained by the measurement of blood flow. Their value in anatomic appraisal of the larger visible vessels cannot be challenged. Nitroglycerin exerts harmacological effects on both the venous and arterial circulation. Mason, 15 using normal patients, demonstrated that nitroglycerin dilated capacitance vessels of the forearm and caused significant pooling of blood. This finding represents additional evidence for the fall in cardiac output following nitroglycerin. W illiamsl3 demonstrated with cineradiograms a decrease in ventricular dimensions after nitroglycerin. These observations further suggest that nitroglycerin may relieve angina by reducing the work and oxygen requirements of the heart. Cohenl4 has attempted to correlate in sixty patients the findings of selective coronary cinearteriography with clinical history, physical examination, electrocardiogram, Kr85 coronary blood flow studies, and myocardial oxygen and lactate extraction at rest and during stress. Some predictions could be made from the patient's history which were not previously possible. Disease of a single coronary vessel usually indicated pain less than one year's duration. Increasing duration in years revealed more extensive pathology. Pain limited to the chest usually indicated milder anatomic pathology than when the patient had pain in two or more sites or experienced prandial or nocturnal angina. Disease of three vessels was more common in this group. Seventy percent of the resting electrocardiograms were abnormal and two-thirds of the remainder were abnormal with exercise. The measurement of coronary flow at rest or after stress could not distinguish patients with coronary disease from those without, and no consistent correlation could be made with anatomic pathology. MyQcardial lactate production or decreased extraction of lactate by the myocardik could be correla ted with the severity of disease. Raab15 feels that interest in the metabolic and neuro-regulatory factors affecting the myocardium has been lagging due to a "one-sided preoccupation" with vascular anatomic factors. According to Raab, data on total coronary flow, arteriography and coronary sinus oxygen saturation do not locate circumscribed areas of anoxia or define the causative mechanism. In addition to the atherosclerotic process he feels that environmental, emotional and nicotine-induced over-stimulation of the sympatho-adrenal system and the deterioration of counter-regulatory mechanisms secondary to physical inactivity should receive more attention. Since catecholamines augment the uptake and consumptior.of oxygen far beyond energy requirements, factors such as stress, smoking, emotion and unusual physical exercise must be controlled by measures which can cushion this sympathetic activity. Emotional relaxation, nicotine abstinence and systematic physical training are recommended. Thus far we have limited our review to a few of the current techniques used to study the coronary circulation and in so doing have shown some of the controversy surrounding the mechanism of action of nitroglycerin. The problem of angina pectoris and its relief is equally complex. Angina cannot be shown by the arteriogram or measured by coronary sinus oxygen or lactate extraction studies, or identified by the varied techniques used to calculate coronary flow. Vasodilation is not synonymous with increased coronary blood flow and neither expression means relief of angina. Several factors, the exact inter-relationship of which are not understood are probably etiologic, and relief of angina
Chap. 8A
Antianginal
Kennedy
81 -
can probably be attributed to several mechanisms which are also not fully understood as yet. Sublingual nitroglycerin has long been considered the most useful agent for the relief of acute anginal attacks and for the prevention of an attack if taken prior to a stressful situation known to precipitate angina. While evidence has been mainly subjective, various exercise tests have been developed to achieve objectivity. Nitroglycerin and other compounds are studied for their effect on prevention, delay or decrease of anginal pain associated with a standard amount of exercise. An evaluation of simultaneous or post-exercise electrocardiographic changes may be included in the evaluation. Bernsteinld has criticized these approaches because the patients studied are often limited to those whose anginal attacks are reproducible after a given amount of exercise or to those with reproducible electrocardiographic abnormalities. These patients represent but a small fraction of the total group of patients with angina pectoris. Sandler, l7 using a double-blind technique has reported that nitroglycerin does not alter the duration of an established anginal attack when compared to placebo, but that the drug increased work performance and shortened the duration of ensuin angina when administered prophylactically three minutes before exercise. RussekfB corroborated this later phase of Sandler's experiment giving nitroglycerin five minutes prior to exercise. Fischlg has been unable to demonstrate any effect of nitroglycerin on the duration of the actual attack, and in addition, found the drug no better than placebo when given three, five and ten minutes before exercise. Because of the difficulty in matching nitroglycerin with a perfect placebo Fisch feels that the responses of patients in the previously mentioned studies may have been influenced by drug recognition. This controversy involving nitroglycerin accentuates the host of difficulties inherent in the evaluation of drug efficacy in angina pectoris. If the attacks are of very short duration, for example, under ninety seconds, it is conceivable that the effects of nitroglycerin might not have time to be distinguished from those of placebo. It should also be pointed out that Fisch's patients were carefully picked for reproducibility of symptoms and are not necessarily representative of the majority of patients with angina pectoris. While angina is frequently related to effort, it also occurs at rest, during or after eating and at the time of emotional stress. Nitroglycerin, despite controversy, remains the drug of choice for immediate relief from an acute anginal attack and for very short-term prophylaxis. Amy1 nitrite though faster in'onset of action, has a shorter duration of action and must be inhaled. Isosorbide dinitrate and erythrol tetranitrate are used sublingually, and by this route have been shown to afford clinical protection in anginal patients for periods up to two hours. These agents'have little or no value in aborting the acute anginal episode. Newer sublingual nitrates, such as clonitrate20 and stereo-isomers of pentanitrates21 do not seem to possess any advantages over nitroglycerin. Several long-acting nitrates are available for long-term prophylaxis of anginal attacks. This concept of therapy is far different from treatment of acute attacks or the relatively short prophylaxis mentioned previously in relation to the sublingual agents. The efficacy of the organic nitrates available for oral administration such as pentaerythritol tetranitrate, erythrol tetranitrate,
82 -
Sect. I1 - Pharmacodynamics
A r c h e r, Ed.
isosorbide dinitrate and trolnitrate phosphate 'must be established by long term investigation. As a class they seem to have pharmacological activity similar to nitrogl~cerin~~-~4 but the results of long term treatment are difficult to evaluate in terms of their effect on anginal pain. Investigations conducted without placebo control are generally enthusiastic, while those employing double-blind methods have frequently not shown a statistical difference from placebo. The stresses of every day living involve a myriad of difficult-tomeasure variables which influence the number and severity of anginal attacks, and therefore, a high degree of placebo responses can be expected. Bernstein16 in considering this problem, suggests that treatment periods continue at least one year for each drug under evaluation. Unfortunately, longer studies of this type are extremely difficult to undertake from a practical standpoint. Dipyridamole, a relatively new entry in the antianginal field, and quite unrelated to the nitrates, has a chemical nucleus of pyrimido-pyrimidine rings. When administered intravenously or orally to laboratory animals, the drug increases coronary blood flow and coronary sinus oxygen content. Normal individuals, as well as patients with impaired coronary circulation, have shown similar increases in these parameters following intravenous administration.25 Laboratory studies with heart preparations have shown dipyridamole to protect against disturbances in function and fall in high energy phosphate levels induced by hypoxia.26 Heart mitochondria of animals pretreated with the drug and exposed to hypoxia demonstrate preservation of anatomic structure. 27 Vineberg28 employed long-term oral administration of dipyridamole in animals with experimental coronary occlusion, resulting in enhanced survival and increased coronary collateral circulation as compared to untreated controls. B ~ n a g has ~ ~shown that dipyridamole, in the presence of intact red blood cells, prevents the deamination of exogenous adenosine suggesting this mechanism may account for effects on the coronary blood flow. Recently Emmons30 and co-workers demonstrated a favorable effect by dipyridamole on human platelet aggregation. Dipyridamole is not intended for the relief of an acute attack of angina pectoris but for long-term administration. In some instances several months of continuous therapy may be required to achieve a satisfactory response. Clinical observations without placebo controls in long-term treatment of angina pectoris have been quite enthusiastic and investigations have run as long as 24 months.31 The results of studies using placebo controls and the double blind technique have been equivocal. Chromonar hydr~chloride~~ and phenylamine,33 not yet available commercially in the United States, are agents that increase coronary blood flow. In addition, phenylamine is reported to have sympatholytic, adrenolytic and central sedative actions. Clinical reports from abroad have been, for the most part, encouraging. The monoamine oxidase inhibitors have been used in the therapy of angina pectoris as well as in hypertension and certain psychiatric disorders. While experimental evidence for this effect on angina may be scant, several theories regarding mechanisms of action have been proposed.34 These include central nervous system stimulation, mood elevation, central analgesic effect, increase in coronary flow (though this seems unlikely in man), a blocking effect on pain transmission, and decreased oxygen requirement of the tissues. However, there is no clear pharmacological basis for beneficial effects of these compounds on the coronary circulation or the myocardium.
Chap. 8A
Antianginal
Kennedy
83 -
According to a recent review35 most clinical studies indicate that the monomine oxidase inhibitors cause a subjective increase in exercise tolerance and patients can do more work during standardized exercise tests than during control periods. Nevertheless, ischemic ECG changes are not altered or delayed and may be more severe. Controlled and uncontrolled studies, while not unanimous, do seem to suggest some effect on anginal pain or the patient's reaction to it. This group of drugs can produce serious toxic reactions which have limited their use, by and large, to cases resistant to other forms of therapy. The use of beta-adrenergic blocking agents in the therapy of angina pectoris has been the subject of recent interest. Since the catecholamines increase oxygen utilization by the heart as previously discussed,l5 compounds that may block this effect present an interesting approach to the problem. Pronethalol has been studied fairly extensively abroad. The drug reduces heart rate at rest and after exercise. While there appears to be a normal exertional increase in stroke volume, overall cardiac output after exercise may be red~ced.3~9~7 The drug should not be used in patients with cardiac failure or impending failure because of its myocardial depressant action. There were several favorable reports on the use of this agent in angina pectoris. More extensive use has been partly limited by frequent CNS side effects and by a report of its tumor-producing activity in mice.38 Propanalol has a similar mode of action, and has been reported to have a therapeutic effect ten times greater than pronethalol without carcenogenic otential. Initial impressions of this agent have been generally favorable.39-11 No attempt has been made to consider all possible approaches to the problem. The use of sedatives and tranquilizers in angina pectoris can be quite useful for those individuals in whom anxiety, excitement and tension are precipitating factors. Alcohol in moderation, should not be overlooked in this regard. Papaverine, xanthines and anticoagulants have their advocates. Treatment of coexisting cardiac decompensation, arrythmias and hypertension benefits the anginal patient, as does reduction of weight and correction of anemia. Chemical or surgical thyroidectomy has been successful in some severe cases. Interest in surgical revasculization seems to be gaining some momentum. Though many if not all approaches are probably beneficial to certain individual patients or groups of patients, none as yet represent the ideal. None cure or halt the atherosclerotic process. The search must continue. References
1. 2. 3.
4.
5. 6. 7.
Brachfeld, N.; Bozer, J, and Gorlin, R.: Circulation 19, 697 (1959). Gorlin, R., Brachfeld, N., MacLeod, C. and Bopp, P.: Circulation 3 705 (1959). Johnson, P.C. and Sevelius, G.: JAMA 173, 1231 (1960). Bing, R.J., Bennish, A., Bluemchen, G., Cohen, A., Gallagher, J.P. and Zaleski, E. J. : Circulation 29. 833 (1964). Ross, R.S., Ueda, K., Lichtlen, P.R. and Rees, J.R.: Circulat. Res. 15, 28 (1964). Bernstein, L., Friesinger, G.C., Lichtlen, P.R. and Ross, R.S.: Circulation -9 33 107 (1966). Sones, F.M., Jr.: presented at 14th Annual Convention of the American College of Cardiology, Boston, Mass., February 18, 1965.
a4 -
Sect. 11
- Pharmacodynamics
A r c h e r, Ed.
Winbury, M.M. : Advances . i n Pharmacology, S. G a r a t t i n i ; P.A. Shore (ed.), New York: Academic Press, 1964, vol. 3, pp 1-78. 9. Conn, H.L., Jr. : C i r c u l a t . Res. 10, 505 (1962). C i r c u l a t . Res. 527 (1959). 10. West, J.W. and Guman, S.V.: C i r c u l a t i o n 26, Likoff, W., Lehman, J.S., Kasparian, H. and Segal, B.I.: 11. 751 (1962). 12. Mason, D.T. and Braunwald, E. : C i r c u l a t i o n 32. 755 (1965). C i r c u l a t i o n 32. 767 (1965). 13. W i l l i a m s , J.F., Jr., Glick, G. and Braunwald, E.: h e r . J. Cardiol. 14. Cohen, L.S., E l l i o t t , W.C., Klein, M.D. and Gorlin, R.: 17, 153 (1966). 15. Raab, W.: Amer. Heart J. 66. 685 (1963). Vasc. D i s . 2, 357 (1965). 16. Bernstein, A. and Simon, F.: Lancet #7415, 747 (1965). 17. Sandler, G.: 18. Russek, H. I. and Howard, J.C., Jr, : JAMA 189, 108 (1964). 19. Fisch, S.: presented a t t h e American Therapeutic Society, 66th Annual Meeting, June 1965. 20. Warshaw, L.J., Shafer, N., Caginalp, N. and Stein, I.: Med. Times 93, 614 (1965). Koretsky, S. and Altman, G.E.: h e r . J. Cardiol. 15, 220 21. Riseman, J.E.F., (1965). J. New Drugs 5, 143 (1965). 22. Scriabine, A. and McShane, W.K.: Amer. J. Med. S c i . 23. Afonso, S., Rowe, G.G., Lowe, W.C. and Crumpton, C.W.: 246, 584 (1963). Chelius, C.J., Afonso, S., Gurtner, H.P. and Crumpton, C.W.: 24. Rowe, G.G., J. Clin. Invest. 40, 1217 (1961). Amer. Heart J. 63, 146 (1962). 25. Kinsella, D., Troup, W. and McGregor, M.: 26. Kunz, W., Schmid, W. and Siess, M.: Arzne 12, 1098 (1962). Rev. Argent. Cardiol. 27. Lozada, B.B., Laguens, R.P. and Riuz Beramendi, A,: 32(5), (1965). Canad. Med. Ass. 28. Vineberg, A., Chari, R.S., P i f a r r e , R. and Mercier, C.: J. 87, 336 (1962). Douglas, C.R., I m a i , S. and Berne, R.M. : C i r c u l a t . Res. 15. 29. Bunag, R.D., 83 (1964). 30. Enrmons, P.R., Harrison, M.J.G., Honour, A.J. and Mitchell, J.R.A.: Lancet 603 (1965). 31. Griep, A.H. : Vasc. D i s . 1, 299 (1964). 32. Lochner, W. and Hirche, H j . : Arzneimittelforsch. 13, 251 (1963). Deutsch. Med. Wschr. 85. 1405 (1960). 33. Bohm, C.: 34. Zbinden, G.: Amer. J. Cardiol. 5, 1121 (1960). "Vasodilator Drum". i n Goodman, L.S.: and Gilman. A.: 35. Nickerson. M.: The Pharmacological Basis of Therapeutics, ed. 5, New-York: The k c m i l l a n Co., 1965, chap. 34, p. 749. 36. Dornhorst; A. C: and. Robinson, B.F. : Lancet #7251, 314 (1962). 37. Schr'dder, G. and Werk'd, L.: Amer. J. Cardiol. 15, 58 (1965). B r i t . Med. J. 2, 1266 (1963). 38. Paget, G.E.: 39. Srivastava, S.C., Dewar, H.A. and N e w e l l , D.J.: B r i t . Med. J. 2, 724 (1964) B r i t . Med. J. 2, 337 (1965). 40. G i l l a m , P.M.S. and Prichard, B.N.C.: 41. Keelan, P.: B r i t . Med. J. 1, 897 (1965). 8.
L
.
~
-
+u ~
-
I
Chapter 8 B.
Antiarrhythmics
Ralph D. Tanz, Department of Pharmacology, Geigy Chemical Corp., ArdsleY, IJ. Y.
From the therapeutic approach, despite ~rmerousinvestigations, the degree of advance in the area of antiarrhythmic therapy has not been as mked 88 one might desire. Every year many new dn;lgs are reported, but few ever reach clinical evaluation and none have thus far surpassed the traditional agents. A systematic synthesis of antiarrhythmic and antifibrillatory compounds is rendered difficult by the fact that most antiarrhythmic agents are quite different in chemical structure. A rnrmber of substances with entirely different chemical structures are known to possess antiarrhythmic activity and it is extremely difficult to attribute this action to a basic structure commn to a l l agents in this field. Diverse drugs m y abolish or prevent arrhythnias by influencing different cardiac parameters (e.g., refmctoriness, excitability, rhythmicity and conductivity). Cardiac stimulants or depressW, ,synpathamimetics, sympatholytics, agents enhancing catecholanine depletion or storage, cholinergics, anticholinergics, local anesthetics, sntihistaminics, autonomic and central neural depressants all have offered ~lurmhrougpathways for pharnracological investigation. Thus a clear demonstration of structure-activityrelationships is relatively impossible and meaningless.
-
The basis for this relative lack of success may be in the anatomical a d physiological nature of the heart itself, which, from the standpoint of arrhythmias, can really be considered to possess five distinct structures. The epecialized conduction system, which allows the heart to contract in a synchronous manner, consists of the sino-atrial node, the atrioventricular node, and the Bundle of His and diffuse Purkinje fiber system. In addition, the auriculssr and ventricular musculature also conducts impulses, and m y , under certain conditions, initiate impulse formation resulting in ectopic beats. Disturbances in either the conduction system or musculature, can lead to a ,disorganizedbeat and inefficient cardiac contraction which in turn m y diminish cardiac output. Such disturbances in iqpulse formation and/or conduction are referred to as cardiac arrhythdas, though a preferable term might be dysrhythmias. Since most serious arrhythmias result in a faster than normal ventricular rate, it is not surprising that the two principal agents, qlinidine and procaine amide have, as a camon property, the ability to depress impulse formation and, therefore, rate. As mentioned, there are msny chemical substances that can accompUsh the same end, but quinldine and procaine amide also possess pharmacological specificity for cardiac tissue that other agents often lack. Cardiac glycosides (alone or in combination), although usually used to improve the contractile force of the heart, are often employed to depress specific areas of the arrhythmic heart with the hope of restoring a more normal conduction time and efficient ventricular rate. The complex nature of the problem ha8 of necessity forced pharmacologists to resort to a number of different laboratory models in order to screen potential antiarrhythmic compounds, for no one model is suf'f'iciently useful by itself. The phsnaacologist must test for action upon rate production, excitability and conduction time. Deraagenents of impulse formtion due to chemical
86 -
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
agents (e .g. aconitine, cardiac glycosides, acetylcholine, catecholamines, etc.) o r physical events ( e l e c t r i c a l l y o r surgically induced arrhythmias) must be measured, and the degree of protection afforded by a test substance t o a standard agent, usually quinidine And, he must be ever c-ed mindm of the toxic properties of a new compound. These d i f f i c u l t laboratory limitations have t o date, yielded no chemlcal agent possessing greater therapautic efficacy than the three time-tested stalwarts, quinidine, procaine amide and cardiac glycosidides. What is equally disturbing i s the fact that the original observations of the antiemrhythmic properties of these substances resulted, not Avlm laboratory study, but rather from astute c l i n i c a l observation.
.
The presence of acetylcholine and norepinephrine i n proper ratio i n the f'unctional heart is Important i n the maintenance of cardiac rhythmicity. The ideal antiarrhythmic should therefore support a balanced r a t i o bsttreen cardiac norepinephrine and acetylcholine, yet at the same time it should ensure a diminution of myocardial e x c i t a b i l i t y t o circulating catecholamines. I n addition, the ideal agent should depress the i n t r i n s i c rhythmicity of the conducting pathways, and regulate the flux of intracellular sodium and potassium, thereby maintaining ionic balance. It seems obvious from the outset that no one drug will be found t o possess all the properties inherent i n the definition o f ' t h e ideal antiaxrhythmic. More likely, the i d e a l agent becomes many drugs capable of interfering with, or reversing, the numerous abnormal physiologic patterns of the heart. 1. Beta Adrenergic Blockers. With the a v a i l a b i l i t y of beta adrenergic blocking agents, pharmacologists have been handed a most important research tool. The agents of greatest current i n t e r e s t are dichloroisoproterenol ( X I ) , M J 1999,pronethala 1, propranolol and N-isopropyl-p-NitrophenylethamUznine (INPW). A l l have been shown t o protect against the i n i t i a t i o n of various, laboratory induced arrhythmias and t o terminate SQPY! existing arrhythmias Pronethalol and DCI have been reporged t o afford protection against u b a i n induced f i b r i l l a t i o n i n guinea pigs and t o reduce hythmias resulting from a combination of ouabain plus e l e c t r i c a l s t i m u l a t i o r Doubt has been cast, however, as t o whether the antierrhythmic properties of these agents are solely attributable t o t h e i r beta adrenergic blocking action? ye Recent evidence obtained by comparing the beta adrenergic blocking and antiarrrhythmic a c t i v i t y of the dextro-isomer and the racemic mixture of propranolol has resulted i n the current view that antiarrhythmic a c t i v i t y i s i n part due t o a non-sqcific (depressant) "quinidine-lib'' action, as w e l l as beta blocactivity. This conclusion i s based in p a r t on the f a c t that the racemic mixture of propranolol reversed the arrhythmias resulting from coronary ligation plus epinephrine, but the d-isomer did not; yet both agents reversed ouabain-induced arrhythmias and neither was effective against ventricular arrhybhmias due t o coronary l i g a t i o n alone. Since the d-is-r possesses only 1/50 the beta adrenergic blocking action of the racemic mixture, it appears that i n those arrhythmias associated with catecholamine release, beta blockade i s of importance.
,
.
Chap. 8B
Antiarrhythmics
Tanz
87 -
A number of studies have been performed comparing the antiarrhythmic activities of these agents with quinidine?"The results obtained appear to depend on the laboratory models employed, but, in general, propranolol is more potent than pronethalol insofar as beta adrenergic blocking and antiarrhythmic activity are concerned. Several British clinicians have also geported success in the treatment of ventricular arrhythmias with propranolol.l ' Pronethalol is somewhat different than its newest derivative, propranolol, in that it possesses both sympathom5metic activity and an antivagal action, both of which result in increased heart rate. Moreover, pronethalol lengthenes the . reflractory period, diminishes excitability and is a potent local anesthetic equa to procaine .1',13 One of the newer ents, INPEA, was compared to pronethalol for antiarrhythmic activlty ? '% Both agents antagonized catecholamine-induced arrhythmias (epinephrine and methylchloroform plus epinephrine), but were ineffective against the arrhythmias resulting f'rom coronary artery ligation. Furthermore, only pronethalol was effective in reversing ouabain-induced ventricular tachpxixdia, indicating once again, that pronethalol also possesses a nonspecific depressent action, similar to quinidine.
MJ 19% is a beta adrenergic blocker which also has the ability to antagonize cardiac irregularities produced by (large doses o f ) catecholamines, but affords no protection against the arrhythmias resulting f'rom ouabain or coronary 1igation.l' Insofar as protective potency against arrhythmias is concerned it appears that propranolol > pronethalol > MJ 1999.
.
2. Catecholamine Depletors It follows that since beta adrenergic blocking agents are able to antagonize certain types of arrhythmias that catecholaminedepletion might also afford protection against some arrhythmias. In 1963 Roberts et al.17 reported that following reserpinization the ability of digitalis to induce ventricular arrhythmias was diminished. Moreover, $TM 10, an agent which prevents the release of catecholamines, markedly reduced the response of the ventricular pacemaker to digitalis. The abilit of reserpine to antagonize but it should be noted arrhythmias has been confirmed by several workers,al'* that the degree of success is much higher if an adrenalectomized preparation is employed so as to reduce the circulating catecholamines. In addition, guanethidine and bretylium have been reported to antagonize the arrhythmias pro21 duced by acetylcholine and electrical stimulation
-
.'"
3 . Sympathomimtic and Pressor Agents. Certain types of arrhythmias (especially
supraventricular tachycardias) may be converted to normal sinus rhythm by raising the blood pressure, thereby eliciting reflex vagal stimulation. E l l i s a2 has reported that metho-ne and some closely related substituted phenylisopropylamines can effectively convert ventricular tachycardias to sinus m h m . Special mention was made of a-methyl-$-hydroxy-$-( 2,5 diethoxyphenyl)-N-isopropyl ethylamine, which was found to be effective in restoring sinus rhythm under a number of experimentally produced ventricular tachycardias (e .g ouabain, epinephrine with or without hydrocarbon anesthesia, DMPP and coronary artery ligation). Similarly, isopropyl methoxamine has been found to be effective in converting digitalis-induced ventricular tachycardia to sinus rhythm, though the duration was rather transient.'' In their review on the use of vasopressor d r u g s in the therapy of cardiac arrhythmias, Corday and co-workerg4note that in addition
.
88
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
to methoxmuine, such agents as norepinephrine, mephentermine, m e t a r a m l , phenylephrine and angiotensin have been used successAiLly. However, such therapy is only u s e m when the arrhythmia is associated wlth hypotension. A possible exception lies in the usage of angiotensin which has been found to protect against a variety of experimentally induced arrhythmias both in vitro and in vivo ?,' aeAccordingly, these investigators also ascribed a "quinidine-like" action to angiotensin. In the presence of heart block, ventricular tachycardia and quinidine The mechanism inintoxication, isoproterenol has been used success~ully.~~ volved is apparently based on the fact that isoproterenolaccelerates the basic idioventricular pacemaker thereby suppressing ectopic ventricular activity. The increase in heart rate, coronsry f l o w and cardiac output may also be responsible for terminating arrhythmias. O f course, driving the heart at a more rapid rate could achieve the s8me result as drug therapy. The inherent danger in the use of isoproterenol is that it is almost a pure beta adrenergic stimulator and may precipitate ventricular tachycssdia or fibrillation.a7
4. Local Anesthetics. Since the observation that procaine was effective in suppressing arrhythmias, and the subsequent developnt of procaine amide, numerous local anesthetics psVe been employed in antiarrhythmic drug therapy. Lidocaine, a synthetic local anesthetic, has recently been reported to be of value in the treatment of cardiac arrhythmias.asThe mechanism of action appears to be similar to that of procaine. The conduction time is slowed, excitability depressed and the refractory period prolonged. In therapeutic doses mlyocardial contractility does not appear to be depressed nor is the blood pressure depressed. It ha8 a brief duration, is relatively safe and may be given i.v., all of which may mske it useful in arrhyt,hmias which sometimes occur during cardiac surgery. Pruss and Hidalgo2@have reported on a new substance kvoxadrol!, which is a local anesthetic and a ganglionic blocking agent. The authors claim that it is slightly less potent than quinidine but more potent than either procaine amide or lidocaine in reversing atrial fibrillation caused by the topical application of acetylcholine. Moreover, it is very effective in restoring sinus rhythm in dogs with coronary artery ligation ventricular arrhythmias.
5. htihistaminics. In 1948 it was demonstrated that a number of antihistamines possessed sane pharmacologic properties in common with atropine, procaine amide and quinidine. By 1952 the suppression of ventricular premature
systoles by antazoline had been described, and in 1959 a report appeared noting that antazoline was more effective than quinidine in the suppression of spontaneous and surgically induced ventricular fibrillation in the hypothermic dog?' In conrmDn with quinidine, antazoline is a local anesthetic, possesses sane anticholinergic properties and causes mild adrenergic blockade. However, as opposed to quinidine, It increases peripheral vascular resistance but decreases both stroke volume and cardiac output without altering mean blood pressure. Thus, pressor agents are never required?* Like quinidine it produces its antiarrhythmic effects primarily by depressing conduction velocity. Apparently it is effective in atrial, nodal and
Chap. 8B
Antiarrhythmics
T anz
89 -
ventricular tachycardias, as well as arrhythmias associated with d i g i t a l i s intoxication. Diphenhydramine has also proven t o be an effective31antif l b r i l l a t o r y agent at low doses both i n the laboratory and c l i n i c .
6. Central Nervous System (CNS) Agents. Diphenylhydantoin (Dilantifl) is a potent antiepileptic which produces generalized depression of the CNS. It has been used successfldly i n abolishing numerous arrhythmias both i n the laboratory and i n the c l i n i c ?1 j a 4 * 7 Its duration of action i s however, relatively short (2 30 mins .) I n the heart Dilantin i s said t o diminish conduction velocity, may depress c o n t r a c t i l i t y and produces a net efflux of i n t r a c e u u l a r sodium and an influx of potassium, which tends t o r a i s e the resting membrane potential thereby reducing the likelihood of cardiac arrhythmias. The general impression i s that it should not be used as an antiarrhythmic u n t i l procaine amide and quinidine have been tried f i r s t .
-
.
38
Fekete and Borsy have shown that certain thymoleptics, such as imipramine, desmethylimipramine, amitriptyline and trimepropimine display mild antiarrhythmic a c t i v i t y i n rats and dogs.
7. Miscellaneous Agents. Space limitations preclude the inclusion of the
numerous substances that have been tested for antiarrhythmic a c t i v i t y . The antimalarial substance chloroquine, depresses myocardial e x c i t a b i l i t y and exerts a n t i f i b r i l l a t o r y a c t i v i t y as does the o r a l hypoglycemic phenformin (DBfl).33 Sparteine is a potent, short acting a n t i f i b r i l l a t o r y substance which, i n contrast t o quinidine, increases myocardial conduction velocity. 33 Much i n t e r e s t has been generated i n the antiarrhythmic properties of synthetic oxytocin (Syntocino#) especially by Canadian workers. Syntocinon has been demonstrated t o suppress a variety of laboratory and c l i n i c a l srrythmias, including those related t o catecholamines as w e l l as arrhythmlas induced by injecting metrazol into the fourth ventricle. 39-43 It should be noted however, that 0.55 chlorobutanol is used i n the vehicle and that it a l s o displays antiarrhythmic a c t i v i t y (un ublished observations). The cholinergic drug edrophonium chloride (Tensilo& has been reported t o display transient antiarrhythmic a c t i v i t y , eliminating paroxysmal auricuLar tachycardia i n about 505 of treated patients .a4 Russian workers have recently described the use of cocarboxylase as being effective against a variety of c l i n i c a l l y observed arrthythmias .45 Iproveratril (Isoptin@) i s a new beta adrenergic blocker that has been claimed t o possess antiarrhythmic a c t i v i t y greater than e i t h e r pronethalol or MJ l ~ f ~ ~ 4 7 H o w e v it e r i, s also a toxic substance with a ra.t;her n a r r o w margin of safety. Chelating agents, such as EUI!A, have been employed with various degrees of success i n the past. A new substance in t h i s group i s 10-phenanthroline which was reported t o be as effective as quinidine i n reversing auricular f i b r i l l a t i o n of isolated rabbit hearts. Apparently it accomplishes t h i s by lengthening the refractory period and the depolarization p e r i ~ d f * r ~ ~ Newer chemicalmieties which have been reported t o possess antiarrhythmic activity, but which cannot be c r i t i c a l l y evaluated a t t h i s t i m e , are:
90 -
Sect. I1
-
Pharmacodynamics
A r c h e r , Ed.
,
a s e r i e s of N,N-diisopropyl-N' -isoamyl-N' -diethylaminourea (P-286)s0 N-(~aminoalkyl)phthalimidese~ *5 the procaine amide analogs of p-&no-N[2-( substituted amino) ethyl) benzamides,66 derivatives of morphanthridineB7 2-diethylmino-l-phenylethy1, 2-ethoxy HC1 and i t s 4-ethoxy analoff*, and the l o c a l anesthetic N,N-bis (phenykarbamoyl-nethyl) dimethylaamnium C 1 (QX$ 7 ~ ? ) ' ~More . work w i l l have t o be done on these substances before a fair pharmacologic appraisal can be made.
,
,
References 1. b e , R. A. and Abrams, W. B.: i n "Cardiovasculaz Drug Therapy", ed. A. N. w e s t and J. H. Moyer, G r u n e and Stratton, I?. Y. p.455 (1965). 97 ( 1 9 ~ 1 2. E r l i j , D. and Mendez, R.: J. m c o l . , 21, 462 (1963). 3. Selciya, A. and E. M. Vaughan W i l l i a m s : 4. Wyte, S. R. and R. E. Tan Eick: Fed. Proc., 5. Lucchesi, B. R.: J. Pharmacol., 6. Stickney, J. L., B. R. Lucchesi and G, D. Abrams : Fed. Proc a , 6 2 1 (1966.. 7. Lucchesi, B. R., L. S. Whitsitt and J. L. Stickney: Confr. on New Adrenergic Blocking Drugs; N. Y. Acad. Sci., Feb. 24-26, 1966. 8. Benfey, B. G. : Fed. Proc 24, 234, (1965) 9. Benfey, B. G. and D. R. Varma: Brit. J. P h w c o l . , 26, 3 (1966) 10. Rowlands, D. J,, G. Howitt and P, Ihrkman: Brit. Med. J., 1,891 (1965) ll. Sloman, G., J. S. Robinson and K. Mchan: B r i t . Med. J., 1, 895 (1965). 12. G i l l , E. W. and E. M. Vaughan W i l l i a m s : Nature, 201, 199 T1964) 13. Wallace, A . G., W. G. Troyer, M, A. Lesage and Zotti: 140 (1965) 14. Somani, P. and B. K. B. Lua: J. Pharmacol., 147, 194 (1964). Fed. Proc., &, 712 (1965). 15 Somani, P. and B. K. B. h: 16. Somani, P., J. G. Fleming, G, K. Chan and B. K. B. Lum: J. Phe;rmacol., 151, 32 (1966) 149 (1963). 17. Roberts, J., R . Ho, J. Reilly and V. J. Cairoli: Circ. Res., 325 (1964) 18. Lu, G. G.: Fed. Proc. 19 Ievitt, B., F. Ciofalo and J. Roberts: Fed. 20. Leveque, P. E. and R. C. Grubbs: Fed. Proc. M.: ~ m .J. cardioi., 21. -caner, (1964). 22. E l l i s , C H. : Arch. i n t Phamcodyn., JJO, 23 Paradise, R. R. and V. K. Stoelting: Proc. SOC. Exp , Biol. Med., U6,72 (1964) 24. Corday, E., F. F. Barbieri and T-W. lang: i n Cardiovascular Drug Therapy, ed. A. N. Brest and J. H. Moyer, Grune and Stratton, N. Y., p. 485, 1965. 25 8 Beltrami, E. and A. Beaulnes: Rev. Can. B i o l . , a , 191 (1964). 121 (196; Beaulnes, A., G. Gariepy, J. Brodeur and E. Beltrami : Fed. Proc 25 26. Dreifus, L. S., M. D. Rabbino and Y. Watanabe: i n Cardiovascular Drug Them y, ed. A. N. Brest and J. H. Moyer, G r u n e and Stratton, N. Y., p.491,
144,
145,
.
.,
0
E. x., 18,
a,
a,
.
.
IJ,=~
h.4
a,
0
(196523. . - _ _ 27. Dresel, P. E., M. 28. 29
30 31 32
.
140, 67
C Hart and B. C Stromblad: J. Pharmcol., Frieden, J. : Am. H e a r t J., 713 (1965). pruss, T. P. and J. Hidalgo: Fed. Proc., 32'7 (1964). Angelakos, E. T. and A. R. Hegnauer : J. Pharmacol., 12, 37 (1959) Dreifus, L. S., M. D. Rabbino and Y. batanabe: Med. m n . N. Amer., 371 (1964). Bellet, S : B r i t . Pract 19 (1961).
.
s,
., 186,
a,
(1963).
. 48,
Chap. 8B
Tanz
Antiarrhythmic s
x,
33 34 35 36
9
37 38 39
91 ,-
Lamla, M.: Arch. int. Pharmacodyn., 442 (1965). Mixter, C. G., J. M. &ran and W. Austen: Am. J. Cardiol., 332 (1966). Ruthen, G. C.: Am. Heart Jln., 70, 275 (&). Bernstein, H., H. Gold, T-W. Law, S. Pappelbaum, V. Bazika and E. Corday: JAA-A., 695 (1965)Conn, R. D.: New Engl. J. Med., 2J2, 277 (1965). Fekete, M. and J. Borsy: _Med. exp. l0, 93 (1964). Klassen, G. A.,J. W. Rubin and M. McGregor: Am. J. Cardiol., l2, 523 (1963). Varma, D. R., K. I . Melville and M. D. S i l v e r : Arch. i n t . Pharmacodyn., 4-40(1963). M e l v i l l e , K. I. and D. R. Varma: Biochem. Pharmacol., 8, 136 (1961). Panesset, J. C. and A. Baulnes: Rv. Can. Biol., 20, 47-(1961).
x,
a,
40.
41.
.
42.
43 Bircher, R. P. : Fed. Proc 3, 560 (1964). 44. Moss, A. J. and L. M. Aledort: Am. J. Cardiol., JJ, 62 (1966). 45 Bakumenka, M. S.: Kardioloaiya (U.S.S .R.), abstracted i n Excerpta Med. 2, 1965. 46. Melville, K. I., Shister, H. E. and S. Huq: C a n . Med- Jln., g,761 (1964). 47. Schmid, J. R . and C. Hanna: Fed. Proc., 3, 382 (1966). 48. Yaw, W. C., S. Rothman and A. Gimeno: Proc. SOC. EXP Biol. Med., 2, 136 (1963). 49 Rothmsn, S. and W. C. Yaw: Am. J. Physiol., 206, 283 (1964) 50 Garrett, J., M. Goncalves Moreira, W. Osswald and S. GUimaraeS: 9
s.,
.
143,
51 52
53
54. 55
-
56 57
.,
J. Pharmacol., 243 (1964). Kempen, R. R . : Fed. Proc 3, 327 (1964). Hideg, K and H. 0. Hankovszky: Acta Chima. Acad. Sci. Hun@;., 3, 391 (1963) Hideg, K., L. Szekeres, H. 0. Hankovszky and J. Pam: Biochem. pharnaacol. (Suppl.), 12, 171 (1963). Hideg, K. and H. 0. Hankovszky: J. Med. Chem., 8 257 (1965). Szekeres, L., K. Hideg, H. 0. Hankovoszky and G. Papp: Acta phxsiol. Hung., 26, 287 (1965). Thyrum, P and A . R. Day: J. Med. Chem., 107 (1965) Werner, L. H., S . Ricca, E. Mohacsi, A , Rossi and V. P o Arya: J. Med. Chem.,
6
-8 74 (1965). 58. Grelak, R. P. and T. R. Sherrod: Fed. Proc. 24, 234,(1965). 59 Covino, B. G. and P. Rachwell: J. New Dru@;6 , Jan-Feb., 30 (1964). 0
92 -
Sect. I1 Chapter 9 .
- Pharmacodynamics
A r c h e r, Ed.
Pulmonary and A n t i a l l e r g y Agents.
Walter T. Moreland, Chas. P f i z e r ti Company, Inc.,
Groton, Conn.
Medicinal chemical p r o g r e s s i n t h e f i e l d s of pulmonary and a n t i a l l e r g y a g e n t s * h a s been slow i n r e c e n t y e a r s . A t least t h r e e f a c t o r s a p p e a r t o have been r e s p o n s i b l e , i n v a r y i n g d e g r e e s , f o r t h i s h i a t u s : ( 1 ) t h e r e have been r e l a t i v e l y few advances i n i n s i g h t i n t o t h e n a t u r e of u n d e r l y i n g mechanisms, SO t h a t s c r e e n i n g methods have tended t o remain u n s p e c i f i c o r i n a p p r o p r i a t e ; ( 2 ) t h e p u r s u i t of e x i s t i n g s t r u c t u r a l l e a d s h a s f a i l e d t o p r o v i d e a g e n t s s u p e r i o r to t h o s e a l r e a d y i n u s e ; and ( 3 ) i n some i n s t a n c e s t h e r e h a s n o t been a n obvious need t o improve upon e x i s t i n g d r u g s , e s p e c i a l l y i n t h e f a c e of more u r g e n t probl e m s i n o t h e r areas, which h a s tended to d i s c o u r a g e s p e c i f i c r e s e a r c h c a l c u l a t e d t o produce new l e a d s and new methodology. R e t r o s p e c t i v e l y , t h i s p a t t e r n was s u b s t a n t i a l l y unchanged i n 1965, and a d e q u a t e summaries of c u r r e n t s t a t u s are provided i n a p p r o p r i a t e s e c t i o n s of newly r e v i s e d e d i t i o n s of s t a n d a r d reference t e x t s. 192 The f i e l d of pulmonary a g e n t s seems c e r t a i n t o become c o n s i d e r a b l y more a c t i v e i n t h e f u t u r e , however, i n t h e l i g h t of c l i n i c a l developments t h a t have r e c e i v e d widespread a t t e n t i o n i n 1965. The N a t i o n a l Heart I n s t i t u t e , i n a r e p o r t t o t h e S e n a t e A p p r o p r i a t i o n s Subcommittee,3 s t a t e d t h a t "emphysema h a s mushroomed i n t o a major h e a l t h problem, seemingly o v e r n i g h t d i s a b i l i t y benef i t s f o r emphysema are (now) exceeded o n l y by d i s a b i l i t y b e n e f i t s f o r a t h e r o s c l e r o s i s and coronary h e a r t d i s e a s e . 'I Many c l i n i c a l d i s c u s s i o n s of c h r o n i c o b s t r u c t i v e lung d i s e a s e p r e s e n t e d similar c o n c l u s i o n s .4 I n s p e c t i o n of t h e a g e n t s p r e s e n t l y a v a i l a b l e t o t h e p h y s i c i a n shows t h e l i s t 5 t o be dominated by sympathomimetic and x a n t h i n e b r o n c h o d i l a t o r s , e x p e c t o r a n t s and mucolytic a g e n t s and none of t h e s e i s p a r t i c u l a r l y new. ( C e r t a i n r e s p i r a t o r y s t i m u l a n t s 3 , 6 and a n t i i n f l a m a t o r y a g e n t s 3 are a l s o r e p o r t e d , b u t t h e i r u s e i s n o t u n i v e r s a l l y f a v o r e d . 4 ~ 7 ) The e n t i r e f i e l d was t h o r o u g h l y reviewed by Aviado i n two volumes c i t i n g ' s e v e r a l thousand r e f e r e n c e s . 8 It i s clear t h a t t h e r e i s room f o r improvement i n a l l classes, and i t may be e x p e c t e d t h a t o t h e r approaches t o complement o r d i s p l a c e t h o s e i n c u r r e n t use w i l l emerge as r e s e a r c h i n t e r e s t i n c r e a s e s .
...
****** *For t h e purpose of t h i s review, t h e c a t e g o r y "pulmonary and a n t i a l l e r g y a g e n t s " is c o n s i d e r e d t o i n c l u d e b r o n c h o d i l a t o r s , a n t i t u s s i v e s , e x p e c t o r a n t s , m u c o l y t i c s , n a s a l d e c o n g e s t a n t s and a n t i p r u r i t i c s ( a n t i h i s t a m i n e s ) . A n t i b i o t i c s , which occupy a n important t h e r a p e u t i c p o s i t i o n i n t h e r e s p i r a t o r y area, and a n t i i n f l a m m a t o r y a g e n t s are excluded because they u s u a l l y would n o t be developed s p e c i f i c a l l y f o r these indications (although antiinflammatory s t e r o i d s d e s i g n e d f o r t o p i c a l u s e might c o n s t i t u t e a n i m p o r t a n t e x c e p t i o n ) . D e s e n s i t i z a t i o n p r o c e d u r e s are c o n s i d e r e d t o be o u t s i d e t h e scope of medicinal chemistry.
Chap. 9
Mo reland
Pulmonary, Antiallergy
93 -
There can be l i t t l e doubt t h a t b r o n c h o d i l a t i o n by sympathom i m e t i c a g e n t s i s mediated through p - r e c e p t o r s , so t h a t i t i s n o t s u r p r i s i n g t h a t s i d e e f f e c t s such as t a c h y c a r d i a , r e s u l t i n g from e x c e s s i v e s t i m u l a t i o n o f p - r e c e p t o r s a t o t h e r s i t e s , should be a common o c c u r r e n c e . l a , 2a Poor o r e r r a t i c o r a l a b s o r p t i o n o f t e n p r e s e n t s an a d d i t i o n a l problem. I s o p r o t e r e n o l (I) , t h e p r o t o t y p e p-sympathomimetic, dominates !he group. 3Y4 Most o f t h e newer a g e n t s are c l o s e l y r e l a t e d t o i s o p r o t e r e n o l , and a l l are most o f t e n a d m i n i s t e r e d l o c a l l y i n some form o f a e r o s o l t o minimize s i d e e f f e c t s . Two a d d i t i o n a l a n a l o g s , c l o r p r e n a l i n e ( I n 9 and metaprot e r e n o l ( o r c i p r e n a l i n e , 111) ,lo r e c e i v e d c o n s i d e r a b l e c l i n i c a l a t t e n t i o n , e s p e c i a l l y i n Europe. The former i s s u i t a b l e f o r o r a l a d m i n i s t r a t i o n , b u t
I
i t a p p e a r s t o e l i c i t s u f f i c i e n t CNS s t i m u l a t i o n t o r e q u i r e concomitant a d m i n i s t r a t i o n o f a CNS d e p r e s s a n t . The l a t t e r , which i s r e p o r t e d t o have a minimal e f f e c t on h e a r t r a t e , h a s been most o f t e n a d m i n i s t e r e d by a e r o s o l . A v e r y r e c e n t report'' d e s c r i b e d a s e r i e s o f catecholamine a n a l o g s i n which t h e p h e n o l i c hydroxyls a r e r e p l a c e d by a l k y l - o r a r y l sulfonamido s u b s t i t u e n t s o f comparable a c i d i t y . When t h i s s u b s t i t u t i o n i s meta t o t h e ethanolamine s i d e c h a i n , p o t e n t a - o r p - r e c e p t o r s t i m u l a n t s r e s u l t ; t h e most a c t i v e p - a g o n i s t s o f t h e s e r i e s ( I V Y V and VI) approach t h e potency of e p i n e p h r i n e o r i s o p r o t e r e n o l i n smooth muscle p r e p a r a t i o n s . B r o n c h o d i l a t o r s t u d i e s w i t h t h e s e a n a l o g s have n o t been r e p o r t e d , and l i t t l e can be d i s c e r n e d from p r e s e n t e v i d e n c e r e g a r d i n g s p e c i f i c i t y o f a c t i o n . I n t e r e s t i n g l y , comparable s u b s t i t u t i o n i n t h e para p o s i t i o n
R1 IV V
R2
H
H
OH
H
VI a f f o r d s predominantly p-blocking a g e n t s . The problem o f s p e c i f i c i t y of a c t i o n among $-sympathomimetics remains a s u b s t a n t i a l c h a l l e n g e , which many would a r g u e t o be e s s e n t i a l l y u n r e s o l v a b l e because of t h e wide a n a t o m i c a l d i s t r i b u t i o n o f p - r e c e p t o r s . However, t h e work o f Lands and Brown," showing t h a t a - e t h y l s u b s t i t u t i o n i n c e r t a i n 6 - a g o n i s t s markedly f a v o r s p - r e c e p t o r s i n t h e b r o n c h i o l e s o v e r t h o s e i n t h e h e a r t ( T a b l e I ) , s u g g e s t s t h a t d i f f e r e n t i a t i o n among p - r e c e p t o r s i s p o s s i b l e and that c a r e f u l s t u d y may r e v e a l c o n s i d e r a b l e o p p o r t u n i t y t o achieve s p e c i f i c i t y f o r a particular site.
Sect. I1
94 -
- Pharmacodynamics
A r c h e r , Ed.
Table I E f f e c t of a - E t h y l S u b s t i t u t i o n on t h e S e c i f i c i t y o f A c t i o n o f P2 Sympat homime t i c A m i ne s
Rl -
H C2H5 H C2H5
R2 isopropyl isopropyl cyc l o pent y 1 cyclopentyl
R e l a t i v e P o t e n c i e s ( I s o p r o t e r e n o l = 1) +Cb Bronchodi l a t i o n +Ia -
1 0.06 .6
.016
1 0.001 .6 .0005
1 0.33
.7
.45
(a) positive inotropic effect (b) positive chronotropic e f f e c t Over tbe y e a r s , a c o n s i d e r a b l e number of x a n t h i n e a n a l o g s and d e r i v a t i v e s have been s t u d i e d . However, none h a s y e t succeeded i n d i s p l a c i n g t h e o p h y l l i n e , which remains t h e predominant non-sympathomimetic bronchol b , 21 d i l a t ~ r , ~ i n- s~p i t e of s u b s t a n t i a l o r a l a b s o r p t i o n and s i d e e f f e c t problems. Because of t h e a p p a r e n t s t r u c t u r a l and pharmacological l i m i t a t i o n s i n h e r e n t i n t h e sympathomimetic approach, t h e f u t u r e seems c e r t a i n t o b r i n g a s u b s t a n t i a l i n c r e a s e i n e f f o r t s t o d e v e l o p a g e n t s more c l o s e l y r e l a t e d t o t h e x a n t h i n e s . A novel workin h y p o t h e s i s , which d e r i v e s from t h e e l e g a n t work of S u t h e r l a n d and h i s g r o u p Y f 3 o f f e r s a p o s s i b l e new approach t o t h e development o f improved a g e n t s i n t h i s class. Although t h e r e i s some evidence t h a t i s not e n t i r e l y c o n s i s t e n t , l b t h e h y p o t h e s i s s u g g e s t s t h a t t h e b r o n c h o d i l a t o r a c t i o n of theop h y l l i n e i s t h e r e s u l t o f i n c r e a s e d l e v e l s of c y c l i c 3',5-AMP brought about by p h o s p h o d i e s t e r a s e i n h i b i t i o n . T h i s would d i r e c t l y r e l a t e t h e o p h y l l i n e t o p - r e c e p t o r s , where c y c l i c 3 ' ,5'-AMP s y n t h e s i s i s thought t o be i n c r e a s e d through s t i m u l a t i o n of a d e n y l c y c l a s e by a p p r o p r i a t e a g o n i s t s . There i s y e t l i t t l e d i r e c t e v i d e n c e , however, t o s u g g e s t t h a t t h i s i s t h e o n l y , o r even t h e major, m e c h a n i s t i c component o f t h e o p h y l l i n e b r o n c h o d i l a t i o n , so i t remains t o be determined how f r u i t f u l t h e approach w i l l be. Mucolytic a g e n t s and e x p e c t o r a n t s l C y 2a' r e used t o d e c r e a s e t h e v i s c o s i t y o f , and a i d i n c l e a r i n g b r o n c h i a l s e c r e t i o n s . A number o f a g e n t s are a v a i l a b l e Y 5 i n c l u d i n g many o l d e r p r e p a r a t i o n s such as i o d i d e s and g u a i a c o l a t e s . The more r e c e n t a d d i t i o n s , N - a c e t y l e y s t e i n e , r i b o n u c l e a s e and v a r i o u s p r o t e o l y t i c enzymes, are u s u a l l y a d m i n i s t e r e d l o c a l l y i n a nebul i z e d form. The c l i n i c a l v a l u e o f t h e s e a g e n t s does n o t a p p e a r t o be unanimously acce t e d Y 4and o b j e c t i v e d e m o n s t r a t i o n of e f f i c a c y i s o f t e n d i f f i c u l t t o o b t a i n . l I T h i s s u g g e s t s a decided need f o r more e f f e c t i v e p r o d u c t s , s i n c e t h e r e seems t o be l i t t l e doubt t h a t t h i s i s a v a l u a b l e t h e r a p e u t i c a p p r ~ a c h . ~ , ~
Chap. 9
Mo reland
Pulmonary, Antiallergy
95 -
Better a g e n t s w i t h l o c a l a c t i o n , designed from chemical knowledge o f s p e c i f i c components i n b r o n c h i a l s e c r e t i o n s , l5 r e p r e s e n t a n obvious avenue o f a t t a c k . The r e p o r t s t h a t p i m e t i n e ( V I I I ) 1 6 and Bisolvon ( I X ) 1 7 reduce sputum v i s c o s i t y a f t e r systemic a d m i n i s t r a t i o n a r e probably of g r e a t e r p o t e n t i a l i n t e r e s t , s i n c e a g e n t s n o t dependent on d e l i v e r y through a i r w a y s t h a t may be s e v e r e l y o b s t r u c t e d would be e x p e c t e d t o have i n h e r e n t advantages.
Br VIII
IX
A n t i t u s s i v e d r u g s l c y Z cwere reviewed by Bucher,18 who c l e a r l y p o i n t e d o u t t h e need f o r more s o p h i s t i c a t e d s c r e e n i n g t o o l s based on a b e t t e r u n d e r s t a n d i n g of t h e cou h r e f l e x . A n t i t u s s i v e a c t i v i t y i n s e v e r a l s t r u c t u r a l t y p e s was r e p o r t e d , f9-25 b u t t h e s e do not a p p e a r t o r e p r e s e n t 26 s u b s t a n t i a l d e p a r t u r e s from t h o s e reviewed e a r l i e r by Chappel and von Seeman. Drug t r e a t m e n t of a l l e r g i c d i s o r d e r s , i f a n t i i n f l a a o r y a g e n t s a r e excluded, i s l i m i t e d almost e x c l u s i v e l y t o antihistamines','d and c e r t a i n sympathomimetic a g e n t s . l a , 2a The l a t t e r class i n c l u d e s b o t h a-mimetics, used as n a s a l d e c o n g e s t a n t s , and p - m i m e t i c s ( d i s c u s s e d a b o v e ) , which are g e n e r a l l y f o r a c u t e use as i n a n a p h y l a c t i c r e a c t i o n s . A new a - m i m e t i c , amidephrine (X) , from t h e s e r i e s of sulfonamido a n a l o g s a l r e a d y 11,2 mentioned, was r e p o r t e d t o be a n e f f e c t i v e and l o n g - a c t i n g n a s a l d e c o n g e s t a n t .
CHCHzNHCH3
I
OH
CH3
X The complexity o f a l l e r g i c phenomena, and t h e need f o r t r u e understanding o f t h e i n t e r p l a y of t h e v a r i o u s c o n t r i b u t i n g f a c t o r s h i s t a m i n e , s e r o t o n i n , k i n i n s and o t h e r s - i s a p p a r e n t i n the m e c h a n i s t i c s t u d i e s 2 8 t h a t c o n t i n u e t o i n v e s t i g a t e v a r i o u s a s p e c t s of h y p e r s e n s i t i v i t y and e s p e c i a l l y i n t h e review o f methods f o r t h e i n d u c t i o n o f e x p e r i m e n t a l h y p e r s e n s i t i v i t y by Spencer and West.29 A symposium c h a i r e d b Ungar e x p l o r e d t h e v a r i e t y of p h y s i o l o g i c a l f u n c t i o n s proposed f o r h i s t a m i n e ," and G a r a t t i n i and V a l z e l l i p r e s e n t e d a n e x t e n s i v e review of ~ e r o t o n i n . ~ ' Cursory reviews o f p r e s e n t a n t i h i s t a m i n e usage32 s e r v e d t o emphasize t h e r e l a t i v e q u i e s c e n c e o f t h e f i e l d i n terms of d r u g development.
96
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
Various 6-7-6 t r i c y c l i c r i n g systems - s t r u c t u r a l l y t h e most i n t e r e s t i n g class of a n t i h i s t a m i n e s , even though t h e i r impact h a s been f a r g r e a t e r i n o t h e r f i e l d s - continued t o receive a t t e n t i o n . Structurea c t i v i t y s t u d i e s i n dibenzocycloheptene a n a l o g s r e l a t e d t o cyproheptadine were reported.33 Rubin d e s c r i b e d t h e pharmacology of a dibenzoxazepine w i t h 1-10 times t h e potency of p y r i l a ~ n i n e ,and ~ ~ P r o t i v a reviewed r e c e n t I n o t h e r areas, a developments i n s e v e r a l o t h e r , r e l a t e d systems.35 series of t e t r a h y d r o q u i n a z o l i n e s w a s described,36 one of which (XI) was r e p o r t e d t o be comparable t o chlorpheniramine i n t h e c l i n i c . 3 7 CH2CH2N(CH3)2
0
XI References (1)
" D r i l l ' s Pharmacology i n Medicine," 3rd ed., J . R. D i P a l m , Ed., M c G r a w - H i l l Book Company, New York, N. Y . , 1965. ( a ) B. Levy and R. P. A h l q u i s t , Chapter 31; ( b ) E . B. T r u i t t , Chapter 27; ( c ) E. M. Boyd, Chapter 49; ( d ) F. E . Roth and I. I. A. Tabachnick, Chapter 48.
(2)
'The Pharmacological Basis of T h e r a p e u t i c s , ' ' 3rd e d . , L. S. Goodman and A. Gilman, Ed., Macmillan Company, New York, N. Y . , 1965. ( a ) I. R. Innes and M. Nickerson, Chapter 24; ( b ) J . M. R i t c h i e , Chapter 19; ( c > J. H. J a f f e , p. 280; ( d ) W. W. Douglas, C h a p t e r s . 2 9 and 30.
(3)
Anon., Drug Research Reports, 4, No. 34 ( s u p p l . ) , S-2 (August 25, 1965)
(4)
see, f o r example: H. A . Lyons, J . Am. Med. ASSOC., 1 9 4 , 1234 (1965); R. J . Johnston and H. W . Harris, Med. C l i n . N. Am., 49, 1309 ( 1 9 6 5 ) ;
w.,
B. M. Cohen, Geriatrics, 20, 999 ( 1 9 6 5 ) ; F. J . C . M i l l a r d , 20, 854 (1965); R. F. Corpe, S. Grzybowsbi, F . M. MacDonald, M. M. Newman, A. H. Niden, A. B. Organick, and W. Lester, Am. Rev. Respirat. Dis., 92, 513 (1965); R. M . Cherniak, Ann. N. Y. Acad. S c i . , 121,942 (1965). (5)
Anon.
, pharmhdex,
41 ( J a n u a r y 1965).
Chap. 9
Pulmonary, Antiallergy
P. Sadoul, Ann. N. Y . Acad. S c i . ,
121, 836
Mo reland
97
(1965).
M. E . Bader and R. A. Bader, Am. J. Med., 38, 165 ( 1 9 6 5 ) . D. M. Aviado, 'The Lung C i r c u l a t i o n , " Vole. I and XI, Pergamon P r e s s , New York, N. Y . , 1965.
B. K r a f t and J. G. Armstrong, Appl. Ther.,Z,
829 ( 1 9 6 5 ) .
M. E . Coleman and L. A. Howard, Ann. Alergy, 23, 434 ( 1 9 6 5 ) ; examples from t h e European l i t e r a t u r e i n c l u d e : A. Knopp, Med. Welt., 764 (1965); H. I l l i g , Med. Klin.(Munich), 60, 1452 ( 1 9 6 5 ) ; M. F i s c h e r and U. Mielki, g ,1824 ( 1 9 6 5 ) .
a.,
R. H. Uloth, J . R. K i r k , W. A. Gould, and A. A. L a r s e n , J. Med. Chem., 88 (19661, and r e f e r e n c e s t h e r e i n .
-9 ,
Lands and T. G. Brown, Jr., Proc. SOC. E x p t l . B i o l . Med., 116, cf. D. R. Van Deripe and N. C. Moran, E e d e r a t i o n P r o c . , 24, 712 (1965); B. Levy, J. Pharmacol. E x p t l . Therap., 129 (1964) f o r r e l a t e d observations with p-blocking agents. A. M.
331 (1964);
146,
E . W. S u t h e r l a n d , I. $ye, and R. W . B u t c h e r , Recent P r o g r . Hormone Res 21, 623 (1965)
- - 3
Committee on Drugs of t h e Research C o u n c i l , J. A l l e r g y ,
3,:488
(
1965).
P. L. Masson, J. F . Heremans, and J. P r i g n o t , Biochim. Biophys. Acta, (1965).
111, 466
S. Chodosh, A b s t r a c t s , 6 6 t h Annual Meeting of t h e American T h e r a p e u t i c S o c i e t y , June 1965, p . 29. see f o r example, W . Junge, W. Guenthner, E . Haslreiter, K . Hess, and M. Loos, Med. K l i n . (Munich), @, 2058 (1965); cf. J. Hamm and E . Hunekohl, A r z n e i m i t t e l - F o r s c h . , l6, 209 (1966). K . Bucher i n " P h y s i o l o g i c a l Pharmacology," V o l . 11, W. S . Root and F. G. Hofman, Ed., Academic P r e s s , New York, 1965, p . 175. M. C a r i s s i m i , A . C a t t a n e o , R. D'Ambrosio, V. DePascale, E . G r u m e l l i , E. Milla, and F. Ravenna, J . Med. Chem., 2, 542 ( 1 9 6 5 ) . F . P . Doyle, M. D. Mehta, R. Ward, J . B a i n b r i d g e , and D . M. Brown, 571 ( 1 9 6 5 ) .
m.,2,
S. Casadio, G. P a l a , E . C r e s c e n z i , T . Bruzzese, E . Marazzi-Uberti, -8, 589 (1965). and G. Coppi,
w.,
Sect. I1
98 -
- Pharmacodynamics
A r c h e r , Ed.
#
(22)
J . C. LeDouarec, G. Regnier, and R. C a n e v a r i , A r z n e i m i t t e l - F o r s c h . , 1 5 , 1330 (1965).
(23)
E . M a r c h e t t i , G. Mattalia, and F. Samueli, Farmaco, Ed. S c i . , 696 (1965).
(24)
M. Pesson, S. Dupin, M. Antoine, D . Humbert, and M . J o a n n i c , SOC. Chim. F r a n c e , 2262 ( 1 9 6 5 ) .
(25)
K . Takagi, I. Takayanagi, and M. Imamura, J . Pharm. SOC. J a p a n , 85, 550 (1965).
(26)
C.
(27)
(28)
I . Chappel and C . von Seeman, P r o g r . Med. Chem.,
m.
89 (1963).
H. C. S t a n t o n , K . W. Dungan, and P. M. L i s h , I n t e r n . J . Neuropharmacol., 235 ( 1 9 6 5 ) ; K . W. Dungan, H . C . S t a n t o n , and P . M. L i s h , 4, 219 ( 1 9 6 5 ) .
w.,
4,
T y p i c a l examples are:
209, 545, 550 ( 1 9 6 5 ) ; 13, 189 (1965).
B. M. A l t u r a and B. W. Zweifach, Am. J . P h y s i o l . , G. B. Fregnan and A. H . G l b s e r , Med. E x p t l . ,
P. S . J. Spencer and G. B. West, P r o p r . Med. Chem., G. Ungar, F e d e r a t i o n P r o c . ,
24,
1293ff.
4,
1 (1965).
(1965).
S . G a r a t t i n i and L. V a l z e l l i , " S e r o t o n i n , " N e w York, N . Y . , 1965.
(32)
3,
E,
E l s e v i e r P u b l i s h i n g Company,
R. W. M o r r i s , p h a r m h d e x , 4 ( J a n . 1 9 6 6 ) ; J . D. Horan, Can. Med. Assoc. 93, 1031 (1965).
2-9
(33)
E . L. E n g e l h a r d t , H . C . Z e l l , W. S . S a a r i , M. E . C h r i s t y , C. D . C o l t o n , C. A. S t o n e , J . M. S t a v o r s k i , H. C . Wenger, and C. T . Ludden, J . Med. Chem., 2 , 829 ( 1 9 6 5 ) .
(34)
B. Rubin, J . J . P i a l a , R. M i l l o n i g , and B. N . C r a v e r , Arch. I n t e r n . Pharmacodyn., 155, 47 ( 1 9 6 5 ) .
(35)
M. P r o t i v a , Farmaco, Ed. S c i . ,
(36)
G . Muacevig, H .
(37)
H. J. Lange,
J
(1965).
21,
76 ( 1 9 6 6 ) .
S t B t z e r , and H . Wick, A r z n e i m i t t e l - F o r s c f i . ,
m.,l5, 1411 ( 1 9 6 5 ) .
l5, 613
Chapter 10.
Agents Affecting G a s t r o i n t e s t i n a l Functions
W i l l i a m A. Bolhofer and David A. Brodie, Merck Sharp & Dohme Research Laboratories, West Point, Pa. EXPERIMENTAL INVESTIGATIONS Stimulation of Gastric Secretion
A major advance i n t h e biochemistry of g a s t r i c s e c r e t i o n has the determination of s t r u c t u r e and synthesis of g a s t r i n I and I1 from yarious species. Porcine g a s t r i n I has been shown t o be the heptadecapeptide I. Porcine g a s t r i n I1 (11) has t h e same peptide sequence but with n
RL
1-GluGluGluGluGluAlaTyrGlyTryMetAspPheNH2 I
@GluGlyProTry-R
2
R1 = Met, R = H 1 2 11, R = Met, R = SO H I,
3
111,
R
1
= Leu, R~ = H
IV, R~ = Leu, R~
= SO~H
Both were equipotent t h e tyrosine hydroxyl i n t h e form of i t s s u l f a t e ester.' and showed the same b i o l o g i c a l e f f e c t s . The pure h y n g a s t r i n s have been isol a t e d , 2 and degradative analyses3 and t o t a l synthesis showed t h a t human gast r i n I (111) and human g a s t r i n I1 (IV) w e r e heptadecapeptides i d e n t i c a l t o t h e porcine g a s t r i n s except f o r replacement of one of t h e methionine components by leucine. The porcine g a s t r i n s stimulated s e c r e t i o n i n other species including dogs and man. Elucidation of t h e amino acid sequence of t h e g a s t r i n s permitted an exami n a t i o n of the e f f e c t of s t r u c t u r e modification on the b i o l o g i c a l a c t i v i t y and presented an opportunity f o r the synthesis of i n h i b i t o r y analogs of t h e n a t u r a l The Chormone. A series of peptides r e l a t e d to g a s t r i n I has been t e ~ t e d . ~ terminal t e t r a p e p t i d e (V) was the minimum fragment of t h e g a s t r i n molecule which V,
TryMetAspPheNH2
showed a l l t h e physiological a c t i v i t i e s of t h e n a t u r a l hormone. Based on s t i h u l a t i o n of g a s t r i c acid s e c r e t i o n i n dogs, i t was about 20% as potent as gast r i n . The C-terminal amide was e s s e n t i a l f o r a c t i v i t y , whereas acylation of t h e N-terminal amino group had l i t t l e e f f e c t on t h e a c t i v i t y . The e f f e c t on a c t i v i t y o f a numb r of s t r u c t u r a l modifications of the t e t r a p e p t i d e (V) has been determined.' The v a r i a t i o n s i n t h e main group of analogs studied consisted of s i n g l e or multiple s u b s t i t u t i o n of one or more of the amino acid residues, including replacement o f the normal L amino acids by D amino acids. Activity of products with respect t o g a s t r i c s e c r e t i o n i n dogs varied from equipotent with g a s t r i n f o r c e r t a i n acylated d e r i v a t i v e s (VI, VII)
100 -
Sect. 11. - Pharmacodynamics VI9
A r c h e r , Ed.
H2NCOTryMetAspPheNH2
VII, (CH3) 3COCD.&AlaTryMetAspPheNH2 to inactive for those peptides not having a terminal amide group. In addition, the effect of some of the analogs on other physiological functions such as gastric motility was not uniformly consistent with the direction of the effect on gastric secretion, thus indicating a separation of the various gastrin activities. The presence of D amino acids gave peptides of decreased activity, and none of these products, including the inactive all D tetrapeptide, inhibited the action of gastrin. It was concluded that the most important structural feature of the tetrapeptide for activity was the aspartic carboxyl-terminal amide combination.
In humans, gastrin was 80-fold more potent than histamine in stimulating ~ecretion.~At present, the major clinical use of gastrin or active fragments thereof would appear to be for the replacement of histamine and other secretagogues for diagnostic analysis of gastric secretion^.^" Gastrin appeared to exert a stimulatory and inhibitory effect on acid secretion, at l o w and high doses, respectively, and a stimulatory effect on pepsin secretion at high doses regardless of whether the initial stimulation was histamine or However, it has been suggested that timulation was the normal effect and inhibition was the result of overdosage.” The histamine content of the stomach mucosa was decreased by astrin, indicating that it may act as a secretory agent by releasing histamine.f2 Acid secretion stimulated b exogenous gastrin was inhibited by heparin13 and by insulin hypoglycemia. ll Gastrin I1 has been shown o increase oxygen consumption and cause vasodilation in the stomach m u c o ~ a . ~It~ also caused a pronounced increase in gastrointestinal motility which was inhibited by atropine.16 Gastrin I and I1 were approximately 20-fold more active than histamine for the stimulation of intrinsic factor secretion by the human ~tomach.~ 2-Deox~glucose: Study of acid secretion stimulated by 2-deoxyglucose indicated that it functions by foming nonmetabolizable 2-deoxyglucose-6-phosphate, resulting in cytoglucopenia at the vagal secretory center. Thus, in effect, this mechanism of stimulation of gastric secretion was apparently equivalent to the hypoglycemic mechanism of stimulation resulting from insulin administration. It has recently been shown that, after insulin stimulation, the increase in f l o w of gastric contents occurred simultaneously with or followed the lowest point reached by the blood sugar. l8 Since the central regulatory mechanism for gastric secretion acts through the vagus nerve, stimulation of the secretory center by insulin is a method which has been used to study the completeness of vagotomy in the surgical treatment of peptic ulcer. Tests in humans showed that 2-deoxyglucose produced the same hypersecretion as insulin without the attendant side effects. Therefore, it has been suggested that insulin be re laced by 2-deoxyglucose for evaluation of patients who have undergone vagotomy. P9
Chap. 10
Gastrointestinal
Bolhofer and Brodie
101 -
Histamine: Numerous studies devoted to the evaluation of the role of histamine in stimulating gastric secretion have been reported. All results indicated that histamine is the chemical mediator of gastric secretion c m o n to all stimulants. Inhibition of specific histidine decarboxylase by the hydrazino analog of histidine and NSD-1055 4-bromo-3-hydroxybenzyloxyamine), agents which lower tissue histamine levels,‘O in pylorus-esophagus-ligated rats prevented stimulation of acid secretion by reserpine, bethanechol chloride (2-carbamoylpropyltrimethylanrmonium chloride), insulin and gastrin, but not exogenous histamine. These results showed hat acid secretion was dependent on the presence of histamine in the mucosa.“ It has also been shown that vagal stimulation led to mobilization of gastric histamine.22 Gastric secretagogues, such as gastrin, insulin, betazole &(&aminoethyl)pyrazola and bethanechol chloride, lowered gastric tissue histamine levels, but it was not luiown if their stimulatory effect on secretion was a consequence of gastric histamine release. However, the enzyme histaminase prevented gastric acid secretion in dogs under the stimulating effect of a gastrin extract.23 Portacaval shunt, which in man results in an increased incidence of duodenal ulcer, in rats caused an increase in acid secretion. Als6, histidine decarboxylase activity in the fundus, the acid-secreting portion of the stomach, has been shown to undergo a 4-fold increase after this operation. The elevated acid secretion was reduced essentially to normal by treatment with NSD-1055, the previously mentioned inhibitor of histidine decarboxylase. 24 Inhibition of Gastric Secretion Benzothiazoles: Antisecretory activity in a series of 3-amincr2,l-benzisothiazoles (VIII), determined by measuring gastric volume reduction after
VIII,
c , ” > s R 1/
\R2
f
subcutaneous administration to pylorus-li ated rats, varied from an ED50 of 1.5 mg./kg. to greater than 50 mg./kg. R and R2 consist of hydrogen, lower alkyl and phenyl, and some members of the series were also substituted in the benzenoid ring. Representative examples from the series did not show anticholinergic activity.25 Anticholinergics: The effects of anticholinergic agents on gastric acid secretion were compared with pharmacological effects on gastric emptying and pupil diameter, and it was concluded that the relationship of the secondary actions to the desired action’ofgastric acid inhibition was more important in evaluation than the absolute potency. 26 Experimental Ulcer Production The major objectives of the examination in laboratory animals of agents which produced gastrointestinal irritation or ulceration have been the discovery of preventative or counteracting agents and elucidation of the mechanism
102
Sect. I1 - Pharmacodynamics
A r c h e r , Ed.
of ulceration. The ulcerative action of serotonin was significantly diminished by administration of the antiserotonin methysergide (Deseril; 1-methyl-Dlysergic acid butanolamide tartrate) .29, 2g Antienzymes of pancreatic origin (Kunitz inhibitor) 29 or parotid origin (Frey inhibitor)3O markedly reduced the number of lesions resulting from reserpine or phenylbutazone. Aspirin damage to the intestinal mucosa occurred regard1 ss of whether It has been contact with the drug was from the lumen or the cir~ulation.~~ shown that aspirin greatly increased the ionic permeability of the mucosa and broke down its normal barrier to diffusion of sodium, potassium and hydrogen ions, so that absorption of hydrogen ions through the damaged barrier from the stomach led to mucosal bleeding. During active secretion of acid these effects It has also been proposed that aspirin decreased the rate may be enhan~ed.~~t33 of formation of the mucous lining and also lowered its resistance to proteolysis.34 Acetazolamide damage to the mucosa appeared to depend upon the presence of acid and, in addition, it accelerated the l o s s of hydrogen ions from the luminal fluid through the surface muc0sa.~5 Enhancement of gastric secretion was suggested to be a part of the mode of action of caffeine in ul~erogenesis.3~ The polysaccharide carrageenin has been found to have a protective effect from ulceration induced by histamine, cortisone or the Shay t e ~ h n i q u e . ~ ~ , ~ ~ Absorption and Transport Most experimental studies on absorption and transport were carried out to determine mechanism of these actions rather than to search for agents affecting in vivo action. Much of the work was done in in vitro gut sac preparations. Stimulation of glucose and sodium transport by reserpine resulted, at least in part,3$s a result of release of catecholamines from storage sites in the intestine. Similarly, Lepinephrine and &norepinephrine stimulated glucose and sodium absorption, but stimulation was blocked by prior treatment with dichloroisoproterenol or ergotamine, although the latter two agents alone had no effect. Cyclic AMF’ also had no effect.40 It was concluded that calcium binding substances reduced gastrointestinal absorption of drugs mainly by markedly decreasing the rate of gastric emptying.41 Transport of amino acids across the intestinal wall was inhibited by 4deoxypyridoxine, a vitamin B6 antagonist, whereas glucose transport was unaffected. It was concluded that vitamin B6 may be necessary for a metabolic process involving the amino acid carrier systems.42 CLINICAL INVESTIGATIONS Peptic Ulcer Therapy Anticholinergics: Although anticholinergic drugs are prescribed for the inhibition of gastric acidity in peptic ulcer disease, there was no indication that average doses of these agents significantly inhibited gastric acid secre-
Chap. 10
Gastrointestinal
Bolhofer and Brodie
103 -
Thus, for any significant degree of inhibition of gastric secretion, an anticholinergic agent must be administered at the maximally tolerated However, combinations of antacids and anticholinergics were found to be more effective in reducing gastric acidity than either drug given alone. Several new anticholinergics have undergone clinical trial, but none appeared to be any more potent or selective in action than a t r ~ p i n e . ~ ~Glycopyrrolate ,~~ (1-methyl-3-pyrrolidyl aphenylcyclopentaneglycolate methobromide) (IX) has been
CH3
'CH3
Br-
shown to be a clinically useful anticholinergic,47'48 but the drug had no special qualities which distinguished it from the more than 50 anticholinergics now available. The Wphenylcyclohexaneglycolate congener of glycopyrrolate, which was equiactive in animals, was found to be only minimally effective in suppressing gastric acidity in man.49 Antacids: These agents are widely used to reduce gastric acidity and relieve pain in the peptic ulcer patient. The mechanism of pain relief was unclear, since new telemetry techniques for measuring gastric pH50 have confirmed the older reports that the acid-neutralizing action lasted only from 30 to 40 minutes, while pain relief lasted for hours. A new antacid, bismuth aluminate, has been reported to be effective in relief of pain, but this agent had no effect on gastric acidity or peptic a~tivity.~' The effect was postulated to be due to a coating action of the gastric mu~osa.~* As with anticholinergics, the antacids53 gave symptomatic relief, but did not alter the natural course of the disease. Antipeptic Agents: Since acid-pepsin digestion is considered to be essential for the production of peptic ulceration, regardless of the underlying cause of the disease, reduction of pepsin concentration of gastric juice remains a practical aim in ulcer therapy. Sun54 has reviewed this area with particular attention to a new antipeptic agent, Depepsen, a sulfated amylopectin. The place of these agents in peptic ulcer treatment is still controversial. Gastric Ulcer Therapy Gastric ulcer patients differ from those with duodenal ulcer, in that the former have normal or low gastric acidity and -amuch higher incidence of gastric cancer Carbenoxolone (B iogastrone) , the pentacyc 1ic triterpene, glycyrrhetinic acid, has been reported to give symptomatic relief in gastric ulcer patients and to increase the rate of gastric ulcer healing, confirming the original clinical s t ~ d i e s . 5 ~Some ~ ~ investigators, however, have failed to find effects better than placebo,58 and side effects related to salt and water retention were common. The mechanism of the antiulcer action was not clear, but could be related to the drug's antiinflannnatory effects.
.
104
Sect. I1 - P h a r m a c o d y n a m i c s
A r c h e r , Ed.
Functional Gastrointestcnal Disorders Anticholinergics have been used f o r treatment of hypermotility s t a t e s with some success, but with t h e usual s i d e e f f e c t s . A l a r g e series of thioxanthene d e r i v a t i v e s was studied f o r s e l e c t i v e anticholinergic action, and 9-flN-methyl3-piperidy1)methylJ thioxanthene, marketed as methixene (Trest) (X) , has been found t o provide symptomatic r e l i e f w i t h l o w incidence of atropine-like s i d e
H C-
.
3
e f f e c t s 59s60 It i s too e a r l y t o t e l l i f t h i s drug w i l l replace t r a d i t i o n a l anticholinergic treatment i n hypermotility states. I n t h e carcinoid syndrome, i t has been suggested t h a t serotonin was responsible f o r t h e d i a r r h e a seen i n t h i s condition. Treatment with a serotonin a n t a g o n i s t J 6 l methysergide, was e f f e c t i v e i n c o n t r o l l i n g t h e diarrhea and was f u r t h e r evidence f o r t h e r o l e of serotonin i n i n t e s t i n a l m o t i l i t y . The search f o r agents which a l t e r smooth muscle a c t i v i t y yielded several new compounds. Antispasmodic e f f e c t s were reported f o r ipyrrole, 62 acetophenone63 and piperidine derivatives,64 as w e l l as d e h y d r o m e t h y s t i c ~ s nand ~ ~ 2-(2'phenylace tylhydraz ino)-4,6-bisdiethylamino- 1,3 ,5- t r i a z ine (Ciba 28,882-Ba) . 66 The spasmo enic e f f e c t of dihydrocodeine w a s reversed by n i c o t i n i c acid esteri f i ~ a t i o n . Nicotinyldihydrocodeine ~~ was found t o i n h i b i t drug-induced spasm of t h e b i l e duct sphincter. Stimulation of smooth muscle a c t i v i t y w a s reported f o r t et r ahydr oaminoacr i d i n e c ompounds 68
.
Metoclopramide ~-(2-diethylaminoethyl)-2-methoxy-4-amino-5-chlorobenzamide d i h y d r c x h l o r i d g (XI) has been widely used i n Europe as a "digestive C O W C H ~ C H ~ - N(C 2139
I
c1QH3
2 HC1
modifier" t o r e l a x t h e pylorus and increase g a s t r i c m o t i l i t y and as an a i d t o t h e x-ray study@ of the g a s t r o i n t e s t i n a l t r a c t . I t s primary use has been as an antiemetic. A t t h e present t i m e , t h i s d k g i s not a v a i l a b l e i n t h e United States.
Chap. 10
Gastrointestinal
Bolhofer and Brodie
105 -
Ulcerative Colitis Therapy The choice between medical and surgical treatment of this disease remains a problem to the clinician. Reviews of the l i t e r a t ~ r e ~indicated ~ , ~ ~ that steroids were the most commonly used drugs; however, as with anticholinergic therapy for peptic ulcer, they alleviated the symptoms but did not cure the disease. Drug Effects on Gastrointestinal Motility Stimulation of gastrointestinal motility has been studied, usually with isolated tissues, with a wide variety of drugs. Serotonin has been suggested to be a naturally occurring material which stimulates motility, perhaps as a local hormone. However, its role remained unclear, since it has been shown to stimulate human tissues in ~ i t r o but ,~~ up to 90% depletion in the rat did not inhibit peri~talsis.~3 A study on the isolated rat colon indicated that the effect of serotonin was dose-related: small doses had a direct effect on muscle fibers, while higher doses acted by stimulating parasympathetic ganglia in the gut wall.74 Bile Drug-induced jaundice as a side effect of phenothiazine derivatives is well documented. The effect of these drugs and C17~alkyl-substitutedsteroids was studied by in vivo and in vitro t e s t ~ , ~and s it was concluded that these agents inhibited glucuronyl transferase. The steroids prevented excretion of conjugated bilirubin by blocking a stage after conjugation, but the mechanism of phenothiazine jaundice was still unclear. The steatorrhea observed in patients receiving cholestyramine (a basic ion exchange resin which binds bile acids) and a diet containing triglyceride fats of normal chain length was eliminated by replacing the long chain triglycerides with medium chain triglycerides (less than C12). Bile acid absorption by the cholestyramine was comparable for both diets. The medium chain triglycerides may be of value in clinical management of patients with malabsorption due to biliary 0bstruction.7~ Salivary Glands Physalaemin, a polypeptide was found to be the most active sialogogic agent tested in rats and dogs.7f Its action appeared to be a direct one on the salivary gland, since its effect was not blocked by sympathomimetic, parasympathomimetic or ganglionic blockers, but its effect was reduced by serotonin. Drug-Induced Gastrointestinal Lesions The incidence of pathological changes in the gastrointestinal tract due to therapeutic agents has increased as new drugs and formulations appeared on the market. Gastrointestinal ulceration due to steroids and antiinflammatory drugs is well known and continues to be a major side effect. Reduction of ulcerogenic activit was reported with ketophenylbutazone as compared to phenylbutazone itself,78 while the use of indomethacin capsules reduced the incidence of peptic ulcers seen with indomethacin The mechanism of steroid-
tablet^.^'
106
Sect. I1
-
Pharmacodynamics
A r c h e r , Ed.
induced g a s t r o i n t e s t i n a l l e s i o n s i s s t i l l not resolved. Hydrocortisone d i d not a f f e c t g a s t r i c s e c r e t i o n i n t h e r a t , leading t o t h e conclusion t h a t some mechanism o t h e r increased g a s t r i c a c i d i t y was t h e cause of c o r t i c o s e r o i d ulceration.86518' There d i d not s e e m t o be a s p e c i f i c s t e r o i d ulcer8' a s distinguished from u l c e r s due t o o t h e r causes. It has been suggested83 t h a t s t e r o i d s aggravated e x i s t i n g inflammation by loosening i n t e r c e l l u l a r cement and permitting p e n e t r a t i o n of t h e mucosa by t h e g a s t r i c j u i c e . S t e r o i d therapy i n cancer p a t i e n t s appeared t o induce more severe g a s t r i c complications than ,in p a t i e n t s with nonmalignant disease.84
A new i a t r o g e n i c .lesion, small bowel u l c e r a t i o n following a d m i n i s t r a t i o n of enteric-coated t a b l e t s of potassium c h l o r i d e and a t h i a z i d e d i u r e t i c , 8 g 39 described i n l a t e 196485 and r a p i d l y confirmed by numerous c a s e r e p o r t s . Experimental s t u d i e s i n d i c a t e d t h a t t h e l e s i o n was due t o t h e release of a high l o c a l c o n c e n t r a t i o n of potassium from t h e enteric-coa ed t a b l e t over a s h o r t segment of t h e i n t e s t i n e . 9 0 I n one c l i n i c a l report," a p a r t i a l l y digested t a b l e t was found i n a l e s i o n c r a t e r i n t h e i n t e s t i n e . The t h i a z i d e d i u r e t i c d i d n o t appear t o be connected with t h e l e s i o n p r o d u c t i ~ n . ~ ~ , ~ ~ REFERENCES
1. 2. 3. 4. 5. 6. 7. 8. 9.
10. 11. 12. 13. 14. 15. 16.
17.
18.
19. 20. 21. 22.
23.
H. Gregory, P.M. Hardy, D.S. Jones, G.W. Kenner and R.C. Sheppard, Nature, 204, 931 (1964). R.A. Gregory, H.J. Tracy and M.I. Grossman, Nature, 209, 583 (1966). P.H. Bently, G.W. Kenner and R.C. Sheppard, Nature, 209, 583 (1966). J. Beacham, P.A. Bently, R.A. Gregory, G.W. Kenner, 3.K. MacLeod and R.C. Sheppard, Nature, 209, 585 (1966). H.3. Tracy and R.A. Gregory, Nature, 204, 935 (1964). J.S. Morley, H.J. Tracy and R.A. Gregory, Nature, 207, 1356 (1965). G.M. Makhlouf, J.P.A. McManus and W . I . Card, Lancet, 2, 485 (1964). L.S. Semb and J.A. Myren, Scand. J. Clin. Lab. Invest., 1 7 , 311 (1965). W.J. I r v i n e , Lancet, 1, 736 (1965). S . Konturek and M.I. Grossman, Proc. SOC. Exptl. Biol. Med., 119, 443 (1965). R.B. Quintana, C. D e La Rosa and L.R. Dragstedt, U e s t . D i s . , 10, 745 (1965). B.J. Haverback, L.B. Tecimer, B.J. Dyce, M. Cohen, M . I . S t u b r i n and A.D. Santa Ana, L i f e Sci., 3, 637 (1964). P.H. Jordan and R. Quintana, Gastroenterology, 47, 617 (1964). W.G. Gobbel, Jr., R.H. Edwards and C.F. Zukoski, Southern Med. J., 58, 1044 (1965). J.D. Cunnning, E.H.L. H a r r i e s and P. Holton, J. Physiol. (L0nd.Z 181, 33P (1965) A.N. Smith and D. Hogg, Lancet, 1, 403 (1966). B.I. Hirschowitz and G. Sachs, Am. J. Physiol., 209, 452 (1965). R.A. Davis, F.P. Brooks and C.McN. Robert, Jr., Am. J. Physiol., 208, 6 (1965). W.W. Duke, B.I. Hirschowitz and G. Sachs, Lancet, 2, 871 (1965). R.J. Levine, T.L. S a t 0 and A. Sjoerdsma, Biochem. Pharmacol., 14, 139 (1965). R.J. Levine, Fed. Proc., 24, 1331 (1965). P.A. Shore, Fed. Proc., 24, 1322 (1965). M. S t u b r i n , €3. Dyce, L. T e c i m e r and B.J. Haverback, Clin. Res., 13, 97 (1965).
.
Chap. 10 24. 25. 26. 27. 28. 29. 30. 31. 32. 33. 34. 35.
Gastrointestinal
Bolhofer and Brodie
J.E. F i s c h e r and S.H. Snyder, Science, 150, 1034 (1965). C o l l i e r , J. Med. Chem., 8, R.F. Meyer, B.L. Cummings, P. Bass and H.O.J. 515 (1965). D.A. Brodie, Gastroenterology, 50, 45 (1966). R. Lambert, L. Descos, J. Pasquier and M. Martin, Gastroenterologia, 103, 365 (1965). R. Lambert, L. Descos and J. Pasquier, Compt. Rend. SOC. Biol., 158, 1367 (1964). F. Guerrin, A. D e m a i l l e , P. Merveille and C. B e l , Compt. Rend. SOC. Biol., 159. 1172 (1965). F. Guerrin, A. Clay, C. L'Hermine, A. D e m a i l l e and R. Druart, Compt. Rend. SOC. Biol., 158, 1626 (1964). A. Lynch, H. Shaw and G.W. Milton, Gut, 5, 230 (1964). H.W. Davenport, Gastroenterology, 49, 189 (1965). K.W. Anderson, Arch. I n t e r n . Pharmacodyn., 157, 181 (1965). R. Menguy and Y.F. Masters, Surg. Gynecol. Obstet., 120, 92 (1965). J.L. Werther, F. Hollander and M. Altamirano, J. Physiol., 209, 127 (1965). C.J. P f e i f f e r and G.H. Gass, Toxicol. Appl. Pharmacol., 7, 732 (1965). W. Anderson and P.D. Soman, Nature, 206, 101 (1965). G. Lambelin, Med. Exptl., 14, 136 (1966). K.A. Aulsebrook, Proc. SOC. Exptl. Biol. Med., 119, 387 (1965). K.A.,,Aulsebrook, Biochem. Biophys. Res. C m n . , 18, 165 (1965). E. Sognen, Acta Pharmacol. Toxicol., 22, 31 (1965). B.G. Munck, Biochim. Biophys. Acta, 94, 136 (1965). J.B. Kirsner and H. Ford, _Current Therap. Res., 7, 116 (1965). J.E. Berk, Current Therap. Res., 7, 149 (1965). S.M. Chernish and B.D. Rosenak, Am. J. Digest. D i s . , 10, 697 (1965). P.B. Rowe, B. Fenton and D. Beeston, Am. J. Digest. D i s . , 10, 205 (1965). W.P. S i n c l a i r and E.S. Schnier, Am. J. Gastroent., 44, 62 (1965). B.O. Amure, P r a c t i t i o n e r , 195, 335 (1965). M.D. Kamionkowski and B. F l e s h l e r , Current Therap. R e s . , 6, 459 (1964). H.G. Noeller, Therapiewoche, 15, 47 (1965). Swan and J. Kelleher, B r i t . Med. J., 1, 753 (1965). S.G.F. Matts, C.H.J. G.W. Milton, B r i t . Med. J., 1, 1672 (1965). Thomas, Postgrad. Med. J., 41, 48 (1965). P.R.C. Evans, S. N o w e l l and I.A.P. D.C.H. Sun, Current Therap. Res., 7, 790 (1965). R. Doll, I.D. H i l l , C. Hutton and D.J. Underwood, Lancet, 2, 793 (1962). R. Doll, I.D. H i l l , and C.F. Hutton, Gut, 6, 1 9 (1965). L. Horwich and R. Galloway, B r i t . Med. J., 2, 1274 (1965). W.R. Middleton, A.R. Cooke, D. Stephen and A.P. Skyring, Lancet, 1, 1030 (1965). H. Lauener and R.C. Pogge, J. Pharm. Sci., 53, 568 (1964). J.K. Martins, Clin. Med., 72, 1313 (1965). K.L. Melmon, A. Sjoerdsma, J.A. Oates and L. L a s t e r , Gastroenterology, 48, 18 (1965); A. Robelet, F. Erb-Debruyne, N. Bizard-Gregoire and J. Bizard, Therapie, 20, 427 (1965). R. Cahen, A. Boucherle, M. H i c t e r , M. S a u t a i , J. Pessonier and F. Rambert, Compt. Rend. SOC. Biol., 159, 1353 (1965). A. Vaccari, F. Cugurra and M. Ferro, Clin. Terap., 32, 483 (1965).
&I.
36. 37. 38. 39 40. 41. 42. 43.
.
44.
45. 46. 47. 48 49 50. 51. 52. 53. 54. 55. 56. 57. 58
.
.
59 60. 61. 62.
63. 64.
107 -
108
Sect. I1
- Pharmacodynamics
A r c h e r , Ed.
65. H.J. Meyer, Arch. Intern. Pharmacodyn., 154, 449 (1965). 66. P.P. Spinnler, Arch. Intern. Pharmacodyn., 156, 217 (1965). 67. R.A. Cahen, A. Boucherle and M. Sautai, Compt. Rend. SOC. Biol., 159, 1123 (1965). 68. M.J. Bleiberg, Life Sci., 4, 449 (1965). 69. R. Van Lerberghe, Acta Gastroent. Belg., 28, 440 (1965). 70. M. Sparberg and J.B. Kirsner, Current Therap. Res., 7, 324 (1965). 71. T.P. Almy and A.G. Plaut, Gastroenterology, 49, 295 (1965). 72. D.J. Fishlock, A.G. Parks and V. Dewell, Gut, 6, 338 (1965). 73. D.J. Boullin, Brit. J. Pharmacol., 23, 14 (1964). 74. K. Ulrich, J. Pharm. Pharmacol., 17, 710 (1965). 75. T. Hargreaves, Nature, 206, 154 (1965). 76. R.B. Zurier, S.A. Hashin and T.B. Van Itallie, Gastroenterology, 49, 490 (1965). 77. G. Bertaccini and C. de Caro, J. Physiol. (Lond.1, 181, 68 (1965). 78 2. Horakova, 3. Metys and V. Cepelak, Therapie, 20, 617 (1965). 79. 0. L%rgren and E. Allander, Brit. Med. J., 1, 996 (1965). 80. P.H. Guth and R. Mendick, Am. J. Gastroenterol., 44, 545 (1965). 81. R.E. Wiederanders, J, Lancet, 85, 315 (1965). 82. A.E. Garb, E.H. Soule, L.G. Bartholmew and J.C. Gain, Arch. Intern. Med., 116, 899 (1965). 83. D.H. Johnston, Gastroenterology, 48, 823 (1965). 84. D.L. Roseman and S.C. Economou, Arch. Surg., 90, 488 (1965). 85. D.R. Baker, W.H. Schrader and C.R. Hitchcock, J. Am. Med. ASSOC., 190, 586 (1964). 86. R.J. Rosen and D.T. Borucki, J. Am. Med. ASSOC., 191, 419 (1965). 87. D.J. Buchan, F. Murphy and C.S. Houston, Gastroenterolopy, 48, 808 (1965). Lancet, 2, 593 (1965). 88. L. 89. T.B. Binns, A.K. Pittman, D.M. Burley and J.M. O'Brien, Brit. Med. J., 1, 248 (1965). 90. S.J. Boley, L. Schultz, A. Krieger, S. Schwartz, A. Elguezabal and A.C. Allen, J. Am. Med. ASSOC., 192, 763 (1965). 91. H. Payan and A. Blaustein, Gastroenterology, 48, 877 (1965). 92. R.M. Diener, D.H. Shoffstall and A.E. Earl, Toxicol. Appl. Pharmacol., 7, 746 (1965). 93. F.D. Lawrason, E. Alpert, F.L. Mohr and F.G. McMahon, J. Am. Med. Assoc., 191, 641 (1965).
sf,
S e c t i o n I11 Editor:
Edwin H.
Chemotherapeutic Agents
Flynn, E l i L i l l y a n d Co.,
C h a p t e r 11. Edwin H.
-
Indianapolis,
Ind.
A n t i b i o t i c s and R e l a t e d Compounds
Flynn, E l i L i l l y and Co.,
Indianapolis,
Ind.
The y e a r 1965 w a s marked by a p p e a r a n c e of a number of v a l u a b l e r e p o r t s b e a r i n g on t h e u s e of a n t i b i o t i c s i n t h e chemotherapy of i n f e c t i o u s d i s e a s e s . Nek advances have been made i n u n d e r s t a n d i n g t h e b i o s y n t h e s i s of some a g e n t s and e x p e r i m e n t s have been r e p o r t e d which were d e s i g n e d t o make t h e mode of a c t i o n u n d e r s t a n d a b l e . Although n o t a l l - i n c l u s i v e , p a p e r s r e f e r r e d t o i n t h e f o l l o w i n g pages s h o u l d g i v e t h e r e a d e r a s t a r t i n g p o i n t f o r f u r t h e r r e a d i n g and may i n d i c a t e t h e d i r e c t i o n s b e i n g t a k e n by r e s e a r c h i n t h i s a r e a . Penicillins new d e r i v a t i v e s of 6 - a m i n o p e n i c i l l a n i c a c i d ( I) c o n t i n u e t o
f i n d a p l a c e b o t h i n e x p e r i m e n t a l work on i n f e c t i o u s d i s e a s e Two d e r i v a t i v e s c l o s e l y r e l a t e d t o and i n m e d i c a l p r a c t i c e . o x a c i l l i n ( 11) a r e c l o x a c i l l i n ( 111) and d i c l o x a c i l l i n ( IV) These compounds, though d e s c r i b e d e a r l i e r , have been s t u d i e d further. It has been said1 t h a t c l o x a c i l l i n i s p r i m a r i l y u s e f u l i n i n f e c t i o n s c a u s e d by p e n i c i l l i n a s e p r o d u c i n g s t a p h y l o c o c c i . Blood l e v e l s a f t e r o r a l and i n t r a m u s c u l a r a d m i n i s t r a t i o n w e r e s l i g h t l y more d e l a y e d when compared w i t h o x a c i l l i n b u t l a s t e d longer. Peak l e v e l s were t h o u g h t t o be s i m i l a r , a l t h o u g h o t h e r workers2 have r e p o r t e d b e t t e r a b s o r p t i o n t h a n t h a t o b t a i n e d w i t h oxacillin. A c l i n i c a l s t u d y 2 of c l o x a c i l l i n showed good r e s u l t s i n s t a p h y l o c o c c a l , pneumococcal and s t r e p t o c o c c a l i n f e c t i o n s and c o n s i s t e n t l y h i g h e r a n t i b a c t e r i a l blood l e v e l s
.
110
Sect. 111
-
Chemotherapeutics
F l y n n , Ed.
a f t e r o r a l administration. It w a s c o n c l u d e d t h a t c l o x a c i l l i n c o u l d s u b s t i t u t e f o r m e t h i c i l l i n when o r a l t h e r a p y i s f e a s i b l e . D i c l o x a c l l l i n a p p e a r s t o be a b s o r b e d e x t r e m e l y w e l l , g i v i n g p e a k blo& l e v e l 8 t w i c e t h u s e of c l o x a c l l l i n and f o u r - f o l d greater than o x a c i l l i n . g It w a s f e l t t h a t serum b i n d i n g w a s comparable t o t h e o t h e r i s o x a z o l y l p e n i c i l l i n s . These blood l e v e l s have been confirmed.4 A m p i c i l l i n ( V ) , known t o be a b s o r b e d w e l l o r a l l y and t o have a b r o a d e r s p e c t r u m of a c t i v i t y t h a n o t h e r p e n i c i l l i n s , has been s t u d i e d a s t h e sodium s a l t f o r p a r e n t e r a l a d m i n i s t r a t i o n . 5 R e s u l t s i n d i c a t e d t h i s form t o be s a t i s f a c t o r y f o r p a r e n t e r a l u s e , t h u s e n h a n c i n g t h e c l i n i c a l v a l u e of a m p i c i l l i n . H e t a c i l l i n ( V I ) , t h e r e a c t i o n p r o d u c t of a m p i c i l l i n and a c e t o n e , has been r e p o r t e d . 6 It is s a i d t o g i v e more p r o l o n g e d b l o o d l e v e l s a f t e r o r a l dosage t h a n does a m p i c i l l i n , and a p p a r e n t l y is a c t i v e i n v i v o by v i r t u e of h y d r o l y s i s t o ampicill~n.~
N a f c i l l i n ( V I I ) has been r e p o r t e d t o be a n e f f e c t i v e and w e l l t o l e r a t e d a n t i s t a p h y l o c o c c a l a g e n t comparable t o o t h e r penicillinase resistant penicillins.* a - a l k y l d e r i v a t i v e s of phenoxymethyl p e n i c i l l i n ( p e n i c i l l i n V) have been d e s c r i b e d and t u r n o u t t o be e s s e n t i a l l y i n a c t i v e as a n t i b a c t e r i a l s u b s t a n c e s when compared w i t h t h e u n s u b s t i t u t e d compound.8 A c t i v e d e r i v a t i v e s of 6 - a m i n o t h i o p e n i c i l l a n i c a c i d ( V I I I ) have been r e p o r t e d . 1 0 An i n t e r e s t i n g s e r i e s i s t h a t r e p r e s e n t e d by I X ; t h i s member showing good gram n e g a t i v e as w e l l as gram p o s i t i v e a c t i v i t y . ' l
(VIII)
A p r o p o s a l c o n c e r n i n g t h e mechanism of a c t i o n of p e n i c i l l i n s on t h e b a c t e r i a l c e l l has been advanced.12 An i n t e r e s t i n g p a p e r c o n c e r n i n g t h e i n i t i a l s t r u c t u r a l l e s i o n s roduced by p e n i c i l l i n a c t i n g on t h e b a c t e r t a l c e l l has appeared. It v e r i f i e s a h i g h l y s p e c i f i c p o i n t o f a t t a c k by t h i s a n t i b i o t i c .
Antibiotics
Chap. 11
Flynn
111 -
A w o r t h w h i l e r e v i e w of p e n i c i l l i n s h a s a p p e a r e d L 4 and a book h a s been p u b l i s h e d x S which is c o n c e r n e d p r i m a r i l y w i t h b i o c h e m i c a l and b i o l o g i c a l f a c t o r s r e l a t e d t o p e n i c i l l i n . Cephalosporins The c e p h a l o s p o r i n g r o u p of a n t i b i o t i c s , whose g e n e s i s may be t r a c e d t o t h e d i s c o v e r y of c e p h a l o s p o r i n C ( X ) , h a s demons t r a t e d t h e i r v a l u e i n t h e t r e a t m e n t of i n f e c t i o u s d i s e a s e . C e p h a l o t h i n ( X I ) , t h e f i r s t of t h e s e s u b s t a n c e s t o find wides p r e a d u s e , w a s f o l l o w e d by c e p h a l o r i d i n e ( X I I ) which is now employed in many c o u n t r i e s f o r t h e r a p y of b a c t e r i a l i n f e c t i o n s . It seems a p p a r e n t t h a t o t h e r v a l u a b l e compounds of t h i s c l a s s may be e x p e c t e d .
X, R = H 0 2 C - C H N H 2 ( C H 2 ) 3 C O XI,
R = O H z C O - , S
XIII,
-
R'
, R'
= CHsC02-;
= CH3C02-;
R = D - C B H ~ C H N H ~ C O - , R'
CH3C02-
C e p h a l o r i d i n e h a s been e v a l u a t e d i n a number of c l i n i c a l and l a b o r a t o r y o t h e r r e p o r t s n o t c i t e d h e r e may be f o u n d in t h e A b s t r a c t s of t h e F i f t h I n t e r s c i e n c e C o n g r e s s on A n t i m i c r o b i a l Agents and Chemotherapy. It c a n be s a i d i n g e n e r a l t h a t t h e a g e n t w a s e f f e c t i v e i n a v a r i e t y of b o t h gram n e g a t i v e and gram p o s i t i v e b a c t e r i a l i n f e c t i o n s . Cephaloridine was ' i n e f f e c t i v e a g a i n s t Pseudomonas, t h e t u b e r c l e b a c i l l u s , a n d fungi. I n a comparison w i t h c e p h a l o t h i n s i g n i f i c a n t d i f f e r e n c e s in t h e r a p e u t i c r e s p o n s e were n o t d e t e c t e d . 1 7 G e n e r a l l y s a t i s f a c t o r y r e s u l t s were s e e n i n a p e d i a t r i c study" of cephaloridine. A s e r i e s of 92 c a s e s w i t h a v a r i e t y of i n f e c t i o n s w a s s t u d i e d with impressive r e s u l t s . l s !Cwo c a s e s of r e n a l f a i l u r e were e n c o u n t e r e d w h i l e u n d e r t r e a t m e n t w i t h 8-12 grams of c e p h a l o r i d i n e d a i l y ; t h e complex h o s p i t a l c o u r s e s d i d n o t I n a n o t h e r s e r i e s of 70 a l l o w d i r e c t i m p l i c a t i o n of t h e d r u g . c a s e s a t what would seem t o be low d a i l y d o s e s , good r e s u l t s were r e p o r t e d . 2 0 The same r e p o r t m e n t i o n s t o x i c c h a n g e s in r a b b i t k i d n e y a t a s i n R l e d o s e of 90 mg./kg. b u t not a t 45 mg./kg. d a i l y f o r e i g h t weeks. A l l of t h e f o r e g o i n g s t u d i e s employed p a r e n t e r a l a d m i n i s t r a t i o n . The b a c t e r i c i d a l a c t i v i t y o f c e p h a l o r i d i n e h a s been commented upon f a v o r a b l y 2 1 a n d i t s s t a b i l i t y t o s t a p h y l o c o c c a l p e n i c i l l i n a s e h a s been ~ t u d i e d . ~ ~ AJ l ~ l e 3r g y t o c e p h a l o r i d i n e h a s r e c e i v e d n o t i c e 2 * as h a s a c a s e of a n a p h y l a x i s a t t r i b u t e d t o c e p h a l o t h i n . 2g
112
S e c t I11
- Chemotherapeutics
F l y n n , Ed.
A n i n t e r e s t i n g i n v e s t i g a t i o n of s y n e r g i s m between p e n i c i l l i n s and c e p h a l o s p o r i n s a g a i n s t pS. pyocyanea h a s been p u b l i s h e d show‘ing marked enhancement of a c t i v i t y i n c e r t a i n c a s e s . 26 C e p h a l o g l y c i n ( X I I I ) has been e v a l u a t e d 2 7 I n t h e l a b o r a t o r y b o t h in v i t r o and in v i v o and shows a good l e v e l of a c t i v i t y v e r s u s gram n e g a t i v e organisms. The a r t i c l e p o i n t s o u t some d i f f i c u l t i e s i n h e r e n t in e v a l u a t i n g a s u b s t a n c e which is r e l a t i v e l y u n s t a b l e in s o l u t i o n as is t h e c a s e w i t h c e p h a l o g l y c in. Chemical p a p e r s have a p p e a r e d , one d e s c r i b i n g p h y s i c a l c h e m i c a l d a t a on a s e r i e s of c e p h a l o s p o r i n s P 8 and a n o t h e r m e n t i o n i n g p r e p a r a t i o n of a number of d e r i v a t i v e s . = e Lincomyc in L l n c o m n i n . a n a n t i b i o t i c e f f e c t i v e in t r e a t m e n t of i n f e c t i o n s caus;d by gram p o s i t i v e organisms, is f i n d i n g Earlier w i d e s p r e a d u s e in t h e . t r e a t m e n t of human d i s e a s e . r e p o r t s ( 1 9 6 3 and l a t e r ) d e m o n s t r a t i n g c l i n i c a l e f f i c a c y have been e x t e n d e d . 30-91 T h a t s t r u c t u r a l m o d i f i c a t i o n of l i n c o m y c i n is p o s s i b l e w i t h o u t loss of a n b i b a e t e r i a l a c t i v i t y has been shown in s e v e r a l papers.32’3s*34 Some s t u d i e s o n b i o s y n t h e s i s have been r e p o r t e d . 3 5
\
w r a l r e p o r t s c o n c e r n e d w i t h a new e n t i t y c a l l e d kasugamycin hav; a p p e a r e d . T h i s s u b s t a n c e has been shown t o have t h e s t r u c t u r e , XIV.36 O r i g i n a l l y d i s c o v e r e d b e c a u s e of i t s
H2N-i-iPHs NH
H
~~
( XIV)
H
OH
o
~
o
~
OH
a c t i v i t y i n p. o r y z a e i n f e c t i o n s of t h e r i c e p l a n t , it has a n t i b a c t e r i a l a c t i v i t y of a f a i r l y wide r a n g e , though of a low order.37 O r a l l y a b s o r b e d , and a p p a r e n t l y r e l a t i v e l y n o n - t o x i c , kasugamycin may f i n d a p p l i c a t i o n in t r e a t m e n t of human infections. I t s u t i l i t y in Pseudomonas i n f e c t i o n s of t h e g e n i t o u r i n a r y t r a c t has been s u g g e s t e d in one pa er.36 D e r i v a t i v e s of r i f a m y c i n have been r e p o r t e d e * 4 0 a n d a t l e a s t one compound has been shown t o be e f f e c t i v e in human disease.41 The d i e t h y l a m i d e of r i f a m y c i n B has shown e f f e c t i v e n e s s i n a c u t e c h o l e c y s t i t i s and i n s t a p h y l o c o c c a l i n f e c t i o n s . L e s s favorab1.o r e s u l t s were o b t a i n e d in pneumonia. A revidw has a p p e a r e d on r i f a m y c i n SV.42
P
Chap. 1 1
Antibiotics
Flynn
113 -
A d d i t i o n a l i n f o r m a t i o n on t h e g e n t a m i c i n complex, f i r s t r e p o r t e d i n 1963, h a s been made a v a i l a b l e d u r i n g 1965. T h i s m u l t i p l e f a c t o r a g e n t ( s ) has been shown t o have v a l u e i n t h e t r e a t m e n t of Pseudomonas s e p s i s i n burns4cg and t h e ( r a b b i t ) eye44 and h a s been u s e d i n p e d i a t r i c s t o t r e a t gram n e g a t i v e i n f e c t i o n s . 4 5 Although somewhat t o x i c , g e n t a m i c i n a p p e a r s t o have c l i n i c a l v a l u e . Some c h e m i c a l s t u d i e s have been r e p o r t e d , 4 6 showing t h e p r e s e n c e i n t h e m o l e c u l e of D-glucosamine, 2 - d e o x y s t r e p t a m i n e and a n amino s u g a r named g e n t o s a m i n e A. A c o n f e r e n c e t o d i s c u s s new a n t i t u b e r c u l o u s a g e n t s w a s h e l d by t h e New York Academy of S c i e n c e s September 13-15, 1965, i n N e w York C i t y . The u s e of e t h a m b u t o l and capreomycin i n t h e r a p y was discussed. Aatinospectacin, a n a g e n t w i t h broad spectrum a ~ t i v i t y , 4 ~ showed promise i n a c u t e i n f e c t i o n s of t h e g e n i t o u r i n a r y t r a c t s 4 ' The r e l a t i v e l y low p e r c e n t a g e of "good" r e s p o n s e s w a s p r o b a b l y due t o i n a d e q u a t e dosage. I s o l a t i o n a n d b i o l o g i c a l a s s e s s m e n t of coumermycin has been reported.4a The s t r u c t u r e has been e s t a b l i s h e d 5 O and i t s s y n t h e s i s from a n o v o b i o c i n i n t e r m e d i a t e h a s been mentioned.'l Chemically r e l a t e d t o n o v o b i o c i n , coumermycin A 1 shows c r o s s r e s i s t a n c e w i t h novobiocin; i t a p p e a r s t o be more a c t i v e i n It is i d e n t i c a l t o sugordomycin. Coumermycin A 2 i s general. c l o s e l y r e l a t e d t o A 1 hhemically.s2 Chemistry of t h e polymyxins h a s been discassed.'" S y n t h e s i s of polymyxin E ( c o l i s t i n A) w a s t h e s u b j e c t of a r e c e n t study.s4 S t r u c t u r e s t u d i e s were d e s c r i b e d showing t h e i d e n t i t i e s of polymyxin El and E2 w i t h c o l i s t i n A and B, respectively.' F u s i d i c a c i d , t h e s t e r o i d a l a n t i b i o t i c now i n c l i n i c a l u s e , has been shown t o be i d e n t i c a l w i t h ramycin.56 A comprehensive s t u d y of t h e e f f e c t of s t r u c t u r a l v a r i a t i o n on a n t i b a c t e r i a l The s t r u c t u r a l r e l a t i o n s h i p w i t h a c t i v i t y has been r e p o r t e d . s 7 h e l v o l i c a c i d and c e p h a l o s p o r i n P1 i s mentioned. Erythromycin has been shown t o be e f f e c t i v e c l i n i c a l l y 5 * in pneumonia due t o Mycoplasma pneumoniae, t h e Eaton a g e n t pneumonia. Bios n t h e s i s and metabolism of e r t h r o m y c i n s were s t u d i e d u s i n g 1-f4c p r o p i o n a t e as p r e c u r s o r . sg The a g l y c o n e w a s formed and gave e r y t h r o m y c i n s A, B, and C. A biosynthetic scheme w a s proposed. The s t r u c t u r e s of s p i r a m y c i n and magnamycin were published.6o The s t r u c t u r e of magnamycin r e p r e s e n t s a r e v i s i o n of an e a r l i e r p r o p o s a l . The s t r u c t u r e of viomycin h a s been d e t e r m i n e d . e l Moenomycin, a macromolecule h a v i n g h i g h i n t r i n s i c a n t i b a c t e r i a l a c t i v i t y % v i t r o and i n v i v o when a d m i n i s t e r e d The recommendation p a r e n t e r a l l y , has been r e p o r t e d . 6 2 , 6 3 , 6 4 w a s made t h a t t h i s i n t e r e s t i n g s u b s t a n c e be r e s e r v e d f o r u s e a s a n a n i m a l growth s t i m u l a n t .
114
Sect. III
-
Chemotherapeutics
F l y n n , Ed.
T e t r a c y c l i n e d e r i v a t i v e s have been p r e p a r e d by a l k o x y a l k y l a t i o n of t h e amide f u n c t i o n . 6 5 The mode(s) of a c t i o n of t e t r a c y c l i n e s have been s t u d i e d u s i n g A. a e r o g e n e s . 0 0 They a r e s a i d t o i n t e r f e r e w i t h hydrogen t r a n s f e r r e a c t i o n s . A disturbing r e p o r t of t r a n s d u c t i o n of 2. a u r e u s t o t e t r a c y c l i n e r e s i s t a n c e in v i v o h a s a p p e a r e d . 6 7 Although a similar c i r c u m s t a n c e seems A further remote in humans, t h e p o s s i b i l i t y w a s noted. e l a b o r a t i o n of b i o s y n t h e t i c pathways f o r t e t r a c y c l i n e s h a s been provided.ee The i s o l a t i o n and c h a r a c t e r i z a t i o n of h-hydroxy-6m e t h y l p r e t e t r a m i d , a t e t r a c y c l i n e p r e c u r s o r accumulated by a b l o c k e d mutant, has been r e c o r d e d . e a A new t o t a l s y n t h e s i s of 6-deoxy-6-demethyltetracycline w a s a c h i e v e d by an e l e g a n t p r o c e d u r e .70 The c h e m i s t r y of t h e d e p s i p e p t i d e t y p e a n t i b i o t i c s ( s t r u c t u r e s made up of hydroxy- and amino a c i d m o i e t i e s l i n k e d t h r o u g h e s t e r a n d amide bonds) apd t h e i r mechanism of a c t i o n has been reviewed.71 A d e t a i l e d a c c o u n t of t h e c h e m i s t r y a l s o h a s been p u b l i s h e d . 7 2 It is t h o u g h t t h a t t h e s e s u b s t a n c e s a c t by a l t e r i n g ion t r a n s p o r t t h r o u g h c e l l membranes v i a changes in t h e l i p o p r o t e i n component of t h e c e l l membrane. Some s t r u c t u r a l a s p e c t s of t h e vancomycin m o l e c u l e have been d e f i n e d . 7 3 C l i n i c a l l y , vancomycin has been shown t o be e f f e c t i v e in s t a p h y l o c o c c a l e n t e r o c o l i t i s . 7 4 , 7 5 L y s o s t a p h i n , a l y t i c enzyme p r e p a r a t i o n s p e c i f i c f o r t h e genus S t a p h y l o c o c c u s , h a s been r e p o r t e d t o be a m i x t u r e of two enzymes, a h e x o s a m i n i d a s e and a p e p t i d a s e . 7 6 L y t i c a c t i o n is due t o t h e p e p t i d a s e . I t s t h e r a p e u t i c a c t i v i t y i n animals has been d i s c u s s e d . 7 7 A paper h a s been p u b l i s h e d which r e c o g n i z e s t h e d i f f i c u l t y of d e t e r m i n i n g r e l a t i v e c l i n i c a l e f f i c a c y of a n t i b i o t i c s and proposes p o s s i b l e alternatives.78 The i m p o r t a n c e of o b t a i n i n g a n optimum b a l a n c e of p r o p e r t i e s i n a d d i t i o n t o u s a b l e a n t i b a c t e r i a l a c t i v i t y has been n e g l e c t e d by many e x p e r t s . A comprehensive s t u d y and d i s c u s s i o n of serum b i n d i n g of a n t i b i o t i c s has been p u b l i s h e d . 7 e S t i l l t o be c o r r e l a t e d e x p e r i m e n t a l l y is t h e s u g g e s t e d d e l e t e r i o u s e f f e c t on c l i n i c a l e f f e c t i v e n e s s v i t h t h e n a t u r e and d e g r e e of serum p r o t e i n binding P o s s i b l e involvement of p r o t o p l a s t forms of b a c t e r i a in an i n f e c t i o n have been c o n s i d e r e d . I n a n e x p e r i m e n t a l approach, e v i d e n c e w a s o b t a i n e d t o s u g g e s t t h a t a c o m b i n a t i o n of p e n i c i l l i n a n d kanamycin e l i m i n a t e d b o t h c l a s s i c a n d p r o t o p l a s t forms in e x p e r i m e n t a l p y e l o n e p h r i t i s . 8 0 Major advances in i n f e c t i o u s d i s e a s e t h e r a p y a r e d e s t i n e d t o o r i g i n a t e from s t u d i e s of t h e r e l a t i o n s h i p of a b e r r a n t b a c t e r i a l forms t o disease. The b i o s y n t h e s i s of m a c r o l i d e a n t i b i o t i c s w a s considered.81 A s p e c t s of t h e b i o g e n e s i s of s e v e r a l o t h e r a n t i b i o t i c groups have been c o v e r e d in a c o l l e c t i o n of papers.82 A u s e f u l r e v i e w of t h e c h e m i s t r y of nev a n t i b i o t i c s h a s appeared.89
--
.
Chap. 11
115 -
Flynn
Antibiotics
References
-
1. J. W. Kislak, T. C. Eickhoff and M. W. Finland, Am.' J. Med. Sci., 249,
636 (1965).
2. M. Turck, A. Ronald and R. G. Petersdorf, J. Am. Med. Assoc. , 13, 961.
(19651 3. C. F. Gravenlramper, J. V. Bennett, J. L. Brodie and W. M. M. Kirby, Arch. Int. Med., 15-6, 340 (1965).
4. P. Naumann, "Fifth Interscience Conference on Antimicrobial Agents and 5.
6.
7. 8.
Chemotherapy" Abstracts , American Society for Microbiology, Ann Arbor? Mich., 1965, p. 71. T. Eickhoff, J. W. Kislak, M. W. Finland and C. Wilcox, Am. J. Med. -*sci 9 2 9 , 163 (1965). G. A. Hardcastle, D. A. Johnson, C. A. Panetta, A. I. Scott and S. A. Sutherland, J. Org. Chem. , 31, 897 (1966). P. Bunn, J. Lunn and S. Milicich, "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich. , 1965, p. 71. T. C. Eickhoff, J. W. Kislak and M. W. Finland, New EnKl. J. Med. , 272,
699 (1965) 9. T. Leigh, J. Chem.
SOC.,
1965, 3616.
10. W. J. Gottstein, R. B. Babel, L. B. Crast, J. M. Essery, R. R. Fraser,
J. C. Godfrey, C. T. Holdredge, W. F. Minor, M. E. Neubert, C. A.
Panetta and L. C. Cheney, J. Med. Chem., 5 794 (1965). ll. P. Bamberg, B. Ekstrom, K. Undheim and B. Sjoberg, Acta Chem. Scand., 19, 352 (1965)J. Tipper and J. L. Straninger, Proc. Natl. Acad. Sci., 2, 1133 12. 13
14. 15
16.
17
18. 19
20.
21.
22.
23
24.
25
(1965).
P. Fitz-James and R. Hancock, J. Cell. Biol., ,&, 657 (1965). F. P. Doyle and J. H. C. Nayler, Adv. Drug Res. ,A, 1 (1964). G. T. Stewart, "The Penicillin Group of Drugs." Elsevier Publishing Co., New York, N. Y., 1965. P. G. Cohen, M. J. Romansky and A. C. Johnson, "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965, p. 68. E. J. Benner, J. L. Brodie and W. M. M. Kirby, E. p. , 67. G. Flux, A. W. Nunnery and H. D. Riley, Jr., E.,p. 70. M. A. Apicella, R. L. Perkins and S. Saslaw, Am. J. Med. Sci., 2 , 266 (1%). G. Moessner, H. Maurer and M. Flege, Med. Klin., 60, 19b4 (1965). Chem. Abstr., 9,2645 (1966). J. Bernard and S. Lambin, Ann. Inst. Pasteur, 109, 907 (1965). M. Ridley and I. P h i l l i p s , Nature, 208, 1076 (1965). E. J. Benner, J. V. Bennett, J. L. Brodie and W. M. M. Kirby, J. Bacteriol., g, 1599 (1965). J. H. Mitchell, Lancet, I, 125, 915. S. A. Kabins, B. Eisenstein and S. Cohen, J. Am. Med. Assoc., 193, 159
(1965)
e,
-
26. L. D. Sabath and E. P. Abraham, Nature, 1066 (1964). 27 W. E. Wick and W. S. Boniece, Appl. Microbiol., 2 (2), 248 (1965). 28. G. F. H. Green, J. E. Page and S. E. Staniforth, J. Chem. S O C . , lE5,
-
1595
116 -
Sect. I11
- Chemotherapeutics
F l y n n , Ed.
E. Van Heynhgen, J. Med. Chem., 5 22 (1965). W. J. Holloway and E. B. Scott, Am. J. Med. Sci., &9, 691 (1965). A. J. McLeod, H. B. Ross, R. L. Ozere, G, Digout and C. E. van Rooyen, Can. Med. Assoc. J., 2,1056 (1964). B. J. Magerlein, WFifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts , American Society for Microbiology, AM Arbor, Mich., 1965, p. 17. B. Bannister, p. 17. R. B. Birkenmeyer, p. 18. A. D. Argoudelis, J. A. Fox and D. J. Mason, Biochemistry, 5 710
29 30 31 32
s., s.,
(1965)
Y. Suhara, K. Mae& and H. Ihnezawa, Tetrahedron Letters, l s , 1239. M. Hamada, T. Hashimto, T. Takahashi, M. Miyake, S. Yokoyama, T. Takeuchi, Y. Okami and H. Umezawa, J. Antibiotics (Tokyo), Ser. A, I&,
104 (1965). T. Takeuchi, M. Ishizuka, H. TakaJrema, K. Kineha, M. Hamada and H. Umezawa, E., 107 (1965). 39. N. Maggi, V. Arioli and P. Sensi, J. Med. Chem.,i, 790 (1965). 40. N. Maggi, R. Pn'lza and P. Sensi, "Fif'th Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, AM Arbor, Mich., 1965, pp. 47, 48. 41. B. C. Stratford, S. Dixon, B. F. Stratford and J. Forbes, ibid., p. U4. 42. N. Bergami and G. Forust, Arzneimittel-Forsch., 2,951 (lm. 43 H. H . Stone, J. D. Martin and L. Kolb, Surg., Gynecol. Obstet., 120,
38
44.
45
g,
351 (1965).
F. P. Furgiuele, R. Kiesel and L. Martyn, Am. J. Opthahol.,
(1965).
&, 818
A. W. Nunnery and H. D. Riley, Jr., "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965, p. 37. 46. C. P. Schaffher and H. Maehr, Abstracts, 149th lational Meeting of the American Chemical Society, Detroit, Mich., April, 1965, p. 9C. 47 C. Lewis and H. Clapp, Antibiot. Chemotherapy, &&, 127 (1961). 48. R. Marsh and F. Ceccarelli, CUm. Med., 82'7 (1965). 49 Hi Kawaguchi, H. Tsukiura, M. Okanishi, T. Miyaki T. Ohmori, K. Fudisawa and H. Koshiyama, J. Antibiotics. (Tokgoj, Ser. A, l8, 1 0
-
50 51
53
54 55
56 57 58
9
(1965)
H. Kawaguchi, T. Naito and H. Tsukiura, g., 18, ll (1965). A. Furlenmeier, J. Berger, A. Batcho, €I Spiegelberg, . H. Schocher, 0. Keller, B. Pecherer and B. Vaterlaus, Chimia, 597 (1965). H. Kawaguchi, T. Miyaki and H. Tsukiura, J. Antibiotics (Tokyo),
a
Ser. A, &l 220 (1965). K. Vogler, h e w . Chem., 77, 974 (1965). R. 0. Studer, Helv. Chim.Tcta, 48, 1371 (1965). T. Suzuki, K. Hayashi, K. FujikaG and K. Tsukamoto, J. Biochem. (Tolgro), 57, 226 (1965). H. VanderGghe, P. VanDijck and P. DeScmer, Nature, 225, 710 (1965). W. 0. Godtfredsen, W. VonDaebne, L. Tybring and S. Vangedsl, J. Med. B., 8, 15 (1966). J. R. Rasch and W. J. Mogabgab, "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich. , 1965, p. 36.
Antibiotics
Chap. 1 1
Flynn
59. P. Hung, C. L. Marks and P. Tardrew, J. Biol. Chem., 60. M. Kuehne and B. Benson, J. Am. Chem. S O C . , ~ , 4660 61. J. Dyer, C. Kellogg, R. Nassar and W. Streetman, Tetrahedron Letters, 1965, 585. 62. m e s e m a n n , P. Prave, A. Steigler and K. H. WaUhauser, "Fifth
63. 64. 65. 66.
Interacience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965, p. 44. E. V. Wasielewski, R. Muschaweck and E. Schutze, E., p. 45. F. Bauer and G. Dost, E.,p. 46. C. R. Temorria and R. C. Esse, J. Med. Chem.,& 870 (1965). J. Benbough and G. A. Morrison, J. Pham. Phannscol., 17 409 (1965). H. Jarolmen, A. Bondi and R. L. Crowell, J. Bacteriol.T&, 1286 (1965). P. A. Miller, J. A. Hash, M. Lincks and N. Bohonos, Biochem. Biophys. Res. Cam., 325 (1965). J. R. D. McCormick and E. R. Jensen, J. Am. Chem. SOC., ,7'8 1794 (1965). H. lvfuxfeldt and W. Rogalshi, 87, 933 (1965). M. M. Shemyakin, "Fifth Interscience2onference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965, p. 16. M. M. Shemyakin, E. I. Vinogradova, M. Yu. Feigina, N. A. Aldanova, N. F. Loginova, I. Ryabova and I. Pavlenko Experientia, 21, 548 (1965). F, J. Marshall, J. Med. Chem.,A ' , 18 (19651. J. F. Wallace, R. H. Smith and R. G. Petersdorf, New Engl. J. Med., 2 3 , 1014 (1965)W. E. Herrell, Clin. Med., 72, 19U (1965). H. P. Browder, W. A. Zy-7 J. R. Young and P. A. Tavormina, Biochem. &383 (1965). Biophys. Res. Canrm., I E. F. Harrison and C. B. Cropp, "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965, p. 115. B. A. Waisbren, Am. J. Med. Sci., 2 0, 406 (1965). G. N. Rolinson and R. Sutherland, J. E'harmacol., 3, 638 (1965). J. Z. Montgamerie, G. M. Kalmanson, W. L, Hewitt and L. B. Guze, "Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy" Abstracts, American Society for Microbiology, Ann Arbor, Mich., 1965,
E.,
72.
73 74. 75 76
77. 78 79
80.
117 -
At.
P. 78. 81. H. Brisebach, p. 22. 82. Z. Vanek and Z. Hostalek, Eds., "Biogenesis of Antibiotic Substances," Academic Press, New York, N. Y., 1965. 83 E. P. Abraham, Am. J. Med., 39, 692 (1965).
s.,
K.
118 -
Sect. I11
-
Chemotherapeutics
Flynn, Ed.
Chapter 12. Synthetic Antibacterial Agents Robert G. Shepherd, Lederle Laboratories, American cyanamid Co., Pearl River, New York Developments during 1965 involved primarily laboratory and clinical study of analogs of known antibacterial structures and of their metabolism and mechanism of action. The importance of antibacterials is indicated by the large research effort being expended. The difficulty of finding new antibacterial structures is demonstrated by the fact that Only a very few have been reported in this decade in spite of this effort. Most of the 119 y e a r s since the beginning (Semlweiss 1847 and Lister 1865) of modern(1) antibacterial chemotherapy have been spent in stagnation or in significant but slow improvement on the small numbers of different active types so far discovered. Into the attack on the antibacterial frontiers are being brought biochemistry at the enzyme level, molecular vibrations, electronic energy-level calculations and pharmacokinetics via computers but the push-button age of "magic bullets" is still far in the future. In Vivo Actives.--The new compounds first shown by published data in 1965 to be active against infections in animals are discussed here. A laboratory study(2) on 2-sulfanilamido-4,6-diethyl-s-triazine showed it to be the most active of the sulfatriazines in vlvo an3 the first clinical report was promising(3). It is highly soluble, well absorbed, less conjugated than other clinical sulfas, and excreted largely unchanged(3). Its behavior is between short-acting and long-acting and its renal clearance is uniquely acceleratable by adjustment of urinary pH(3). Chemotherapeutic application of 4-sulfa-1,2,3-thiadiazoles is limited by their explosive intermediates (4). 5-Dimethylsulfamyl-antnthranilic hydrazide is only formally a sulfanilamide derivative since it is not antagonized by PAB. The in vivo antibactes ial activity(5) is rather specific structurally and is limited to Staphylococcus @D50 25-5Orng/kg) and Pneumococcus (ED50 250mg/kg) but, curiously, shows up in vitro only against Pneumococcus. Low activity against the expen imental TF3 infection in mice was reported for 2-carbethoxyaminoethylnbutylsulfide(6) and for beta-alanylhydroxamic acid(7). The latter shows some similarities in mechanism of action to cycloserine. Additional data(8) on 1-(aralkoxy and higher alkyloxy)-k, 6-diamino-l,2-dihydro-2,2-dimethyls-triazines show that some are active in vivo against Strep. hemolyticus but only at just below toxic doses. The broad-spectrum in vitro activity and the toxicity appear to be antifolic in nature. New activity (leprosy, below) was reported for ethambutol and for thalidomide as well as for some azo dyes. Antituberculous Agents.-Although major advances in TI3 therapy have been made, treatment is still far from satisfactory and the incidence of new urban cases is increasing, i n some instances drastically(9). Ethambutol (dextro-2,2'-ethylenediimino-di-l-butanol), one of two new active types reported in this decade, has successf'ully undergone clinical trials (10, 11, 12, 13) in several countries. Ethambutol acts clinically (12, 13) and experimentally(l4, 15) against strains of mycobacteria resistant to other agents, and combinations of sub-effective concentrations are inhibitory (16) in vitro. Resistant strains, which develop with difficulty(17, IS), have different biochemical characteristics than isoniazid-resistant strains (19). Human and bovine mycobacterial strains, which were experimentally
-
Chap. 12
Antibacterials
Shepherd
119 -
made resistant to ethambutol, have been fo~na(16) to be attenuated for mice. Using 3513 and 32P to estimate protein and nucleic acid synthesis, it has been concluded(l9, 20) that ethambutol acts by interfering with a function of cellular polyamines and divalent cations in the synthesis or stabilization of RNA. Preliminary reports of its activity against human(21) and mine(22) leprosy have appeared. Quickly following a report drawing attention to the carcinogenic activity of isoniazid was a word of caution(23), much needed in the present, solnewhat hysterical atmosphere'surraundingW s . The production of tumors only in mice may well have prevented introduction of isoniazid in recent years but should not diminish its use until a harmful effect is established and weighed against its proven merits. Extensive investigation of N,N'-diaryl and N-aryl-N'Aeteroaryl thioureas appears to be ending in naught. N,N'-Bis(k-isoamyloxyphenyl)thiourea, the member most studied clinically, is judged to be only slightly active in man, by the usual criteria(24, 25, 26), on the basis of all the published controlled trials(27) in several countries. In addition, there is a high frequency(28) of natural resistance to this agent and cross-resistance with 4acetamidobenzalthiosemicarbazone(29). 2-Ethyl isonicotinic thicamide kthionamide) is undergoing clinical study at decreasing dosage. Although effective(30, 31) in producing clinical improvement and preventing emergence of resistance, high incidence of liver (31, 32, 33) and gastrointestinal(30, 34, 35) toxicity seems likely to restrict its use to retreatment of resistant cases. Mental disturbance and neural effects were cited(31, 36) as reasons for not using it in ambulatory patients. It is converted in man to several metabolites(37), among them the thioamide sulfoxide. It is not cross-resistant with isoniazid but shows B?m cross-resistance with thiocarbamylhydrazides (thiacetazone) and diarylthioureas(38, 39, 40, 41). Reports on the N-morpholino-methylde of pyrazinoic acid, proposed as a form of pyrazinamide with decreased toxicity and maintained activity(froln conversion to pyrazinamide), fail to confirm either of these characteristics(&). Gram-negative Antibacterials. -l-Ethyl-7-methyl-~oxo-l, 8-naphthyridine3-carbo~ylicacid(na1idixic acid) is one of two new active types reported & this decade. Its Gram-negative activity was first published by Lesher in 1962 and a brief structure-activity summary followed in 1964(43). There is no cross-resistance(44, 45) with other agents used in Gram-negative infections and its ED50 is comparable(4.6). The primary antibacterial action of nalidixic acid against E. coli is specific inhibition of DNA synthesis(47, 48). This antibacterial is unusual in being active as such and in rapidly forming an equally active metabolite, the 7-hydroxymethyl anslog(49). About one-third is excreted as this metabolite plus two-thirds as glucuronides of parent and metabolite. Antibacterial activity(50) in urine is predominantly (7:l) due to 7-hydroxymethyl metabolite while in tissue the two agents are about equal in concentration(@). Clinical assessments(51, 52) rate it rapidly effective orally against certain Gram-negative bacteria. Since genitourinary tract infections due to these organisms should be treated for several weeks to avoid relapse, it is an important shortcoming that a high 53) or after a degree of resistance can develop rapidly during therapy(% s m a l l number of transfers in vitro. A small trial(54) against brucellosis was successful. As is common in the early stages of clinical use, reports are conflicting on the breadth of application(55, 56, 57, 58) to urinary
120
Sect. 111 - Ghemotherapeutics
F l y n n , Ed.
infections (reported percentages of sensitive strains: 2-22s) Wb 8% 9%) and on side-reactions( 51, 59). Sulfanilamides.-Work on sulfa drugs is beginning its 4th decade with i& terest in and use of these agents continuing, especially since microbes ap~n apPliparently have not meanwhile progressively developed resistance(@). cation for sulfas (and other antibacterials) now receiving attention(6l) is treatmt of bacteriuria(frequently asymptamatic) of P r e V t W-n, a Condition with serious consequences for the child (higher incidence of' prematurity, neonatal death, congenital abnormalities, cerebral palsy, and lower I&) as well as for later chronic disease of the mother. The various drug-ofchoice uses of sulfas have been sunmarized(62) and chemotherapeutic research with sulfanilamide derivatives reviewed(63). B means of pharmacokinetic equations and computers, various papers(64, 657 attempt to adjust experimental and clinical dosage of sulfas to get equitherapeutic plasma-water concentration-time curves. Several long-acting sulfas introduced in recent y e a r s are in clinical evaluation (in approximate order of increasing persistence): 4-sulfa-3,6dimethoxypyrid~zine(66), 3-sulfa-4-iodo-5-methylisoxazole(67), 2-sulfa-5methoxypyrimidine(68), 2-sulfa-3-methoxypyrazine( 69), and ksdfa-5,6-dimethoxypyrimidine(70). The latter is so slowly excreted that oral, parenteral or rectal doses once per week or per disease episode are being explored(71, 72, 73). In contrast to its 2,&dimethoxy is-r, It yields only about 2$ of glucuronide. In relation to crystalluria potential(68), the l o w solubility of the long-acting sulfa8 is partly compensated for by glucuronide formation, but more significant is the amount of sulfa and/or metabolite excreted per unit time in relation both to actual urine flow rate and to the therapeutic dosage required for the particular sulfanilamide. Considerable study has been made of the binding of sulfas to blood albumin. Although bacterial inhibition varies directly with the percent unbound in a simple experimental mode1(74), the activlty relationship in vivo can not be aseumed to be the same as that of relative binding, and a highly bound compound need not be less desirable than a slightly bound one. Two agents with different degrees o f binding to blood albumin also differ in binding to tissue, in vltro potency, &, lipid solubility, excretion, metabolism, and distribution in body water, all of which directly or indirectly affect in vivo efficacy. In addition, the relationship of blood albumin binding to the degree of binding to the key enzyme site where the sulfa competes with PAB(75) is unknown. In an excellent sympoeium on interaction between drugs, Brodie(76) pointed out that binding is an advantageous and necessary characteristic without which a therapeutic agent would oscillate between toxic and inactive plasma concentrations and require frequent administration. Releasing an agent from binding to protein can be accomplished by means of a broadly similar chemical compound because of the rela tively non-specific nature of the binding but this release can lead to greater toxicity(76) and excretion and metabolism as w e l l as to the desired physiological action. Of interest in laboratory and clinical studies, it has been observed that the mouse, dog, man and other species v a r y 17-fold in extent of albumin binding of sulfas. Variation of binding is 2-fold among normal human sera, and 10-fold in certain illnesses(77) partly due to circulating blood constituents and partly due to albumin variation. The locus of binding of several sulfas to serum albumin has been shown(78) by relaxation-time
Chap. 12
Antibacterials
Shepherd
121 -
measurements on high-resolution pmr spectra to involve the benzene ring and not the heterocycle; in 5-sulfa-1-phenylpyrazole the two benzene rings bind at different sites. Infonoation about sulfa drug metabolism in man has been reviewed(79). &Acetylation has been known to occur enzymatically to an extent dependent on N1-substituent and animal species. -Glucuronides(l-4$) result from nonenzymatic chemical reaction whileI*!J sulfamstestl (about I$) are true metabolites. Formation of N1-glucuronides occurs quite generally; with some N1heterocycles it amounts to only a few percent of dosage(sulfisoxazole, sulfathiazole) but with sulfamethoxyppidazine is substantial(l5-20$) and with sulfadimethoxine is 60-85$ of the substances excreted. 4-Sulfa-6-methoxy-2methylpyrimidine yields a large amount of 2-hydroxymethyl 0-glucuronide. Wfferences in the So;! infrared frequency in amino and imino isomers led to assignment of the sulfadimethoxine metabolite as NL rather than ring-N substltuted(80, 81). 5-Sulfa-1-phenylpyrazole is 70-9srenally excreted as a glucuronide of still uncertain structure( 82 ). 2-Sulf'a-4,5-dimethyloxazole is reported(83) in a study by thin-layer chromatography to be grossly unstable in water as w e l l as urine and blood, but a paper chrumatographic study (84)flatly contradicts this. Nitrof'urans.-Twenty-two years after the first report of their antibacterial activity, this class is receiving renewed clinical and laboratory interest. In spite of several thousand publications cove ng some six hundred analogs and 803116) structure-activity generalizations required: 5-N% o 3- or 4-substituan ring, some kind of 2-substituent and the critical characteristics that govern their activity especial. ly in vivo are far from clearly defined, The chemotherapeutic properties of the earlier nitrofurans have been reviewed(86). 4-(5'-Nitro-2'-furyl)-2-(3' '-pyridy1)thiazole is unusual in being a nitrofurylheterocycle bearing a heterocyclic substituent and in having broadspectrum activity in vivo (about 8 times as active as furaltadone and furadantin). Unfortunately, blood dyscrasias occur at doses just below the therapeutic range(87). An experimental model was reported(88) for the polyneuropathy which occurs with furadantin and other nitrofurans(86, 89). Recent work has involved linking nitrofuran to various heteroaromatic rings either directly or through one or more ethylene units. 3-(5'-Nitro2'-fUryl)-1,2,4oxadiazoles and thiadiazoles and 2-(nitrofury1)thiazoles were found low in activity in vitro and "largely ineffectivev in animals (90)while the 1,3,4-isamers and 4-(nitro 1)thiazoles reported earlier were active in vivo (many at max. tol. doses Hydroxymethyl- and bishydroxymethyl-amino derivatives(g1) are less active and less toxic acutely than the parent known nitrofbylvinyl-aminoheterocycles. It is stated that in vitro activity is increased by insertion of vinyl or substituted vinyl between the 5-nitro-2-furyl unit and a pyridazine or thiadiazole(92), oxadiazole(93, 94), quinoline(g5), pyridine(96) and its l-oxl&?(97), range of minimal inhibitory concentration6 being 0.03 to lOmcg/ml. The insertion of another vinyl group is claimed to increase the in vitro activity still W h e r for oxadiazoles(98) and pyrimidines(gg), range of m.i.c. 0.02 to O.%cg/ml. Several were found active in vivo but only at maximum tolerated doses. 3-( beta-Substituted ethyl)-1-( 5'-nitro-2'-~furylideneamino)-imidazolidin-2-ones are claimed(100) to be more active in vivo but less active in vitro than the 3-H parent(101).
r
E%5T,
7.
122
Sect. I11
-
Chemotherapeutics
F l y n n , Ed.
Antileprotic Agents.--Although the age of chemotherapy has benefitted its treatment, the effect on this wide-spread(lW) disease is incomplete and slaw. The slowness is befitting this, the most ancient infectious disease of man, which has the longest known incubation period (from 3 to 8 or more years) and the longest generation time (30 dws)(l(X?, 103). New agents have come from trying in human leprosy anything active against tuberculosis, hoping for activity on the basis of the taxonomic relationship of the causative organisms. Neither an in vitro test nor an experimental form of the disease has been available but recent advances have been made(lOe, 103, 104, 105). Although some antituberculotics are effective against human leprosy, activity against tuberculosis is an unreliable indicator(l06) of humin antileprotic activity, and vice versa. Three reports of activity have come from clinical use of agents available for widely differing purposes. ~li~de(cCphthalimidoglutarimide),while being employed as a sedative, showed activity against human lepromatous leprosy in 6 consecutive cases by several criteria. It will be interesting to await confirmation of this preliminary report(107). In another preliminary report(108) involving a more extensive trial(50 patients) in a controlled comparison with diaminodiphenylsulfone, ethambutol was reported equally active. Against an experimental Wco. lepraemurium infection(109) in mice it was estimated to be s o m e a t less active than the sulfone. &re active than this standard in the murine infection are Lsulfa-6-methoxypyrimidine and 3-sulfa-6-methoxypyridazine. Several papers on clinical ficacy of the latter have appeared(ll0, 111). Using the murine test, 1$44- ubstituted phenyl or pyridyl)-5,6,7,8-tetrahydro-l-naphthyltuninopropyiJ piperidines were found to have an interesting level of activity(ll2). In Vitro Actives.-Such compounds are potentially useful for bacterial control of body cavities, genitourinary tract, wounds, skin prior to operations, hands of medical personnel, and for preservation of parenteral and topical~dicinals. The significance of many publications can not be judged since tests are not adequately defined or related to standards nor are toxicity, in vivo results and effect of protein on activity given. The following were active against Gram-positive and Gram-negative organisms at the minimal inhibitory concentrations given: 6-( 4t-methoxyphenyl)-Mdazo @, at 8-60, 2-(phenyl and 2' -pyridyl)-isatogen( 114) at 25-200, -2-(dichloroacetyl)guanidine(ll5) at 0.05-25, and 3-(methyl and ethyl)-l-hydroxy-2-oxoquinoline(116) at 0.3-5mcg/ml. In the latter which is 1-10 times as active as aspergillic acid, the hydroxamic acid moiety is necessary but not sufficient for activity. Dibenziodolium(ll7, 118) and dibenzoxaiodinium analogs(119) were claimed to be more stable and more active (m. i. c. 0.3-25mcg/ml) than the diphenyliodonium analogs; acute LD50 10-
1-d
1oow/kg.
Work continues on detergent bases and cationic surfactants, whose activity was first reported in 1935. Antibacterials of this kind generally inhibit both Gram-positive and Gram-negative organisms. 2-(N-Decylpyrrolidinium) ethyl trans-beta-(l-naphthyl)acrylate(l20) was 50-100-fold less active in the presence of serum, an effect common to many agents of this class. Other compounds active were polychloro-2,3-diphenylpropylamines( 121) and 3,3,3tris(4' -chlorophenyl)propyl-N,N-bis(beta-pyridinium ethy1)amine dichloride at l-lOOmCg/ml. Several kinds of phenylenebis (4-amino-6-amidinoquinainoquines (122) were active at the same concentration but were not active in vivo. The activity of N-( 3-phenyl-2-propyl)-3,3-diphenylpropylamine( 123) at l-lOmcg/ml
Chap. 12
Antibacterials
Shepherd
123 -
against Gram-positive organisms is reversed by nucleic acids or by divalent cations. The latter also antagonized the action of steroidal tertiary amines or quaternaries(l24) whose cellular damage is prevented by spermine also. 5-Azacytidine at 0.2mcg/ml inhibits growth of E. coli as a result of spontaneous triazine ring-opening in the nucleic acid into which it is incorporated( 125). Mono and di-chloro Z-benzamido-4,6-dialkoxypyrimidines (126) inhibited Staph. aureus at l-5mcg/ml but the somewhat more active Lsulfa-2, 6-dimethoxypyrimidine standard inhibited Gram-negative organisms also. Their activity may be a variant of the halo-salicylanilide type(l27). 2,bDialkanoyl phloroglucinols( 128) also have narrow spectra(Staph. and Strep. inhibition at 0.1-0.5 mcg/ml); related resacetophenones are inactive(129). A rela tively unstable chelate permits cell penetration by salicylaldehydes whose activity against Pseud. aeruginosa is dependent on the amount of free aldehyde group liberated inside the cells(l29). This organism is subject to bactericidal action (130) by ethylenediaminetetraacetic acid but not other chelators; it produces damage to the protoplast membrane. Research Techniques and Screening &tho&.-Radioactive tracers have been used in studying pharmacology and mechanism of action. The primary antibacterial action of nalidixic acid was shown(47, 48) to b specific inhibition of DNA synthesis by following the incorporation of lEC- and 3H- labeled purines, pyrimidines and amino acids into DNA, RNA and protein of E coli. Ethionamid ' 8 mechanism of action was investigated(38) by me s of j2P-, 35S- and lEC- labeled nucleic acid and protein precursors. lg-Ethambutol was e loyed in human pharmacological(20) and mechani.sm of action(l9) studies. lq-Iabeled quinaldinium compounds were used to determine their mechanism of antibacterial action( 131). Pharmacokinetic equations are being solved by analog computers and used (64, 65, 132, 133) to devise optimal dosage regimens which are important to safe, effective clinical trials and can make laboratory comparisons more incisive by equalizing exposure of infections to drugs. These equations have been applied in a series of papers to sulfa drugs(64, 65, 133) for which extensive pk, protein binding, excretion, and distribution data are available. Adequate screening methods for leprosy have been lacking but tissue-culture(102) and in vitro growth(lO5) have been disclosed. Growth of the human strain in cell-free medium has resulted(105) from use of unisolated growth factors from lysed saprophytic mycobacteria. One method available has been the mouse foot-pad growth(103) of Myco. leprae which does not produce a leprosy infection and might be considered a form of tissue-culture. A mco. lepraemurium infection(109) in mice has several similarities to the human disease but also certain differences. According to a recent report(104), the infection of black mice with "Chatterjee" bacilli is not the hoped-for major step forward in antileprotic screening but seems to be a modified M. lepraemurium infection. A lethal Tl3 infection was developed(134) in guinea pigs by intracardial injection of M. tuberculosis H37Rv but has a more variable survkvaltime than the mouse infection and requires more compound for testing. Various kinds of delayed and intermittent treatment of tuberculous mice have been studied(l35) with half a dozen reference drugs. Correlations of molecular vibrations,7%electron energies and of calculated molecular orbital and bond-hybridization character with antibacterial activity(l36, 137, 1-38>139) provide interesting summaries of where one has
124 -
Sect. III
- Chemotherapeutics
F l y n n , Ed.
been rather than where one is going. Perhaps when we know how to transfer in vitro data successfully to in vivo tests, we will be able to make use of such specialized, "unidirectional" theoretical approaches. Modern physical methods and chromatographic techniques are being applied to problems of separation and identification of synthetic antibacterial structures and their metabolites, which in the case of nalidixic acid makes a major contribution to activity: gas chrmtography (14, 140); thin-layer chromatography of sUlfanilamides(l41, lk),amines(143), and heterocycles (144); mass spectrametry of pyrimidines(145) and d s ( 1 4 6 ) ; nmr spectrometry of phenols(147, 148), peptides(l49), and pyrimidines(l50); X-ray spectrompem of P-, s-, and halogen- containing ccarrpounds(l5l.); and --ray spectrof neutron-activated pharmaceuticals(1%) employed in forensic investigations but broader in potential(l53). enzymic bases of now well-defined mechanisms Mechanism Of Action.-The for bacterial control (cmpetitive inhibition of essential enzymes, feed-back inhibition of biosynthesls of the natural competitor, repression of fonnation of a necessary enzyme, and non-competitive inhibition by reacting with the enzyme active center) have been reviewed(l54). The biochemical basis for differential action of an antibacterial toward host and microorganism is clear for a number of synthetic agents(156). Differences in response to dihydrofolate reductase inhibitor6 reflect differences in the structural limitations of the binding site of the same enzyme from different bacteria(l55). Sulfanilamides are unique in having their mode of action almost completely known at the enzyme level. The step in folic acid synthesis at which they intervene has recently been shown to be the reaction of PAB with the pyrophosphate ester of 2-amin0-4-0~0-6-hydro~thyldihydropteridine (155). The sulfa8 are now known to participate in this reaction and form spurious folic acids, but their significance in growth inhibition is not certain. Some differences in responses of bacteria are due-to relative abilities to transport and assimilate folic acid. Sulfanilic acid is an inhibitor of a cell-free enzyme system but not of bacterial growth, presumably due to difficulty with cellular transport(155). Bactericidal action of sodium tetrapropylenebenzenesulfonate resulted. from lysis of protoplast membranes; in contrast to many other agents, this action decreased as cellular metabolic activity increased( 156). Sodium lauryl sulfate produces inhibition of biosynthesis of S. aureus cell walls similar to that produced by penicillin(157). Prevention of emergence in vitro of drug resistance to a variety of antibacterials by spermine or atabrine was reported(l58) to result f r o m preventing induction of resistance. An antimutagenic action of spermine toward random as well as induced mtations(159) confirms the effect (stated not to be co-inhibition) in vitro but demonstration of a ureful effect in vivo is still lacking. Reviews.-Reviews appeared on tuberculosis(15, 29, 160, 161), leprosy( 106), sulfa antgs(63, 64, 65, "7, 79, 1331, nitrofuram(%), drug interaction(76), protein binding(77, 133), mechanisms of action(154, 155, 162), and combinstion therapy( 163). REFEREmCES 1. The mercurial8 used for syphilis in the 1500's might also be considered as the first antibacterials. 2. W. E. Taft, H. M. Krazinski, F. C. Schaefer, and R. G. Shepherd, J. Med. -* 8, 784 (1965).
-
Chap. 12
Antibacterials
125 -
Shepherd
3. A. R. Frisk and E. Hultman, 4th Internat. Congr. Chemotherapy, 1965, Washington, D. C., Abstracts, p. 33. 4. D. L. Pain and R. Slack, J. Chem. SOC. (Lond. ) 5166 (1965). 5. P. Schmidt and L. Neipp, Proc. 3rd Internat. C o n g r . Chemotherapy, 1963, Stuttgart, 1355 (1964). 6. G. Siefert, Arzneimittel-Forsch. 9, 1359 (1965). 7. G. R. Gale and J. E. Hawkins, Am. Rev. Resp. D i s . E, 64.2 (1965). 8. P. Mmalis, L. J e f f r i e s , S. A. Price, M. J. R i x , and D. J. Outred, J. Med. Chem. 8, 684 (1965). 9. Editors, Mod. Wd. 32, 54 (1964). 10. I. Ksss, Tubercle ( E d . ) 46, 166 (1965). 11. Conference on New Antitubezulous Agents, Sept. 1965, Ann. N. Y. Acad. Sci. 135, 680-1120 (1966). 12. T F . Corpe and F. A. Blalock, MS. Chest 48, 305 (1965). 13. I. D. Bobrowitz and K. S. Gokulanathan, DiK Chest 48, 239 (1965). 14. J. Po !L'honkasy C. 0. Baughn, R. G. Wilkinson, and R . 3 . Shepherd, Am. Rev. Resp. D i s . 5, 891 (1961); R. G. Wilkinson, M. L. Cantrall, and R. G. Shepherd, J. Meed. Chem. 5, 835 (1962). 15. F. Grumbach, Advan. Tuberc. Res. 2, 74 (1965). 16. S. K O Gupta and I. S. Eilathur, Indian J. Exptl. Biol. 2, 81 (1964). 17. M. Forbes, N. A. Kuck, and E. A. Peets, J. ~acteriol.-89, 1299 (1965). 18. F. Grumbach, Ann. Inst. Fasteur 110, 69 (1966). 19. S. K. Gupta and I. S. Mathur, InJ. E x p t l . Biol. 3, 176 (1965).
20. E. A. Peets, W. M. Sweeney, V. A. Place, and D. A. BU%ke, Am. Rev. Reap. D i s . 91, 51 (1965). 21. J. G.Tolentino, R. S. Quint0 and R. M. Abalos, 25th Res. Conf. i n Pulm. Diseases of VA-Armed Forces, Jan. 1966, Cincinnati, Ohio. 22. Y. T. Chang, Antimicrobial Agents Chemotherapy 777 (1965). 23. Editors, B r i t . Med. J. 1(5449), 1508 (1965). 24. M. Olejnicek, M. Weberova, M. Novak, and E. Jancik, Tubercle (Lond.)
1964,
188 (1965).
5,
25. A. S. Moodie, M. Aquinas, and R. D. Foord, Tubercle (Lond.) G , 1% (1964). 26. S. Sunahara, Tubercle (Lond.) 46, 178 (1965). 27. Editors, Tubercle (Lond.) 46, 8 8 (1965). 28. G. Meissner, Praxis h e w r 19, 387 (1965). 29. F. Grumbach, Advan. Tuberc. R G . 14, 70 (1965). 30. M. Boszormenyi, I. Fauszt, I. B ,* and 0. Schweiger, Tubercle (Lond.) 46, 143 (1965). 31.
J.M.
Schless, R. F. Allison, R. M. Inglis, E. F. White, and S. Topperman,
Am. Rev. Resp. Die. 91, 728 (1965). 32. F. I t o and K. HayanoTAm. Rev. Resp. Ms. 91, 796 (1965). 33. A. W. Lees, B r i t . J. D i s . Chest 59, 228 (1'965)34. A. Pines, Tubercle (Lond.) 46, l z (1965). 35. I. Kass, Tubercle (Lond.) 4 c 151 (1965).
36. A. W. Lees, Am. Rev. R e s p . 3 8 . 91, 966 (1965). 37. H. Iwainsky, I. Sehrt, and M. G r u n e r t , Arzneimittel-Forsch. 15, 195 (1965). 38. M. T s ~ ~ k a m r aIgaku , To Seibutsugaku 67, 80 (1963); Chem. Absc. 63, 12024f (1965). 39. H. Hartwlgk, Tuberculosearzt 9, 522 (1965).
40. S. Oka, J. Konno, M. Kudo, K. Oiztani, and S. Yamaguchi, Am. Rev. Resp. D i s .
41.
919 638 (1965). Verbist, 4th Internat. Congr. Chemotherapy, 1965, Washington, D, Abstracts, p. 60.
C.,
126
Sect. I11 - Chemotherapeutics
F l y n n , Ed.
42. L. Tnka, J. K u s k a , and A. Havel, Chemtherapia 9, 158, 168 (1965). 43. G. Y. Lesher, Proc. 3rd Internat. Congr. Chemoth
-
Chap. 12
Antibacterials
127 -
Shepherd
82. W. Riess, K. Schmid, and H. Keberle, KLin. Wochschr. 43, 740 (1965). 83. J. Seydel, H. Buettner, and F. Portwich, Klin. WochscG. 43, 1060 (1965). 84. E. Serick and W. Loop, Chemotherapia 10, 74 (1965). 85. V. N. Solov'ev, G. A. Konyaev. S. S. Xvikov, L. I. Khel'nitskii, and T. S. Novikova, Fbrmakol. i Toksikol. 28, 316 (1965). 86. H. E. Paul and M. F. Paul i n "Experimexal Chemotherapy", R. J. Schnitzer and F. Hawking, Eds., Acad. Press, New York, 1964, V o l . 11, p. 307. 87. J. K, LEtndquist and A. R. Martin, Antimicrobial Agents Chemotherapy 1964,
-
-
591.(1965).
88. A.
Behar, E. Rachmilewitz, R. Rahamimoff, and M. Denman, Arch. Neurol.
13, 160 (1965).
w. Beverungen,
K. W. F r i t z , and J. Ross, Muench. Med. Wochschr. 107, 953 ( 19651 90. W. R. Sherman and A. V. Esch, J. &d. Chem. 8, 25 (1.965). 91. K. Miura, M. Ikeda, T. Oohashi, Y. Igarashi,-and I. Okada, Chem. Pharm.
89.
Bull* ( T O W O ) 13, 529 (1965). 92. W. Voemel, P r o z 3rd Internat. Congr. Chemotherapy, 1963, Stuttgart, 530 (1964). 93. I. Saikawa and A. Takai, Yakugaku Zasshi 85, 948 (1965). 94. I. Saikawa, H. Kodsma, A. Takai, T. Wada,%hd Y. Suzuki, Japanese patent 12,619 (1965). 95. K. Miura, M. Ikeda, T. Oohashi, Y. Igarashi, I. Okada, T. Shikimi, and S. I s h i i , Y a k u g a k u Zasshi 85, 289 (1965). 96. K. H a r a d a and S. Emto, ChG. Pharm. B u l l . (Tokyo) 13, 389 (1965). 97. S. Minami, A. Fujita, and J. Matsumoto, Japanese p a c n t 28,591 (1965). 98. I, Saikawa, Y. Kodama, A: Takai, T. Pllaeda, and I. Takamichi, Japanese patent 12,706 (1965). 99. I. F a i k a w a , Y. Kodama, S. Krtnamori and A. Takai, Japanese patents 19~65% 4 and 26,408 (1964). 100. Norwich Pharm. Co., Belgian patent 653,hl (1965). 101. J. R. O'Connor, H. E. Russell, J. G. Michels, P. V. Newland, and W. F. Carey, Proc. 3rd Internat. Congr. Chemotherapy, 1963, Stuttgart, 558
(1964).
102. Editors, J. Am. Med. Assoc. 192, 32-36 (1965). 103. C. C. Shepard and D. H. M c R & T J . Bacteriol. 2, 365 (1965). 104. H. M. La1 and J. M. Robson, B r i t . J. Exp. Pathol. 46, 318 (1965). 105. A. L Olitzki and Z. Gershon, I s r a e l J. Med. Sci. 1F1004 (1965). 106. R. J. Schnitzer, Antibiotica e t Chemotherapia, Fohschr. 9, 145 (1961). 107. J. Sheskin, Clin. Pharmacol. Therap. 6 , 303 (1965). 108. J. G. Tolentino, R. S. Quinto, and R.-M. Abalos, 25th Res. Conf. i n Pulm. Diseases of VA-Armed Forces, Jan. 1966, Cincinnati, Ohio. log. Y. T. Chang, Antimicrobial Agents Chemotherapy 777 (1965). ll0. J. Schneider and J. Languillon, Internat. J. Leprosy 31, 551 (1963). 111. E. Asshauer, Tropenmed. Parasitol, 16, 73 (1965). 112. Y. T. Chang, 4th Internat. Congr. Chemotherapy, 1965, Washington, D. C., Abstracts, p. 82. 113. W. Weuffen, T. Pyl, W. Gruebner, and W. D. Juelich, F'harmazie 20,
1964,
-
629 (1965).
-
114. M. Hooper, D. A. Wtterson, and D. G. Wibberly, J. pharm. Pharmacol. 17,
734 (1965).
115. A. F. Mcky, U. S. patent 3,169,146
116. R. T. Coutts, 792 (1965).
(1965).
W. N. Pitkethly, and D. G. Wibberly, J. Pharm. Sci.
54,
128
Sect. 111 - Chemotherapeutics
F l y n n , Ed.
117. W. N. Cannon, U. S. patent 3,207,660 (1965). 118. H. T. Openshaw and E. Walton, B r i t i s h patent L,013,571 (1965). 119. E. L i l l y and Co., Belgian patent 652,071 (1965). 120. G. Coppi and C. C. Bonardi, Farmaco (Pavla), Ed. Scl. 20, 203 (1965). 121. M. Schorr, Proc. 3rd Internat. Congr. Chem. 1963, Stuttgart, 1396 (1964). 122. H. Loewe and J. Urbanietz, Arzneimittel-Forsch. 15, 604 (1965). 123. H. M. Rauen, Arzneimittel-Forsch. 2,1318 (1965T l24. R. F. Smith and D. E. Shay, Appl. Microbiol. &I 706 (1965). 125. A. Cihak and F. Sorm, Collection Czech. Chem. .C2,2091 (195). 126. Y. N i t t a , T. Miyamoto, T. Nebashi, and>F. Yoneda, Chem. Pharm. B u l l . ( T O e O ) 13, 901 (1965). 127. A. &aushaar, Arzneimittel-Forsch. 4, 548 (1954). 128. K. Bowden and W. J. Ross, J. l?harm.-F'harmacol. 3, 239 (1965). 129. D. E. Barton, K. C l a r k e , and G. W. Gray, J. Chem. SOC. 438 (1965). 130. G. W. Gray and S. G. Wilkinson, J. Appl. Bacteriol. 28, 153 (1965). 131. W. A. Cox, Appl. Mlcrobiol. 956 (1965). 132. W. E. Moore, G. A. portmann, H. Stander, and E. W. McChesney, J. Pharm. Sci. 2, 36 (1965). 133. E. Ihteger-Thiemer, W. Diller, L. D e t t l i , P. Buenger, and J. Seydel, Antibiotica e t Chemotherapia, Fortschr. 12, 171 (1964). 134. S. K. Gupta and I. S. Elathur, Indian J. %d. Res. 52, 973 (1964). 135. B, Kreis and S. Fournaud, Ann. Inst. Pasteur 108, 113 (1965). 136. F. Yoneda and Y. N l t t a , Chem. Pharm. B u l l . ( T x o ) 12, 1264 (1964). 137. J. Seydel, Antlbiotica e t Chemotherapia, Fortschr. 12, 135 (1964). 138. R. S. Schnaare and A. N. Martin, J. Pharm. Sci. 54,1707 (1965). 139. J. Seydel, 4th Inter. Congr. Chemo. 1965, Washinzon, D. C., Abstr. p. 88. 140. E. Brochmann-Hanssen and A. B. Svendsen, Pharmazie 20, 591 (1965). 141. G. Ritschel-Beurlln, Arzneimittel-Forsch. 15, 1247 7i965). 142. J. Pastor and R. Raimondi, B u l l . Soc. Chim. France 1965, 24.26. 143. H. Grasshof, J. Chromatog. 20, 165 (1965). 144. H. Bieling, W. A l m s , and A.Pogadl, Z. Chem. 5, 376 (1965). 145. J. M. Rice, G. 0. Dudek, and M. Barber, J. Am7 Chem. SOC. 87, 4569 (1965). 146. R. G r l g g , M. V. Sargent and J. A. Knight, Tetrahedron 21, 3441 (1965). 147. R. J. Highet and P. F. Highet, J. Org. Chem. 30, 902 (1965). 148. M. -do, Bull. Chem. SOC. Japan 38, I271 (19bj). 149. B. J. Millard, Tetrahedron ~ e t t e r T l 9 6 5 ,3041. 150. L. Bauer, G. E. Wright, B. A. Milcrut and C. L. B e l l , J. Heterocyclic Chem. 2, 447 (1965). 151. S. Natelson, cline chem. 290 (1965). J. Assoc. Offic. Agr. 152. H. L. Schlesinger, M. J. Pro and C. M. Hof-, chemists 48, -U39 (1965). 153. J. M. A. Lenand S. J. Thomson, Eds., "Activation Analysis", Acad. Press, New York, 1965. 154. M. H. Richmond, Blol. Rev. Cambridge Phllos. Soc. 40, 93 (1965). 155. G. H. Hitch* and J. J. Burchall, Advan. EnzymolTg, 418 (1965). 156. A. C. Schwartz, Z. Allgem. Mikrobiol. 2, 147 (1965). 157. T. B e r t 1 and M. Trocca, Giorn. Microblol. 2, 129 (1963). 158. M. G. Sevag and B. Ashton, Antimicrobial Agents Chemo. I & + 410 , (1965). 159. H. G. Johnson and M. K. Bach, Nature 208, 408 (1965). 160. D. A. Mltchison, B r i t . Med. J. 1(5446), 1333 (1965). 161. F. Trendelenburg, Progress i n Drug Research 7, 196 (1964). 162. A. Albert, "Selective Toxicity", Wiley and Sons, New York, 1965. , 163. M. Barber, Proc. Roy. SOC. Med. 2, R. 2, 990 (1965).
a,
-
-
s,
136 -
Sect.
III - Chemotherapeutics
Chapter 14a.
F l y n n , Ed.
Human A n t i p a r a s i t i c Agents
Edward F. Elslager Parke, Davis and ComFny, Ann Arbor, Mich.
The g r e a t advances made i n chemotherapy during t h i s century have enabled some measure of control of t h e major k i l l i n g diseases of t h e t r o p i c s . Notwithstanding p a s t progress, man today i s confronted by a catalog of challenging problems, and t h e incentive t o develop novel and improved a n t i p a r a s i t i c agents has not diminished. Adequate drugs a r e s t i l l lacking for t h e treatment of many chronic and d e b i l i t a t i n g d i s eases including leishmaniasis, Chagas' disease, f i l a r i a s i s , schistosomiasis, dmmcchiasis, t r i c h u r i a s i s , and s t r o n g y l o i d i a s i s . Moreover, r e p o r t s of d r u g r e s i s t a n c e have o f t e n followed advances i n chemotherapy l i k e a " f a i t h f u l shadow", and t h i s shadow w i l l no doubt lengthen i n t h e f u t u r e . The philosophy of global eradication of communicable diseases' and t h e evolution of techniques for i t s achievement have added a new dimension t o research i n p a r a s i t e chemotherapy, namely t h e urgent need f o r drugs with protracted a c t i o n . While t h e c l i n i c i a n i n t e r e s t e d i n t r e a t i n g an individual o f t e n has a v a r i e t y of good drugs a t h i s disposal and may f e e l l i t t l e need f o r new agents, t h e public h e a l t h worker, whose aim i s t h e ultimate eradication of a disease from an e n t i r e community, f a c e s problems of a magnitude and type not encountered by t h e c l i n i c i a n and i s frequently unable t o achieve h i s objective of t o t a l coverage with currently a v a i l a b l e drugs. Future progress i n p a r a s i t e chemotherapy w i l l depend mainly on an increased awareness of such c r i t i c a l problems and needs and on appropria t e recognition of biochemical processes within both p a r a s i t e and host. Intensive e f f o r t s t o develop useful agents for t h e treatment of p a r a s i t i c diseases of livestock, poultry, and o t h e r domestic animals have a l s o y i e l d ed a v a r i e t y of promising new substances (see Chapter 14b), and t h e b e n e f i t s derived from i n t e r p l a y between human and veterinary research a r e already apparent. 11.
MALARIA
I n s p i t e of t h e impressive gains made i n global malaria eradication, malaria s t i l l d i s a b l e s more people and imposes a heavier economic burden than any o t h e r disease. Today more than one b i l l i o n people l i v e i n malarious regions: 723 m i l l i o n i n a r e a s where e r a d i c a t i o n programs a r e i n progress and 393 m i l l i o n i n a r e a s where programs have not y e t s t a r t e d O 2 The ready a v a i l a b i l i t y of a v a r i e t y of useful synthetic a n t i m a l a r i a l drugs i n t h e post-World War I1 e r a contributed t o a f e e l i n g t h a t malaria would soon cease t o be a world problem, and i n t e r e s t i n t h e development of
Chap. 14a.
Antipa r as i tic s
Elslager
137 -
new drugs waned. Moreover, only r e c e n t l y has t h e p o t e n t i a l usefulness of A chemotherapy i n a l l phases of malaria e r a d i c a t i o n been f u l l y recognized.' r e a p p r a i s a l indicated: (1)t h e need f o r long-acting drugs i n malaria eradica(2) t h e seriousness of t h e s i t u a t i o n created by t h e possition b i l i t y of widespread r e s i s t a n c e of Plasmodium falciparum t o t h e 4-aminoquinol i n e s and t h e r e s u l t i n g urgent need f o r new types of f a s t - a c t i n g suppressive drugs;'J7 and ( 3 ) t h e importance of developing s a f e and e f f e c t i v e a n t i - r e l a p s e drugs capable of e f f e c t i n g a r a d i c a l cure of p. vivax and p. malariae, p r e f e r ably i n a s i n g l e dose o r a t most i n a three-day regimen.' Several excellent, a u t h o r i t a t i v e reviews on malaria chemotherapy have recently been p u b l i ~ h e d . ' , ~ ~
-
A. Repository Rrugs. The development of repository a n t i m a l a r i a l drugs required t h e synthesis of substances t h a t would prolong t h e r e l e a s e of a c t i v e moieties from depot s i t e s or, l i k e 6,8-dichloro-2-phenyl-a-2-piperidyl-4-quinolinemethanol (SN-10,275), be firmly bound by host t i s s u e s and then slowly released. lo
-
1. Dihydrotriazine and Pyrimethamine S a l t s . The synthesis of cycloguanil (DRP)pamoate (Camolas) ( I)lO and o t h e r dihydrotriazinelo~ll and p y r i methaminel', l2 s a l t s t h a t e x h i b i t remarkable repository a n t i m a l a r i a l properties5J1' has been reported. A s i n g l e intramuscular dose of cycloguanil pamoate has t h e unusual capacity t o p r o t e c t man f o r many months against challenges with susce t i b l e s t r a i n s of Plasmodib ~ i v a x , ~ "P., ~f a~l ~ i p a r u m , ~ ~P., ~ ' malariae,lg and 2. ova1e.l' Although cycloguanil g m o a t e has so f a r noF shown a l i a b i l i t y t o induce rapid r e s i s t a n c e , p a r a s i t e s known t o be r e s i s t a n t t o chlorguanide, DRT, o r pyrimethamine are less susceptible t o it .14,17-1s
NHR
I
I1
-
2. Sulfones and Sulfonamides. The sulfones and sulfonamides (vide i n f r a ) a c t a t a d i f f e r e n t s i t e than DHT o r pyrimethamine, presumably by preventing t h e incorporation of E-aminobenzoic a c i d i n t o f o l i c acid.20 P o t e n t i a l long-acting sulfone and sulfonamide d e r i v a t i v e s were synthesized t o provide substances t h a t , i n combination with cycloguanil pamoate o r r e l a t e d compounds,11,12 might enable a sequential block i n t h e metabolic synthesis of nucleotides and a f f o r d broader repository a c t i o n a g a i n s t drug-resistant l i n e s than e i t h e r drug alone .21 Various 4-acylaminodiphenylsulfones exhibited
138
Sect. 111
-
F l y n n , Ed.
Chemotherapeutics
i.
promising repository a’ction i n mice. Against trophozoite-induced berghei i n f e c t i o n s i n mice, a s i n g l e subcutaneous 100-400 mg./kg. dose of N,N’-diacetyl-4,4’ -diaminodiphenylsulfone (WE) (IIb) almost invariably prevented or strongly suppressed patent i n f e c t i o n s through 6 t o 14 weeks. A single 50 mg./kg. intramuscular dose of DADDS prevented patent g. cynomolgi i n f e c t i o n s i n monkeys f o r 63-268 (average 158) days and g r e a t l y suppressed t h e p a r a s i t e mia f o r many weeks longer. A comparison of DADDS, cycloguanil pamoate, and a 1:l mixture a g a i n s t l i n e s of 2. berghei highly r e s i s t a n t t o e i t h e r D I E or DBT demonstrated t h a t t h e mixture had broader repository a c t i o n against t h e drugr e s i s t a n t l i n e s than e i t h e r d r u g alone.21J22 Further evaluation of t h e DAD%cycloguanil p m o a t e mixture i n connection with t h e prevention and e r a d i c a t i o n of malaria i s i n progress.
-
3 . 4-Aminoquinolines . Several novel 4aminoquinolines have a l s o been t e s t e d f o r therapeutic and repository a c t i v i t y against trophozoite~ * most i n t e r e s t i n g of these, 4,4’-[1,4induced 2. b e r h e i i n m i ~ e . ~ ~ ,The piperazined&l-methylethyleneimino) 1b i s [ 7-chloroquinoline] (III)? prot e c t e d mice against intervening challenge with 2. berghei f o r 8 weeks followi n g a s i n g l e o r a l dose of 500 mg./kg. The compound has a marked a f f i n i t y f o r l i v e r and kidney, and a delay i n t h e r e l e a s e of t h e drug from l i v e r parenchym a l and Kupffer c e l l s i s apparently responsible f o r t h e s t r i k i n g repository e f f e c t s . No r e p o r t s have y e t been published t o i n d i c a t e whether or not t h e drug has s i g n i f i c a n t repository a c t i o n i n o t h e r laboratory animals or i n man. The synthesis of I11 and many r e l a t e d compounds has been reported.25
-
4. Silicone Rubber Implants. S i l a s t i c capsules have been used successfully i n experimental animals f o r t h e sustained r e l e a s e of antimalarial and antischistosomal agents .26
-
B. Suppressive Agents. From t h e dawn of chemotherapy progress has been shackled by t h e appearance of drug r e s i s t a n c e . Sporadic observations of l e s s ened s e n s i t i v i t y of malarial p a r a s i t e s t o quinine, quinacrine, pamaquine, chlorguanide, and pyrimethamine appeared p r i o r t o 1960, but t h e impact of t h i s phenomenon on malaria eradication was considered i n s i g n i f i c a n t .? Recent i n v e s t i g a t i o n s i n d i c a t e t h a t c e r t a i n s t r a i n s of 2. falciparum from South America t h e most widely and Southeast Asia are r e s i s t a n t t o t h e 4aminoquinolines used drugs i n malaria chemotherapy and t h a t some of t h e s e strains a r e a l s o l e s s susceptible t o many, o r i n a f e w instances widely used a n t i m a l a r i a l The possible i m p a c t of these findings on t h e prevention, treatment, and e r a d i c a t i o n of malaria i s obvious and underscores t h e need for new a n t i m a l a r i a l d r u g s . 3, 6-8,27,30
-
-
s,
-
1. Sulfones and Sulfonamides. It has been known for several decades t h a t sulfones and sulfonamides have a n t i m a l a r i a l action, but none has been used extensively i n t h e treatment of human malarias .3,8,21 Recent observations, however, have revived i n t e r e s t i n t h e possible u t i l i t y of t h e s e substances both a s repository (vide supra )21,22 and s u p p r e s ~ i v e ~ ~ -agents. ”5
Certain l i n e s of 2. berghei, p. cynomolgi, and p. allinaceum made r e s i s t a n t t o 4,4’-diaminodiphenylsulfone (diaphenylsulfone, ? DDS7 7 IIa - or t o DIIT or pyrimethamine were s t i l l susceptible t o t h e heterologous drug with only a l o w order of cross-resistance.31 Further, a 1:l mixture of DIEI) and DDS proved
Chap. 14a.
Antiparasitic s
El slager
139 -
highly e f f e c t i v e against t h e parent, DHT-resistant, and DDS-resistant l i n e s of 2. berghei, and t h e r a t e of emergence of r e s i s t a n c e i n t h e parent s t r a i n was s i g n i f i c a n t l y l e s s with t h e mixture than with e i t h e r drug alone.31 In man d a i l y o r a l doses of 25 t o 50 mg. of D B protected 22 of 26 volunteers from i n f e c t i o n by s t r a i n s of r e s i s t a n t 2. falciparum i s o l a t e d i n Southeast Asia.30 Pyrimethamine ( 5 0 mg. d a i l y f o r 3 days) o r sulfadiazine (2.0 g. d a i l y f o r 5 days) given alone did not cure i n f e c t i o n s with t h e m l a y a (Camp.) s t r a i n of
chloroquine-resistant 2. falciparum; these doses of pyrimethamine and s u l f a diazine administered concurrentlgb although not rapidly effe t i v e , cured i n f e c t i o n s i n 5 of 6 volunteers. Sulforthomidine (Fanasi& (IV) given weekl y i n 500 mg. doses alone o r i n combination with 25 mg. of pyrimethamine cleared symptomless asexual parasitemia i n East African schoolchildren i n f e c t e d with pyrimethamine-resistant 2. falciparum. 32 Although t h i s study indicated t h a t sulforthomidine acted t o o slowly f o r use a g a i n s t acute a t t a c k s , 25 semiimmune p a t i e n t s were subsequently t r e a t e d with s i n g l e 1 . 0 g. doses, and a l l but 3 were cured within 3 days.33 Sulforthomidine appears t o have no sporontocidal a c t i o n against 2. falciparum.34 The above findings, together with i n d i c a t i o n s t h a t t h e combined o r a l use of a sulfone or su1fonami.de with pyrimethamine o r chlorguanide may l e a d t o p o t e n t i a t i o n of a n t i m a l a r i a l effects,8,24.t31.t35 pinpoint an area worthy of extensive i n v e s t i g a t i v e e f f o r t s .
Iv
I11
-
2. 4-Aminoquinolines. In therapeutic s t u d i e s a g a i n s t a normal 2. berghei s t r a i n i n mice, I11 had an o r a l CD50 of 1 0 mg./kg. d a i l y x 4.23 A l though chloroquine-resistant s t r a i n s studied t o date have proved uniformly r e s i s t a n t t o other 4 - a m i n o q ~ i n o l i n e s , ~ a chloroquine-resistant s t r a i n of 2. berghei s u r p r i s i n g l y was reported t o be cross-resistant t o III.24
3 . New S t r u c t u r e s . - Several new a c t i v e chemical moieties have been reported. 3-Piperonylsydnone ( V ) was a c t i v e a g a i n s t 2. berahei a t a dose of 1 0 mg./kg." The glyoxal dithiosemicarbazones VIa and b showed high a c t i v i t y a g a i n s t P. pallinaceum i n t h e chick; t h e median e f f e c t i v e doses per 0s were 0.7 rug./&. x 7 and 0.5 mg./kg. x 7, respectively.37 It i s not y e t c l e a r whether these or r e l a t e d compounds will have p r a c t i c a l application.
-
C. Radical Curative Agents. The 8-aminoquinolines are t h e only substances having s u f f i c i e n t a c t i v i t y against secondaq t i s s u e schizonts t o be of p r a c t i c a l value i n achieving r a d i c a l cure of r e l a p s i n g malarias. However, primaquine and c e r t a i n o t h e r 8-aminoquino~inesproduce acute hemolytic anemia
140
Sect. I11
- Chemotherapeutics HC=N-NBCSNHX
a,X=H b, X = C&OCHs
I
HCd-NHCSNBX
V
F l y n n , Ed.
VI
i n persons whose red c e l l s are unusally susceptible t o drug-induced hemolysis. The rapid degradation and elimination of primaquine necessitates d a i l y @&inist r a t i o n , which c o n s t i t u t e s - a f u r t h e r drawback l i m i t i n g i t s use. The discovery that 4- (2-bromo-4,5-dimethoxyphenyl)-1,1,7,7-tetraethyldiethylenetriamine (RC-12) ( V I I ) has a pronounced effect on t h e exo-erythrocytic stages of 2. cathemerium i n canaries3 stimulated an appraisal of the a c t i v i t i e s of RC-12 against 2. cynomolRi i n t h e monkey.38 Although t h e drug per se had l i t t l e promise as a schizonticidal or suppressive drug, it showed s i g n i f i cant promise as a prophylactic or r a d i c a l curative agent and m i g h t f i n d use when: (1)t h e cambination of chloroquine-primaquine i s not e f f e c t i v e i n causal prophylaxis, as appears t o be t h e case where there i s chloroguine resistance; ( 2 ) there i s a need f o r a curative agent which can produce benefits i n l e s s than 14 days; and (3) there a r e fears of enhanced susce t i b i l i t y t o the hematot o x i c i t y of primaquine. Clinical studies are planned. Si:
m
S
VIII
VII
6- [ [4-(Diethylamino)-l-methylbutyl]amino]-5,8-dimethoxyquinaldine (B-505) (VIII)39 a l s o produced r a d i c a l cures of 12. cathemerium infections i n canaries
but the relative t o x i c i t y of t h i s compound precluded c l i n i c a l studies i n man. ?i
-
D. Test Methods. The demonstration of multiple drug resistance i n 2. falciparum (vide supra) spurred research t o develop better experimental models for studying t h i s phenomenon. Strains of 2. bernheihave been induced t o acaquire resistance t o representatives of a l l the major classes of suppressive drugs, and the r e s i s t a n t l i n e s have been employed i n cross-resistance tests t o determine the i n t e r r e l a t i o n s h i p among t h e various chemical types,20,31,40-44 Anopheles ste&ensi has been shown t o be a suitable experimental vector of 2. berghei t o serve as a source of sporozoites and f o r cyclic transmissions and the existence of primary t i s s u e stages of 2. berRhei has been c o n f i r ~ n e d . ~ ~ , ~ ~ The r e l a t i v e ease of infecting the splenectomized gibbon with blood-induced infections of 2.S c i m r u m indicates that t h i s species may be a suitable l a b oratory model f o r studies of fa3.cimm.m malaria. 47
Chap. 14a.
Elslag e r
Antipa r a s itic s
141 -
Leishmania i s responsible f o r millions of smoldering u l c e r s among inhabi t a n t s of endemic regions i n Africa, t h e Americas, and t h e Near and Far East. Antimonials a r e usually e f f e c t i v e i n leishmaniasis, but t h e necessity f o r r e peated (10-30)i n j e c t i o n s and t h e well-known contraindications of t h e s e drugs impose serious r e s t r i c t i o n s on t h e i r widespread use. Inasmuch a s some regression of e a r l y l e s i o n s of dermal leishmaniasis was observed i n malaria p a t i e n t s t r e a t e d with c h l o r g ~ a n i d e ,it ~ ~was of i n t e r e s t t o i n v e s t i g a t e t h e p o t e n t i a l usefulness of t h e repository drug cycloguanil pamoate ( I ) (vide supra). Early r e s u l t s from Costa Rica and Mexico a r e encouraging; a s i n d e intramuscular i n j e c t i o n of cycloguanil pamoake (280-350 mg. base) cured 26 of 30 p a t i e n t s with b r a ~ i l i e n s i s ~and ' 31 of 40 percutaneous and mucocutaneous i n f e c t i o n s of sons with cutaneous leishmaniasis produced by &. nexicana .49
L.
IV. CHAGAS' DISEASE A t l e a s t 7 m i l l i o n persons i n South and Centrql America a r e i n f e c t e d with Trypanosoma cruzi, t h e causative agent of Chagas' disease. In c o n t r a s t t o t h e success attending t h e development of e f f e c t i v e drugs f o r t h e African trypanosomiases, t h e treatment of cruzi i n f e c t i o n s has been generally unsatisfactory. There i s some evidence t h a t n i t r o f u r a n s may be e f f e c t i v e a g a i n s t acute i n f e c t i o n s , but no curative agent has y e t been found.50 The discovery t h a t strong chemotherapeutic i n t e r e s t . 51 The nature modifications of t h e N1-
N1- (3-dimethylaminopropyl )piperazines (IX) e x h i b i t a c t i v i t y against 2. c r u z i i n mice i s of p a r t i c u l a r of t h e R s u b s t i t u e n t i s r e l a t i v e l y non-specific, but (3-dimethylaminopropy1)piperazine moiety d r a s t i c a l l y
X reduce a c t i v i t y . In comparative s t u d i e s with 2. cruzi i n mice, piperamide maleate (X), given o r a l l y i n s i x t e e n 2.5 or 10 m g x doses over 7 days, prolonged t h e median survival t i m e of t r e a t e d mice s i g n i f i c a n t l y longer than mice t r e a t e d with these doses of furaltadone or primaquine.sl However, t h e curat i v e value and t h e s a f e t y of piperamide maleate and r e l a t e d substances52 have y e t t o be established.
v.
IS
The i d e a l antiamebic agent must be capable of e r a d i c a t i n g Ehtamoeba h i s t o l y t i c a from both t h e bowel and from e x t r a - i n t e s t i n a l s i t e s and should b y v i r t u a l l y non-toxic. Agents with sustained, prophylactic antiamebic p r o p e r t i e s a r e a l s o needed. Although many s a t i s f a c t o r y antiamebic agents a r e available, no s i n g l e preparation i s capable of exerting a l l t h e a c t i o n s required. Theref o r e , t h e search f o r new agents continues.=
Sect. I11
142 -
- Chemotherapeutics
F l y n n , Ed.
-
A. 2-Amino-5-nitrothiazoles. Over a decade ago it was reported t h a t 2-acetamido-5-nitrothiazole (aminitrozole ) ( X I ) possessed curative a c t i o n
against i n t e s t i n a l amebiasis i n r a t s and dogs and k i l l e d a d u l t Schistosoma mansoni i n mice a t well-tolerated 0 s e s . ~ 4 More r e c e n t l y a new 2-amino-5n i t r o t h i a z o l e d e r i v a t i v e ( f m b i l h a h , 32, 644-Ba ) ( X I I ) having strong therapeut i c e f f e c t s against amebiasis and schistosomiasis (vide i n f r a ) was discovered.55 !The minimum i n h i b i t o r y concentration of 32,644-& against g. h i s t o l y t i -
XI
XI1
ca i n v i t r o w a s 10 pg./ml.
G emetine
This i s approximately t h e same potency exhibited
or 4,7-phenanthroline-5,6-quinone under comparable conditions. 56
!Phe compound strongly suppresses amebic l i v e r abscess i n hamsters following d a i l y o r a l doses of 60-120 mg./kg. f o r 7 days (chloroquine was e f f e c t i v e a t 100-200 mg./kg. ). I n t e s t i n a l amebic i n f e c t i o n s i n rats and guinea-pigs were markedly reduced following d a i l y o r a l doses of 30-60 mg./kg. f o r 4 and 5 days, respectively .56 Results of preliminary human t r i a l s i n d i c a t e t h a t 32,644-&, administered i n d a i l y doses of 20-25 mg./kg. f o r 5 t o 10 days, i s e f f e c t i v e against both amebic dysentery and amebic l i v e r abscess, although s i d e e f f e c t s including frequent ECG changes and occasional neuropsychic episodes were noted.57 More extensive t r i a l s w i l l be required t o a s s e s s t h e r e l a t i v e s a f e t y and e f f i c a c y of t h e drug compared with o t h e r forms of treatment. Rel a t e d heterocyclic compounds a r e a l s o reported t o have antiamebic and a n t i schistosomal p r o p e r t i e s .58
-
B. 7-Quinolinols. Another new amebicide of p o t e n t i a l i n t e r e s t i s 5chloro-7- 3-diethylaminopropylaminomethyl ) -8-quinolinol (clamoxyquin PAA-3854 CI-433) ( X I I I ) s9 The r e l a t i v e amebicidal concentrations of clamoxyquin hydrochloride and emetine hydrochloride a r e 20-40 pg./ml. and 2.5 pg./ml. respect i v e l y . 6o The e f f e c t s of clamoxyquin hydrochloride and chloroquine against amebic h e p a t i t i s i n hamsters were roughly comparablej clamoxyquin hydrochloride,
.
,
,
OH
c1 XI11
XIV
pamoate, and s a l i c y l a t e w e r e a c t i v e against i n t e s t i n a l amebiasis i n r a t s i n gavage doses ranging from 75 t o 600 mg./kg. d a i l y f o r 4 days." Clamoxyquin hydrochloride and pamoate cured amebic dysentery in do s i n d a i l y doses of 3.13 t o 50 mg./kg. and 12.5 t o 25 mg./kg. respectively.6' Relative t o t h e 8-quinol i n o l s i n c l i n i c a l use t h e clamoxyquin s a l t s were deemed worthy of c l i n i c a l
Chap. 14a.
Antipar as itic s
Elslager
143 -
t r i a l . Clamoxyquin hydrochloride was t o l e r a t e d w e l l i n man following d a i l y 1 5 mg./kg. doses f o r 5-10 days and was highly e f f e c t i v e against various forms of Additional s t u d i e s w i l l be required before the r e l a i n t e s t i n a l amebiasis."' t i v e importance of the clamoxyquin salts i n amebiasis chemotherapy can be assessed
.
C. Anisomycin. - The determination of t h e s t r u c t u r e and stereochemistry of the potent antiprotozoal a n t i b i o t i c anisamycin (XIV)62 may serve t o stbiul a t e f u t u r e research on t h e synthesis and biological properties of r e l a t e d substances.
VI,
SCHISTOSOMIASIS
Nearly 200 m i l l i o n people a r e infected with schistosomiasis, and on a world b a s i s these i n f e c t i o n s a r e ~ p r e a d i n g . ~The degree of prevalence, t h e seriousness of t h e infection, and t h e paucity of adequate drugs make schistosomiasis one of t h e g r e a t e s t challenges i n p a r a s i t e chemotherapy today. Seve r a l promising new agents have been discovered, but t h e i r usefulness i n man has yet t o be adequately evaluated. Therefore, one s t i l l must r e l y on the a n t i monials with some assistance from lucanthone hydrochloride (ma) against Schistosoma haematobium and c e r t a i n s t r a i n s of S. mansoni. Research on schistosomiasis6Y'64 and other trematode infections63 has r e c e n t l y been reviewed.
-
A. 2-Amino-5-nitrothiazoles. To date 1-(5-nitro-2-thiazolyl)-2-imidazolidinone ( A m b i l h d 32 644-E!a) ( X I I ) has been evaluated more extensively i n ~ c h i ~ t o s a m i a s i than s ~ ~ i n ~amebiasis ~ ~ ~ ~(vide ~ ~ supra). " ~ ~ ~ When ~ adult S . mansoni were exposed t o 32,644-Ba i n v i t r o for prolonged periods (100 hr.), oviposition was i n h i b i t e d a t concentrations of 1 pg./ml. and worms were k i l l e d a t 100 p g . / m l . 5 5 ~ 6 5 The destruction of the v i t e l l o g e n i c gland i n the female coincides with a reduction i n body-length i n both male and female worms and i n t h e s i z e of t h e ovary i n t h e female.57 The drug.was highly a c t i v e against S . manSOn155,65 and 2. j a ~ o n i c u mi ~ n ~mice i n o r a l doses of 100 mg./kg. d a i l y f o r 10 days and had a strong prophylactic and chemotherapeutic e f f e c t on experimental 2. mansoni infections i n monkeys .57 Temporary, r e v e r s i b l e impairment of sljermatogenesis occurred i n mice- the drug apparently a c t s d i r e c t l y on t h e germinal epithelium of t h e t e s t e s . 66 Results of preliminary c l i n i c a l t r i a l s i n man i n d i c a t e t h a t 72 644-h has considerable e f f i c a c y against 2. h a e m a t ~ b i u m ~ ~and , " ~2. mansoni5 j Q 8 i n o r a l doses of 20-40 mg./kg. d a i l y f o r 5-15 days; S . japonicum i n f e c t i o n s appear t o be more refractory.57 Three types of side e f f e c t s were encountered which merit s p e c i a l a t t e n t i o n : (1)frequent ECG changes, involving mainly t h e T waves; ( 2 ) neuropsychic e f f e c t s , ranging from severe headaches t o convulsive a t t a c k s with infrequent hallucinations; (3) t r a n s i t o r y impairment of spermatogenesis .57 The ultimate place of 32,&4-& i n schistosomiasis chemotherapy w i l l depend l a r g e l y on t h e incidence and s e v e r i t y of these side e f f e c t s a t e f f e c t i v e dose l e v e l s when compared with t h e side e f f e c t s encountered i n t h e c l a s s i c a l treatments. The drug has a l s o been reported t o be e f f e c t i v e i n t h e treatment of Dracunculus medinensis (guinea worm) i n f e s t a t i o n i n humans .69
144
Sect. III
-
Chemotherapeutics
F l y n n , Ed.
-
B. Thiaxanthenones. Incubation of lucanthone (XVa) with sclerotiorum produces t h e a c i d - l a b i l e hydroxymethyl d e r i v a t i v e Surprisingly, t h e (Xvb) together with smaller amounts of t h e aldehyde five-day ED50 f o r lucanthone and hycanthone a g a i n s t S . mansoni i n hamsters were 8.0 mg./kg. and 0.78 mg./kg., respectively.70 The unusual potency of hycanthone l e d t o t h e hypothesis t h a t it might indeed be t h e e l u s i v e a c t i v e metabol i t e of lucanthone. The a c i d s e n s i t i v i t y of Xvb could explain why it had
escaped detection by previous i n v e s t i g a t o r s . Accordingly, monkeys were medicated with lucanthone, t h e w i n e s were c a r e f u l l y e x t r a c t e d avoiding a c i d treatment, and t h e e x t r a c t s were examined by thin-layer chromatography. In agreement with e a r l i e r work,71 t h e sulfoxide (XVd) was t h e major metabolite, and only t r a c e s of XVb w e r e detected. When t h e urine e x t r a c t s were incubated with glucuronidase p r i o r t o chromatography, however, hycanthone appeared as a major component.7o Idthough t h e sulfone XVe i s reported t o be t h e major urinary metabolite i n hycanthone was a l s o found i n mouse urine a f t e r glucuronidase incubation but t o a much l e s s e r extent t h a n i n t h e monkey.7o The results of t h e s e elegant s t u d i e s support t h e hypothesis t h a t hycanthone i s an important a c t i v e metabolite of lucanthone; it now becomes apparent why a 2-toluidine function i s an absolute requirement f o r a c t i v i t y among all lucanthone r e l a t i v e s . Other s t u d i e s u t i l i z i n g s u b t i l i s suggest t h a t t h e major i n vivo a c t i o n of lucanthone i s t o complex with DNA, thereby blocki n g DNA-dependent RNA synthesis .73 Various o t h e r schistosomicides r e l a t e d t o hycanthone and t h e aldehyde XVc have been prepared.74 It has a l s o been disclosed t h a t lucanthone N-oxide (XVI) i s considerably l e s s t o x i c than lucanthone .75
-
Tris (paminophenyl )carbonium Salts. Tris (paminopheny1)carbonium C. (TAC) pamoate (XVII)76 and c e r t a i n antimonials have broad antischistosome a c t i v i t y i n experimental animalsT7 and i n man.78 However, both groups have important l i m i t a t i o n s . Thus t h e slow-acting TAC pamoate must be administered for s e v e r a l weeks t o achieve a strong degree of e f f e c t while t h e f a s t - a c t i n g antimonials have a r e l a t i v e l y narrow therapeutic index.
In a recent study of t h e j o i n t a c t i o n of TAC s a l t s and t a r t a r emetic a marked degree of synergism was observed against S. mansoni i n v i t r o and i n mice, Moreover, n e i t h e r drug had p a r t i c u l a r l y a f t e r pretreatment with TAC pamoate?” an appreciable a f f e c t on t h e gross t o x i c i t y of t h e other f o r normal mice. An encouraging degree of j o i n t antischistosomal a c t i o n by TAC pamoate and t a r t a r
Chap. 14a.
Antiparasitics
-OOC
.OH
145
Elslager
H(
XVIII
XVII
emetic was also observed in monkeys. The therapeutic advantage of such a combination hinges largely upon whether o r not the co-administration of TAC pamoate produces higher o r more sustained antimony levels in the blood or tissues. A subsequent study utilizing 124Sb-labeled tartar emetic demonstrated that co-administration or pretreatment with TAC pamoate had no significant effect on the disposition of antimony in mice o r monkeys." Available evidence suggests that the mode of action of TAC pamoate and the trivalent antimonials is dissimilar. Briefly, the antimonials interfere with schistosome glycolysis by inhibiting phosphofructokinase, which catalyzes the reaction: fiuctose-6-phosphate
f
ATP
F'ructose-1,6-diphosphate
+ ADP
Recent studies with 14C-labeled glucose indicate that tartar emetic blocks both the Ehbden-Meyerhof and the hexose-monophosphate pathways of glycolysis Organic antimonials have also been reported to inhibit schistosome glutamicpyruvic transaminase
.
.
The TAC salts apparently act by an entirely different mechanism.e2 In mice subcurative doses of TAC chloride have no demonstrable effect on the carbohydrate and protein metabolism of the worms but produce a localized paralysis of the acetabulum, pharynx, and oral sucker which histochemically has been correlated with a pronounced decrease of cholinesterase activity in the central ganglia. This paralysis is completely reversed in vitro by the cholinergic blocking agent mecamylamine, suggesting an accumulation of acetylcholine in these structures. Simultaneously, glycogen depletion is observed in the papillae located below the cuticle of the worm. Either one or a combination of these changes could account for the antischistosomal effects observed.82
-
D. Cucurbitine. For several years reports emanating from mainland China have claimed that the dried, ripe seeds of the pmpkin varieties Cucurbita pep0 L. and C. moschata Duch. are effective in the treatment of schistosomiasis. The amino acid cucurbitine (XVIII) has recently been isolated from C. moschata Duch." Cucurbitine reportedly inhibits the growth of immature 2. japonicum, produces degenerative changes in the genital organs of the worms resulting in depressed egg-producing capacity, and is virtually nontoxic.s3 It would appear worthwhile to confirm the structure of cucurbitine and study its effects on 2. haematobium and 2. mansoni. VII.
CLONORCHIASIS
Clonorchiasis is caused by the human liver fluke Clonorchis sinensis (syn.
Sect. 111 - Chemotherapeutics
146 -
F l y n n , Ed.
Opisthorchis s i n e n s i s ) and i s widely d i s t r i b u t e d i n t h e Far East, especially i n Indochina, Central and South China, Formosa, Korea, and Japan. Approximatel y 19 million people are a f f l i c t e d with t h i s disease, y e t no r e l i a b l e treatment i s known. Therefore, preliminary r e p o r t s t h a t t h e f a s c i o l i c i d e a,a,a,a',@,a'hexachloro-2-xylene (XIX) i s highly e f f e c t i v e against C. s i n e n s i s i n experimen-
t a l animalss4"' and i n a t well-tolerated doses a r e most encouraging. Expanded human t r i a l s a r e indicated.
The world-wide incidence of i n t e s t i n a l helminthic i n f e c t i o n s i n man approaches t h e staggering f i g u r e of two b i l l i o n . * The prevalence of these i n f e c t i o n s and t h e i r complex and far-reaching e f f e c t s upon body function cause them t o rank among t h e most important disease problems of man. F i r s t reports" on tetramisole ( X X ) , a potent new anthelmintic with broad a c t i o n against nematodes, a r e highly encouraging. The drug i s reported t o be e f f e c t i v e against Ascaris lumbricoides and Enterobius vermicularis i n man" and against a v a r i e t y of adult and immature g a s t r o i n t e s t i n a l and pulmonary nematodes i n laboratory animals, poultry, and livestock. ,l' s2 Although devoid
xx
XXI
XXII
of antihistaminic, anticholinergic, adrenolytic o r other c l a s s i c a l pharmacol o g i c a l properties, tetramisole e x e r t s a rapid paralysing a c t i o n on a variety of nematodes i n v i t r o a t low concentrations.
''
The evolution of tetramisole points once again t o t h e importance of strong biochemical support i n drug development. Thus, t h e observation t h a t t h i a z o t h i en01 (XXI)'~ was a c t i v e against nematodes during a routine screening program i n chickens stimulated a search for a c t i v e metabolites of XXI and l e d t o t h e isol a t i o n and i d e n t i f i c a t i o n of XXII a s t h e major transformation product i n t h e feces. The c y c l i c metabolite XXII was a c t i v e a t s i g n i f i c a n t l y lower dose l e v e l s t h a t t h e parent compound (XXIX and these results prompted the s n t h e s i s ?' . and b i o l o g i c a l evaluation of an extensive s e r i e s of r e l a t e d compounds Tetramisole emerged a s t h e most promising substance f o r expanded s t u d i e s .
Antipa rasitics
Chap. 14a.
147 -
Els lage r
IX. BIBLIOGRAPHY
&I.
m., a.s.
(1) E. H. Hinman, 2. Tro Med. 2, 125 (1966). (2) Chronicle, 3 3 d a (3) L. J. Bruce-Chwatt, Trans. Trop. g . 2, 105 (1965). (4) E. F. Elslager and P. E. Thompson, Pharmacol.,& 193 (1962). ( 5 ) P. E. Thompson, B. J. Olszewski, E. F. Elslager, and D. F. Worth, &.' J& 481 (1963 -J. Tro Med. (eRexution, JJ, 361 (1964).
.
&. &.
m.,
m.,
w.,
1965,
S. Goodman and A. Gilman, Ed., t h e Mamillan Co., New York, N.Y.,
1087-1117.
ed., L. pp.
(10)E. F. Elslager and P. E. Thompson, Abstracts, 9th National Eledicinal Chemistry Symposium of t h e American Chemical Society, Minneapolis, Minn., June 1964, p. 6A. (11)E. F. Elslager and D. F. Worth, U. S. Patents 3,223,705 (1965) and 3,248 422 (1966). (12) E. F. Elslager and D. F. Worth, U. S. Patents 3,161,641 (1964); 3,236,849 (1966); 3,244,716 (1966)j and 3,248,422 (1966). (13) G. R. Coatney, P. G. Contacos, and J. S. Lunn, J. Trop. &d. &g.,
&I.
-
13 383 (1964)")(14) R. D. Powell, R. L. DeGowin, and R. B. Eppes, M.,&, 913 (1965). (15) P. G. Contacos, G. R. Coatney, J. S. Lunn, and J. W. Kilpatrick,
L;zI 386
u.,
(u@+)*
(16) 1. A. McGregor, K. Williams, G. H.'Walker, and A. K. Rahman, Brit. E .
2 . , 3 695 (1966).
- m.,
(17 P. E. Thompson, B. Olszewski, and J. A. Waitz, &. 2. m.Med. 343 (1%5)* (18)W. Chin, J. S. Lunn, J. Buxbaum, and P. G. Contacos, w., &I 922
&
(1965)
(20) A.
(19) P. G.
(1965
Contacos, G. R. Coatney, J. S. Lunn, and W. Chin,
a
w.,
925
Bishop, ParasitolopV, 53, 10 (1963); 407 (1965). (21) E. F. Elslager and D. F. S r t h , Nature, 206 630 (1965). (22) P. E. Thompson, B. Olszewski, and J. A. &z, &. 2.
r14 U1
343 (1965)-
&. Med. a.,
(23) J. Schneider, M. Bouvry, and J. Le Quellec, Abstracts, I n t e r n a t i o n a l Colloquium on , P a berghei, I n s t i t u t e of Tropical Medicine "Prince Leopold," Antwerp, Belgium, December 1964. (24) J. Hill i n "mperimental Chemotherapy," V o l N, R. J. Schnitzer and F. Hawking, Ed., Academic Press, New York, N.Y., 1966, p. 448. (25) Rhone-Poulenc S. A., B r i t i s h Patent 973,903 (1964); Eire Patents 461/62, 1097/62, 591/63, and 620/63 (1963). (26) K. G. Powers, J. Parasitol., 2, 53 (1965). (27) C. G. H u f f , 'Itrop. m e , & 339 (1965). (28) R. L. De Gowin and R. D. Powell, 519 (1965). (29) R. L. De Gowin and R. D. Powell, J. &&.B. 851 (30) 3. % (131, 38 ( i s ) . (31) P. E. Thompson, A. Bayles, B. Olszewski, and J. A. Waitz 198 (1965).
&.-z.
m.
m,
- a*,*,
@.
w.,
s., a,
, Am-
148
Sect. IU
- Chemotherapeutics
'Flynn, Ed.
(35) P. C. Basu, N. N. Singh, and N. Singh, B u l l . World Health Qrgan., & 699 -_ ( .1-964.). (36) W. H. Nyberg and C. C. Cheng, 2. B., 531 (1965). (37) P. A. Barrett, E. Beveridge, P. L. Bradley, C. G. D. Brown, S. R. M. Bushby, M. L. Clarke, R. A. Neal, R. Smith, and J. K. H. Wilde, Nature, 1340 (1965). (38) L. H. Schmidt, R. N. Rossan, R. Fradkin, J. Woods, W. Schulemann, and L. Kratz, presented a t t h e 14th Annual Meeting of t h e American Society of Tropical Medicine and Hygiene, New Orleans, L a . , Nov 1965. (39) F. Schonhofer and W. Schulemann, B r i t i s h Patent 970,949 (1964). (40) R. L. Jacobs, 2. Parasitol., 481 (1965). (41) W. Peters, 9. Parasitol., 80, 90, 97 (1%5)(42) W. Peters, Nature, (43) P. E. Thompson, B. %ze:ski, A. Bayles, and J. A. Waitz, 2. P a r a s i t o l . , /s 51 (21, 54 (1965). (44) P. E. Thompson, A. Bayles, B. Olszewski, and J. A. Waitz, Science, 1240 (1965). (45) M. Yoeli and H. Most, &. 2. Trop. €&., 700 (1965). (46) M. Yoeli, J. Vanderberg, R. Nawrot, and H. Most, & 927 (1965). (47) R. A. Ward, J. H. Morris, D. J. Gould, A. T. C. B u r k e , and F. C. Cadigan, Jr., Science, 1604 (1965 ) (48) A. Pel& Chavarria, E. Kotcher, and C. Lizano, 2. Assoc., 1142 (1965). (49) F. Beltrh, F. Biagi, and S. Gonza'lez, presented a t t h e 14th Annual hketing of t h e American Society of Tropical Medicine and Hygiene, New Orleans, La., NOV 1965. H&., 211 (1964). (50) F. Hawking, 2. Trop. (51) A. S. Tomcufcik, R. I. Hewitt, P. F. Fabio, A. M. Hoffman, and J. Entwistle, Nature, 2ez, 605 (1965). , (52) American Cyanamid Co., South African Patent 3833/63 (1964) and Belgian Fatent 654,017 (1965). (53) G. Woolfe i n "Drug Research," Vol VIII, E. Jucker, Ed., Birkhauser AG, Basel, Switzerland, 1965, pp. 13-52. (54) A. C. Cuckler, A. B. Kupferberg, and N. Millman, Antibiot. Chemother540 (1955). C. R. Lambert, M. Wilhelm, H. S t r i e b e l , F. Kradolfer, and P. Schmidt, Ek e r i e n t i a , 452 (1964). %adolfer and R. Jarumilinta, Trop. E.Parasitol., 210
@.
&
a
.
e.
s. & u., &. w.
a
2
&.
(19651* (57) "Th6rapeutique Nouvelle de l a Bilharzioae e t de 1'Amibiase, Symposium de Lisbonne, June, 1965, Acta WOE., SuppL. 9, 1-314 (1966). ( 5 8 ) Ciba Ltd., South African Patents 3781/64 (1965) and 4336/65 (1966); Neth. Patents 6,505,225 and 6,505,226 (1965). (59) J. H. Burckhalter, W. S. Brinigar, and P. E. Thompson, 2. & 4070 (1961). I'
a. e., Meisenhelder, J. e-
(60) P. E. Thompson, A. Bayles, P. McClay, and J. E. sitol., 817 (1965). (61)R. Hugonot, E. Granotier, and J. P. Farges, Therapie, & 329 (1965). (62) J. J. Beereboom, K. Butler, F. C. Pennington, and I. A. Solomons, 2. B., 2334 (1965).
a-
Chap. 14a.
Antiparas iti cs
Elslager
149 -
s., &,
(63) G. Uinrmler, 2. Tropenmed. Parasitol., 95, 164, 337 (1964). (64) World Health Organ. Tech. Rep. 317. (65) C. R. Lambert, Trop. Parasitol., 292 (1964). (66) C. R. Lambert, V. S. P. S i n a r i , and J. Tripod," Acta T r o ~ . , & , 155 (1965). (67) C. R. Lambert and F. S. I& C r u z F e r r e i r a , B u l l . World Health Organ.,& 73 (1965)(68) P. Jordan, Brit. w .z., A 276 (1966). (69) G. Raffier, Acta T r o ~ . ,.& 350 (1965).
a., s.
(70) D. Rosi, G. Peruzzotti, E. W. Dennis, D. A. Berberian, H. Freele, and
S. Archer, Nature,%
(71) R. Strufe,
1006 (1965).
w. Chem.
%.--.
Abhandl. Forschungsstaetten Farbenfabriken Bayer, & 337 (1963). (72).Gijnnert, B u l l . World Health O r g a n . , a 702 (1961). (73) I. B. Weinstein, R. Chernoff, I. Finkelstein, and E. Hirschberg, Pharmacol. 1 297 (1965). m e r h 'n4g Drug Inc., South African Patent 4081/64 (1965). (75) Farbenfab. Bayer A. G., Belgian Patent 663,790 (1965). (76) F. W. Short and E. F. Elslager, U. S. Patent 3,218,339 (1965). (77) E. F. Elslager, F. W. Short, D. F. Worth, J. E. Meisenhelder, H. Najarian, and P. E. Thompson, Nature, 628 (1961). (78) J. R. da Silva, A. Prata, C. A. Argento, H. American0 do B r a s i l , and L. F. Ferreira, Hospital (Rio de Janeiro), & 25 (1964). (79) P. E. Thompson, J. E. Meisenhelder, A. K. Moore, and J. A. Waitz, B u l l . World Health Organ., 2 517 (1965). (80) J. A. Waitz, R. E. Ober, J. E. Meisenhelder, and P. E. Thompson,
s.
z,
w.,
81) J. A. Waitz, Life Sci., 3 377 (1964). (82) E. L. S c h i l l e r and E. Buding, 2. P a r a s i t o l . Supplement, 51, 43 (1965). (83) J. H. Zhou, F. Y. Fu, and H. P. Lei i n "Proceedings of t h n e c o n d International Pharmacological Meeting, Prague, 20-23 August, 1963," Vol V I I , K. K. Chen, B. Mukerji, and L. Volicer, Ed., t h e Macmillan Co., New York, N. Y., 1965, p. 25. N. N. Plotnikov and L. I. Sinovich, Meed. Parazitol. & Parazitarn. Bole301 (1964); Diseases g., l m ) . 9 6 5 % . Yokogawa, H. Koyama, H. Yoshimura, and C. S. Tsai, J. Chiba Med. SOC., & 286 (1965). ( 8 6 ) H. L. Chung, Chinese Med. J., & 232 (1965). (87) J. Liu, (19657. ( 8 8 ) N. N. Plotnikov, No N. Ozeretskovskaya, V. K. Karnaukhov, N. S. Zalnova, G. M. Faibusovich, G. I. Kukhta, and M. I. Alekseeva, Med. Parazitol. i Egmzitarn. Bolezni, 676 (1964); IIl.op. Diseases B u l l . , & 32771965). Tv. N. mozdov, Diseases & 59 (1966). (90) M. Yokogawa, M. Tsuji, K. Araki, T. Nomoto, M. mtsumoto, M. Koyama, R. Yoshiba, S. Fukuchi, A. Hiratsuka, and M. Kitamura, Japan. 3. P a r a s i t o l . , & 526 (1965)(91) D. Thienpont, 0. F. J. Vanparijs, A. H. M. Raeymaekers, J. Vandenberk, P. A. Demoen, F. T. N. Allewijn, R. P. H. Marsboom, C. J. E. Niemegeers, K. H. L. Schellekens, and P. A. J. Janssen, Nature, 3 & 1084 (1966). (9) J. K. Walley, Vet. Record, J&, 4 0 6 m ) . (93) Janssen &arm., N. V., Belgian Patent 653,087 (1965). (94)Janssen Pharm., N. V., Neth. Patent 6,505,806 (1965).
(a)
-
m.
=.-
a
J.
us,
m.
u.,
136 -
Sect.
III - Chemotherapeutics
Chapter 14a.
F l y n n , Ed.
Human A n t i p a r a s i t i c Agents
Edward F. Elslager Parke, Davis and ComFny, Ann Arbor, Mich.
The g r e a t advances made i n chemotherapy during t h i s century have enabled some measure of control of t h e major k i l l i n g diseases of t h e t r o p i c s . Notwithstanding p a s t progress, man today i s confronted by a catalog of challenging problems, and t h e incentive t o develop novel and improved a n t i p a r a s i t i c agents has not diminished. Adequate drugs a r e s t i l l lacking for t h e treatment of many chronic and d e b i l i t a t i n g d i s eases including leishmaniasis, Chagas' disease, f i l a r i a s i s , schistosomiasis, dmmcchiasis, t r i c h u r i a s i s , and s t r o n g y l o i d i a s i s . Moreover, r e p o r t s of d r u g r e s i s t a n c e have o f t e n followed advances i n chemotherapy l i k e a " f a i t h f u l shadow", and t h i s shadow w i l l no doubt lengthen i n t h e f u t u r e . The philosophy of global eradication of communicable diseases' and t h e evolution of techniques for i t s achievement have added a new dimension t o research i n p a r a s i t e chemotherapy, namely t h e urgent need f o r drugs with protracted a c t i o n . While t h e c l i n i c i a n i n t e r e s t e d i n t r e a t i n g an individual o f t e n has a v a r i e t y of good drugs a t h i s disposal and may f e e l l i t t l e need f o r new agents, t h e public h e a l t h worker, whose aim i s t h e ultimate eradication of a disease from an e n t i r e community, f a c e s problems of a magnitude and type not encountered by t h e c l i n i c i a n and i s frequently unable t o achieve h i s objective of t o t a l coverage with currently a v a i l a b l e drugs. Future progress i n p a r a s i t e chemotherapy w i l l depend mainly on an increased awareness of such c r i t i c a l problems and needs and on appropria t e recognition of biochemical processes within both p a r a s i t e and host. Intensive e f f o r t s t o develop useful agents for t h e treatment of p a r a s i t i c diseases of livestock, poultry, and o t h e r domestic animals have a l s o y i e l d ed a v a r i e t y of promising new substances (see Chapter 14b), and t h e b e n e f i t s derived from i n t e r p l a y between human and veterinary research a r e already apparent. 11.
MALARIA
I n s p i t e of t h e impressive gains made i n global malaria eradication, malaria s t i l l d i s a b l e s more people and imposes a heavier economic burden than any o t h e r disease. Today more than one b i l l i o n people l i v e i n malarious regions: 723 m i l l i o n i n a r e a s where e r a d i c a t i o n programs a r e i n progress and 393 m i l l i o n i n a r e a s where programs have not y e t s t a r t e d O 2 The ready a v a i l a b i l i t y of a v a r i e t y of useful synthetic a n t i m a l a r i a l drugs i n t h e post-World War I1 e r a contributed t o a f e e l i n g t h a t malaria would soon cease t o be a world problem, and i n t e r e s t i n t h e development of
Chap. 14a.
Antipa r as i tic s
Elslager
137 -
new drugs waned. Moreover, only r e c e n t l y has t h e p o t e n t i a l usefulness of A chemotherapy i n a l l phases of malaria e r a d i c a t i o n been f u l l y recognized.' r e a p p r a i s a l indicated: (1)t h e need f o r long-acting drugs i n malaria eradica(2) t h e seriousness of t h e s i t u a t i o n created by t h e possition b i l i t y of widespread r e s i s t a n c e of Plasmodium falciparum t o t h e 4-aminoquinol i n e s and t h e r e s u l t i n g urgent need f o r new types of f a s t - a c t i n g suppressive drugs;'J7 and ( 3 ) t h e importance of developing s a f e and e f f e c t i v e a n t i - r e l a p s e drugs capable of e f f e c t i n g a r a d i c a l cure of p. vivax and p. malariae, p r e f e r ably i n a s i n g l e dose o r a t most i n a three-day regimen.' Several excellent, a u t h o r i t a t i v e reviews on malaria chemotherapy have recently been p u b l i ~ h e d . ' , ~ ~
-
A. Repository Rrugs. The development of repository a n t i m a l a r i a l drugs required t h e synthesis of substances t h a t would prolong t h e r e l e a s e of a c t i v e moieties from depot s i t e s or, l i k e 6,8-dichloro-2-phenyl-a-2-piperidyl-4-quinolinemethanol (SN-10,275), be firmly bound by host t i s s u e s and then slowly released. lo
-
1. Dihydrotriazine and Pyrimethamine S a l t s . The synthesis of cycloguanil (DRP)pamoate (Camolas) ( I)lO and o t h e r dihydrotriazinelo~ll and p y r i methaminel', l2 s a l t s t h a t e x h i b i t remarkable repository a n t i m a l a r i a l properties5J1' has been reported. A s i n g l e intramuscular dose of cycloguanil pamoate has t h e unusual capacity t o p r o t e c t man f o r many months against challenges with susce t i b l e s t r a i n s of Plasmodib ~ i v a x , ~ "P., ~f a~l ~ i p a r u m , ~ ~P., ~ ' malariae,lg and 2. ova1e.l' Although cycloguanil g m o a t e has so f a r noF shown a l i a b i l i t y t o induce rapid r e s i s t a n c e , p a r a s i t e s known t o be r e s i s t a n t t o chlorguanide, DRT, o r pyrimethamine are less susceptible t o it .14,17-1s
NHR
I
I1
-
2. Sulfones and Sulfonamides. The sulfones and sulfonamides (vide i n f r a ) a c t a t a d i f f e r e n t s i t e than DHT o r pyrimethamine, presumably by preventing t h e incorporation of E-aminobenzoic a c i d i n t o f o l i c acid.20 P o t e n t i a l long-acting sulfone and sulfonamide d e r i v a t i v e s were synthesized t o provide substances t h a t , i n combination with cycloguanil pamoate o r r e l a t e d compounds,11,12 might enable a sequential block i n t h e metabolic synthesis of nucleotides and a f f o r d broader repository a c t i o n a g a i n s t drug-resistant l i n e s than e i t h e r drug alone .21 Various 4-acylaminodiphenylsulfones exhibited
138
Sect. 111
-
F l y n n , Ed.
Chemotherapeutics
i.
promising repository a’ction i n mice. Against trophozoite-induced berghei i n f e c t i o n s i n mice, a s i n g l e subcutaneous 100-400 mg./kg. dose of N,N’-diacetyl-4,4’ -diaminodiphenylsulfone (WE) (IIb) almost invariably prevented or strongly suppressed patent i n f e c t i o n s through 6 t o 14 weeks. A single 50 mg./kg. intramuscular dose of DADDS prevented patent g. cynomolgi i n f e c t i o n s i n monkeys f o r 63-268 (average 158) days and g r e a t l y suppressed t h e p a r a s i t e mia f o r many weeks longer. A comparison of DADDS, cycloguanil pamoate, and a 1:l mixture a g a i n s t l i n e s of 2. berghei highly r e s i s t a n t t o e i t h e r D I E or DBT demonstrated t h a t t h e mixture had broader repository a c t i o n against t h e drugr e s i s t a n t l i n e s than e i t h e r d r u g alone.21J22 Further evaluation of t h e DAD%cycloguanil p m o a t e mixture i n connection with t h e prevention and e r a d i c a t i o n of malaria i s i n progress.
-
3 . 4-Aminoquinolines . Several novel 4aminoquinolines have a l s o been t e s t e d f o r therapeutic and repository a c t i v i t y against trophozoite~ * most i n t e r e s t i n g of these, 4,4’-[1,4induced 2. b e r h e i i n m i ~ e . ~ ~ ,The piperazined&l-methylethyleneimino) 1b i s [ 7-chloroquinoline] (III)? prot e c t e d mice against intervening challenge with 2. berghei f o r 8 weeks followi n g a s i n g l e o r a l dose of 500 mg./kg. The compound has a marked a f f i n i t y f o r l i v e r and kidney, and a delay i n t h e r e l e a s e of t h e drug from l i v e r parenchym a l and Kupffer c e l l s i s apparently responsible f o r t h e s t r i k i n g repository e f f e c t s . No r e p o r t s have y e t been published t o i n d i c a t e whether or not t h e drug has s i g n i f i c a n t repository a c t i o n i n o t h e r laboratory animals or i n man. The synthesis of I11 and many r e l a t e d compounds has been reported.25
-
4. Silicone Rubber Implants. S i l a s t i c capsules have been used successfully i n experimental animals f o r t h e sustained r e l e a s e of antimalarial and antischistosomal agents .26
-
B. Suppressive Agents. From t h e dawn of chemotherapy progress has been shackled by t h e appearance of drug r e s i s t a n c e . Sporadic observations of l e s s ened s e n s i t i v i t y of malarial p a r a s i t e s t o quinine, quinacrine, pamaquine, chlorguanide, and pyrimethamine appeared p r i o r t o 1960, but t h e impact of t h i s phenomenon on malaria eradication was considered i n s i g n i f i c a n t .? Recent i n v e s t i g a t i o n s i n d i c a t e t h a t c e r t a i n s t r a i n s of 2. falciparum from South America t h e most widely and Southeast Asia are r e s i s t a n t t o t h e 4aminoquinolines used drugs i n malaria chemotherapy and t h a t some of t h e s e strains a r e a l s o l e s s susceptible t o many, o r i n a f e w instances widely used a n t i m a l a r i a l The possible i m p a c t of these findings on t h e prevention, treatment, and e r a d i c a t i o n of malaria i s obvious and underscores t h e need for new a n t i m a l a r i a l d r u g s . 3, 6-8,27,30
-
-
s,
-
1. Sulfones and Sulfonamides. It has been known for several decades t h a t sulfones and sulfonamides have a n t i m a l a r i a l action, but none has been used extensively i n t h e treatment of human malarias .3,8,21 Recent observations, however, have revived i n t e r e s t i n t h e possible u t i l i t y of t h e s e substances both a s repository (vide supra )21,22 and s u p p r e s ~ i v e ~ ~ -agents. ”5
Certain l i n e s of 2. berghei, p. cynomolgi, and p. allinaceum made r e s i s t a n t t o 4,4’-diaminodiphenylsulfone (diaphenylsulfone, ? DDS7 7 IIa - or t o DIIT or pyrimethamine were s t i l l susceptible t o t h e heterologous drug with only a l o w order of cross-resistance.31 Further, a 1:l mixture of DIEI) and DDS proved
Chap. 14a.
Antiparasitic s
El slager
139 -
highly e f f e c t i v e against t h e parent, DHT-resistant, and DDS-resistant l i n e s of 2. berghei, and t h e r a t e of emergence of r e s i s t a n c e i n t h e parent s t r a i n was s i g n i f i c a n t l y l e s s with t h e mixture than with e i t h e r drug alone.31 In man d a i l y o r a l doses of 25 t o 50 mg. of D B protected 22 of 26 volunteers from i n f e c t i o n by s t r a i n s of r e s i s t a n t 2. falciparum i s o l a t e d i n Southeast Asia.30 Pyrimethamine ( 5 0 mg. d a i l y f o r 3 days) o r sulfadiazine (2.0 g. d a i l y f o r 5 days) given alone did not cure i n f e c t i o n s with t h e m l a y a (Camp.) s t r a i n of
chloroquine-resistant 2. falciparum; these doses of pyrimethamine and s u l f a diazine administered concurrentlgb although not rapidly effe t i v e , cured i n f e c t i o n s i n 5 of 6 volunteers. Sulforthomidine (Fanasi& (IV) given weekl y i n 500 mg. doses alone o r i n combination with 25 mg. of pyrimethamine cleared symptomless asexual parasitemia i n East African schoolchildren i n f e c t e d with pyrimethamine-resistant 2. falciparum. 32 Although t h i s study indicated t h a t sulforthomidine acted t o o slowly f o r use a g a i n s t acute a t t a c k s , 25 semiimmune p a t i e n t s were subsequently t r e a t e d with s i n g l e 1 . 0 g. doses, and a l l but 3 were cured within 3 days.33 Sulforthomidine appears t o have no sporontocidal a c t i o n against 2. falciparum.34 The above findings, together with i n d i c a t i o n s t h a t t h e combined o r a l use of a sulfone or su1fonami.de with pyrimethamine o r chlorguanide may l e a d t o p o t e n t i a t i o n of a n t i m a l a r i a l effects,8,24.t31.t35 pinpoint an area worthy of extensive i n v e s t i g a t i v e e f f o r t s .
Iv
I11
-
2. 4-Aminoquinolines. In therapeutic s t u d i e s a g a i n s t a normal 2. berghei s t r a i n i n mice, I11 had an o r a l CD50 of 1 0 mg./kg. d a i l y x 4.23 A l though chloroquine-resistant s t r a i n s studied t o date have proved uniformly r e s i s t a n t t o other 4 - a m i n o q ~ i n o l i n e s , ~ a chloroquine-resistant s t r a i n of 2. berghei s u r p r i s i n g l y was reported t o be cross-resistant t o III.24
3 . New S t r u c t u r e s . - Several new a c t i v e chemical moieties have been reported. 3-Piperonylsydnone ( V ) was a c t i v e a g a i n s t 2. berahei a t a dose of 1 0 mg./kg." The glyoxal dithiosemicarbazones VIa and b showed high a c t i v i t y a g a i n s t P. pallinaceum i n t h e chick; t h e median e f f e c t i v e doses per 0s were 0.7 rug./&. x 7 and 0.5 mg./kg. x 7, respectively.37 It i s not y e t c l e a r whether these or r e l a t e d compounds will have p r a c t i c a l application.
-
C. Radical Curative Agents. The 8-aminoquinolines are t h e only substances having s u f f i c i e n t a c t i v i t y against secondaq t i s s u e schizonts t o be of p r a c t i c a l value i n achieving r a d i c a l cure of r e l a p s i n g malarias. However, primaquine and c e r t a i n o t h e r 8-aminoquino~inesproduce acute hemolytic anemia
140
Sect. I11
- Chemotherapeutics HC=N-NBCSNHX
a,X=H b, X = C&OCHs
I
HCd-NHCSNBX
V
F l y n n , Ed.
VI
i n persons whose red c e l l s are unusally susceptible t o drug-induced hemolysis. The rapid degradation and elimination of primaquine necessitates d a i l y @&inist r a t i o n , which c o n s t i t u t e s - a f u r t h e r drawback l i m i t i n g i t s use. The discovery that 4- (2-bromo-4,5-dimethoxyphenyl)-1,1,7,7-tetraethyldiethylenetriamine (RC-12) ( V I I ) has a pronounced effect on t h e exo-erythrocytic stages of 2. cathemerium i n canaries3 stimulated an appraisal of the a c t i v i t i e s of RC-12 against 2. cynomolRi i n t h e monkey.38 Although t h e drug per se had l i t t l e promise as a schizonticidal or suppressive drug, it showed s i g n i f i cant promise as a prophylactic or r a d i c a l curative agent and m i g h t f i n d use when: (1)t h e cambination of chloroquine-primaquine i s not e f f e c t i v e i n causal prophylaxis, as appears t o be t h e case where there i s chloroguine resistance; ( 2 ) there i s a need f o r a curative agent which can produce benefits i n l e s s than 14 days; and (3) there a r e fears of enhanced susce t i b i l i t y t o the hematot o x i c i t y of primaquine. Clinical studies are planned. Si:
m
S
VIII
VII
6- [ [4-(Diethylamino)-l-methylbutyl]amino]-5,8-dimethoxyquinaldine (B-505) (VIII)39 a l s o produced r a d i c a l cures of 12. cathemerium infections i n canaries
but the relative t o x i c i t y of t h i s compound precluded c l i n i c a l studies i n man. ?i
-
D. Test Methods. The demonstration of multiple drug resistance i n 2. falciparum (vide supra) spurred research t o develop better experimental models for studying t h i s phenomenon. Strains of 2. bernheihave been induced t o acaquire resistance t o representatives of a l l the major classes of suppressive drugs, and the r e s i s t a n t l i n e s have been employed i n cross-resistance tests t o determine the i n t e r r e l a t i o n s h i p among t h e various chemical types,20,31,40-44 Anopheles ste&ensi has been shown t o be a suitable experimental vector of 2. berghei t o serve as a source of sporozoites and f o r cyclic transmissions and the existence of primary t i s s u e stages of 2. berRhei has been c o n f i r ~ n e d . ~ ~ , ~ ~ The r e l a t i v e ease of infecting the splenectomized gibbon with blood-induced infections of 2.S c i m r u m indicates that t h i s species may be a suitable l a b oratory model f o r studies of fa3.cimm.m malaria. 47
Chap. 14a.
Elslag e r
Antipa r a s itic s
141 -
Leishmania i s responsible f o r millions of smoldering u l c e r s among inhabi t a n t s of endemic regions i n Africa, t h e Americas, and t h e Near and Far East. Antimonials a r e usually e f f e c t i v e i n leishmaniasis, but t h e necessity f o r r e peated (10-30)i n j e c t i o n s and t h e well-known contraindications of t h e s e drugs impose serious r e s t r i c t i o n s on t h e i r widespread use. Inasmuch a s some regression of e a r l y l e s i o n s of dermal leishmaniasis was observed i n malaria p a t i e n t s t r e a t e d with c h l o r g ~ a n i d e ,it ~ ~was of i n t e r e s t t o i n v e s t i g a t e t h e p o t e n t i a l usefulness of t h e repository drug cycloguanil pamoate ( I ) (vide supra). Early r e s u l t s from Costa Rica and Mexico a r e encouraging; a s i n d e intramuscular i n j e c t i o n of cycloguanil pamoake (280-350 mg. base) cured 26 of 30 p a t i e n t s with b r a ~ i l i e n s i s ~and ' 31 of 40 percutaneous and mucocutaneous i n f e c t i o n s of sons with cutaneous leishmaniasis produced by &. nexicana .49
L.
IV. CHAGAS' DISEASE A t l e a s t 7 m i l l i o n persons i n South and Centrql America a r e i n f e c t e d with Trypanosoma cruzi, t h e causative agent of Chagas' disease. In c o n t r a s t t o t h e success attending t h e development of e f f e c t i v e drugs f o r t h e African trypanosomiases, t h e treatment of cruzi i n f e c t i o n s has been generally unsatisfactory. There i s some evidence t h a t n i t r o f u r a n s may be e f f e c t i v e a g a i n s t acute i n f e c t i o n s , but no curative agent has y e t been found.50 The discovery t h a t strong chemotherapeutic i n t e r e s t . 51 The nature modifications of t h e N1-
N1- (3-dimethylaminopropyl )piperazines (IX) e x h i b i t a c t i v i t y against 2. c r u z i i n mice i s of p a r t i c u l a r of t h e R s u b s t i t u e n t i s r e l a t i v e l y non-specific, but (3-dimethylaminopropy1)piperazine moiety d r a s t i c a l l y
X reduce a c t i v i t y . In comparative s t u d i e s with 2. cruzi i n mice, piperamide maleate (X), given o r a l l y i n s i x t e e n 2.5 or 10 m g x doses over 7 days, prolonged t h e median survival t i m e of t r e a t e d mice s i g n i f i c a n t l y longer than mice t r e a t e d with these doses of furaltadone or primaquine.sl However, t h e curat i v e value and t h e s a f e t y of piperamide maleate and r e l a t e d substances52 have y e t t o be established.
v.
IS
The i d e a l antiamebic agent must be capable of e r a d i c a t i n g Ehtamoeba h i s t o l y t i c a from both t h e bowel and from e x t r a - i n t e s t i n a l s i t e s and should b y v i r t u a l l y non-toxic. Agents with sustained, prophylactic antiamebic p r o p e r t i e s a r e a l s o needed. Although many s a t i s f a c t o r y antiamebic agents a r e available, no s i n g l e preparation i s capable of exerting a l l t h e a c t i o n s required. Theref o r e , t h e search f o r new agents continues.=
Sect. I11
142 -
- Chemotherapeutics
F l y n n , Ed.
-
A. 2-Amino-5-nitrothiazoles. Over a decade ago it was reported t h a t 2-acetamido-5-nitrothiazole (aminitrozole ) ( X I ) possessed curative a c t i o n
against i n t e s t i n a l amebiasis i n r a t s and dogs and k i l l e d a d u l t Schistosoma mansoni i n mice a t well-tolerated 0 s e s . ~ 4 More r e c e n t l y a new 2-amino-5n i t r o t h i a z o l e d e r i v a t i v e ( f m b i l h a h , 32, 644-Ba ) ( X I I ) having strong therapeut i c e f f e c t s against amebiasis and schistosomiasis (vide i n f r a ) was discovered.55 !The minimum i n h i b i t o r y concentration of 32,644-& against g. h i s t o l y t i -
XI
XI1
ca i n v i t r o w a s 10 pg./ml.
G emetine
This i s approximately t h e same potency exhibited
or 4,7-phenanthroline-5,6-quinone under comparable conditions. 56
!Phe compound strongly suppresses amebic l i v e r abscess i n hamsters following d a i l y o r a l doses of 60-120 mg./kg. f o r 7 days (chloroquine was e f f e c t i v e a t 100-200 mg./kg. ). I n t e s t i n a l amebic i n f e c t i o n s i n rats and guinea-pigs were markedly reduced following d a i l y o r a l doses of 30-60 mg./kg. f o r 4 and 5 days, respectively .56 Results of preliminary human t r i a l s i n d i c a t e t h a t 32,644-&, administered i n d a i l y doses of 20-25 mg./kg. f o r 5 t o 10 days, i s e f f e c t i v e against both amebic dysentery and amebic l i v e r abscess, although s i d e e f f e c t s including frequent ECG changes and occasional neuropsychic episodes were noted.57 More extensive t r i a l s w i l l be required t o a s s e s s t h e r e l a t i v e s a f e t y and e f f i c a c y of t h e drug compared with o t h e r forms of treatment. Rel a t e d heterocyclic compounds a r e a l s o reported t o have antiamebic and a n t i schistosomal p r o p e r t i e s .58
-
B. 7-Quinolinols. Another new amebicide of p o t e n t i a l i n t e r e s t i s 5chloro-7- 3-diethylaminopropylaminomethyl ) -8-quinolinol (clamoxyquin PAA-3854 CI-433) ( X I I I ) s9 The r e l a t i v e amebicidal concentrations of clamoxyquin hydrochloride and emetine hydrochloride a r e 20-40 pg./ml. and 2.5 pg./ml. respect i v e l y . 6o The e f f e c t s of clamoxyquin hydrochloride and chloroquine against amebic h e p a t i t i s i n hamsters were roughly comparablej clamoxyquin hydrochloride,
.
,
,
OH
c1 XI11
XIV
pamoate, and s a l i c y l a t e w e r e a c t i v e against i n t e s t i n a l amebiasis i n r a t s i n gavage doses ranging from 75 t o 600 mg./kg. d a i l y f o r 4 days." Clamoxyquin hydrochloride and pamoate cured amebic dysentery in do s i n d a i l y doses of 3.13 t o 50 mg./kg. and 12.5 t o 25 mg./kg. respectively.6' Relative t o t h e 8-quinol i n o l s i n c l i n i c a l use t h e clamoxyquin s a l t s were deemed worthy of c l i n i c a l
Chap. 14a.
Antipar as itic s
Elslager
143 -
t r i a l . Clamoxyquin hydrochloride was t o l e r a t e d w e l l i n man following d a i l y 1 5 mg./kg. doses f o r 5-10 days and was highly e f f e c t i v e against various forms of Additional s t u d i e s w i l l be required before the r e l a i n t e s t i n a l amebiasis."' t i v e importance of the clamoxyquin salts i n amebiasis chemotherapy can be assessed
.
C. Anisomycin. - The determination of t h e s t r u c t u r e and stereochemistry of the potent antiprotozoal a n t i b i o t i c anisamycin (XIV)62 may serve t o stbiul a t e f u t u r e research on t h e synthesis and biological properties of r e l a t e d substances.
VI,
SCHISTOSOMIASIS
Nearly 200 m i l l i o n people a r e infected with schistosomiasis, and on a world b a s i s these i n f e c t i o n s a r e ~ p r e a d i n g . ~The degree of prevalence, t h e seriousness of t h e infection, and t h e paucity of adequate drugs make schistosomiasis one of t h e g r e a t e s t challenges i n p a r a s i t e chemotherapy today. Seve r a l promising new agents have been discovered, but t h e i r usefulness i n man has yet t o be adequately evaluated. Therefore, one s t i l l must r e l y on the a n t i monials with some assistance from lucanthone hydrochloride (ma) against Schistosoma haematobium and c e r t a i n s t r a i n s of S. mansoni. Research on schistosomiasis6Y'64 and other trematode infections63 has r e c e n t l y been reviewed.
-
A. 2-Amino-5-nitrothiazoles. To date 1-(5-nitro-2-thiazolyl)-2-imidazolidinone ( A m b i l h d 32 644-E!a) ( X I I ) has been evaluated more extensively i n ~ c h i ~ t o s a m i a s i than s ~ ~ i n ~amebiasis ~ ~ ~ ~(vide ~ ~ supra). " ~ ~ ~ When ~ adult S . mansoni were exposed t o 32,644-Ba i n v i t r o for prolonged periods (100 hr.), oviposition was i n h i b i t e d a t concentrations of 1 pg./ml. and worms were k i l l e d a t 100 p g . / m l . 5 5 ~ 6 5 The destruction of the v i t e l l o g e n i c gland i n the female coincides with a reduction i n body-length i n both male and female worms and i n t h e s i z e of t h e ovary i n t h e female.57 The drug.was highly a c t i v e against S . manSOn155,65 and 2. j a ~ o n i c u mi ~ n ~mice i n o r a l doses of 100 mg./kg. d a i l y f o r 10 days and had a strong prophylactic and chemotherapeutic e f f e c t on experimental 2. mansoni infections i n monkeys .57 Temporary, r e v e r s i b l e impairment of sljermatogenesis occurred i n mice- the drug apparently a c t s d i r e c t l y on t h e germinal epithelium of t h e t e s t e s . 66 Results of preliminary c l i n i c a l t r i a l s i n man i n d i c a t e t h a t 72 644-h has considerable e f f i c a c y against 2. h a e m a t ~ b i u m ~ ~and , " ~2. mansoni5 j Q 8 i n o r a l doses of 20-40 mg./kg. d a i l y f o r 5-15 days; S . japonicum i n f e c t i o n s appear t o be more refractory.57 Three types of side e f f e c t s were encountered which merit s p e c i a l a t t e n t i o n : (1)frequent ECG changes, involving mainly t h e T waves; ( 2 ) neuropsychic e f f e c t s , ranging from severe headaches t o convulsive a t t a c k s with infrequent hallucinations; (3) t r a n s i t o r y impairment of spermatogenesis .57 The ultimate place of 32,&4-& i n schistosomiasis chemotherapy w i l l depend l a r g e l y on t h e incidence and s e v e r i t y of these side e f f e c t s a t e f f e c t i v e dose l e v e l s when compared with t h e side e f f e c t s encountered i n t h e c l a s s i c a l treatments. The drug has a l s o been reported t o be e f f e c t i v e i n t h e treatment of Dracunculus medinensis (guinea worm) i n f e s t a t i o n i n humans .69
144
Sect. III
-
Chemotherapeutics
F l y n n , Ed.
-
B. Thiaxanthenones. Incubation of lucanthone (XVa) with sclerotiorum produces t h e a c i d - l a b i l e hydroxymethyl d e r i v a t i v e Surprisingly, t h e (Xvb) together with smaller amounts of t h e aldehyde five-day ED50 f o r lucanthone and hycanthone a g a i n s t S . mansoni i n hamsters were 8.0 mg./kg. and 0.78 mg./kg., respectively.70 The unusual potency of hycanthone l e d t o t h e hypothesis t h a t it might indeed be t h e e l u s i v e a c t i v e metabol i t e of lucanthone. The a c i d s e n s i t i v i t y of Xvb could explain why it had
escaped detection by previous i n v e s t i g a t o r s . Accordingly, monkeys were medicated with lucanthone, t h e w i n e s were c a r e f u l l y e x t r a c t e d avoiding a c i d treatment, and t h e e x t r a c t s were examined by thin-layer chromatography. In agreement with e a r l i e r work,71 t h e sulfoxide (XVd) was t h e major metabolite, and only t r a c e s of XVb w e r e detected. When t h e urine e x t r a c t s were incubated with glucuronidase p r i o r t o chromatography, however, hycanthone appeared as a major component.7o Idthough t h e sulfone XVe i s reported t o be t h e major urinary metabolite i n hycanthone was a l s o found i n mouse urine a f t e r glucuronidase incubation but t o a much l e s s e r extent t h a n i n t h e monkey.7o The results of t h e s e elegant s t u d i e s support t h e hypothesis t h a t hycanthone i s an important a c t i v e metabolite of lucanthone; it now becomes apparent why a 2-toluidine function i s an absolute requirement f o r a c t i v i t y among all lucanthone r e l a t i v e s . Other s t u d i e s u t i l i z i n g s u b t i l i s suggest t h a t t h e major i n vivo a c t i o n of lucanthone i s t o complex with DNA, thereby blocki n g DNA-dependent RNA synthesis .73 Various o t h e r schistosomicides r e l a t e d t o hycanthone and t h e aldehyde XVc have been prepared.74 It has a l s o been disclosed t h a t lucanthone N-oxide (XVI) i s considerably l e s s t o x i c than lucanthone .75
-
Tris (paminophenyl )carbonium Salts. Tris (paminopheny1)carbonium C. (TAC) pamoate (XVII)76 and c e r t a i n antimonials have broad antischistosome a c t i v i t y i n experimental animalsT7 and i n man.78 However, both groups have important l i m i t a t i o n s . Thus t h e slow-acting TAC pamoate must be administered for s e v e r a l weeks t o achieve a strong degree of e f f e c t while t h e f a s t - a c t i n g antimonials have a r e l a t i v e l y narrow therapeutic index.
In a recent study of t h e j o i n t a c t i o n of TAC s a l t s and t a r t a r emetic a marked degree of synergism was observed against S. mansoni i n v i t r o and i n mice, Moreover, n e i t h e r drug had p a r t i c u l a r l y a f t e r pretreatment with TAC pamoate?” an appreciable a f f e c t on t h e gross t o x i c i t y of t h e other f o r normal mice. An encouraging degree of j o i n t antischistosomal a c t i o n by TAC pamoate and t a r t a r
Chap. 14a.
Antiparasitics
-OOC
.OH
145
Elslager
H(
XVIII
XVII
emetic was also observed in monkeys. The therapeutic advantage of such a combination hinges largely upon whether o r not the co-administration of TAC pamoate produces higher o r more sustained antimony levels in the blood or tissues. A subsequent study utilizing 124Sb-labeled tartar emetic demonstrated that co-administration or pretreatment with TAC pamoate had no significant effect on the disposition of antimony in mice o r monkeys." Available evidence suggests that the mode of action of TAC pamoate and the trivalent antimonials is dissimilar. Briefly, the antimonials interfere with schistosome glycolysis by inhibiting phosphofructokinase, which catalyzes the reaction: fiuctose-6-phosphate
f
ATP
F'ructose-1,6-diphosphate
+ ADP
Recent studies with 14C-labeled glucose indicate that tartar emetic blocks both the Ehbden-Meyerhof and the hexose-monophosphate pathways of glycolysis Organic antimonials have also been reported to inhibit schistosome glutamicpyruvic transaminase
.
.
The TAC salts apparently act by an entirely different mechanism.e2 In mice subcurative doses of TAC chloride have no demonstrable effect on the carbohydrate and protein metabolism of the worms but produce a localized paralysis of the acetabulum, pharynx, and oral sucker which histochemically has been correlated with a pronounced decrease of cholinesterase activity in the central ganglia. This paralysis is completely reversed in vitro by the cholinergic blocking agent mecamylamine, suggesting an accumulation of acetylcholine in these structures. Simultaneously, glycogen depletion is observed in the papillae located below the cuticle of the worm. Either one or a combination of these changes could account for the antischistosomal effects observed.82
-
D. Cucurbitine. For several years reports emanating from mainland China have claimed that the dried, ripe seeds of the pmpkin varieties Cucurbita pep0 L. and C. moschata Duch. are effective in the treatment of schistosomiasis. The amino acid cucurbitine (XVIII) has recently been isolated from C. moschata Duch." Cucurbitine reportedly inhibits the growth of immature 2. japonicum, produces degenerative changes in the genital organs of the worms resulting in depressed egg-producing capacity, and is virtually nontoxic.s3 It would appear worthwhile to confirm the structure of cucurbitine and study its effects on 2. haematobium and 2. mansoni. VII.
CLONORCHIASIS
Clonorchiasis is caused by the human liver fluke Clonorchis sinensis (syn.
Sect. 111 - Chemotherapeutics
146 -
F l y n n , Ed.
Opisthorchis s i n e n s i s ) and i s widely d i s t r i b u t e d i n t h e Far East, especially i n Indochina, Central and South China, Formosa, Korea, and Japan. Approximatel y 19 million people are a f f l i c t e d with t h i s disease, y e t no r e l i a b l e treatment i s known. Therefore, preliminary r e p o r t s t h a t t h e f a s c i o l i c i d e a,a,a,a',@,a'hexachloro-2-xylene (XIX) i s highly e f f e c t i v e against C. s i n e n s i s i n experimen-
t a l animalss4"' and i n a t well-tolerated doses a r e most encouraging. Expanded human t r i a l s a r e indicated.
The world-wide incidence of i n t e s t i n a l helminthic i n f e c t i o n s i n man approaches t h e staggering f i g u r e of two b i l l i o n . * The prevalence of these i n f e c t i o n s and t h e i r complex and far-reaching e f f e c t s upon body function cause them t o rank among t h e most important disease problems of man. F i r s t reports" on tetramisole ( X X ) , a potent new anthelmintic with broad a c t i o n against nematodes, a r e highly encouraging. The drug i s reported t o be e f f e c t i v e against Ascaris lumbricoides and Enterobius vermicularis i n man" and against a v a r i e t y of adult and immature g a s t r o i n t e s t i n a l and pulmonary nematodes i n laboratory animals, poultry, and livestock. ,l' s2 Although devoid
xx
XXI
XXII
of antihistaminic, anticholinergic, adrenolytic o r other c l a s s i c a l pharmacol o g i c a l properties, tetramisole e x e r t s a rapid paralysing a c t i o n on a variety of nematodes i n v i t r o a t low concentrations.
''
The evolution of tetramisole points once again t o t h e importance of strong biochemical support i n drug development. Thus, t h e observation t h a t t h i a z o t h i en01 (XXI)'~ was a c t i v e against nematodes during a routine screening program i n chickens stimulated a search for a c t i v e metabolites of XXI and l e d t o t h e isol a t i o n and i d e n t i f i c a t i o n of XXII a s t h e major transformation product i n t h e feces. The c y c l i c metabolite XXII was a c t i v e a t s i g n i f i c a n t l y lower dose l e v e l s t h a t t h e parent compound (XXIX and these results prompted the s n t h e s i s ?' . and b i o l o g i c a l evaluation of an extensive s e r i e s of r e l a t e d compounds Tetramisole emerged a s t h e most promising substance f o r expanded s t u d i e s .
Antipa rasitics
Chap. 14a.
147 -
Els lage r
IX. BIBLIOGRAPHY
&I.
m., a.s.
(1) E. H. Hinman, 2. Tro Med. 2, 125 (1966). (2) Chronicle, 3 3 d a (3) L. J. Bruce-Chwatt, Trans. Trop. g . 2, 105 (1965). (4) E. F. Elslager and P. E. Thompson, Pharmacol.,& 193 (1962). ( 5 ) P. E. Thompson, B. J. Olszewski, E. F. Elslager, and D. F. Worth, &.' J& 481 (1963 -J. Tro Med. (eRexution, JJ, 361 (1964).
.
&. &.
m.,
m.,
w.,
1965,
S. Goodman and A. Gilman, Ed., t h e Mamillan Co., New York, N.Y.,
1087-1117.
ed., L. pp.
(10)E. F. Elslager and P. E. Thompson, Abstracts, 9th National Eledicinal Chemistry Symposium of t h e American Chemical Society, Minneapolis, Minn., June 1964, p. 6A. (11)E. F. Elslager and D. F. Worth, U. S. Patents 3,223,705 (1965) and 3,248 422 (1966). (12) E. F. Elslager and D. F. Worth, U. S. Patents 3,161,641 (1964); 3,236,849 (1966); 3,244,716 (1966)j and 3,248,422 (1966). (13) G. R. Coatney, P. G. Contacos, and J. S. Lunn, J. Trop. &d. &g.,
&I.
-
13 383 (1964)")(14) R. D. Powell, R. L. DeGowin, and R. B. Eppes, M.,&, 913 (1965). (15) P. G. Contacos, G. R. Coatney, J. S. Lunn, and J. W. Kilpatrick,
L;zI 386
u.,
(u@+)*
(16) 1. A. McGregor, K. Williams, G. H.'Walker, and A. K. Rahman, Brit. E .
2 . , 3 695 (1966).
- m.,
(17 P. E. Thompson, B. Olszewski, and J. A. Waitz, &. 2. m.Med. 343 (1%5)* (18)W. Chin, J. S. Lunn, J. Buxbaum, and P. G. Contacos, w., &I 922
&
(1965)
(20) A.
(19) P. G.
(1965
Contacos, G. R. Coatney, J. S. Lunn, and W. Chin,
a
w.,
925
Bishop, ParasitolopV, 53, 10 (1963); 407 (1965). (21) E. F. Elslager and D. F. S r t h , Nature, 206 630 (1965). (22) P. E. Thompson, B. Olszewski, and J. A. &z, &. 2.
r14 U1
343 (1965)-
&. Med. a.,
(23) J. Schneider, M. Bouvry, and J. Le Quellec, Abstracts, I n t e r n a t i o n a l Colloquium on , P a berghei, I n s t i t u t e of Tropical Medicine "Prince Leopold," Antwerp, Belgium, December 1964. (24) J. Hill i n "mperimental Chemotherapy," V o l N, R. J. Schnitzer and F. Hawking, Ed., Academic Press, New York, N.Y., 1966, p. 448. (25) Rhone-Poulenc S. A., B r i t i s h Patent 973,903 (1964); Eire Patents 461/62, 1097/62, 591/63, and 620/63 (1963). (26) K. G. Powers, J. Parasitol., 2, 53 (1965). (27) C. G. H u f f , 'Itrop. m e , & 339 (1965). (28) R. L. De Gowin and R. D. Powell, 519 (1965). (29) R. L. De Gowin and R. D. Powell, J. &&.B. 851 (30) 3. % (131, 38 ( i s ) . (31) P. E. Thompson, A. Bayles, B. Olszewski, and J. A. Waitz 198 (1965).
&.-z.
m.
m,
- a*,*,
@.
w.,
s., a,
, Am-
148
Sect. IU
- Chemotherapeutics
'Flynn, Ed.
(35) P. C. Basu, N. N. Singh, and N. Singh, B u l l . World Health Qrgan., & 699 -_ ( .1-964.). (36) W. H. Nyberg and C. C. Cheng, 2. B., 531 (1965). (37) P. A. Barrett, E. Beveridge, P. L. Bradley, C. G. D. Brown, S. R. M. Bushby, M. L. Clarke, R. A. Neal, R. Smith, and J. K. H. Wilde, Nature, 1340 (1965). (38) L. H. Schmidt, R. N. Rossan, R. Fradkin, J. Woods, W. Schulemann, and L. Kratz, presented a t t h e 14th Annual Meeting of t h e American Society of Tropical Medicine and Hygiene, New Orleans, L a . , Nov 1965. (39) F. Schonhofer and W. Schulemann, B r i t i s h Patent 970,949 (1964). (40) R. L. Jacobs, 2. Parasitol., 481 (1965). (41) W. Peters, 9. Parasitol., 80, 90, 97 (1%5)(42) W. Peters, Nature, (43) P. E. Thompson, B. %ze:ski, A. Bayles, and J. A. Waitz, 2. P a r a s i t o l . , /s 51 (21, 54 (1965). (44) P. E. Thompson, A. Bayles, B. Olszewski, and J. A. Waitz, Science, 1240 (1965). (45) M. Yoeli and H. Most, &. 2. Trop. €&., 700 (1965). (46) M. Yoeli, J. Vanderberg, R. Nawrot, and H. Most, & 927 (1965). (47) R. A. Ward, J. H. Morris, D. J. Gould, A. T. C. B u r k e , and F. C. Cadigan, Jr., Science, 1604 (1965 ) (48) A. Pel& Chavarria, E. Kotcher, and C. Lizano, 2. Assoc., 1142 (1965). (49) F. Beltrh, F. Biagi, and S. Gonza'lez, presented a t t h e 14th Annual hketing of t h e American Society of Tropical Medicine and Hygiene, New Orleans, La., NOV 1965. H&., 211 (1964). (50) F. Hawking, 2. Trop. (51) A. S. Tomcufcik, R. I. Hewitt, P. F. Fabio, A. M. Hoffman, and J. Entwistle, Nature, 2ez, 605 (1965). , (52) American Cyanamid Co., South African Patent 3833/63 (1964) and Belgian Fatent 654,017 (1965). (53) G. Woolfe i n "Drug Research," Vol VIII, E. Jucker, Ed., Birkhauser AG, Basel, Switzerland, 1965, pp. 13-52. (54) A. C. Cuckler, A. B. Kupferberg, and N. Millman, Antibiot. Chemother540 (1955). C. R. Lambert, M. Wilhelm, H. S t r i e b e l , F. Kradolfer, and P. Schmidt, Ek e r i e n t i a , 452 (1964). %adolfer and R. Jarumilinta, Trop. E.Parasitol., 210
@.
&
a
.
e.
s. & u., &. w.
a
2
&.
(19651* (57) "Th6rapeutique Nouvelle de l a Bilharzioae e t de 1'Amibiase, Symposium de Lisbonne, June, 1965, Acta WOE., SuppL. 9, 1-314 (1966). ( 5 8 ) Ciba Ltd., South African Patents 3781/64 (1965) and 4336/65 (1966); Neth. Patents 6,505,225 and 6,505,226 (1965). (59) J. H. Burckhalter, W. S. Brinigar, and P. E. Thompson, 2. & 4070 (1961). I'
a. e., Meisenhelder, J. e-
(60) P. E. Thompson, A. Bayles, P. McClay, and J. E. sitol., 817 (1965). (61)R. Hugonot, E. Granotier, and J. P. Farges, Therapie, & 329 (1965). (62) J. J. Beereboom, K. Butler, F. C. Pennington, and I. A. Solomons, 2. B., 2334 (1965).
a-
Chap. 14a.
Antiparas iti cs
Elslager
149 -
s., &,
(63) G. Uinrmler, 2. Tropenmed. Parasitol., 95, 164, 337 (1964). (64) World Health Organ. Tech. Rep. 317. (65) C. R. Lambert, Trop. Parasitol., 292 (1964). (66) C. R. Lambert, V. S. P. S i n a r i , and J. Tripod," Acta T r o ~ . , & , 155 (1965). (67) C. R. Lambert and F. S. I& C r u z F e r r e i r a , B u l l . World Health Organ.,& 73 (1965)(68) P. Jordan, Brit. w .z., A 276 (1966). (69) G. Raffier, Acta T r o ~ . ,.& 350 (1965).
a., s.
(70) D. Rosi, G. Peruzzotti, E. W. Dennis, D. A. Berberian, H. Freele, and
S. Archer, Nature,%
(71) R. Strufe,
1006 (1965).
w. Chem.
%.--.
Abhandl. Forschungsstaetten Farbenfabriken Bayer, & 337 (1963). (72).Gijnnert, B u l l . World Health O r g a n . , a 702 (1961). (73) I. B. Weinstein, R. Chernoff, I. Finkelstein, and E. Hirschberg, Pharmacol. 1 297 (1965). m e r h 'n4g Drug Inc., South African Patent 4081/64 (1965). (75) Farbenfab. Bayer A. G., Belgian Patent 663,790 (1965). (76) F. W. Short and E. F. Elslager, U. S. Patent 3,218,339 (1965). (77) E. F. Elslager, F. W. Short, D. F. Worth, J. E. Meisenhelder, H. Najarian, and P. E. Thompson, Nature, 628 (1961). (78) J. R. da Silva, A. Prata, C. A. Argento, H. American0 do B r a s i l , and L. F. Ferreira, Hospital (Rio de Janeiro), & 25 (1964). (79) P. E. Thompson, J. E. Meisenhelder, A. K. Moore, and J. A. Waitz, B u l l . World Health Organ., 2 517 (1965). (80) J. A. Waitz, R. E. Ober, J. E. Meisenhelder, and P. E. Thompson,
s.
z,
w.,
81) J. A. Waitz, Life Sci., 3 377 (1964). (82) E. L. S c h i l l e r and E. Buding, 2. P a r a s i t o l . Supplement, 51, 43 (1965). (83) J. H. Zhou, F. Y. Fu, and H. P. Lei i n "Proceedings of t h n e c o n d International Pharmacological Meeting, Prague, 20-23 August, 1963," Vol V I I , K. K. Chen, B. Mukerji, and L. Volicer, Ed., t h e Macmillan Co., New York, N. Y., 1965, p. 25. N. N. Plotnikov and L. I. Sinovich, Meed. Parazitol. & Parazitarn. Bole301 (1964); Diseases g., l m ) . 9 6 5 % . Yokogawa, H. Koyama, H. Yoshimura, and C. S. Tsai, J. Chiba Med. SOC., & 286 (1965). ( 8 6 ) H. L. Chung, Chinese Med. J., & 232 (1965). (87) J. Liu, (19657. ( 8 8 ) N. N. Plotnikov, No N. Ozeretskovskaya, V. K. Karnaukhov, N. S. Zalnova, G. M. Faibusovich, G. I. Kukhta, and M. I. Alekseeva, Med. Parazitol. i Egmzitarn. Bolezni, 676 (1964); IIl.op. Diseases B u l l . , & 32771965). Tv. N. mozdov, Diseases & 59 (1966). (90) M. Yokogawa, M. Tsuji, K. Araki, T. Nomoto, M. mtsumoto, M. Koyama, R. Yoshiba, S. Fukuchi, A. Hiratsuka, and M. Kitamura, Japan. 3. P a r a s i t o l . , & 526 (1965)(91) D. Thienpont, 0. F. J. Vanparijs, A. H. M. Raeymaekers, J. Vandenberk, P. A. Demoen, F. T. N. Allewijn, R. P. H. Marsboom, C. J. E. Niemegeers, K. H. L. Schellekens, and P. A. J. Janssen, Nature, 3 & 1084 (1966). (9) J. K. Walley, Vet. Record, J&, 4 0 6 m ) . (93) Janssen &arm., N. V., Belgian Patent 653,087 (1965). (94)Janssen Pharm., N. V., Neth. Patent 6,505,806 (1965).
(a)
-
m.
=.-
a
J.
us,
m.
u.,
150 -
Sect. 111
Chapter Ikb.
-
F l y n n , Ed.
Chemotherapeutics
Animal Antiparasitic Agents
Dale R. Hoff, Merck Sharp & Dohme Research Laboratories Rahway, New Jersey
I. Introduction Developments during 1965 in the field of animal health included reports of two new anthelmintics, tetramisole and bunamidine, which are representative of neu chemical classes. Other reports described modifications of the older antiparasitic leads as well as new therapeutic applications of established agents. A number of investigations into the biochemistry of metazoan and protozoan parasites appeared, and the results of such studies may be hoped ultimately to point out new approaches in the search for new antiparasitic agents. Lack of space rohibits discussion of these papers in this survey, but pertinent references are included for the use of interested readers.
E
Two books which became available during 1965 are important additions to the literature of antiparasitic chemotherapy. Gibson' s review2 of veterinary anthelmintics covers the literature throunh 1962 and into 1963: and Schktzer and Hawking's vol. IV3, conta&s an appendix which - volumes dealim with t-k&nosoPliasis, enterohepatitis, coccidiosis, babesiasis, theilekasis, anaplasmosis, filariasis, and myiasis.
11. Anthelmintics
A.
Anthelmintics for R.eatment of Roundworm Infections.
Tetramisole. Preliminary reports of an entirely new class of anthelmintics, hydrogenated derivatives of imidazop, l-k7thiazolesY appeared from the Janssen Laboratories4r4a. Discovery of the Mdazo~,l-b7thiazoles followed from the observation that 2-acetylimino-3-/?-hydro~-2-~2-thienyl)-ethyg-thiazoline (thiazothienol, I), under investization as an anthelmintic in poultry, was met bolized to the more potent 6-(2-thienyl)-~,6-dihydroimidazo_/2,l-b~thiazole (11)t. Further development of t h e lead led to 6-phenyl-2,3,~,6-~etrahydroimidazo fiYl-k7thiazole hydrochloride (111), for which the generic name tetramisole was proposed.
-
I
I1
I11
Tetramisole
Antiparasitics
Chap. 14b.
Hoff
151 -
Tetramisole was found by t h e Janssen groupb t o be a water-soluble (21% a t 2OoC. ), broad-spectrum anthelmintic which can be administered o r a l l y , o r by subcutaneous, intramuscular, o r i n t r a p e r i t o n e a l i n j e c t i o n . Doses of 40 mg/kg, o r a l l y o r by i n j e c t i o n , e f f i c i e n t l y removed immature and mature forms of- all t h r e e of t h e common chicken nematodes, Ascaridia g a l l i , H e t e r a k i s gallinarum, and obsignata. Tpxicity t o chickens was s a i d t o be low, doses up being t o l e r a t e d . Doses of 5-20 mg/kg. . o r a l l y o r by i n j e c t i o n , were reported e f f e c t i v e i n t h e removal of a wide’range of mature and immature g a s t r o i n t e s t i n a l nematodes i n sheep, as w e l l as t h e lungworm, D i c t ocaulus v i v i arus. Dose levels up t o 40 mg/kg, o r a l l y , o r 10 mg/kg., parent& by sheep, S i m i l a r r e s u l t s were r e p o r t e d with c a t t l e . The drug was a c t i v e a t 20 mg/kg, o r a l l y , a g a i n s t Toxascaris, Toxocara, and Uncinaria i n dogs, but was poorly a c t i v e a g a i n s t Trichuris. I n allauthors catalogued a c t i v i t y with t e t r a m i s o l e a g a i n s t a t l e a s t 56 s p e c i e s of nematodes i n t h i r t e e n hosts, i n c l u d i n g man. No a c t i v i t y a g a i n s t f l u k e s ( F a s c i o l a h e p a t i c a ) o r tapeworms (Moniezia ) was observed.
&
z.
Tetramisole was found t o have a r a p i d paralyzing a c t i o n in v i t r o a g a i n s t a v a r i e t y of nematodes. Walleys confirmed some of t h e observations described above concerning t h e e f f i c a c y of tetramisole. I n t e s t s with 1,076 sheep and 18 goats, tetramis o l e a t 15 mg/kg gave good r e s u l t s a g a i n s t all mature and immature nematodes, with t h e exception of Trichuris. Adult worms were removed by a 5 mg/kg dose. S l i g h t s i d e - e f f e c t s , c o n s i s t i n g of h y p e r i r r i t a b i l i t y and loss of a p p e t i t e , were observed with t h e 15-20 mg/kg o r a l doses. These e f f e c t s were more pronounced a t doses above 50 mg/kg, and one sheep died a f t e r a 80 mg/kg dose. Clonic convulsions were induced by t h e h i g h e s t l e v e l s . These r e p o r t s are p r e l i m i n a r y and l i m i t e d , hence f i n a l assessment of t h e e f f i c a c y and s a f e t y of t e t r a m i s o l e must await r e p o r t s o f wider i n v e s t i gations. Thiabendazole. A d e t a i l e d r e p o r t concerning t h e toxicology and pharmacology of thiabendazole (IV) w a s contained i n a paper by Robinson, Stoerk, and Graessle6. The o r a l a c u t e LD 0 of thiabendazole i n mice, rats, and r a b b i t s w a s 3600, 3100, and g r e a t e r t.2 an 3800 mg/kg, respectively. In sub-acute t o x i c i t y t e s t s , mice and rats grew normally when f e d thiabendazole i n t h e d i e t f o r 30 days. A t l e v e l s of 0.2%, 0.4$, o r 0.6% i n t h e r a t i o n , o r with s i n g l e o r a l doses of 100 o r LOO mg/kg f o r 30 days, all mice and r a t s survived; and, except f o r reductions i n food consumption and weight gain, no outward signs of t o x i c i t y were seen. The e f f e c t i v e oral dose of thiabendazole a g a i n s t nematode i n f e c t i o n s i n man and animals h a s been found t o be i n t h e range of 25-50 mg/kg.6,7 Thiabendazole was r e p o r t e d t o be e f f e c t i v e i n t h e e r a d i c a t i o n of Hyostrongylus rubidus i n pigs, using a single oral dose of 100 mg/kg.8
152
Sect. 111 - Chemotherapeutics
F l y n n , Ed.
Thiabendazole was active against the l a r v a l stages of Capillaria obsignata infectiohs i n chickens a t 1000 mg/kg, but was not e f f e c t i v e against mature parasites a t this high dose.9 Trials were conducted w i t h thiabendazole i n the treatment of nematode infections in horses.lO,ll A t h mg/kg and 88 mg/kg, orally, the drug was effective against immature and mature small strongyles and against Probstmayria vivipara and O x y u r i s equi. Campbell and Timinskil2 observed development o f itnmunity t o Ascaris i n r a t s cured of t h i s i n f e c t i o n by treatment w i t h thiabendazole.
H
IV Thiabendazole
Other Benzimidazoles. Deaths of sheep following the use of 2phenylbenzimidazole a t 250 mg/kg under conditions o f reduced water intake was investigated by Jones, Leaver, and Milne.l3 Toxicity was a t t r i b u t e d t o kidney damage caused by deposition of a c r y s t a l l i n e metabolite, most l i k e l y 5-0-glucuronyloxy-2-phenylbenzimidazole. The pH of t h e urine and r a t e of urine output were thought t o be c r i t i c a l f a c t o r s affecting deposition of t h e metabolite. A pH of 8.4 o r higher was considered important t o protect animals against the deposition phenomenon when water intake was low. Use of 2-phenylbenzimidazole formulations containing alkalizing i n redients, such as potassium c i t r a t e a , sodium carbonatea, or magnesium s a l t s 5 was proposed by t h e manufacturer (Imperial Chemical Industries) t o minimize the r i s k of t o x i c i t y with t h i s anthelmintic.
B
Preliminary reports of other new anthelmintic benzimidazoles have appeared, although d e t a i l s of biological t e s t i n g are not y e t availablel6-19. Quaternary Ammonium Anthelmintics. A group of related quaternized heterocyclic compounds have been under investigation f o r the treatment of Ascaris infections i n pigs and hookworms in dogs.
I n e a r l i e r reports20, 21, it was f aund that l-methyl-2-(pdimethylaminostyry1)-quinolinium methosulfate (V) protected pigs from l i v e r damage
caused by experimental infections with migrating ascarids. A t a l e v e l of O.Ol@ i n the d i e t , the drug lessened t h e severity of the infection. A l e v e l of 0.056% completely prevented l i v e r lesions when administration of t h e drug w a s s t a r t e d p r i o r t o establishment of the infection. This l e a d has now been extended t o the styrylp idinium analog22 ( V I ) , and t o c e r t a i n phenylbenzothiazolium salts ( V I I ) . 3 Diet l e v e l s of approximately 0.02%, o r lower, of V I o r V I I prevented l i v e r damage i n Ascaris-infected pigs, when medication was i n i t i a t e d two days before inoculation w i t h Ascaris larvae.
F
Chap. 14b.
Antiparasitics
Hoff
153 -
In a p a r a l l e l development, 2-(~-chlorostyryl)-pyridiniurn salts ( V I I I ) were reported t o be highly effective against mature and immature hookworms (Anc lostoma caninurn) in do s a t 5 mg/kg, and could be given i n t h e ration,* -ule24,25. The benzdithiylium salts IX and X, described by Wizinger and Soder26, and f o r which broad anthelmintic a c t i v i t y was claimed, would seem t o conform t o t h i s same general lead. Insufficient data have been published t o a l l o w f i n a l conclusions about the safety and u t i l i t y of these compounds.
VI
V
VII, R
=H
X@
Ix
o r CH3
X O X
Sect. I11
154 -
-
Chemotherapeutics
F l y n n , Ed.
Organophosphate h t h e l m i n t i c s . S veral additional studies of the use of t h e -organophosphates phthalophos27,28 (0,O-diethyl-0-naphthaloximide phosphate, X I ) and haloxon29,30 /6,0-di-( 2-chloroethyl)-0-( 3-chloro-4-methyl -7-coumarinyl)phosphate, XI27 appeared during the year. PhthaloDhos w a s found by Hebden and H a l l 2 7 t o be completely effective against Haemonchus contortus, Osterta l a Trichostro lus E i , and T. colubriformis i n sheep a t g d ( n a t u r a 1 - t this l e v e l , Fhthalophos had variable (38-94$ removal) efficacy against Nematodirus species, and poor a c t i v i t y against the l a r g e bowel worms Oesophagostomum columbianum and 0. venulosum. I n p a r a l l e l t e s t s , thiabendazole was completely effective in the removal of Oesophagostomum species a t 50 mg/kg.
a.,
Studies i n c a t t l e 2 8 showed phthalophos t o be highly effective against Haemonchus, Ostertagia, Trichostrongylus, and Cooperia species a t 5'0 mg/kg and 75 mg/kg, and t o reduce the l e v e l s of Bunostomum infections a t these doses. Hebden and H a l l 2 7 found no toxic e f f e c t s with phthalophos i n sheep a t up t o s i x times the effective doses a t up t o 300 mg/kg), and reported-only a transient diarrhea a t 400 mgfig.
(i.z.,
I n t r i a l s with haloxon, Baker29 confirmed e a r l i e r reports of the anthelmintic effectiveness and r e l a t i v e safety o f t h i s substance i n sheep a t Efficiency against O s t e r t a e circumcincta and Trichostrongylus 50 mg/kg. spathiger was not v i t r i n u s were 95% and 98% respectively, removed by this drug a t 50 mg/kg.
i i m '
(c1cH2cH,0),Po
XI1
XT Phthal ophos
Haloxon
Other Nematocides. A new piperazine derivative3l, 3 2 (l-methylp i p e r a z i n e m p h o n y l p i p e r i d i d e , X I I I ) a sulphonyl analog of diethylcarbamazine ( X I V ) , was found by Teusche1-3~t o eliminate lungworm (Dict ocaulus e form of two f i l a r i a ) infections i n sheep. The drug was administered i n consecutive d a i l y 20 mg/kg doses, subcutaneously. The t o x i c i t y of X I 1 1 r e l a t i v e t o d i ethylcarbamazine was not reported.
,
+
+
Of a s e r i e s of standard anthelmintics studied f o r the control of expefimental C a i l l a r i a obsignata infections i n chickens, methyridine ( X V ) proved highly e ec i v e against both mature and innnature parasites a t doses of 100-15'0 mg/kg given subcutaneously. Complete eradication of Capillaria
,
Chap. 14b.
Hoff
Antiparasitics
155 -
i n f e c t i o n s was achieved with 200 mg/kg of methyridine by t h e oral route33. Haloxon was found f u l l y e f f e c t i v e a g a i n s t a d u l t C a p i l l a r i a a t 50-60 mg/kg i n t h i s study, whereas e f f i c i e n c y a g a i n s t immature p a r a s i t e s was n o t s a t i s f a c t o r y .
XI11
XIV
XV
Die thylcarbamazine
B.
Me t h y r i d i n e
-
Anthelmintics f o r Treatment of Tapeworm I n f e c t i o n s .
Bunamidine. Bunamidine (N,N-dibutyl-4-hexylo phthamidine, XVI) i s r e p r e s e n t a t i v e of a new c l a s s of c e s t o c i d a l agents 3 4 T In i n i t i d experiments, t h e drug was r e p o r t e very e f f e c t i v e a g a i n s t Taenia p i s i f o r m i s , The same substance partially c l e a r e d o r a l l y , a t 25 mg/kg, i n t h e dog3 Dipylidium caninum i n dogs, and some v a r i a b l e e f f e c t a g a i n s t the a s c a r i d Toxascaris leonina was reported. I n c a t s , bunamidine a t a dose of 25 mg/kg Cats w i t h r e s u l t e d i n the complete e l i m i n a t i o n of Taenia taeniaformis. concurrent ascaxis i n f e c t i o n s (Toxocara ‘-experienced an average of 80% clearance of t h i s p a r a s i t e with t h i s dose of bunamidine.
2.
-
The preliminary announcement d i s c l o s e d a c t i v i t y a g a i n s t o t h e r s p e c i e s of tapeworms i n c a t s , dogs, and sheep, but without d e t a i l s of the t e s t s . Good a c t i v i t y a g a i n s t Echinococcus ulosus i n dogs was reported as an e s p e c i a l l y important q u a l i t y of bunamidhe S i d e r e a c t i o n s in dogs and c a t s c o n s i s t e d of occasional emesis and d i a r r h e a with 25 o r 50 mg/kg doses. Chronic treatment of pregnant dogs with 100 mg/kg /day of bunamidine s t a r t i n g f o u r weeks p r i o r t o d e l i v e r y was n o t harmful t o t h e mothers o r pups.35
c1 XVI Bunamidine
XVII Niclosamide
Sect. 111
156 -
- Chemotherapeutics
F l y n n , Ed.
e ~ ~ data on the e f f e c t of niclosamide Niclosamide. S t r ~ f reported (5,2 1 -dicaoro-4' -nitkosalicylanilide, XVII) on tlie metabolism of Hymenolepis diminuta. The compound was found t o i n t e r f e r e with glucose u t i l i z a t i o n i n m o m o g e n a t e s prepared from t h i s parasite.
In a c r i t i c a l trial with niclosamide i n do s infected with Taenia species, clearance was obtained w i t h 100-200 mg/kg.3
4
-
Male Fern Constituents., Blakemore, Bowden, Broadbent, and D r y ~ d a l e ~ ~ isolated some o n e phloroglucihol derivatives from Dryopteris rhizomes and tested them individually f o r cestocidal activity. Flavaspidic acid, aspidin, and desaspidin were active o r a l l y against H enole i s nana in mice, but the monocyclic phenol aspidinol was not a c t i v e % v T
In l a t e r p a p e r ~ 3 9 , 4 ~t,h e SKF' group synthesized simpler monocyclic phloroglucinol derivatives related t o Dryopteris constituents. Compounds of the type XVIII were a c t i v e against experimental g . , e infections i n mice o r a l l y a t 400 mg/kg. Tests with lower doses were not, reported. Many other members of the s e r i e s showed a l a s e r order of anthelmintic activity.
.
Cyclohexane4,&-bis-( 2-ethylisothiocyanate) (XIX) This compound was studied in 319 sheep infected with tapewormsw. A 25 mg/kg dose was considered adequate i n the treatment of simple Moniezia expansa i n f e c t i ~ n s . For multiple cestode infections, a l e v e l of 100 & v s e was recommended. Activity against other species of tapeworms was reported as well. The compound was said t o be well-tolerated, the minimum l e t h a l dose i n sheep being about s i x times the highest recommended dose of 100 mg/kg.
OH
0
XVIII
XIX
R'CO
CH,CH,NCS
R = H o r CH, Rl=
C.
i-C3H7;
n-C4H9; n-C5Hll;
Anthelmintics f o r "Ukm Against Liver Flukes.
Salicylanilides. The use of MapheneB, a mixture of three p a r t s -tribromosalicylanilide (XX) and one p a r t 5,4' -dibromosalicylanilide (XXI), f o r t h e treatment of l i v e r fluke disease i n c a t t l e was f i r s t proposed bjr Lienerd29 43.
3,5,4l
Chap. 14b.
Antiparas itic s
157 -
Hoff
H i l o m i d B (Astra Pharmaceuticals), a 1:l mixture of XX and XXI, was reported by Boray, Happich, and Andrewsh t o be effective (86-98g) against 10-12 week o l d Fasciola he a t i c a infections i n sheep tjhen administered i n o r a l doses of 30 m g / m oft60 mg/kg resulted in 90-100$ removal of larger immature flukes (six weeks or older). These authors observed t h a t mortality due t o acute l i v e r fluke disease usually occurs a f t e r seven o r eight weeks from the time of infections, and hence Hilomid 6 may prove effective i n controlling F. hepatica infections.
hoses
-
t5 ,
S a l i c y l a n i l i es related t o DiapheneQ
i n a patent by Stecker
and H i l o m i d B were described
A s e r i e s of chlorinated 21-hydroxysalicylanilides was described in I C I patents46,47. One member of t h i s series, 3,31,5,51,6-pentachloro-2,21dihydroxybenzanilide (oxyclozanide, XXII) w a s studied i n 1226 sheep and 530 c a t t l e by Walle$8. A 15 mg/kg o r a l dose was recommended for treatment of orally, f o r c a t t l e . Tfie author observed a four-fold sheep, and 10-15 mg/kg, margin of safety i n normal animals, but a narrower margin i n dehydrated animals, o r those suffering from l i v e r damage. The s t a t e d doses were reported effective f o r the eradication of mature flukes. Substantially'higher doses (50-60 mg/kg\, removed a high proportion of immature (over six weeks) flukes, but these doses are i n the toxic range. Toxic side-effects were observed in doses above 30 mg/kg: with deaths occurring a t 60 mg/kg. (sheep and c a t t l e ) .
Ry$
CONH O
XXI,
r
c1
Br XX,
-B
R=Br R = H
c1
XXII Oxyclozanide
Other Fasciolacides. Bayer 9015 (2,2~-dihydro~-3,31-dichl.ooo-~,~1d i n i t r o b i p w , XXIII)YJ,51 appears t o be the most potent member of t h e group of anthelmintic bisphenols which includes hexachlorophene, bithionol, and oxyclozanide. I n two recent reports, it was found effective against mature l i v e r and a t 6 mg/kg 51 i n sheep. I n other c r i t i c a l trialsSO, flukes a t 5 mg/kg%, 93-100$ clearance of mature parasites was achieved with 3 mg/kg, orally, i n 21 sheep. No gross t o x i c i t y due t o the drug was reported a t these dose levels, although some reduction i n r a t e of weight gain was seen i n some experiments a t 6 mg/kg. Lee, OINuallain, and Power51 indicated that the manufacturer had observed non-fatal toxic reactions with Bayer 9015 i n 20 sheep dosed with 20 mg/kg. Bayer 9015 a t 5 mg/kg exhibited 40-57% efficiency against immature flukes up t o 10 mm i n length, and 53-100$ a c t i v i t y against l a r g e r immature fonns51. The drug was ineffectiGe against the lancet fluke Dicrocoelium dendriticum i n one sheep which harbored t h i s parasite.
Sect. I11
158
-
Ghemotherapeutics
Flynn, Ed.
A series of novel organophosphates was reported i n Bayer p a t e n t s t o possess a c t i v i t y a g a i n s t l i v e r f l u k e s i n r a t s and sheep a t 5-15 mg/kg, o r a l l y and i n t r a m u ~ c u l a r l y 5 ~ , S 3 .
Kondos and McClymont54 produced evidence that t h e f a s c i o l a c i d a l a c t i v i t y of carbon t e t r a c h l o r i d e i s i n d i r e c t . Anthelmintic e f f e c t of t h e drug i n v i t r o w a s low but was enhanced g r e a t l y by a d d i t i o n of f r e s h l i v e r s l i c e s o r a r n l i v e r preparation. "he i n viva a c t i v i t y of ccl4 w a s much higher than could be explained by t h e o b s e r v e r i n v i t r o e f f e c t of t h e substance. The anthelmintic a c t i v i t y w a s a t t r i b u t e d t o a n unknown metabolic product o r products.
-
Although t h e range of a n t h e l m i n t i c s a c t i v e a g a i n s t t h e l i v e r f l u k e i s widening, t h e goal of a n agent a c t i v e a g a i n s t immature f l u k e s a t safe dose l e v e l s appears y e t t o be achieved. Some of t h e phenolic a n t h e l m i n t i c s described i n t h e papers c i t e d above r e p r e s e n t progress i n t h i s d i r e c t i o n , i n t h a t some e f f e c t a g a i n s t largerimmatures was seen a t elevated dose l e v e l s , b u t t h e reported t o x i c i t y of t h e products would l i m i t o r p r o h i b i t use of t h e s e higher doses. 111. Antiprotozoal Agents A.
Coccidiostats
Quinolines. Reference t o a n t i c o c c i d i a l q u i n o l i n e s appeared i n a number of Datents by Norwich. Comvounds of the tme XXIV were s a i d t o be e f f e c t i v e & t h e c o i t r o l of Eimeria tenella, E. a;&vulina, and E. n e c a t r i x Details of b i o l o g i c a l i n f e c t i o n s a t d i e t l e v e l s between 0 . 7 E d 0.1%W95b. t e s t i n g have n o t y e t been published. Buquinolate (XXIV, R=Rl=A-butyl, R21 e t h y l ) has been proposed f o r treatment o f c o c c i d i o s i s i n b r o i l e r chickens a t a concentration i n f e e d of 75 grams per t o n (0.00825$).57
XXIV
R and R 1 a r e e t h y l , propyl, o r butyl. R,
i s lower a l k y l .
Chap. 14b.
Antiparasitics
-+E.
Hoff
159 -
@minobenzoic Acid Anta o n i s t s . Exceptional a n t i c o c c i d i a l a t i v i t y was found with methyl 4-acetylarmno-2-e ombenzoate (ethopabate. X X V ) . ?8 This substance was reported a c t i v e a g a i n s t maxima chickens'at O;OOOl$ i n t h e d i e t . C o c c i d i o s t a t i c a c t i v i t y of e t h o p x w a s reversed by shultaneous a d m i n i s t r a t i o n of E-aminobenzoic acid. Ethopabate was a l s o found a c t i v e a g a i n s t E. b r u n e t t i and E. acervulina, but a l e v e l of 0.01% i n the f e e d was ineffectTveE. t e n e l l a .
-
NHCOCHH,
xxv Ethopabate Ryley59 examined t h e e f f i c a c y of a combination of 1,l.I -dimethyl-4, 4I-bipyridylium d i c h l o r i d e and sulfamethazine f o r t h e control of outbreaks of c o c c i d i o s i s i n chickens. The combination, known by t h e I C I trademark ParameeQ, was used i n a f i n a l concentration i n water amounting t o 0.02% sodium sulfamethasine and 0.0625% of t h e bipyridylium dichloride. P a r a m e z B w a s s a i d t o be e f f e c t i v e a g a i n s t Eimeria b r u n e t t i , E. maxima, and E. a c e r v u l i n a a t t h i s concentration without diminishing r a t e o f growth of the b i r d s . The bipyridylium compound alone was n o t e f f e c t i v e a t non-toxic l e v e l s . The author speculated t h a t t h e lower l e v e l of sulfa i n t h i s combination should reduce t h e r i s k of development of the haemorrhagic syndrome uhich has been observed wi.th t h e use of sulfonamide c o c c i d i o s t a t s .
Ball and Warren60 reviewed t h e h i s t o r y of sulfonamide combinations as c o c c i d i o s t a t s and s t u d i e d combinations of 4,4' -diaminodiphenylsulfone (DDS) with 2,~-diamino-5-(4-chlorophenyl)-6-ethylpyrimidine (pyrimethamine) and w i t h 2-amino-~-dimethylamino-~-(~-chlorophenyl)-6-ethylpyrimidinehydrochloride (May and Baker 4408), and a l s o combinations of pyrimethamine with sulfaquinoxal i n e . P o t e n t i a t i o n was seen w i t h all of t h e s e combinations, but the f i n a l u t i l i t y w a s not evaluated.
-
Other Coccidiostats. Preliminary r e p o r t s i n p a t e n t s claimed a n t i c o c c i d i a l a c t i v i t y f o r sulfonylurethanes61,62, lincomycin63,- y-pyridone&, . benzoquinones65, -&d n i t r o p y r r o l e s66. Nicotinamid e a n t a g o n i s t s ( 6-aminonico tinamide, pyridine -3 -sulf onamide, and 3-acetylpyridine) were r e p o r t e d by Ball, Warren, and Parnel167 t o possess c o c c i d i o s t a t i c a c t i v i t y . S i m i l a r observations have been made by McManus, Clark, Rogers, and Cuckler68, who noted t o x i c i t y of t h e s e compounds i n chickens. B,
Histomonostats
A study by Flowers, Hall, and Grumbles69 confirmed e a r l i e r r e p o r t s of the u t i l i t y of 1,2-dimethyl-5'-nitroimidazole (dimetridazole, XXVI) f o r t h e
160 -
Sect. 111
-
Chemotherapeutics
F l y n n , Ed.
prevention and treatment of enterohepatitis i n turkeys. The compound was judged equal t o o r b e t t e r than 2-acetylamino-5-nitrothiazole (Enheptin-A) f o r the prevention of enterohepatitis. 5-Nitro-2-furaldehyde acetylhydrazone ( X W I I ) w a s found by Hall, Flowers, and Grumbles70 t o be efficacious (comparable t o Enheptin-A and dimetridazole ) in the prevention of l o s s e s from enterohepatitis when administered prophylactically i n t h e feed a t 0.022%.
XXVI Dime tridazole
XXVI Enheptin-A
Lucas and Goose71 presanted a detailed description of a screening procedure f o r antiblackhead agents, using chickens infected with Histomonas meleagridis. Use of chickens instead of turkeys for screening was said t o be more convenient and economical.
IV. Organophosphate Insecticides A promising new organophosphate insecticide was announced by the Shell group72. This compound, an a-phenylvinyl phosphate (XXVIII) was said t o possess good a c t i v i t y against several species of insects, and i t s acute o r a l LDso was greater than 4000 mg/kg i n mice and r a t s . It i s close in structure t o chlorfenvinphos, (XXIX),which was evaluated i n f i e l d trials for the protection of sheep against the maggot f l y , Lucilia sericata73. Chlorfenvinphos was judge’d equivalent i n efficacy t o d i e l d r i n a t comparable concentration i n a d i p (0.05% compared with 0.04% dieldrin).
Cl XXVIII
XXIX
Details of the synthesis and t e s t i n g (mouse-mosquito assay and mouse t o x i c i t y t e s t s ) of a s e r i e s of phosphorylated benzenesul onamides i n the famophos s e r i e s were presented by Wagner, Baer, and Berkelhammer76
.
Trials with various older o r g ophosphates and other insecticides were reported by S h a m , Chhabra, and KapoorT ( c a t t l e grubs), Unwin76 ( c a t t l e grubs), Dnunmond and Medley77 ( c a t t l e t i c k s ) , and by Drummond and Graham78 ( c a t t l e grubs, Oestrus i n sheep, and Gastrophilus species).
Chap. 14b.
Antipa ras iti c s
161 -
Hoff
References
-
.'--,
Monteoliva, F. S. Rasero, T. L. Gorie and -F. --Mayor, ".-"..", Nature, L 205 'C, 1 111 (1965). -2 Rothstein, Comp. Biochem. Physiol.,- I = I 54.l (1965). TT.. Morales. Del CastillMorales, E e r i e n t i a , 20, lb (1964). S. F. A s h , and J. F. Tucker, Nature, 209, 306 .-9 Q. H. Gibson and M. H. Smith, Proc. Roy.3&. (London), . ondon), Ser. B, 163, 206 (1965). C. F. F e i s t , C. P. Reid, and F. M. Fisher, Jr.,- J. P a r a s i t o l . , - c 7 6 (1965). her. Jr. H. Oya, G. Kikuchi, T. Bando and H. Hayashi,,-qE 2, 229 (1965). 1 (1965). lh. L. G. Warren, n t n e r , J. Biol. Chem., 236, 915 (1961). li. I. Seidman and lj. S. Bloom and N. Entner, Biochim. Biophys. Acta., 99, 22 (1965). l k . E. Kmebec and E. Bueding, Comp. Biochem. Physiol., 15, 271 (1965). 11 W. P. Rogers, Comp. Biochem. Physiol., 311 (196n. l m . N. E. Downey, B r i t . Vet. J., 121, 362 (1965). m. P a r a s i k l . , L6, 353 (1965). laquero. and J. F. Duda. Duda, E Exp. Parasitol., In. J. R. Seed, M. A. Baquero, itment of t h e Domestic 2. T. E. Gibson, Recent Advances i n t h e A n t h e l x t i c Treatment Animals. Animals. Chapter i n Advances in Parasitology, Volume 111, Edited by Ben Dawes, Academic Press, London and New York, 1964. 3. R. J. S c h i t z e r , and F. Hawking, Experimental Chemotherapy, Vol. IV, Academic Press. New York and London.> 1966. 4. D. Thienpont, 0. F. J. Vanparijs, A. H. M. Raeymaekers, J. Vandenberk, P. J. A. Demoen, F. T. N. Allewijn, R. P. H. Marsboom, C. J. E. Niemegeers, K. H. L. Schellekens, and P. A. J. Janssen, Nature, 209, 1084 (1966). 6,505,806, (1965). 4a R. F. Arnold, C. G. Hartland, A. Siedsma, Ne-dnatent 5. J. K. Walley, Vet. Rec., 78, 406 (1966). 6. H. J. Robfison, H. C. Stoerk, and 0. E. Graessle, Toxicol. Appl. Phamacol., 7, 53 (1965). 7. H. D. Brown, A. R. Matzuk, I. R. I l v e s , L. H. Peterson, S. A. Harris, L. H. S a r e t t , J. R. Egerton J. J. Yakstis, W. C. Campbell, and A. C. Guckler, J. Am. Chem. SOC 83, 1761 (1961). 8. M. KarKvic, 0. Vrazic, and I. Drezancic, Vet. Arhiv., 34, 189 (1964); Vet. -Bull 0,35, 1398 (1965). 9. J. Hendriks, Tijdschr. Diergeneesk, 90, 1062 (1965'). 10. M. Meunier, Vet. Thesis, P a r i s ( 1 9 6 n 11. A. J. S n i j d e r s , S. G. Anema and J. P. Louw, J. S. A f r . Vet. Med. ASSOC., 36, 263 (1965). 12. W. C. Campbell, and S. F. Timinski, J. Parasitol., 51, 712 (1965). 13 L. H. P. Jones, D. D. Leaver and A. A. Milne, Res. Et. Sci., 6, 316 (1965). 14. Imperial- Chemical I n d u s t r i e s , A u s t r a l i a n Patent 25733/62. 15. Imperial Chemical I n d u s t r i e s , - E i r e P a t e n t 549/65. 16. T. J. Ursprung, U. S. P a t e n t 3,179,669 (1965). 1 7 T. J. Ursprung, U. S. Patent 3,179,670 (1965). 18. R. Aries, Address t o 84th Congress of t h e French Ass'n. f o r t h e Advancement of Sciences; Reported in Informations Chimie, October, 1965, p. 58. ) 1 9 Farbenfab. Bayer, Beglain-65 20. I. B. Wood, J. A. Pankavich and R. E. Bambury, U. S. P a t e n t 3,152,042 (1964). 21. I. B. Wood, H. Berger, J. A. Pankavich, and E. Waletzky, J. P a r a s i t o l . , 2 (suppl.), 60 (196h). 22. I. B. Wood, R. E. Bambury and H. Berger, U. S. Patent 3,179,559 (1965). 23 American Cyanamid, Netherlands Patent 6,501,092 (1965).
la. lb lc. Id. le If
..
M. M. J. A.
2,
I
I
-
vr I-
w., 9, .
u.
.
-
m,
2,
.
-.J
-
.
-&*A
\ A , " , / .
Sect. 111
162 -
.
- Chemotherapeutics
F l y n n , Ed.
25 26. 27 28.
American Cyanamid, Canadian Patent 698,704 (1964). I. B. Wood, J. A. Pankavich, and R. E. Bambury, U. S. Patent 3,177,116 (1965). R. Wizinger and L. Soder. U. S. Patent 3,2ll,748 (1965). S. P. Hebden and C. A. H i l l , Vet. Rec., ? 7, 207 (1965). D. D. Cox, A. D. Allen, Me T. Mullee, and E. M. Maurer, J. Parasitol.,
29 30. 31
N. F. Baker, Am. J. Vet. Res., 26, 651 (1965). C. J. Bosman, J. S. A f r . Vet. Med. ASSOC., 36, 251 (1965). E. Teuscher, Schweiz, Arch. Tierheilk., E F 7 4 (1964); Vet. Bull.,
32-
A. C. R. 0. V. C.
24 e
33
34.
35 36. 37. 38
39.
40
41
. 44.
42.
43
45
46
47:
48 49
50.
(196h).
52.
55
56
57* 58. 59 60.
61. 62.
63 64. 65
34,
4591
Marzer and A. Ilvespaa, U. S. Patent 3,211,608 (1965). C. Norton and L. P. Joyner, J. Comp. Path., 137 (1965). Baltzly, R. B. Burrows, M. Harfenist, K. A. Fuller, J. E. D. Keeling, D. Standen, C. J. Hatton, V. J. Nunns, D. A. Rawes, B. D. Blood, Moya, and J. L. Lelijveld, Nature, 206, 409 (1965). J. Hatton, Vet. Rec., 77, 4 m 6 $ ‘ J 7 R. Strufe, i n Proceedings of the I I I r d International Congress of Chemotherapy, S t u t t g a r t , Germany, July, 1963, Vol. 11, p. 1544, Hafner, New York, 1964, D. D. Cox and M. T. Mullee, J. Parasitol., 51 (suppl.) 30 (1965). R. C. Blakemore, K. Bowden, J. L. BroadbentFand K. C. Drysdale, J. Pham. Pharmacol., 6 l ., 464 (1964). K. Bowden and W. J. Ross, J. Pharm. Pharmacol., l7, 239 (1965). K. Bowden, J. L. Bro?dbent/ and W. J. Ross, B r i t . J. Pharmacol., 24, 7 l h (1965). M. Graber, Cahiers Med. Vet., 38, 87 (1965). E. Lienert, Arch. E Veterinzrmed, 17, 101 (1963). E. Lienert, T i e r a r z z . Umschau g, 8 n 1 9 6 3 ) . J. C. Boray, F. A. Happich, and J. C. Andrews, Vet. Rec., 77, 175 (1965). H. C. Stecker, Australian Patent 34,997/63 ( 1 9 6 r Imperial Chemical Industries, Netherlands Patent 6,409,241 (1965) Imperial Chemical Industries, Netherlands Patent 6,409,325;. J. K. Walley, V e t . Rec., 267 (1966). Nederl. Combinatie Voor Chem. Ind., Netherlands Patent 6,405,517 (1965). S. E. Knapp, P. A. Nyberg, V. T. Dutsen, and J. N. Shaw, Am. J. Vet. Res., 26, 1071 (1965). R. P. Lee, T. O’Nuallain and J. H. Power, Vet. Rec., 196 (1966). Bayer, German Patent 1,195,750 (1965). Bayer, Netherlands Patent 6,412,023 (196.5). A. C. Kondos, and G. L. McClymont, Nature, 206, 846 (1965). Norwich, Belgian Patent 640,906 (19E. J. Watson, Jr., Canadian Patent 697,792. Federal Register, 31, 4529 (1966). E. F. Rogers, R. L T C l a r k , H. J. Becker, A. A. Pessolano, W. J. Leanza, E. C. McManus, A. J. Andriuli, and A. C. Cuckler, Proc. SOC. Exp. Biol. E., 117, 488 (1964). J. F. Ryley, Vet. Rec., 77, 1498 (1965). S. J, Ball, and E. W. Warren, Vet. Rec., 77, 1028 (1965). Hoechst, Swiss Patent 380,714 (196b). Hoechst, Swiss Patent 392,487 (1965). R. E. Bloss, and R, E. Kohls, U. S. Patent 3,150,042 (1964). G. T. Stevenson, U. S. Patent 3,206,358 (1965). Hoechst, Netherlands Patent 6,415,174 (1965).
.53. 54. 51
2
(su~~L 33)(1965). ,
s,
.
.
2,
2,
-
C h a p . 14b.
66 67 68. 69
70. 71. 72.
73.
74.
Antiparasitics
Rhae-Poulenc, Netherlands Patent S. J. B a l l , E. W. Warren and E. W. E. C. McManus, R. L. Clark, E. F. Indust. Microbiol., 6, 4k (1964). A. I. Flowers, C. F. Hall, and L. (1965) C. F. Hall, A. I. Flowers, and L.
(1965’)
163 -
Hoff
6,405,568 (1965). P a r n e l l , Nature, 397 (1965). Rogers, and A. C. CucMer, Develop.
208,
C. Grumbles, Avian Diseases,
C. Grumbles, Avian Diseases,
2, 9,
395 400
121,
J. M. S. Lucas, and J. Goose, B r i t . Vet. J., 65 (1965). R. R. Whetstone, D. D. P h i l l i p s , Y. P. Sun and L. F. Ward, Jr., Abstr. Papers, Am. Chem. SOC., 12A (1965’). J. C. Wood, K. W. Page, P. R. M. Brown, M. S. Smith, and D. A. M. Fergu.son, Vet. Rec., 77, 896 (1965). F. A. Wagner, Jr., R. W. Baer, and G. Berkelhammer, J. Med. Chem., 377
2,
(1965)
2,
75 R. M. Sharma, R. C. Chhabra, and B. B. Kapoor, Vet. Rec., 77, 107 (1965 ) * 76. D. D. Unwin, Vet. Rec., 77, 593 (1965). 77. R. 0. Drummond and J. G. Medley, J. Econ. Entomol., 58, 1131 (1965). 78. R. 0. Drummond and 0. H. G r a h a m , Vet. Rec., 77, l b l 8 7 1 9 6 5 ) .
S e c t i o n IV - M e t a b o l i c Diseases and Endocrine Function E d i t o r : R. V. Heinzelman, The Upjohn Company, Kalamazoo, Michigan C h a p t e r 1 5 . A n t i d i a b e t i c Agents Rex P i n s o n , Chas. P f i z e r 6 Co., I n c . , Groton, C o n n e c t i c u t The hypoglycemic d r u g s t h a t are used t o d a y t o treat w e l l o v e r a m i l l i o n d i a b e t i c s are descended i n ,a d i r e c t l i n e from two e s s e n t i a l l y chance b o t h made more t h a n 20 y e a r s ago. The t r a n s i t i o n from t h e s e observations o b s e r v a t i o n s ( t h a t c e r t a i n a n t i b a c t e r i a l sulfonamides c a u s e d hypoglycemia' and t h a t a s i m p l e g u a n i d i n e d e r i v a t i v e reduced t h e blood s u g a r of r a b b i t s 2 ) t o s a f e , e f f e c t i v e t h e r a p y i s a real achievement of m e d i c i n a l c h e m i s t r y . N e v e r t h e l e s s , i t would be u n r e a l i s t i c n o t t o r e c o g n i z e t h a t i n s p i t e of t h e v a s t body of f a c t and c o n j e c t u r e now c o n t a i n e d i n t h e l i t e r a t u r e of d i a b e t e s , m e t a b o l i c b i o c h e m i s t r y and t h e c o n t r o l of metabolism; no a n t i d i a b e t i c drug h a s y e t come from r a t i o n a l a p p l i c a t i o n of knowledge a b o u t t h e s e p r o c e s s e s . Compounds u n r e l a t e d t o t h e s u l f o n y l u r e a s o r g u a n i d i n e d e r i v a t i v e s have, t o be s u r e , been s t u d i e d f o r t h e i r hypoglycemic p r o p e r t i e s some e x t e n s i v e l y -b u t a l l were a p p a r e n t l y f i i s t i d e n t i f i e d by a l a r g e l y e m p i r i c a l o b s e r v a t i o n of t h e i r e f f e c t on blood s u g a r i n e x p e r i m e n t a l a n i m a l s .
--
--
B r i e f s e c t i o n s on d i a b e t e s as a d i s e a s e e n t i t y and on some of t h e hormonal f a c t o r s and m e t a b o l i c p r o c e s s e s t h a t are deranged i n d i a b e t e s have been i n c l u d e d . L i m i t a t i o n s b o t h of s p a c e and of t h e t a l e n t s of t h e r e v i e w e r p r e c l u d e e i t h e r comprehensive o r profound t r e a t m e n t of t h e s e a s p e c t s and Rather, t h e a i m i s t o i n v i t e n o t h i n g approaching t h i s h a s been a t t e m p t e d . a t t e n t i o n a g a i n t o t h e r e l a t i o n s h i p of t h e s e f a c t o r s t o t h e d i s e a s e and t o p r o v i d e a few l e a d i n g r e f e r e n c e s t h a t may s t i m u l a t e thought on p o s s i b l e new approaches t o a n t i d i a b e t i c drugs. Diabetes Mellitus D i a b e t e s i s a h e r e d i t a r y d i s e a s e 3 y 4 b u t t h e n a t u r e of t h e g e n e t i c I t i n v o l v e s a widespread d i s d e f e c t and i t s primary l e s i o n are unknown. o r d e r of metabolism b u t e x h a u s t i v e s t u d y h a s n o t y e t determined whether t h i s i s a c a u s e o r consequence of t h e hormonal, v a s c u l a r and n e u r o l o g i c a l abnormali t i e s of t h e d i s e a s e . Reasonably u p - t o - d a t e t r e a t m e n t of a l l of t h e s e a s p e c t s a p p e a r i n t h e symposium volume from t h e F i f t h Congress of t h e I n t e r n a t i o n a l D i a b e t e s F e d e r a t i o n ( T o r o n t o , 1964).5 A c h a p t e r on t h e unanswered q u e s t i o n s about human d i a b e t e s by Williams and Wood6 and t h e d i s c u s s i o n t h a t followed i t s p r e s e n t a t i o n c o n t a i n a h o s t of s u g g e s t i o n s f o r r e a d i n g . Another review by W i l l i a m s Y 7 and B e r s o n ' s 1965 Banting Memorial L e c t u r e 8 are a l s o h e l p f u l g u i d e s t o c u r r e n t thought on d i a b e t e s , Insulin The dominant c h a r a c t e r i s t i c of d i a b e t e s i s an a b s o l u t e o r r e l a t i v e l a c k of e f f e c t i v e i n s u l i n a c t i o n . I n some m a n i f e s t a t i o n s o f t h e d i s e a s e , a d e f i c i e n c y of p a n c r e a t i c 8-cell f u n c t i o n i s c l e a r l y i n v o l v e d , but i n o t h e r s , t h e d e f e c t a p p e a r s most l i k e l y t o be a f a c t o r o r c o n d i t i o n t h a t p r e v e n t s insulin action.
Chap. 15
Antidiabetics
Pinson
165 -
C a h i l l h a s w r i t t e n an o u t s t a n d i n g l y r e a d a b l e account of i n s u l i n e f f e c t s and t h e i r d e f i c i e n c y i n d i a b e t e ~ . ~A review of t h e i n s u l i n l i t e r a t u r e t o J u l y 1965" c o v e r s many a s p e c t s of i n s u l i n s t r u c t u r e , s y n t h e s i s , s t o r a g e and release but does n o t c o v e r i n s u l i n a c t i o n . The review of s t r u c t u r e , p a r t i a l and t o t a l s y n t h e s i s , and t h e i n f l u e n c e o f s t r u c t u r e on a c t i v i t y i s q u i t e e x h a u s t i v e . E v e n t s t h a t o c c u r d u r i n g i n s u l i n release from t h e p a n c r e a s have been observed by e l e c t r o n m i c r o s c o p y , l l and much i s a l s o known about B-cell metabolism.12 The d e t a i l s of t h e p r o c e s s by which g l u c o s e a c t u a l l y t r i g g e r s i n s u l i n release, however, are n o t y e t understood i n any d e t a i l .
One of t h e most fundamental a c t i v i t i e s of i n s u l i n i s t h e removal of a b a r r i e r t o t h e e n t r of g l u c o s e i n t o f a t and muscle c e l l s . The f u n c t i o n s
of i n s u l i n i n glucose13914 and amino acid15 t r a n s p o r t and t h e r o l e of sodium and potassium i o n s i n t h e s e p r o c e s s e s 1 6 are t h e s u b j e c t of a r e c e n t symposium. Important though t h e t r a n s p o r t e f f e c t of i n s u l i n i s , i t i s clear t h a t i t i s n o t the primary a c t i o n from which a l l o t h e r e f f e c t s r e s u l t . Some a c t i o n s of i n s u l i n , as of most hormones, have been t r a c e d t o e f f e c t s on t h e s y n t h e s i s of enzyme p r o t e i n . Some of t h e s e e f f e c t s have been p o s t u l a t e d t o occur a t t h e l e v e l of DNA d i r e c t e d RNA s y n t h e s i s , whereas o t h e r s a f f e c t p r o c e s s e s n o t y e t c l e a r l y i d e n t i f i e d . I n s u l i n e f f e c t s on l i v e r glycogen s y n t h e s i s and breakdownl7 have been e x p l a i n e d as p a r t of a g e n e r a l t h e o r y of i n s u l i n i n d u c t i o n of g l y c o l y t i c enzymes and s u p p r e s s i o n of gluconeogenic enzymes. l8 Regulation of g l u c o k i n a s e and hexokinase a c t i v i t y depends on g l u c o s e c o n c e n t r a t i o n f o r immediate c o n t r o l , b u t on i n s u l i n induced d e novo enzyme s y n t h e s i s , a p p a r e n t l y through c o n t r o l of new RNA p r o d u c t i o n , o v e r t h e l o n g e r term.19 H similar e f f e c t a p p e a r s t o be r e s p o n s i b l e f o r i n s u l i n i n d u c t i o n of s a t u r a t e d and monou n s a t u r a t e d f a t t y a c i d s y n t h e s i z i n g enzymes. 20,21 Evidence h a s also been obt a i n e d t h a t i n s u l i n s t i m u l a t i o n of h e p a t i c p r o t e i n s y n t h e s i s i s due t o an as y e t undefined e f f e c t on ribosomes.22 Plasma f a c t o r s t h a t i n f l u e n c e i n s u l i n a c t i o n . P a t i e n t s t r e a t e d w i t h i n s u l i n develop i n s u l i n a n t i b o d i e s , and t h e r e h a s been much s p e c u l a t i o n , now l a r g e l y d i s c o u n t e d , 8 t h a t an autoimmune r e a c t i o n may be involved i n t h e e t i o l o g y of d i a b e t e s . Immune i n s u l i n r e s i s t a n c e as a t h e r a p e u t i c problem, Considerable research has o c c u r s i n o n l y a small m i n o r i t y o f been devoted t o s t r u c t u r a l m o d i f i c a t i o n s of i n s u l i n i n an e f f o r t t o reduce Even homologous i n s u l i n s , however, have proved t o be a n t i antigenicity." g e n i c , i f a d m i n i s t e r e d i n p a r t i c u l a r ways. 24
patient^.^^,^^
I t i s now beyond d i s p u t e t h a t t h e r e e x i s t i n plasma, s u b s t a n c e s o t h e r than p a n c r e a t i c i n s u l i n and i n s u l i n a n t i b o d i e s t h a t e i t h e r have i n s u l i n l i k e a c t i v i t y o r are c a p a b l e of modifying t h e a c t i o n of i n s u l i n . 2 5 The chemical i d e n t i t y and e s p e c i a l l y t h e p h y s i o l o g i c a l s i g n i f i c a n c e of t h e s e plasma c o n s t i t u e n t s , however, s t i l l remains o b s c u r e . The s u b s t a n t i a l amount of res e a r c h on t h e s e s u b s t a n c e s o v e r t h e l a s t f i v e o r s i x y e a r s stems from two o b s e r v a t i o n s ; 1 ) t h a t t h e amount of i n s u l i n - l i k e a c t i v i t y a s s a y a b l e i n plasma by u s i n g a d i p o s e t i s s u e as t h e a s s a y system i s much.'greater than when muscle i s employed and t h a t b o t h show more i n s u l i n - l i k e a c t i v i t y than c a n be d e t e c t ,32 ed by r a d i o i m m u n ~ a s s a y ~ ~ and 2 ) t h a t v a r i o u s albumin f r a c t i o n s i s o l a t e d from plasma are c a p a b l e of i n h i b i t i n g t h e e f f e c t of i n s u l i n on i s o l a t e d muscle.
166 -
Sect.
IV - Metabolic
& Endocrine
H e i n z e l m a n , Ed.
The first observation has been pursued by several groups most extensively by Antoniades,26,27 Samaan and Fraser,28,29 and Froesch.jo Antoniades and his co-workers have based their investigation on the fractionation of plasma, using an ion exchange resin, into "free" and "bound" insulin. The "free" fraction is apparently pancreatic insulin, since it is detectable by radioimmunoassay and stimulates glucose uptake by muscle. The "bound" fraction is not detectable by radioimmunoassay, stimulates glucose uptake by adipose tissue but not by muscle (unless an adipose tissue extract is added). Samaan and Fraser also distinguish two types of insulin-like activity. One, which they term "typical", is inactivated by insulin antibodies whereas the othef,-or "atypical" insulin is not. Froesch and his collaborators, working along lines very similar to Samaan and Fraser, classify the two kinds of plasma insulin-like activity as antibody "suppressible" and "non-suppressible." Davidson has studied a material with insulin-like activity on the rat diaphragm that is obtained from plasma by acid ethanol treatment.33 Power is working with a serum protein which has insulin-like activity and augments the action of insulin on the rat fat pad and which may prove to have relevance to the theories of A n t o n i a d e ~ . ~ ~ The chief difference between "atypical" or %on-suppressible" insulin, on the one hand, and Antoniades "bound" insulin on the other,is that the plasma concentrations of the former do not vary in response to changing plasma glucose levels, but the latter does. From his work, Antoniades concludes that the plasma insulin system he describes has a physiological role in the modulation of insulin activity. He visualizes a system in which insulin becomes bound or unbound in response to physiological stimuli and that diabetes may represent, in part at least, a disorder of this system. Although Antoniades observations have been confirmedY35his interpretations have been challenged, especially by Berson.8 Froesch appears to be making the most progress toward characterizing "bound" or %on-suppressible" insulin. He and his colleagues are working toward the isolation and characterization of this fraction. Their data thus far suggest that it is a small peptide, not identical with pancreatic insulin, with a molecular weight of about 6000, which is complexed with a large basic protein with a molecular weight over 100,000.3° From present evidence, it is difficult to ascribe a physiological function to these substances. It seems clear that they are r.ot pancreetic insulin in equilibrium with a carrier protein complex as are many hormones such as cortisol and thyroxine. Plasma concentrations (except for Antoniades "bound" insulin) do not vary and the activity is-not found in lymph, where immunoassayable insulin levels closely parallel those in p 1 a ~ m a . l ~Perhaps ~ the isolation work Froesch is now doing will clarify their sratus. Vallance-Owen first reported that dilute solutions of an albumin fraction were capable of inhibiting the effect of insulin on the rat diaphragm and further showed that albumin isolated from the plasma of diabetics was capable of inhibiting insulin action at a lower concentration than was the correspondin fraction from n ~ n - d i a b e t i c s . ~ These ~ observations have now Is hypothesis that the inhibitor, which been ~ o n f i r m e d , ~ but ~ ,Vallance-Owen ~~ he named synalbumin, is the albumin bound B-chain of insulin now seems highly
C h a p . 15
Antidiabetics
Pinson
167 -
q u e s t i o n a b l e . Mixtures of B-chain and albumin i n h i b i t g l u c o s e uptake i n diaphragm o n l y a t c o n c e n t r a t i o n s o f B-cha'in many f o l d h i g h e r than seem p o s s i b l y a t t a i n a b l e i n p l a ~ m a . ~Because ~ , ~ ~ t h e albumin i n s u l i n i n h i b i t o r i s found i n a p p a r e n t l y h i g h e r c o n c e n t r a t i o n s i n t h e plasma of d i a b e t i c s t h a n i n t h e plasma of n o n - d i a b e t i c s , Valiance-Owen h a s suggested t h a t t h i s s u b s t a n c e may be involved i n the e t i o l o g y of d i a b e t e s . The p h y s i o l o g i c a l s i g n i f i c a n c e of t h e Vallance-Owen f a c t o r seems h i g h l y dubious. Undiluted plasma h a s no i n h i b i t o r y e f f e c t on diaphrams g v i t r o and no e f f e c t h a s been d e t e c t e d i n v i v o . Moreover, i n t r a v e n o u s i n f u s i o n s of i n s u l i n B-chain have no e f f e c t on blood s u g a r . 8 Other Hormones and Humoral F a c t o r s S e v e r a l o t h e r hormones have been s t u d i e d i n t e n s i v e l y i n c o n n e c t i o n w i t h d i a b e t e s because of t h e i r e f f e c t s on metabolism and i n s u l i n a c t i o n . 6 Growth hormone and t h e g l u c o c o r t i c o i d s have o f t e n been c l a s s i f i e d as " d i a b e t o g e n i c " because t h e i r e f f e c t s g e n e r a l l y oppose t h o s e of i n s u l i n . Growth hormone d e p r e s s e s t h e p h o s p h o r y l a t i n g c a p a c i t y and i n s u l i n r e s p o n s i v e n e s s of s k e l e t a l muscle and s t i m u l a t e s g l u c o s e o x i d a t i o n i n a d i p o s e t i s s u e w i t h o u t a l t e r i n g i t s r e s p o n s i v e n e s s t o i n s u l i n , b u t t h e mechanism of t h e s e e f f e c t s h a s n o t been e s t a b l i s h e d . The e v i d e n c e o b t a i n e d t h u s f a r , however, i s cons i s t e n t w i t h t h e view t h a t t h e y are t h e r e s u l t of t h e l i p o l y s i s s t i m u l a t i n g e f f e c t of growth hormone.41 The g l u c o c o r t i c o i d s markedly i n c r e a s e t h e a c t i v i t y of key enzymes of g l u c o n e o g e n e s i s and some e v i d e n c e s u g g e s t s t h a t t h i s e f f e c t i s d u e , i n p a r t a t l e a s t , t o i n c r e a s e d enzyme system s n t h e s i s r e s u l t i n g from a s t i m u Other e v i d e n c e , however, does l a t i o n of t h e p r o d u c t i o n of messenger RNA.43 not e n t i r e l y support t h i s hypothesis.43 Glucagon and e p i n e p h r i n e both oppose t h e a c t i o n of i n s u l i n by s t i m u l a t i n g g l y c o e n o l y s i s and g l u c o n e o g e n e s i s t h r o u g h a c y c l i c 3 ' , 5 ' - M medi'ated p r o c e s s .84 I n a d d i t i o n , t h e hyperglycemic a c t i o n of e p i n e p h r i n e i s augmented by two o t h e r a c t i o n s ; a d i r e c t i n h i b i t i o n of i n s u l i n release from t h e pancreas45,46 and a s t i m u l a t i o n of l i p o l y s i s i n a d i p o s e t i s s u e , t h u s i n c r e a s i n t h e c i r c u l a t i n g l e v e l of f r e e f a t t y a c i d s , which oppose i n s u l i n a c t i o n .7' 3 48 G lucagon , a l t h o u g h i t h a s t h e same e f f e c t as e p i n e p h r i n e on g l y c o g e n o l y s i s , h a s now been shown t o have t h e o p p o s i t e e f f e c t on t h e 8 - c e l l , where i t s t i m u l a t e s t h e release of i n s u l i n d i r e c t l y . 1 0 A symposium on t h e m e t a b o l i c e f f e c t s of c a t e c h o l a m i n e s from t h e Second Catecholamine Symposium (Milan 1965) h a s appeared.49 Crude p r e p a r a t i o n s of an e x e r c i s e f a c t o r 5 0 t h a t can a p p a r e n t l y i n crease g l u c o s e u t i l i z a t i o n i n muscle have now bean o b t a i n e d by G o l d s t e i n . From Sephadex column b e h a v i o r , t h e material a p p e a r s t o have a molecular weight of l e s s t h a n lOOO.5l Intermediary hetabolism diabetes.
A wide r a n g i n g d i s o r d e r of e n e r g y metabolism i s c h a r a c t e r i s t i c of
Whether t h i s derangement i s caused by i n s u l i n d e f i c i e n c y o r wholly
Sect. IV - Metabolic & Endocrine
168 -
H e i n z e l m a n , Ed.
or in part by some other lesion remains to be learned, as does whether it is a cause or a consequence of the vascular complications of the disease. Nevertheless, it remains the facet of the disease to which therapy has been' directed and by which the therapy is guided, whether it be diet, insulin, sulfonylureas or biguanides. The hormonal and feedback control of metabolism has been extensively discussed by several authors, but particularly clearly by Randle.5* He points out that there is a simple, primitive feedback control of metabolism, exerted through the effect of metabolic intermediates and substrates on enzymatic processes and that this mechanism of control is important, not omly to simple organisms that depend on it entirely, but also to complex organisms which also have an additional component of hormonal control. That effective management of diabetes can be obtained by drug effects on either hormonal or feedback control of metabolism is attested by the clinical success of the sulfonylureas and biguanides. The role of all members of the trinity of energy metabolism; the liver, muscle and adipose tissue,has been extensively studied. Most of the current knowledge about adipose tissue metabolism is contained in a recent volume in the Handbook of Physiology series53 and has also been discussed by Renold in a recent Banting Memorial Le~ture.5~The elegant and very useful quantitative work from Ball's laboratory on the fate of glucose carbon in adipose tissue has been summarized .55 These researchers have recently shown that, in adipose tissue, the operation of citrate cleavage enzyme and malic enzyme together can provide both the extramitochondrial acetyl CoA and the NADPH2 re uired (in addition to that from the pentose shunt) for lipogene~is.5~The control of metabolism in muscle has been reviewed by Randle.52 Sulfonylureas and their Congeners In the United States, three sulfonylureas are in wide clinical use in the management of maturity onset diabetes; tolbutamide (Orinase), chlorpropamide (Diabinese) and acetohexamide (Dymelor). In other parts of the world, carbutamide (Nadisan) and glycodiazine (Redull,a sulfonamidopyrimidine isostere of the sulfonylureas are also used.
0
S02NHCONHC4Hg
CH3
CH3CO~
~ S O 2 N H C O N H C 3 H 7 Cl
Tolbutamide S
O
2
N
H
C
O
N
H
o
Ch1orpropamide
NH2m2NHCONHC4Hg
Acetohexamide
Carbutamide
Glycodiazine
Chap. 15
Antidiabetics
Pinson
169 -
G l y c o d i a ~ i n eis ~ ~ one member of a large group of closely related compounds, In its pharmacology and clinical application, it appears to resemble tolbutamide most close1 having approximately the same hypoglycemic potency and duration of a ~ t i o n . ~ ”The hypoglycemic effect of glycodiazine is probably due to the action of the compound itself, since the pyrimidine ring has proved to be metabolically stable. The principal metabolite is the carboxylic acid (1) that results from cleavage of the terminal side chain methoxyl group and oxidation of the resulting primary alcohol. A toxicology investigation has also been reported.57
I
Tolazarnide
New sulfonylureas and their congeners continue to be widely reported, but in many cases, apparently from work done some time ago. It is regretable that there is no current structure-activity review, but one is clearly beyond the scope of this discussion. A compilation of a number of compounds that have been studied in animals and humans appeared a few years ago and is still useful.59 Sulfonylsemicarbazides have also been found to have significant hypoglycemic activity and one, Tolazamide,60,61 has received FDA approval,62 but had not, at this writing, been marketed. An extensive series of hypoglycemic sulfamylureas (11, 111) has been d e ~ c r i b e d . ~In ~ general , maximum hypoglycemic activity was found in
R1>S02NHCONHR R2 I1
R2
wS02N I11
X = CH2, N, 0, S R = alkyl, cycloalkyl and haloalkyl R1 and R2 = alkyl and alkoxy this series among the same alkylurea substituents (R) that give maximum activity in the sulfonylureas. The corresponding sulfamyl semicarba~ides~~ also had significant hypoglycemic activity as did a few of the related sulfamylcarbamates.65 Compounds in which the alkylurea portion was derived from a secondary amine, usually heterocyclic, were, in general, less activeP5 A number of the compounds were as active (reduction of blood glucose in fasted rats) as chlorpropamide. Further details of the pharmacology of the sulfamylureas have not been reported, but it seems safe to assume that their mechanism of hypoglycemic action would be very similar to that of the sulfonylureas. Several of the compounds are stated to show hypoglycemic activity in man but their clinical use in the management of diabetes has not been reported.
170 -
Sect.
IV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
This work made good use of the now firmly established correlation, among compounds of this class, of hypoglycemic action with the presence of the compounds in the blood. Synthesis was therefore guided not only by the relationship established between structure and acute hypoglycemic activity, but also by an evolving concept of the influence of physical and chemical properties on absorption, metabolism and excretion, derived from a concurrent investigation.66 The metabolism and excretion of 15 of the compounds were determined in dogs and seven were studied in human subjects. The results of these studies were correlated with physical and chemical properties, of which pKa and lipid-water partition ratio proved to be the most useful. 0 he variants on the sulfonylurea structure have recently included and 2-cyanop-alkenyl-,679 2-acyl- ,69 E-a1koxyalkyl - ,69 E-haloalkyl , as well as 6-s~lfamoylbenzotriazole,~~ benzenesulfonyl-69 6-sulfamoylben~imidazole~~ and 5-indanylsulfonyl70 derivatives. A variety of alkyland aralkylurea71 substituents have been combined with these as well as with the now conventional benzenesulfonyl moieties. A series of compounds in which the urea function was part of a benzimidazolinone ring were devoid of hypog 1 ycemic activity .72
h
-
'
A sulfonarnidothiadiazole very similar to the sulfonamide that started it all has been reported to reduce blood sugar in alloxan diabetic rats, but the experiment was not controlled with a known ~ulfonylurea.7~ Considering its structural similarity to the earlier compound, incomplete alloxanization appears a likely explanation of this result.
Pharmacolom, Mechanism of Action. The pharmacology of the sulfonylureas has been reviewed recently.74~10
It is now almost universally accepted that the primary action of the sulfonylureas is to release insulin from the pancreatic b-cells. Overwhelming evidence indicates that the drugs have no significant hypoglycemic effect in animals or human diabetics who are without functioning @-cells. The details of the process by which the sulfonylureas release insulin, however, remain as much a mystery as the process by which glucose produces the same effect. A vast amount of evidence has been marshalled against the view that the sulfonylureas affect hepatic glucose output or peripheral glucose utilization except through insulin release, but the uestion of a direct effect on the liver has not been entirely re~olved.~?There have been suggestions that sulfonylureas affect the plasma factors that influence insulin action (see above) but the significance of the effect to their hypoglycemic action remains to be assessed.76 It has long been recognized that the hypoglycemic effect of the sulfonylureas is related to their concentration in the blood.77 A s with many acidic drugs, plasma half life is a key determinant of overall effect79 and studies of their physiological disposition have proved to be important in guiding their clinical use.59,78 The metabolism of tolbutamide and chlorpropamide has been reviewed.74 The metabolism of glycodiazine ( lasma half life, 3.5-4 hr. )80,81 and tolazamide (plasma half-life, 7 hrs.) 85 has been studied in human subjects.
Chap. 15
Antidiabetics
Pinson
171 -
From the point of view of metabolism, acetohexamide is the most interesting of the sulfonylureas. Although its plasma half-life is short ( 1 . 3 hrs.), it is reduced in the body to a metabolite, L(-)-hydroxyhexamide, which is not only more active (2-2.4 times acetohexamide), but is also longer lasting (half-life, 4.6 hrs. ).82,83 The net result is that hypoglycemic activity in the blood, which is due to acetohexamide and the metabolite, persists for about the same length of time as it does with tolbutamide. The fact that the metabolite is at least twice as active as the racemic form of the compound would imply that the D(+) form is essentially inactive, which seems incredible, considering how widely significant activity is found among the sulfonylureas. Unfortunately, synthesis of the compound has not yet been reported. Other metabolites of acetohexamide, which are essentially inactive as hypoglycemic agents, result from hydroxylation in the cyclohexyl g roup .83 The importance of solubility, and of solution rate, as a function of surface area, to rate of intestinal absor tion and hence to the time course of blood levels has been i n ~ e s t i g a t e d . ~ ~ , ~ ~ , ' ~Proper ,~~ consideration of these factors in dosage form preparation can be important determinants of overall efficacy.84 Binurnides The biguanides are widely used in the control of diabetes; phenethylbiguanide (phenformin, DBI, Dibotin) in the United States, and, in addition, butylbiguanide (buformin, Silubin) and N,N-dimethylbiguanide (metformin, Glucophage) in Europe. Their principal clinical application is in combination with sulfonylureas for the treatment of patients whose disease is poorly controlled on either agent alone and for smoothing the hypoglycemic response of insulin-dependent brittle diabetic^.^',^^ Few new compounds of the class have been reported recently, but a series of aralkylamino, aryloxyalkylamino, and arylthioalkylamino-s-triazines (V) designed from consideration of the structure of the biguanides when written in the cyclic, hydrogen bonded form (IV) has been prepared. The compounds had only weak hypoglycemic activity in rabbits.89
IV
V
Pharmacolop;y,Mechanism of Action. The mechanism of biguanide induced hypoglycemia has still not been established. Different investigators cannot yet agree on which of the many effects that have been observed in experimental systems are responsible for their clinical action The roblem has been reviewed and discussed from several points of view.74,90,9P,92,93 It seems clear that glucose utilization by anaerobic glycolysis is increased, the further metabolism of the resulting pyruvate is inhibited, and lactate
172
Sect. EV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
t h e r e f o r e accumulates. T h i s i m p l i e s a n a c c e l e r a t i o n of a n a e r o b i c g l y c o l y s i s r e s u l t i n g from a r e d u c t i o n of o x i d a t i v e metabolic a c t i v i t y ; an e f f e c t f i r s t d e s c r i b e d by P a s t e u r and s i n c e known as t h e P a s t e u r e f f e c t , which Randie52 From t h e work of Passonneau and now p r e f e r s t o c a l l " r e s p i r a t o r y c o n t r o l " . LowryYg4P a r k l 3 and h i s co-workers ar,d Randleg5 and h i s associates, t h e mechanism of t h i s e f f e c t i s now understood i n some d e t a i l . A thorough d i s c u s s i o n of t h e s e c o n c e p t s i s c o n t a i n e d i n R a n d l e ' s review.52 Phenformin h a s been shown t o i n h i b i t some m i t o c h o n d r i a l e l e c t r o n t r a n s f e r r e a c t i o n s and t h i s h a s been suggested as i t s primary s i t e of a c t i o n . 9 0 S e v e r a l o b j e c t t o n s t o t h i s h y p o t h e s i s have been r a i s e d , however. F i r s t , t h e concentrations required t o i n h i b i t mitochondrial oxidation & I n view of v i t r o are much h i g h e r than have e v e r been observed i n t h e f r e q u e n t d i s p a r i t y between i n v i t r o and i n v i v o r e s u l t s and problems of t i s s u e and s p e c i e s s e n s i t i v i t y , t h i s o b j e c t i o n i s n o t , of i t s e l f , p a r t i c u l a r t h a t c l o s e l y r e l a t e d hypoglycemic l y s e r i o u s . However, a second o b j e c t i o n b i g u a n i d e s show a similar hypoglycemic e f f e c t but do n o t i n h i b i t m i t o c h o n d r i a l o x i d a t i o n , whereas o t h e r s , which are devoid of hypoglycemic a c t i v i t y , are n e v e r t h e l e s s p o t e n t i n h i b i t o r s of m i t o c h o n d r i a l e l e c t r o n t r a n s f e r r e a c t i o n s g 7 -- d e s e r v e s c a r e f u l c o n s i d e r a t i o n . T h i r d , i t h a s been shown t h a t low conc e n t r a t i o n s of buformin ( 1 - 5 p g / m l ) , which are i n t h e range a t t a i n e d i n v i v o , a c t u a l l y i n c r e a s e t h e a c t i v i t y o f t h e p e n t o s e shunt i n a d i p o s e t i s s u e and t h i s i s c i t e d as e v i d e n c e t h a t t h e hypoglycemic a c t i v i t y of t h e b i g u a n i d e s does n o t i n v o l v e i n h i b i t i o n of o x i d a t i v e p r o ~ e s s e s . 9 ~The c o n c l u s i o n t h a t o x i d a t i v e metabolism i s n o t i n h i b i t e d seems u n t e n a b l e , c o n s i d e r i n g t h a t hypoglycemic d o s e s of phenformin i n v a r i a b l y c a u s e i n c r e a s e s i n blood and u r i n a r y l a c t i c a c i d and t h a t p y r u v a t e t o l e r a n c e i s decreased.98 The buformin e f f e c t on a d i p o s e t i s s u e i s v e r y similar t o t h e e f f e c t of epinephrine99 and, cons i d e r i n g t h e r e a s o n a b l e s t r u c t u r a l analogy between buformin and t h e a l i p h a t i c p r e s s o r amines, may r e s u l t by a similar mechanism.
--
One of t h e most p e r t i n e n t i n v e s t i g a t i o n s of t h e e f f e c t of phenformin on metabolism i s t h a t of Williamson, Walker and Renold.lOO Using t h e i s o l a t e d p e r f u s e d rat h e a r t , t h e y found s u b s t a n t i a l i n c r e a s e s i n g l u c o s e u p t a k e and l a c t a t e f o r m a t i o n and d e c r e a s e d i n t r a c e l l u l a r ATP a t phenformin c o n c e n t r a t i o n s of 3 5 - 5 0 Gg/ml. The a u t h o r s i n t e r p r e t t h e s e f i n d i n g s i n t h e l i g h t of c u r r e n t c o n c e p t s of n e u c l e o t i d e and phosphate feedback c o n t r o l of p h o s p h o f r u c t o k i n a s e , a s t h e rate c o n t r o l l i n g s t e p of g l y c o l y s i s , a n d f u r t h e r s u g g e s t p o s s i b l e i n h i b i t i o n of p y r u v a t e d e c a r b o x y l a t i o n . Like many i n v e s t i g a t o r s of t h e b i g u a n i d e s , Williamson, Walker and Renold d i s c o u n t t h e r e l e v a n c e of t h e i r r e s u l t s t o t h e c l i n i c a l s i t u a t i o n because of t h e r e l a t i v e l y h i g h drug c o n c e n t r a t i o n s used. Such d i f f e r e n c e s seem much less i m p o r t a n t i f one c o n s i d e r s p o s s i b l e t i s s u e and s p e c i e s s e n s i t i v i t y . The rat i s remarkably i n s e n s i t i v e t o phenformin, showing l i t t l e hypoglycemic e f f e c t at 80 m /kg 101 It w h i l e human d i a b e t i c s respond w e l l a t d o s e s of 50-150 mg ( 1 - 2 mg/kg).'8 h a s been p o i n t e d o u t t h a t an a d d i t i o n a l component of hypoglycemic a c t i o n probably r e s u l t s from impairment of t h e r e c o n v e r s i o n of lactate, formed i n The i n h i b i t i o n o f p y r u v a t e decarboxylmuscle, t o g l u c o s e i n t h e liver.90,102 a t i o n mentioned above would a c c o r d w i t h t h e d e c r e a s e d l i o g e n e s i s t h a t h a s been suggested by r e c e n t c l i n i c a l o b s e r v a t i o n s ,103,104,1g5 s i n c e reduced a v a i l a b i l i t y of a c e t y l CoA would be expected t o i m p a i r l i p i d s y n t h e s i s . T h i s a s p e c t of t h e a c t i o n of t h e b i g u a n i d e s does n o t a p p e a r t o have been s t u d i e d
Chap. 15
173 -
Pinson
Antidiabetic s
directly. The possibility of a direct action of the biguanides on adenyl cyclase to cause cyclic 3',5'-AMP activation of phosphofructokinase has not apparently been considered but it is an intriguing one. Although cyclic 3',5'-MP is known to activate mammalian phosphofructokinase, a hormonal effect through adenylcyclase stimulation has not yet been demonstrated.Io6 Y 125 The interesting enigma that the biguanides do not cause hypoglycemia in non-diabetic individuals has received some clarification recently.lo7 Glucose turnover studies in non-diabetic human subjects have shown that glucose utilization is markedly increased but that hypoglycemia does not occur, apparently because the increased utilization is offset by a corresponding increase in glucose output from the liver. It seems reasonable to suggest that an effect on hepatic glucose output is the key difference, in this respect, between diabetics and non-diabetics. Hepatic glucose out ut in diabetics comes mainly from gluconeogenesis, which phenformin inhibits;f02 whereas the hepatic glucose output of non-diabeti.:s, under the conditions of this experiment, would come primarily from glycogmolysis, which phenformin accelerates.90 The distribution, metabolism, and excretion of henformin, metformin and buformin have been investigated.lo8, log ,llo,11'1 The physiological disposition of the biguanides is typical of that of other strong organic bases. The compounds diffuse from the blood, where concentrations are invariably low and not very persistent, into acidic gastric juice, are found in higher concentrations in tissue than in the blood, and are eliminated efficiently in the urine. The identity of their metabolites has not been established with certainty. Other Hypoglycemic Compounds Pyrazoles and Isoxazoles. Since 1963, a series of reports have described two interesting hypoglycemic and lipolysis inhibitin corn ounds, 3,5-dimethylpyrazole (VI) ana 3,5-dimethylisoxazole (VII).112,~13,1p4,115
CH3
pcH3 CH3
CH3
H
VI
VII
HOOC
(flCH3 N/
H
VIII
HOGC (flCH3 O N IX
Both compounds are remarkably potent hypoglycemic agents (50 and 200 times as active as tolbutamide) in glucose primed rats but are much less active in fasted animals. Both are apparently inactive, themselves, but depend for activity on metabolism to 3 -methylpyrazole-5-carboxylic acid (VIlI) and 3methylis0xaz0l~~5-carboxylic acid (IX), respectively.116,11' Although the carboxylic acid is a relatively minor metabolite of dimethylpyrazole (10-15% in the rat), it apparently accounts for all of the activity. The major metabolite, 4-hydroxy-3 5-dimethylpyrazole (70-75% in the rat) shows no hypoglycemic activity.li7 The two carboxylic acids are potent inhibitors of the release of free fatty acids from adipose tissue and the authors make the reasonable suggestion that this is their primary action, from which the hypoglycemic effect r e s ~ l t s . ~ The ~ ~ mechanism . ~ ~ ~ by which inhibition of
174
Sect. IV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
lipolysis might promote glucose utilization has been discussed extensively by Randle,48 and these compounds might well be used in further examination of some of his hypotheses. 5-Methylpyrazole-3-carboxylicacid was effective in reducing the plasma free fatty acid levels of fasted human subjects118 but the concomitant effect, if any, on their blood glucose was not reported. None of a series of pyrazole congeners of 3,s-dimethylpyrazole was apparently more active than the parent compound.120 L-Leucine. The subject of leucine induced hypoglycemia, which occurs in certain sensitive individuals, particularly some children with "idiopathic hypoglycemia'' and patients with functioning islet cell tumors, has been very ably reviewed recently by Fajans.l*I Addition of L-leucine (12 g/day) to the regimen of sulfonylurea secondary failures resulted in good diabetic control in 8 o f 10 patients.122
A series of hexahydroindenio[1,2-~]pyrrols and indanamines have been reported to reduce the blood glucose of orally treated rabbits but details that might permit an assessment of their potential as oral antidiabetic agents are lackirg.123 References 1. 2. 3. 4. 5.
6.
I. 8. 9. 10. 11. 12. 13. 14. 15 * 16.
11. 18. 19. 20. 21.
22. 23.
M. Janbon. J. Chaptal, A. Vedel, and J. Schaap, lontpelller Meed.. 21-22, 441 (1942). 253 (1918). C. K. Watanabe, J. Biol. Chem., P. White. led. Clin. I. An.. 3. 855 (1965). A. E. Renold and 0 . F. Cahill, Jr. in "The Metabolic Basis of Inherited Disease", 2nd Ed., J. B. Stanbury, J. B. Wynngaarden and D. S. Fredrickson. Eds., lcQrau-H111 Book Co., leu York, 1965. B. S. Leibel and 0. A. Wrenshall, Lds. "On the Uature and Treahent of Diabetes", Sxcerpta ledloa Foundation. Xeu York, 1965. R. H. Williams and F. C. Wood. Jr., Reference 5. Chapter 51. -R. II. Williams. Ann. Intern. led., 63, 512 (1965). S. A. Berson and R. A . Yalou. Diabetes, 14. 549 (1965). 0 . F. Cahill. Jr. led. Clin. x. An., 49. 881 (1965). 0. M. Orodsky and P. H. Forsham. Ann. Rev. Physiol.. g.341 (1966). P. P. Lacy. C l b a Found. Collos. Xndoorlnol., 15,15 (1964). S. E. Brolin. B. Hellran and 8 . Knutson. Eds. "The Structure and Metabolism of the Pancreatic Islets", Pergaron Press, !Jew York, 1964. H. P. Morgan. J. R. Xeelg. R. P. Wood, C. Llebecq. €I Liebermeister . and C. 8 . Park, Federation Proc.. 24, 1040 (1965). R. Levine. 1011. I. 0. Wool, 1060. D. X. Klpnl8 and J. E. Parrish, E .1051. J. S. Bishop, R. Steele, I. Altszuler, A. Dunn, C. Bjerknes and R. C. de &do. Physiol.. 208, 301 (1965). Q. Weber and 1. L. Singhal. Life Scl.. 2, 1993 (1965). A. Sols, Reference 5. Chapter 9. D. 1. Klpnis and R. Hallchoff, J. Clin. Invest., 44. 1064 (1965). A. Oellhorn and W. Benjamin. Science, 148,1166 (1964). D. R. Rampersad and I. 0 . Wool, Science, 149, 1102 (1965). E. Sprols. Reference 5, Chapter 16.
a,
s.
s.
uJ.
Chap. 15
Antidiabetic s
Pinson
175 -
24. D. H. Lockwood and T. X. Prout, Uetab. Clin. -2.. l4, 530 (1965). 25. B. H. Segal, Uetab. Clin. XQ 758 (1964). 26. S. H. Oershoff. A. 1. Huber and B. H. Antonlades, Uetab. Clin. Q.. g ,325 (1966). 27. H. H . Antonlades. A. U. Huber. B. R. Boshell. C. A. Saravis and S. Y. Oershoff,
.,s,
28.
29. 30. 31. 32. 33. 34.
35. 36. 37. 38. 39. 40. 41. 42. 43. 44. 45. 46. 47. 48. 49 * 50.
51. 52. 53. 54.
55. 56. 57. 58.
59. 60. 61. 62. 63. 64. 65.
a
Xndocrinoloa. 709 (1965). 1. Samaan, J. Brown, R. Fraser and I. Trayner, Brit. Hed. J.. 1965(1), 1153. T. Welborn, I?. Samaan, R. Fraser and J. Brown. Mabetologla. 1, 74 (1965). B. R . Froesch, H. Burg1 and U. S. Uuller, Helv. Xed. Acts.. 2, 341 (1965). Q . F. Cahlll. Jr., V. Laurls, J. S. Soeldner, D. Slone and J. Steinke. Btab. c u 769 (1964). J. Steinke, S . Uikio and 0 . F. Cahill, Jr., Yew pllg. J. Hed.. 273, 1464 (1965). J. K. Davidson, B. E. Haist and C. H. Best, Diabetes, 12, 448 (1963). L. Power, C. Lucas, and J. Is. Conn. Hetab. Clin. Exp.. l4. 945 (1965). W. 1. Shaw in "Adipose Tissue", A. E. Renold and 0. F. Cahlll. Jr., Pds., Handbook of Phusiologg, Section 5. American Physiological Society. Washington, 1965. J. Vallance-Owen, Reference 5, Chapter 23. H. Alp and L. Recant, 3. Clin. Invest., 44, 870 (1965). U. L. Ashton. J. fndocrinol., 33, 103 (1965). J. U. Xnsinck, R . J. Mahler and J. Vallance-Owen, Blocher J., 2.150 (1965). R. L. Fenichel. W. H. Bechrann, and H. 11. Alburn. Biochemistry, 5 , 461 (1966). I). 1. Kipnis, Reference 5 . Chapter 18. R. C. Haynes, J r . , Advan. X n m e Regulation. 2, 111 (1965). A. B. Xisenstein, 121. X. Y. Sutherland and 0. A. Robison, Pharmacol. Rev., Is,145 (1966). A. 0. Kris. R. L. Xlller, F. P. Wherry and J. Y. Wason, Pndocrinoloeg!. 3, 87 (1966). D. Porte, Jr., A . Oraber. T. Kuzuya and R. H . Uilllans. J. Clin. Invest., &%1087 . (1965) D. Steinberg, Pharmacol. Rev., 18,217 (1966). P. J. Randle. Reference 5. Chapter 25. Pharmacol. lev., B, 145-314 (1966). U. S. Ooldstein, An. J. Physiol., 200, 67 (1961). X. S. Ooldstein. Paderation Proc., 2,441 (1966). P. J. Randle in "HOmeOltaSil)and Feedback Uechanlsms", Society for mperirantal Biology Synposia XVIII. Academic Press Inc., Yew York, 1964. p. 129-156. A. X. Renold and 0 . F. Cahill. Jr., "Adipose Tissue", Handbook of Physiology, Section 5. American Physiological Society, Washington. D. C., 1965. A. P. Renold, 0. B. Cmfford, U. Stauffacher and B. Jearenaud, Mabetologla, 1,4 (1965). J. P. Flatt and P. 6. -11, Reference 53, Chapter 26. H. S. Kornacker and P. 0. Ball, $roc. Hat. Acad. ScI. 0. S., 54. 899 (1965). The preparation of glycodiazine and a number of analogs, with Its PhaFlaColOgJr, metabolism and clinical use deacrlbed in a. series of 10 papers; Arzneirittel-Forsch.. 14. 373 (1964). R. D. H. Stewart and D. X. Anderson, Brit. Hed. J., 1965(21. 682. F . Q. XcUahon. H. L. Upjohn, 0. S. Carpenter, J. B. Wright. H. L. Oster, and U. X. Dulln. Current ,.-T 2, 330 (1962). R. Bressler and R. Katz, Current Therap. Res., 1, 219 (1965). P. H. Orinnell, T. 0. Skillman, R. Barse. and C. L. Holler, Current them^. Res.. 2, 433 (1964). Federal Register, 2,2561 (1966). J. H. UcUanus, J. W. HcFarland, C. P. Oerber. W. U. UcLaPore, and 0 . D. Laubach. J. led. Cher.. 8 , 766 (1965). J. 1. 1cwSnus and C. F . Oerber. J. Ued. Chem., 2, 256 (1966). J. W. UcFarland. C. P. Qerber. and Y. 1. XcLarore, J. Had. Chu.. 2. 781 (1965).
s., 13.
u..
-
Sect. I V
176 66. 61. 68. 69. 10. 71. 72. 13. 14.
75. 76.
11. 78. 19. 80. 81. 82. 83. 84. 85. 86. 81. 88. 89. 90. 91. 92.
93. 94. 95. 96. 91. 98. 99. 100. 101. 102. 103. 104. 105. 106. 101. 108. 109.
- Metabolic
& Endocrine
H e i n z e l m a n , Ed.
E. H. Wiseman. J. 1. Perelm, K. F. Pingor, and R. Plmon. J. Ned. m.,4, 771 (1965). D. P. Hayman. 0 . B. Jackman, V. Petrow, 0 . Stephewon. and A. 1. Wild, J. P h a m . Phamacol., 677 (1964). D. P. H a m , V. Petrow, and 0 . Stephanron, J. P h a m . Pharucol., Is. 538 (1964). J. Lederer, J. Ned. Cham., 2, 370 (1064). L. J. L o n e r DA. Blanahi, an8 A. Borron. Hetab. Clln. Un., 578 (1965). K. 0 . Jo8hl and J. 9. h p t a , J. 1ndi.n Chm. Soc.. g,320 (1965). J. B. Wright, J. Bb8, Cham., g, 589 (1965). D. Bargeton, J . Roquet, A. Rouquer. A. CROrsaIn, and A. Bledar, Aroh. Intern. phamacodmamie, 185,319 (1965). L. J. P. Duncan and B. F. Clarke, Ana. Rev. Pharucol., S, 151 (1966). A. R. Colwell, Metab. Clln. -2.. 13, 1312 (1964). 8. 1. htOkIla8e8, J. A. Borrp.8. R. ~ r l ~ - D . r a l o rH., 1. Pyle, S. J. Naturkle, 0 . Low-Castaneda, and A. Narble, New -1. J. md., 269. 386 (1963). K. N. Wort and P. C. Johawon, Mabetor, 2. 464 (1960). J . Sheldon, J. h8er8on. and L. Stoner. Diabetes. 362 (1965). B. It. Bloar and 0 . D. loubach. Ann. Rev. PharrPcol., 2, 61 (1962). K. 8. Kolb. 1. KraMr. and P. X. Schulre. Arzneirittel-Forsch.. 385 (1964). L. Oerhardr, H. 01bI.n. and K . H. Kolb, Armeirittel-Fonch., 2, m4 (1964). D. 1. Smlth, T. J. Veochio, and A. A. F0ri.t. Netab. Clln. Up., 2, 229 (1965). R. 1. HcNahon. F. J. Narshall, and H. W. Culp, J. P w o o l . U p . Therap., 272 (1965). P. ielson, X. I. Knoeahel, W. X. Hailin, and J . 0 . Wagner, J. P U N . s o l . , 2,509 (1962). X. Nelson, S. Long, and J. 0 . Wagner, J. Pham. S o l . , 53, 1224 (19M). W. I. Higuchi, 1. A. Nlr, A. P. Parker, and W. P. Hailin, J. Pham. S o l . , 54, 8 (1965) J . I. bodman, Xetab. Clin. Un.. 14. 1153 (1965). B. P. Clarke and J. P. Duncan, Lancet, 1966(11, 1248. If. Suter and H. Zutter, Helv. Chim. Acta, 48, 1940 (1965). D. P. Stainer an8 R. H. W l l l i o r s , Mabetar, 8, 154 (1959). H. Dnweke and I. Bach. netab. Clin. UP., l2. 319 (1963). J. Sterna, Netab. Clln. UE..2,191 (1964). 1. Beckmann, Deut. mod. Wochschr.. 90. 1589 (1965). J. V. P a 8 8 O Z U l ~ Uand 0. H. L O W . 1,10 (1962). P. B. Oarland and P. J. llPndle. Blochea. J., 93. 678 (1964). A. B. Falcone, R. L. llao and X. Shrago. J . Blol. Cham.. 237, 904 (1962). Q. Ungar, 5 . PSYChoYO8, and H. A. H a l l , Netab. Clln. U p . . 2, 36 (1960). S. S. Fajans, J . A . Xoorehouse, H. Doorenbos. L. H. Louis, and J. W. COM, Diabetes. 9, 194 (1960). 0 . P. Cahill. Jr.. B. Leboeuf, an8 It. B. Fllnn. J. Biol. Chem., 235. 1246 (1960). J. R. Ullllorson. 1. 5 . Walker and A. E. Itenold, Metab. Clln. an..l2, 1141 (1963). 0 . Wwr. L. Freedman an8 9 . L. Shaplro. Proc. 900. U p . B l o l . ned., 95, 190 (1951). S. J. Patrick, Can. J. bloc her.,^, 27 (1966). D. P. Patel and J. 1. Stowerr, Lancet, l 9 6 4 ( 2 ~ ,282. J. Sch-rtg, s. N l r s k y . and L. X. Schaefer, Lancet, 19SS(ll, 959. J. Pedarren, Acta Xndoorlnol.. 49, 419 (1966). T. X. npmoar. P b u v c o l . Rev., 2,173 (1966). 0 . 1. Searle, 9. Schilling, D. Porte. J. Barbacoia, J . DoQmeia. and 1. ti. Cavalieri, Diabetes. l5. 113 (1966). A - 1-Wicklr.c. J. Stewart. and 0 . 5 . S e r i f , Mabetes. 2. 163 (1960). R. -0kMAn. 0 . Hwbner. Arznoinittel-Forsch., 5 . l, 165 (1965).
Is.
s,
z,
z.
xD
,.-
-
*.
Chap. 15 110. 111. 112. 113. 114. 116.
Ant idiabe tic s
Pinson
177 -
R. BeckroM, Arzneirittel-Forsoh.. 18, 761 (1965). Q. Debry and F . P. Cherrler. Theraple. 2.352 (1965). U. 1. Dulln and 0. C. Oerrltsen, Proc. Soo. PD. Blol. Ned.. 113,683 (1963). 0 . C. Oerrltsen and W. 1. Dulln. Diabetes. & 507 (1965). A . B1r;zI. A. Jorl, 1. Veneronl. and S. Oarattint, Life Solences, 3, 1371 (1964). W. 1. Dulln, 0. H. Lund, and 0. 0. Qerrltsen, Proo. Soe. ZXP. Biol. Ned., 118,
499 (1965). 116. D. L. Slrlth, A. A. lOrl5t. and W. 1. Dulln, J. Hod. Chsr., S, 350 (1965). Therap., 150, 316 117. D. L. Slith, A . A. Forist, 0 . C. Oerrltsen. J. Pharmaool. PD. (1966). 118. 0. C. Oerrltsen and W. 1. Dulln, J. Phosrpcol. P p . Therap., 160, 491 (1965). 119. Y. 1. Dulln and 0. C. Oerrltsen, Proo. Soo. P p . Blol. Ned., 121. 777 (1966). 120. J. B. Wright, Y. 1. Dulln, and J. H. I(arklllle, J. Ned. Chem.. 2 , 102 (1964). 12l. 5 . S. FaJaM, New Kml. J. n o d . , 272, 1224 (1965). 122. H. R l f k l n , 5 . Podolsky, H. Ross. X . 0 . Conason, and S. Nost, Mabetes, l5, 222 (1965). 123. S. C. LphlFi a d B. Pathak, J. b d . Ch-., 1, 131 (1966). 124. 1. A. -5i0, J. S. Soeldner and 0. F. Cphlll. Jr., Dlabetologia, 1,125 (1965). 125. R. M. Denton 8nd P. J. Ilurdle, Bloohem. J., E,6P. (1986).
Sect. I V - Metabolic & E n d o c r i n e
178 -
Chapter 16.
H e i n z e l m a n , Ed.
Atherosclerosis
Joseph J . Ursprung, The Upjohn Company, Kalamazoo, Mich. Introduction. - Atherosclerosis appears t o be a "disease of regulation" (I. H. Page) i n which a g e n e t i c a l l y conditioned cardiovascular system i s rea c t i n g t o an ever-changing environment. The a b i l i t y t o regulate t h i s i n t e r a c t i o n determines i n t h e long run whether a t h e r o s c l e r o s i s w i l l , or w i l l not, p r e v a i l . The disease is a l e s i o n of l a r g e and medium-sized a r t e r i e s charact e r i z e d by i n t i m a l thickening with f o c a l deposits i n t h e intima of yellowish plaques containing l i p i d s , carbohydrates, blood products, fibrous material and calcium. I n t h i s c o n s t r i c t e d a r t e r y thrombus formation occurs i n t h e ulcerated atheromatous plaque which re,sults ultimately i n occlusion. Serum c h o l e s t e r o l l e v e l s and blood pressure a r e useful p r e d i c t o r s of t h e disease and obesity, smoking, l e v e l of physical a c t i v i t y , psycho-social influences, increased t r i g l y c e r i d e and carbohydrate metabolism, enhanced blood c l o t t i n g , hormonal balance and genetics a r e f a c t o r s which play a r o l e but t h e i r r o l e i s as yet unclear. There has evolved t h e concept t h a t a t h e r o s c l e r o s i s i s a multifaceted disease and t h a t no single cause e x i s t s . Two main theories, both of which a r e susceptible t o experimental investigation, e x i s t today. The f i l t r a t i o n concept of Aschoffl focused a t t e n t i o n on disordered l i p i d metabolism and s t i l l c o n s t i t u t e s the broadest approach t o atherogenesis while t h e thrombogenic theory proposed by Rokitansky (1844) and revived by M i d 2 l e d t o increasing i n t e r e s t i n intramural c l o t t i n g mechanisms and t h e i r r e l a t i o n s h i p with plasma l i p i d s . While l i p i d s appear t o bear a r e l a t i o n s h i p t o human a t h e r o s c l e r o s i s and associated thrombosis, t h e i r involvement s t i l l i s based on assumption r a t h e r than f a c t . Whether l i p i d s deposited i n t h e vessel come from t h e blood or a r e synthesized i n t h e blood v e s s e l i s s t i l l debated. Increasing a t t e n t i o n i s being paid t h e blood vessel, i t s e l f . I n t h e atherosclerosissusceptible White Carneau pigeon enhanced a o r t i c f a t t y a c i d and cholesterol e s t e r synthesis i s highly c o r r e l a t e d with t h e s e v e r i t y of t h e disease3. I n t h e rat, hypertension increases c h o l e s t e r o l synthesis4 and c h o l e s t e r o l levels5 i n t h e a o r t a as w e l l as i n t h e l i v e r and o t h e r tissues.' Chapman7 provides evidence t h a t t h e f o r c e which d i s r u p t s an a t h e r o s c l e r o t i c plaque t o form a thrombus proceeds from within t h e v e s s e l w a l l toward t h e lumen. Regardless, by far t h e g r e a t e s t e f f o r t has been concentrated on reducing blood liDid l e v e l s , p a r t i c u l a r l y c h o l e s t e r o l , i n t h e hy-perlipemic p a t i e n t . Diet. - Epidemiological s t u d i e s provide a basis f o r t h e hope t h a t d i e t a r y adjustment may reduce t h e incidence o r a t l e a s t delay the development of atheros c l e r o s i s and coronary h e a r t disease. Preliminary r e s u l t s from t h e national d i e t - h e a r t study8 and t h e "anti-coronary club'ls a r e encouraging and t h e A.M.A. Council on Foods and N u t r i t i o n recommends d i e t a r y treatmental and prophylaxis against coronary heart disease. The r i s k of coronary h e a r t disease seems t o bear a t l e a s t some r e l a t i o n s h i p t o c h o l e s t e r o l i n t h e blood as shown by t h e Framingham s t u d y . l o Among d i e t a r y agents which influence cholesteremia a r e t o t a l fats ,11 polyunsaturated fats ,I2 t h e r a t i o of polyunsaturated t o s a t u r a t e d fat,13 c h o l e ~ t e r o l ,amino ~ ~ a c i d content15 and carbohydrate .I6 A recent review17 discusses t h e r e l a t i o n s h i p of d i e t a r y f a t and coronary heart disease.
-
Chap. 16
Atherosclerosis
Ursprung
179 -
A technique using t h e isotopic steady state24a suggests a limited cholest e r o l absorption i n man and t h i s may be h i s major protection against a high cholesterol diet24 since t h e r e appears t o be no feed-back mechanism i n man t o compensate f o r d i e t a r y c h o l e s t e r o l intake.24b On a high c h o l e s t e r o l d i e t 6080s of t h e serum c h o l e s t e r o l i s derived from endogenous sources.24a This contrasts with a recent report t h a t t h e serum l e v e l of c h o l e s t e r o l i n humans i s proportional t o t h e square root of t h e d i e t a r y intake of cholesterol.25 The r a t e of synthesis of c h o l e s t e r o l i n t h e s m a l l i n t e s t i n e a l s o i s independent of c h o l e s t e r o l feeding o r fasting.26 E a r l i e r work with primates showed that they do not respond t o d i e t a r y cholesterol; however, a t h e r o s c l e r o s i s can be induced27 when s a t u r a t e d f a t s a r e added t o a high c h o l e s t e r o l d i e t t o fac i l i t a t e absorption. Although c h o l e s t e r o l feeding w i l l produce myocardial inf a r c t s i n r a b b i t s , no c o r r e l a t i o n has been seen i n t h i s species between t h e occurrence of i n f a r c t s and t h e l e v e l of c h o l e s t e r o l i n t h e blood.23 The f a l l of serum c h o l e s t e r o l on feeding a d i e t high i n unsaturated f a t s occurs i n t h e absence of c h o l e s t e r o l excretion changes. This f a l l i n cholest e r o l l e v e l s i n t h e rabbit28 and i n man2’ seems t o be due t o plasma-tissue r e d i s t r i b u t i o n . An a l t e r a t i o n i n l i p o p r o t e i n s t r u c t u r e r e s u l t s such t h a t equilibrium between plasma and t i s s u e c h o l e s t e r o l pools favors t h e l a t t e r . 3 0 This c o r r e l a t e s with t h e finding that manipulating t h e d i e t a r y f a t intake i s not accompanied by a reciprocal change i n cholic acid turnover31 nor i s t h e r e a consistent r e l a t i o n s h i p between s t e r o l excretion and changes i n serum cholest e r o l concentrations. 32 The hypocholesteremic e f f e c t of d i e t a r y l i n o l e i c a c i d i n t h e r a b b i t appears t o be proportional t o t h e extent t o which l i n o l e i c a c i d i s incorporated i n t o plasma c h o l e s t e r o l e s t e r s . 34 Measurement of t h e l i p i d composition of a r t e r i a l t i s s u e and atheroma i n humans, however, has shown only an increased l i n o l e i c a c i d content i n atheroma i n those on a d i e t high i n uns a t u r a t e d fats as compared t o controls .33 A serum p r o t e i n deficiency i s reported i n humans with coronary a r t e r y An adequate intake of d i e t a r y p r o t e i n seems t o be necessary f o r disease.” e f f e c t i v e regression of coronary a t h e r o s c l e r o s i s i n chickend’In chickens on an atherogenic d i e t , cerebrosides and soy s t e r o l s reduce serum c h o l e s t e r o l and t h i s reduction c o r r e l a t e s with retarded development of a t h e r o s c l e r o s i s .20 It has a l s o been suggested t h a t a substance i n soy bean meal w i l l p r o t e c t rabb i t s on a high f a t d i e t against a t h e r o s c l e r o s i s .22 Serum Lipids. - Many attempts have been made t o reduce serum c h o l e s t e r o l by i n h i b i t i n g i t s biosynthesis. Triparanol w a s introduced some years ago f o r t h i s purpose but w a s withdrawn because of severe systemic reactionsa7 ( l e n t i c u l a r c a t a r a c t s , alopecia and i c h t h y o s i s ) . It a l s o appears t o increase a o r t i c a t h e r o s c l e r o s i s i n chickens38 and produces congenital malformations i n mice and rats.3s Compounds recently reported, which a r e s i m i l a r i n many respects t o t r i p a r a n o l , include some pyridyl analogs,40 c y a n ~ s t i l b e n e s ,triarylmeth~~ anols42 and other b a s i c ~ a r b i n o l s . ~ ~ Of some b a s i c e t h e r s of N-hetero-substituted a n i l i n e s which show cholest e r o l lowering a c t i v i t y , 4 3 compound 1 i s most a c t i v e . Three new c l a s s e s of
1.
2.
180
Sect. IV
H
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
6 3 0 4.
3.
inhibitors are shown in structures 2 [journal gives name as 4-(2-chlorophenyl)a-(p-methoxyphenoxymethyl) -1-piperazine] , 3 and 4.44 These compounds (2-4)were shown to accumulate ~-dehydrocholesterolin the plasma and tissues of rats and in this respect are similar to compounds related to AY-9944 reported by Ayerst.45 25-Azacholesterol blocks cholesterol synthesis at the desmosterol stage4" as has also been seen with 20,25-dia~a-~~ and 22,25-diazacholesterol.48 In man 20,25diazacholesterol lowers blood cholesterol but toxic effects are numerous 47b Myatonia and Keratoderma have been rep0rted4~and in each instance serum desmosterol was elevated and cholesterol was reduced at the time these toxic effects became evident. Some 4-azachole~tenes~~ have also been reported to inhibit cholesterol synthesis. Cyclization of squalene is inhibited by t0lbutamide5~while phenethylbiguanide inhibits conversion of farnesyl pyrophosphate to squalene 51 Phenyl- and biphenyl-substituted acids have been studied extensively f o r their cholesterol lowering activity.52 Activity is reported also with biphenyl ether-substituted acids.s2c The agent of most interest in this area remains pThe reader is chlorophenoxyisobutyric acid (CPIB, Clofibrate, atromid S) directed to the Atromid for background information. In bovine vascular tissue in vitr054, in rats55 and in man56 CPIB inhibits cholesterol biosynthesis, apparently between mevalonic acid and isopentenyl pyrophosphate 55 It was again confirmed that CPIB alone is as active as the combination of CPIB and androsterone (Atromid)57 and that it lowers triglycerides to a greater extent than cholester01.57b It also markedly decreases low density lipoprotein (a suggested mode of action f o r CPIB)S8 and reduces the glyceride content of high density lipoprotein. CPIB is reported to decrease the B/ol lipoprotein ratios9 and increase uric acid excretion.60 The norepinephrine-induced rise in free fatty acid levels is unaffected by CPIB in humans."l The effect of CPIB on the fibrinolytic system is variable62 but does not appear to be significant.63 Prospective studies of large groups has verified that the risk of myocardial infarctions is substantially greater in cigarette smokers than in non-smokers64 and this appears to be mediated via the nicotine-induced release of e~inephrine.~~ Nicotine, in dogs, has been shown to raise cholestero166 and blood sugar67 and this may be related to the elevation of free fatty acid levels?" Caffeine raises free fatty acid levels68 and it is suggested that coffee intake can be associated with heart disease.64b Agents which will regulate free fatty acid levels are of interest both in diabetes and atherosclerosis. 3,5-Mmethyli~oxazole,~~ 3,5-dirnethylpyra~ole~~ and its metabolite, 5-methylpyrazole-3-carboxylic acid7' dramatically lower fatty acids and blood sugar in animals. Infusion of norepinephrine produces a rapid rise in free fatty acid and in plasma triglycerides of l o w density lipoprotein.72 Nicotinic acid blocks this norepinephrine-induced rise in free fatty acid73r"l and lowers free fatty acid74 and triglyceride75 levels in the blood. It is also reported to reduce the cholesterol content of various tissues in cholesterol-fed
.
.
.
Chap. 16
Atherosclerosis
U r sp rung
181 -
~ l~u m i r a b b i t s .76 I n humans it produces abnormal carbohydrate m e t a b o l i ~ m . A num n i c o t i n a t e i s e f f e c t i v e as a hypocholesteremic agent and appears t o be b e t t e r t o l e r a t e d than n i c o t i n i c acid.78 A s e r i e s of methoxamine analogs7’ and a v a r i e t y of antidepressants80 a r e a l s o reported t o block t h e l i p o l y t i c e f f e c t s of epinephrine. Single i n j e c t i o n s of i n s u l i n cause acute f a l l s i n f r e e f a t t y acids i n man82 while i n another study a combination of potassium, glucose and i n s u l i n has been used t o t r e a t myocardial i n f a r c t i o n with some b e n e f i t .el Various agents reported t o lower c h o l e s t e r o l i n animals a r e chondroitin s u l f a t e A,83 vanadium,84 a mitochondria1 f r a c t i o n from starved rat liver8’ and i n man, 6-azauridine,eSa p-aminosalicylic acide6 and a r e l a t i v e of heparin, a s u l f a t e d polyanion SP54.e7 I n s u l i n i s reported t o decrease t h e c h o l e s t e r o l content of blood and a o r t a while increasing t h e l e v e l i n l i v e r and adrenalse7& i n cholesterol-fed r a b b i t s . I n p r i n c i p l e , feeding substances which remove b i l e acids from t h e i n t e s t i n e and which prevent t h e i r reabsorption should increase b i l e acid excretion and speed up c h o l e s t e r o l degradation. This i s , indeed, possible with agents such as f e r r i c chloride,88 aluminum hydroxide89 and with d i e t a r y saponins. so The b i l e acid-binding anion-exchange r e s i n MK-135 (Cholestyramine)s1 shows marked lowering of serum c h o l e s t e r o l i n t h e chicken, rabbit,s2 dogs3 and mans4 and has u t i l i t y i n r e l i e v i n g p r u r i t i s associated with b i l i a r y c i r r h o s i s .95 Steatorrhea i s a problem with t h i s drug97 but a r e p o r t i n d i c a t e s that when medium chain t r i g l y c e r i d e s a r e s u b s t i t u t e d f o r t h e long chain t r i g l y c e r i d e s i n t h e d i e t t h i s i s controlled.s8 Metamucil, an o r a l hydrophilic c o l l o i d , i s also reported t o lower serum cholesterol.S9 P-SitosterolLo0 plays a r o l e i n i n h i b i t i n g absorption of c h o l e s t e r o l . The a n t i b i o t i c s neomycin, N-methylated neomycin, but not streptomycin or Nacetylated neomycin, reduce c h o l e s t e r o l i n t h e chick,lol presumably by i n t e r f e r i n g with absorption processes. Paramomycin a l s o lowers serum c h o l e s t e r o l while reducing b a c t e r i a l f l o r a . l o 2 The r o l e of hyperglyceridemia i n a t h e r o s c l e r o s i s i s s t i l l cloudylo3 but it appears that t h e t r i g l y c e r i d e l e v e l i s no more u s e f u l than c h o l e s t e r o l l e v e l s i n i d e n t i f y i n g subjects with ischemic h e a r t disease .Io4 P a t i e n t s with elevated t r i g l y c e r i d e s a l s o have a high incidence of elevated f a s t i n g blood sugars and elevated f r e e f a t t y a c i d s l o s and thus have an increased r i s k of myocardial i n f a r c t i o n and l a t e n t diabetes. It i s perhaps s i g n i f i c a n t that i n t h e rat u t i l i z a t i o n of fat for energy a c c e l e r a t e s c h o l e s t e r o l b i o ~ y n t h e s i s . ~ 5 The development of some v a r i e t i e s of hy-pertriglyceridemia i s accompanied by a corresponding increase i n t h e turnover of palmitate but not l i n o l e a t e . This may represent increased synthesis of l i p i d from carbohydrate.106 I n s u l i n decreases t h e plasma l e v e l s of glyceride i n p a t i e n t s with hy-pertriglyceridemia?08 Protamine s u l f a t e , an i n h i b i t o r of l i p o p r o t e i n l i p a s e , i n h i b i t s t h i s a c t i o n . CPIB appears t o be t h e b e s t agent t o date f o r lowering elevated t r i g l y c e r i d e l e v e l s . 5713 Hormones. - I n t e r e s t i n estrogens stems from reports t h a t coronary a r t e r y disease i s a r a r i t y among premenopausal women1o9 and t h a t it i s much g r e a t e r i n c a s t r a t e d women than i n those having undergone hysterectomy but retain t h e i r ovaries,losb although t h i s finding i s not without i t s c r i t i c s . 1 1 0 On t h e o t h e r side, c a s t r a t e d men a r e less prone t o develop coronary disease than normal menyll Estrogens i n humans increase a-lipoprotein ( r i c h i n phospholipid P) l e v e l s but t h e i r e f f e c t on f5-lipoproteins ( r i c h i n c h o l e s t e r o l C ) i s v a r i a b l e . Thus,
182 -
Sect. IV
-
Metabolic 81 E n d o c r i n e
H e i n z e l m a n , Ed.
t h e C/P r a t i o w i l l decrease but t h e r e may o r may not be a drop i n c h o l e s t e r o l l e v e l s . l 1 2 Lecithin appears t o be t h e only major phospholipid f r a c t i o n which i s increased.113 Triglyceride l e v e l s a r e a l s o increased by estrogen administ r a t i o n . l l 4 Estrogens p r o t e c t t h e coronary a r t e r i e s but not t h e a o r t a of t h e chicken.l15 Experiments i n rats had l i k e e f f e c t s but r a b b i t s f a i l e d t o show b e n e f i t from estrogens.l16 Efficacy i n humans s t i l l remains a will-of-thewisp. S i g n i f i c a n t evidence of t h e i r prophylactic value against myocardial i n f a r c t i o n has not as y e t been demonstrated.117 Mental functioning i n p a t i e n t s with cardiovascular and cerebrovascular disease i s reported t o improve with estrogen treatment Since t h e s i d e e f f e c t s of estrogen i n t h e male a r e a problem, much e f f o r t has been devoted t o t h e search f o r compounds having t h e l i p i d p r o f i l e of an estrogen but devoid of i t s feminizing properties.l18 Among recent compounds studied a r e a s e r i e s of 1-methyl l3-alkyl estrogens120 and a s e r i e s of 3-alkyloxy-l7,17-(or 16,16)ethylenedioxy e s t r a t r i e n e s . 1 2 l Compounds 5"' and 6123 a r e reported t o show a possible s p l i t between t h e i r feminizing and l i p i d p r o p e r t i e s . On t h e p o s s i b i l i t y t h a t a metabolite i s responsible f o r
B
C-W2
d
H
3
0
C
H
z
,&b
CH30
CH30
5.
-cH3cH30 HO
6.
@-
OH
' 7.
t h e l i p i d e f f e c t s of estrogens, a s e r i e s of 2-hydroxy- and 2-methoxy-estradiols and t h e i r 16-oxygenated analogs w a s investigated. Com ound 7 i s reported t o have a l a r g e s p l i t between t h e properties i n question. p24 Conjugated equine estrogens increase blood p l a t e l e t levels125 during lipemia following i t s administration but o r a l contraceptives have l i t t l e e f f e c t , i f any, on blood coagulation o r f i b r i n o l y s i s l Z 6 (including p l a t e l e t adhesiveness) except perhaps t o increase f a c t o r V I I l e v e l s .Iz7 Estrogen therapy increases plasma hydrocortisone apparently by increasing t r a n s c o r t i n l e v e l s . 12' Gonadoptropins increase side-chain cleavage of c h o l e s t e r o l but not 20a -hydroxy cholesterol inThis i s i n d i c a t i n g t h a t 20a -hydroxylation i s stimulated by gonadotropins l i n e with t h e recent report that estrogen may decrease c h o l e s t e r o l by increasing t h e turnover r a t e , and therefore, t h e catabolism of c h 0 1 e s t e r o l . l ~ ~The f a c t that it i s not a c t i v e o r a l l y stimulated some e f f o r t i n t o finding an androsterone analog which i s a c t i v e o r a l l y . 3a-Methoxy-17-methyl-5a -androstan-l7@-ol i s reported t o lower c h o l e s t e r o l levels134 and enhance excretion of cholesterol i n t h e b i l e of rats.135 Methalone, an anabolic s t e r o i d , a l s o decreases t h e l e v e l of c h o l e s t e r o l i n man.'" Cortisone increases l e v e l s of triglyceri.de, phospholipid and c h o l e s t e r o l i n rats but does not a l t e r i n t e s t i n a l absorption o r t h e r a t e of incorporation of a c e t a t e i n t o cholesterol.137 I n c h o l e s t e r o l fed r a b b i t s adrenal hypertrophy precedes deposition of c h o l e s t e r o l and it i s suggested t h a t t h e adrenal gland
Chap. 16
Atherosclerosis
U r sp r ung
183 -
may a c t as a regulator intervening i n t h e process r e s p o i s i k l e f o r atheros ~ 1 e r o s i s . l I~n~man, hyperlipemia has been seen i n acute ad-renocortical insufficiency and successfully t r e a t e d with hydrocortisone .13' The use of adrenocorticotropic g e l has given encouraging r e s u l t s i n some cases of acute myocardial infarction.14' The hypothyroid s t a t e i s associated with an elevated plasma c h o l e s t e r o l l e v e l while t h e hyperthyroid s t a t e i s associated with low c h o l e s t e r o l l e v e l s i n plasma.141 It w a s again pointed out that i n a l a r g e number of p a t i e n t s hospitalized with acute myocardial i n f a r c t i o n t h e serum PBI l e v e l s a r e lower than The effectiveness of thyroactive substances i n lowering serum c h o l e s t e r o l and i n reducing atherogenesis has been amply demonstrated i n various animal species14' but t h e i r c l i n i c a l use remains r e s t r i c t e d because of t h e i r a c t i o n on b a s a l metabolic r a t e , and i n p a r t i c u l a r , on oxygen consumpt i o n of t h e myocardium and aggravation of angina. 14' Therefore , i n t e r e s t i s focussed on drugs whose e f f e c t on l i p i d metabolism i s accentuated r e l a t i v e t o t h e i r hypermetabolic e f f e c t . Many thyroxine analogs have been made, some of which a r e reported t o have a d e s i r a b l e " s p l i t " i n t h e two a c t i v i t i e s . 1 4 4 A comprehensive review of t h i s sub Sect has been published r e ~ e n t 1 y . l ~ ~ The thyroxine analogs of most i n t e r e s t a t t h e present time a r e D t h y roxine ( D T , ) and Dtriiodothyronine ( D T 3 ) . A controversy s t i l l e x i s t s as t o whether t h e r e i s any separation of l i p i d and calorigenic e f f e c t s of these two agents as compared t o t h ~ r 0 x i n e . l D ~T ~ 3 i s claimed t o lower serum l i p i d s i n p a t i e n t s with e s s e n t i a l hy-perlipemia but showed no e f f e c t i n nomolipemic controls.'47 As with D T 4 it a l s o appears t o show a worsening of angina o r arrhythmia i n humans. 14' Some more recent thyroxine-like compounds which have been studied extensively include Dtrichlorothyronine,149 4'-methoxy-3 ,3'-5triiodothyroacetic acid150 and a s e r i e s of t h y r ~ a l k a n o l s which l ~ ~ a l s o appeared t o show a " s p l i t " i n animals. !l?hyroidectomy i n rats has no e f f e c t on oxidation of e i t h e r labeled cholest e r o l o r sodium octanoate. Preliminary nuclear changes i n c h o l e s t e r o l take place a t about t h e same r a t e regardless of t h e thyroid s t a t e . This and o t h e r data a r e consistent with the e a r l i e r hypothesis t h a t t h e e f f e c t of t h e thyroid on cholesterol metabolism may be mediated a t t h e l e v e l of nuclear hydroxylation of t h e ~ t e r 0 i d . l ~ ' Increased thyroid l e v e l s decreases t h e production of e s t r i o l from e s t r a d i o l and increases production of 2-methoxyestrone. A recent shows t h a t 2-hydroxyestrone becomes t h e major metabolite i n subjects with high thyroid l e v e l s and t h a t i n myxedema 2-hydroxyestrone l e v e l s a r e diminished. The production of androsterone diminishes i n hypothyroidism and it has been postulated that t h i s produces increased l i p i d l e v e l s .132 These complicated endocrine i n t e r a c t i o n s make a study of thyroid a c t i v i t y d i f f i c u l t and i t s e f f e c t on l i p i d metabolism remains t o be c l a r i f i e d . Thrombosis and F i b r i n o l y s i s . - I n t e r e s t i n t h e thrombogenic theory of a t h e r o s c l e r o s i s proposed by von Rokitansky and revived by t h e s t u d i e s of D u g u i e has an experimental basis. A r t i f i c i a l production of f i b r i n deposits o r thrombi on vessels w i l l give rise t o intimal thickening and eventually a t h e r o s c l e r o s i s .156 Fibrin-like material has been demonstrated i n a t h e r o s c l e r o t i c l e s i o n s . lS7 locali z a t i o n of atheromatus changes may be r e l a t e d t o mechanical forces which lead t o t h e formation of thrombi a t s t r e s s points.15' The influence o f l i p i d s i n t h e pathogenesis of a t h e r o s c l e r o s i s might be f e l t not only i n t h e i r deposition i n t h e intimal l e s i o n but a l s o i n t h e i r clot-promoting effectsL5' (phospholipids
184
Sect. I V
-
Metabolic & E n d o c r i n e
H e i n z e l m a n , Ed.
and f r e e f a t t y acids can produce p l a t e l e t aggregation16') and t h e i r capacity t o i n h i b i t f i b r i n o l y s i s . 161,1ssb Chemical a t t a c k i n t h i s area has been a t i n h i b i t i n g t h e i n i t i a l event, p l a t e l e t aggregation, and a t d i s s o l u t i o n of t h e thrombus ( f i b r i n o l y s i s ) . For background t h e reader i s d i r e c t e d t o a comprehensive review on p l a t e l e t s and atherosclerosisl6* and t h e recent workshop on f i b r i n o l y s i s 163 Adenosine diphosphate (ADP) w i l l aggregate p l a t e l e t s i n v i t r o and t h i s aggregation can be prevented by enzymatic conversion of t h e ADP t o ATP.le4 This induced aggregation requires a complexable c a t i o n and fibrinogen. 16' The formation of thrombin and ADP a few seconds a f t e r blood i s shed has been demonstrated i n vivolB6 and thus both of these agents a r e present before t h e p l a t e l e t s a r e a v a i l a b l e . Epinephrine a l s o induces p l a t e l e t aggregation'" and thrombosis i n rats167 along with norepinephrine and serotonin. Pronethalol, a @-blocker, blocks t h e epinephrine-induced p l a t e l e t rise and @-Blocking agents have a l s o been found u s e f u l i n a l e v i a t i n g angina of effort1" and propranalol i s reported t o reduce t h e mortality from acute myocardial infar~ti0n.l~' I n i t i a l reports17' t h a t l i n o l e n i c acid caused a decrease i n p l a t e l e t adhesiveness and reduced t h e incidence of experimental thrombosis have been controverted by t h e same and by others.173 Among materials which are reported t o reduce p l a t e l e t adhesiveness a r e M p y r a m i d ~ l e ,a~s~e ~ r i e s of adenosine analogs,175 histamine17' and methyl mercuric nitrate.177 M.A.O. i n h i b i t o r s were shown not t o p r o t e c t against experimental thrombosis,178 i n disagreement with an e a r l i e r report. Dextran appears t o have some c l i n i c a l u t i l i t y i n thrombus inhibition17' and has been successfully used i n severe ischemia."' It appears t o i n h i b i t p l a t e l e t f a c t o r I11 by coating t h e platelet The r o l e of anticoagulants i n the treatment of myocardial i n f a r c t i o n i s unclear. Experiments with rabbits,lE3 dogs184 and rats185 have shown t h a t heparin w i l l prevent experimentally induced thrombosis. Conflicting reports suggest that anticoagulants may prolong t h e time f o r p l a t e l e t aggregation186 but heparin i n man showed no consistent changes i n p l a t e l e t economy or platel e t adhesiveness187 and only a feeble e f f e c t i n protecting against thrombotic occlusion a f t e r a r t e r i a l reconstruction.18' Increased s e n s i t i v i t y t o heparin w a s seen i n p a t i e n t s following acute myocardial infarction."' I n patients who suffered a myocardial i n f a r c t i o n while on anticoagulant therapy, t h e r e was a decrease i n anticoagulant l e v e l s as compared t o those with no myocardial infarction.'" I n p a t i e n t s with coronary heart disease t h e hematocrit and whole blood v i s c o s i t y is s i g n i f i c a n t l y higher than i n normals."' The r o l e played by t h e l i p i d - c l e a r i n g a c t i v i t y of heparin is s t i l l under i n v e s t i g a t i o d S 2 Long term anticoagulant therapy a f t e r myocardial infarction, using heparin"' and t h e c o u m a r i n ~appears ~ ~ ~ t o be b e n e f i c i a l and it has been recommendedlS5 t h a t t h i s form of treatment be used routinely. I n a cephalin f r a c t i o n which stimulated t h e c l o t t i n g mechanism, it w a s found that phosphatidyl-ethanolamine w a s t h e only component which showed cons i s t e n t high activity."' I n a study of p a t i e n t s with myocardial i n f a r c t i o n these authors1'' showed t h a t , although t h e t o t a l cephalin f r a c t i o n was similar t o t h a t i n t h e controls, t h e p a t i e n t s had cephalin with higher c l o t t i n g a c t i v i t y and markedly higher o l e i c a c i d content. I n s u l i n produces a c c e l e r a t i o n of blood c l o t t i n g and decreases f i b r i n o l y t i c a c t i v i t y l S 8 i n dogs, a t t r i b u t e d t o t h e sympathico-adrenal mechanisms for r e s t o r a t i o n of normal glycemia since it i s
.
Chap. 16
Atherosclerosis
Ur sprung
185 -
blocked by dihydroergotamine. P r o g e s t a t i o n a l agents a r e a l s o reported t o produce hypercoagulability i n w ~ m e n . ~ ” Thrombolyt i c therapy has r e c e n t l y been reviewed. 2oo The enzymes s t r e p t o ~ ~ ~appear , t o have u t i l i t y i n kinase, 201 staphylokinase202 and u r o k i n a ~ e201c acute thromboembolic v a s c u l a r d i s e a s e s . CA-7 (a f i b r i n o l y t i c enzyme from a s p e r g i l l u s oryzae) has produced l y s i s of arterial thrombi i n dogs 9204 Phenformin205 (DBI) and Metformin206 have shown promise as f i b r i n o l y t i c agents which may be u s e f u l i n t h e prophylaxis of a r t e r i a l occlusion. The authors have suggested t h a t phenformin a c t s l i k e a c o r t i c o i d and have indeed shown i t t o be b e n e f i c i a l i n rheumatoid a r t h r i t i s . 2 c ” An e a r l i e r report207 t h a t atromid has f i b r i n o l y t i c a c t i v i t y w a s c o n t r a d i c t e d recently.208 A l a r g e number of vasoactive drugs, both hyper- and hypotensive a r e reported t o have f i b r i n o l y t i c a c t i v i t y which i s r e l a t e d t o t h e i r vasoactive changes .209 Complamin (xanthinol n i c o t i n a t e ) has been shown t o possess f i b r i n o l y t i c a c t i v i t y i n but t h e p a t i e n t s very quickly develop a t o l e r a n c e t o t h e drug. Psycho-Social Factors. - One group of investigators211 has undertaken t h e study of behavior p a t t e r n s and t h e i r r e l a t i o n s h i p t o coronary artery d i s e a s e . They f i n d t h a t “Behavior P a t t e r n A” ( r e s t l e s s , competitive a t t i t u d e ) men have higher c h o l e s t e r o l levels,212 faster c l o t t i n g times212 and have a much higher incidence of arcus s e n i l i s and coronary artery d i s e a s e O 2 l 3 The same r e l a t i o n s h i p w a s found i n women.214 I n d i v i d u a l s harboring p a t t e r n A e x c r e t e more epinephrine during t h e i r working day t h a n t h o s e i n p a t t e r n B ( r e l a t i v e l y nonambitious, non-aggressive) .215 Subjects of p a t t e r n A have a l s o shown a high incidence of blood sludging a fte r a f a t t y m s a l whether t h e fats were s a t u r a t e d o r unsaturated, while sludging w a s v i r t u a l l y absent i n non-coronary prone ind i v i d u a l s .218 S i m i l a r r e l a t i o n s h i p s occur when animals a r e stressed.216 It i s implied t h a t s o c i a l f a c t o r s may account f o r t h e low incidence of myocardial i n f a r c t i o n i n Roseto, Pa.217 The i n h a b i t a n t s a r e s t r i k i n g l y obese, eat cons i d e r a b l e q u a n t i t i e s of animal f a t and t h e i r serum l i p i d p a t t e r n s do not d i f f e r from those found i n t h e Framingham study,loa y e t t h e y have a very low incidence of myocardial i n f a r c t s as compared t o t h o s e i n t h e Framingham study. Summary. - There i s c l e a r l y no u n i f i e d concept of atherogenesis. Knowledge i n t h e f i e l d i s c h a o t i c and treatment, o r prevention, i s s t i l l a matter of opinion. The p r e f e r r e d method f o r i n h i b i t i n g atherogenesis i s s t i l l c o n t r o l of t h e d i e t . O f i n t e r e s t i s t h e evidence which shows t h a t s u b s t i t u t i n g unsatur a t e d f o r s a t u r a t e d fats i n t h e d i e t causes a plasma-tissue r e d i s t r i b u t i o n r a t h e r t h a n i n h i b i t i n g s y n t h e s i s o r i n c r e a s i n g e x c r e t i o n r a t e s of c h o l e s t e r o l . Dietary c h o l e s t e r o l seems t o play only a minor r o l e , i f any, i n t h e development of human a t h e r o s c l e r o s i s . Drugs which lower serum l i p i d s are s t i l l s c a r c e . Efficacy of CPIB on long term treatment of t h e disease remains t o be seen. Cholestyramine, D T 4 , estrogens and n i c o t i n i c a c i d have t h e i r champions and w i l l f i n d s p e c i a l usage. Increased a c t i v i t y has focusSed a t t e n t i o n on p l a t e l e t adhesiveness, although no promising agent has emerged as y e t . The f i b r i n o l y t i c enzymes s t i l l are t h e b e s t agents f o r f i b r i n o l y s i s therapy. A s t a r t has been made i n unraveling psycho-social f a c t o r s and r e l a t i n g behavior w i t h serum l i p i d p a t t e r n s and proneness t o coronary h e a r t d i s e a s e . Research i n a t h e r o s c l e r o s i s must s t i l l be considered i n i t s infancy. With i n c r e a s i n g i n t e r e s t by medical s c i e n t i s t s and by governmental agencies, progress a t an a c c e l e r a t e d rate can be expected.
Sect. IV
186
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
R e f e renc e s 1.
2. 3. 4.
56.
L. Aschoff, V o r t r l g e fiber P a t h o l o g i e , F i s c h e r , J e n a , Germany, 1925, pp. 62-84. J . B. Duguid, J . P a t h o l . B a c t e r i o l . , 507 (1946). H. B. L o f f l a n d and T. B. Clarkson, Arch. P a t h . , &, 2 9 1 (1965). M. M. Daly, Q. B. Deming, V. M. Raeff and L. M. Brun, J. C l i n . I n v e s t . , 1606 (1963). M. M. Daly and V. R a e f f , B u l l . N. Y. Acad. Med., G, 225 (19651. H. N. Adel, 9. B. Deming, M. M. Daly, V. M. Raeff and L. M. Brun, J . Lab. C l i n . Med.,
2,
2,
66.
571 (1965).
80,
I . Chapman, Arch. P a t h . , 256 (1965). N a t i o n a l Diet-Heart Study, J. Am. Med. Assoc., &, 105 (1963). Medical News, J . Am. Med. Assoc., 31 (1965). 10. ( a ) T. R . Dawber & &., J. Publ. H e a l t h , s u p p l . , 4 (1957). ( b ) W . B. Kannel I n t e r n . Med., 33 (1961). ( c ) A. Kagan 5 &., F e d e r a t i o n P r o c . , 21, s u p p l . , 52 (1962). 11. A. Keys, J . M t . S i n a i Hosp., 20, 118 (1953). 12. E. H. Ahrens, Am. J . Med., 3, 928 (1957). 13. A. Keys, A. T . Anderson, F. F i d a n z a , M. H . Keys and B. Swahn, C l i n . Chem., 1,34 (1955). 14. W. E. Connor, G e r i a t r i c s , 16, 407 (1961). 15. G. V. Mann, C i r c . Res., 9 , 3 3 8 (1961). 16. 0. W. Portman and F. V. S t a r e , P h y s i o l . Rev., 2, 407 (1959). 17. A. N . Howard and G. A . Gresham, Chem. I n d . (London) 831 (1965). 18. D. F. Davis and A. C l a r k , Lancet, I , 29 (1965). 19. R . P i c k , S. J a i n , L. M. Katz and P. Johnson, J . A t h e r o s c l e r o s i s Res., 5, 16 ( 1 9 6 5 ) . 20. R . P i c k , S . J a i n , C. Kakita and P. Johnson, Proc. SOC. E x p t l . B i o l . Med., 850 (1965). 21. S t a t e m e n t , J . Am. Med. Assoc., 2,1194 (1965). 22. A. H. Howard, G. A. Gresham, D. Jones and I . W. J e n n i n g s , J . A t h e r o s c l e r o s i s Res., 5 , 330 (1965). 23 * H. Buchwald, J. A t h e r o s c l e r o s i s R e s . , 5 , 407 ( 1 9 6 5 ) . 24. ( a ) J . D. Wilson and C . A. Lindsey, J r . , J . C l i n . I n v e s t . , %, 1805 (1965). ( b ) C . B. T a y l o r . B. Mikkelson, J . A. Anderson, D. T. Forman and S . S. Choi, E x p t l . Mol. P a t h o l . , -4 , 480 (1965). 52 (1965). 25- F. Grande, J. T. Anderson, S. Chlouverakis, M. P r o j a and A. Keys, J . N u t r .,.J'8 26. J . M. Dietschy and M. D. S i p e r s t e i n , J. Clin. I n v e s t . , 44, 1311 (1965). -27. G . A. Gresham, A. N. Howard, J . Mc'been and D. E. Bowyer, B r . J. E x p t l . P a t h . , 8 4 (1965) 28. F. A. Bieberdorf and J. D. Wilson, J . C l i n . I n v e s t . , 44, 1834 (1965). 29. N . S p r i t z , E. H . Ahrens, J r . and S. Grundy, J . C l i n . I n v e s t . , 2, 1482 1 9 6 5 ) . ( a ) N . S p r i t z , J . C l i n . I n v e s t . , 9, 339 (1965). ( b ) N . S p r i t z , B u l l N . Y. Acad. Med., 30. 41, 244 (1965). 31. S. L i n d s t e d t . J. Avigan, D. S. Goodman, J . S j b v a l l and D. S t e i n b e r g , J . Clin. I n v e s t . , 44, 1845 (1965). 32, J. Avigan and D. S t e i n b e r g , J . Clin. I n v e s t . , &, 1845 (1965). 3 3 . S. Dayton, S. Hashimoto and M. L. Pearce, C i r c u l a t i o n , 32, 911 (1965). 407 (1965). 34. J . H . Moore and D. L. Williams, B r i t . J . N u t r . , 9, 35. J . Dupont, J . Am. O i l Chemists S O C . , 3, 907 ( 1 9 6 5 ) . 37. W. Hollander and A. Chobanian, Boston Med. Q u a r t . , g,37 (1959). 38. M. R . Malinow. M. A. Marini, B. Lema, M. Nebbie a n d J . A. B e r a r d i . Acta P h y s i o l . L a t i n o h.. 71 (1964). 39. F. V i c h i , P. L. Masi, P. P i e r l e o n i and S. Orlando, S p e r i m e n t a l e , 168 (1965). 40. ( a ) J. H. B u r c k h a l t e r eta.,Am. Chem. SOC. Abstr. o f p a p e r s , 147 mtg.. P h i l a d e l p h i a , Pa., Apr. 6-10, 1964, p. 20M. ( b ) W. B. Wright, D. A. Dunnigan and V. Biermacher, J . Med. Chem., 1,113 (1964). 41. ( a ) S. K. F i g d o r , E. C. S c h r e i b e r . R . B. S t e b b i n s , P. F. Moore and R. Pinson, J r . , J . Med. Chem., 1,508 (1964). ( b ) G. M. K. Hughes, P. F. Moore and R . B. S t e b b i n s , J . Med. Chem., 1,511 (1964). 42. J . H . S h o r t g . , J. Med. Chem., 8, 223 (1965). 43. F. T. Bach, J. C . Barclay and E. Cohen, Am. Chem. SOC. Abstr. of p a p e r s , 150 mtg., A t l a n t i c C i t y , N. J . , S e p t . 13-16, 1965, p. 18P.
7. 8. 9.
s.,
z,
m,
5,
u,
5,
-
14,
x.
Chap. 16 44. 45. 46. 47. 48. 49. 50. 51. 52.
53. 54. 55. 56 57 *
-
58. 59. 60. 61. 62. 63. 64. 65. 66. 67. 68. 69 * 70. 71. 72 * 73 * 74. 75. 7677. 78 i 79. 80. 81.
82.
83.
84.
Atherosclerosis
UrsD rung
187
G. Rodney, M. L. Black and 0. D. Bird, Biochem. Pharmacol., 14,445 (1965). (a) M. Kraml, L. G. Humber, J. Dubuc and R. Gaudy, 5 . Med. Chem., 1,5OG (1964). (b) P . Kr. Cushman and J . G. Hilton, Metabolism, 14. 924 (1965). (c) R. Fumagalli, R. Niemiro and R. Paoletti, J. Am. Oil Chemists SOC., 9, 1018 (1565). R. E. Counsell, P. D. Klimstra, L. N. Nysted and R. E. Ranney, J . Med. Chem., 8, 45 (1965). (a) R. E. Ranney and D. L. Cook, Arch. Intern. Pharmacodyn., 51 (1965). (b) B. A. Sachs and L. Wolfman, Arch. Internal Med., 116,366 (1965). D. Dvornik, M. Kraml and J. Dubuc, Proc. SOC. Exptl. Biol. Med.. 116,537 (1964). (a) P. C. Anderson and J. M. Martt, Arch. Derm., p1, 181 (19651. (b) N. Winer, J. M. Martt, J. E. Somers, L. Wolcott, H. E. Dale and T. W. Burns, J. Lab. Clin. Med.,
a,
66, 758 (1965).
J. Doorenbos and M. T. Wu, J. Pharm. Sci., 2, 1290 (1965). J. E. Dalidowicz and H. J. McDonald, Biochemistry, 5. 1138 (1965). (a) R. Hess, Advances in Lipid Research, Vol. 2 , R. Paoletti and D. Kritchevsky, eds., Academic Press, N. Y., 1964, p. 333. (b) P. Morand, J. F. Bagli, M. Kraml and J. Dubuc, J. Med. Chem., 1,504 (1964). (c) D. Nardi, L. Mauri and F. Barzaghi, I1 Farmaco, Ed. Sci., 20, 456 (1965). Atromid Symposium, J . Atherosclerosis Res., 3, 351-739 (1963). S. W. Teal and W. Gamble, Biochem. Pharmacol., 14, 896 (1965). D. L. Azarnoff, D. R. Tucker and G. A. Barr, Metabolism, 2,959 (1965). P. J. Nestcl, E. 2. Hirsch and E. A. Couzens, J. Clin. Invest., 2. 891 (1965). (a) D. R . Avoy, E. A. Swyryd and R. G. Gould, J. Lipid Res., 6, 369 (1965). (b) M. M. Best and C. H. Duncan, Amer. J. Cardiol., 3,230 (1965). (c)- D. Berkowitz, Metabolism,
14,
966 (1965).
E. H. Strisower, A. V. Nichols, F. T. Lindgren and L. Smith, J. Lab. Clin. Med.,
748 (19651.
&,
I. A. Slowe, A. C. Carter and E. B. Feldman, Arch. Intern. Med., 116,523 (1965). G. Trevaks and R. R. H. Lovell, Ann. Rheum. Dis., 24, 572 (1965). C. H. Duncan, M. M. Best and G. C. Robertson, Lancet I, l g l (1965). C. M. Ogston, D. Ogston and G. M. McAndrew, Curr. Ther. Res., 1,437 (1965). B. Sweet, B. M. Rifkind and G. P. McNicol, J. Atherosclerosis Res., 2, 347 (1965). (a) J. T. Doyle, T. R. Dauber, W. B. Kannel, S. H. Kinch and H. A. Kahn, J. Am. Med. Assoc., 886 (1964). (b) 0. Paul e t g . , Circulation, 28, 20 (1963). H. Engelberg, J. Am. Med. Assoc., ,&I 1033 (1965). A. Kershbaum, S . Bellet and R. Khorsandian, Am. Heart J., Q, 206 (1965). A. Tsujimoto, S . Tamino and Y. Kurogochi, Japan. J. Pharmacol.. 3, 415 (1965). S. Bellet, A. Kershbaum and J. Aspe. Arch. Intern. Med., 116,750 (1965). W. E. Dulin, G. H. Lund and G. C. Gerritsen, Proc: SOC. Exptl. Biol. Med., 118,499 (1965). (a) G. C. Gerritsen and W. E. Dulin, Diabetes, 14, 507 (1965). (b) D. L. Smith, A. A. Forist and G. C. Gerritsen, J. Pharmacol. Exptl. Ther., 316 (1965). D. L. Smith, A. A. Forist and W. E. Dulin, J. Med. Chem., g, 350 (1965). L. A. Carlson, S. 0. Liljedahl and C. Wiser, Acta Med. Scand., lJ8, 81 (1965). (a) K. Stock and E. Westermann, Life Sci., 4. 1115 (1965). (b) R. P. Eaton, D. Steinberg and R. H. Thompson, J. Clin. Invest., 9, 247 (1965). (a) R. Bombelli, T. Farkas and R. Vertua, Med. Pharm. Exptl J. Ostman g g . , Acta Med. Scand., 615, 623, 631, 639 N. M. Schulman and G. Galansino, Proc. SOC. Exptl. Biol. Med R . S . Jacobs, M. S. Grebner and D. L. Cook, Proc. Soc. Exptl P. Lipton and J. A. Michels, Geriatrics, 20. 379 (1965). R. Ishigami g g., Bitamin, 2, 232 (1965). (a) M. Verstraete, H. Maes and J. Vermylen, Med. Pharmacol. Exptl.. 3, 401 (1965). (b) J. P. Miale, Curr. Ther. Res., 1,392 (1965). J. J. Burns, K. I. Colville. L. A. Lindsay, S. P. April and R. A. Salvador, Pharmacologist,
a,
z.
x,
-6 ,
186 (1964).
a,
90 (1965). V. Vitek. B. Mosinger and V. Kujalova, Nature, B. Mittra. Lancet 11. 607 (1965). D. P. Jones and R. A. Arky. Metabolism, 14, 1287 (1965). L. M. Morrison K. Murata, J. J. Quilligan, Jr., 0. A. Sahjeide and L. Freeman, Gerontologist. 3, 16 (1965) abstrl Korkhov, Farma 01 Toksik, 28, 83 (1965).
d
.
Sect. IV
188
-
Metabolic 81 Endocrine
H e i n z e l m a n , Ed.
e,
660 (1965) abstrg. 85. B. B. Migicovsky, Federation Proc.. d5a. A. 2 . Buttoo, M. C. G. Israels and J. W. Wilkinson,$rit. Med. J., I, 552 (1965). 86. P. Samuel, H. C. Price and 0. B. Shalchi, Proc. Soc. Exptl. Biol. Med., 654 (1965). 87. H. Hammerl, 0. Pichler and M. Studlap. Med. Klin., 6 0 , 761 (1965). 87a. L. A. Myasnikov, Byul. Ekspes-im. Biol. Med., 2,40 (1965). 88. M. D. Siperstein, C. W. Nichols, Jr. and I. L. Chaikoff, Circulation, 2 , 57 (19651. 89* S . Rodbard. C. Bolene, R. Pick and L. N. Katz. Circulation, 2, 479 (19651. 90. P. Griminger and H. Fisher, Proc. Soc. Exptl. Biol. Med.. 2, 424 (1958). 91. D. M. Tennent. H. Siegel. M. E. Zanetti, G. W. Kuron, W. H. Ott and F. J. Wolf, J. Lipid Res., 1,469 (1960). 92 A. N. Howard, G. A. Gresham, D. Jones and I. W. Jennings. Life Sci., 5. 639 (1965). 93. G. R. Jansen and M. E. Zanetti, J. Pharm. Sci., 2,845 (1965). 289 (1965). 94. S. A. Hashim and T. B. VanItallie. J. Am. Med. Assoc., 95. F. Schaffner, F. M. Klion and A. J. Latuff, Gastroenterology, g,293 (1965). 97* R. W. Harkins, L. M. Hagerman and H. P. Sarett, J. Nutr., 3, 85 (1965). 98* R. B. Zurier, S. A. Hashim and T. B. VanItallie. Gastroenterology, 3, 490 (1265). 99. J. E. Garvan, D. T. Forman, W. R. Eisman and C. R. Phillips, Proc. Soc. Exptl. Biol. Med., 120. 744 (1965). 100. (a) L. Swell, E. C. Trout, Jr., H. Field, Jr. and C. R. Treadwell, J. Biol. Chem.. 2286 (1959). (b) T. Gerson, F. B. Shorland and G. G. Dunckley, Biochem. J., 399 (1965). 101. P. DeSomer. H. Vanderhaeghe and H. Eyssen, Nature, 204. 1306 (1964). 102. W. J. Messinger and C. M. Samet. Angiology, 6, 29 (1965). 103. M. J. Albrink, Annals of Internal Med.. 5p, 581 (196:). 104. D. F. Brown, S. H. Kinch and J. T. Doyle, New Eng. J. Med., 947 (1965). 105. H. Braunsteiner et&.. Klin. Wshr., 9, 715 (1965). 106. P. J. Nestel, Metabolism, 14,1 (1965). 108. 5. Schlief and L. W. Kinsell, Proc. SOC. Exptl. Biol. Med., 120, 272 (1965). 109. (a) L. 0. Underdahl and H. L. Smith, Proc. Staff Meet. Mayo Clin., 22, 479 (1947). (b) B. J. Clawson, Am. Heart J., 22, 607 (1941). (c) A. B. Ritterbrand. I. A. Jaffee, P. M. Densen, J. F. Magagna and E. Reed, Circulation, 3, 237 (1963). 110. F. J. Schilling, 0. K. Christakis. N. J. Bennett and J. F. Coyle. Am. J. Public Health, 2, 461 (1964). 111. R. H. Furman, R. P. Howard, M. R. Shetlar and R. Imagawa, Am. Med. J., 2, 965 (1957). 112. (a) R . H. Furman and R. P. Howard, Ann. Intern. Med., 9, 969 (1957). (b) R. H. Furman, R. P. Howard, L. N. Ncrcia and E. C. Keety, Am. J. Med., &. 80 (1958). (c) M. F. Oliver and G. S. Boyd, Lancet 11, 690 (1959). i13. M. Hagopian and R. W. Robinson, J. Clin. Endocr., 3, 283 (1965). 114. J. W. Gofman, 0. DeLalla. F. Glazier and N. K. Freeman, Plasma, 2, 413 (1954). 115. R. Pick, J. Stamler, S. Rodbard and L. N. Katz, Circulation, 6, T76 (1952). 116. R. Pick, J. Stamler and L. N. Katz, Hormones and Atherosclerosis. G. Pincus, ed., Academic Press, N. Y., 1959, pp. 229-240. 117. (a) M. F. Oliver and G. S. Boyd, Lancet 11. 499 (1961). (b) J. Stamler, Atherosclerosis and its Origin, M. Sandler and G. H. Bourne, Eds., Academic Press, N. Y.. 1963, p. 231. (c) J. Marmorsten, F. J. Moore. C. E. Hopkins. 0. T. Kuzma and J. Weiner. Proc. SOC. Exptl. Biol. Med., 110, 400 (1962). 118. (a) R. Hess, Advances in Lipid Research, Vol. 2, R. Paoletti and D. Kritchevsky, Academic Press, N. Y., 1964, pp. 351-363. (b) V. A. Drill, D. L. Cook and R. A. Edgren, Hormones and Atherosclerosis, G. Pincus, ed., Acadenic Press, N. Y., 1959, Chapt. 19. 119. A. Corbellini, G. Geraldi, G. Ferrara and G. Lugana, Farmaco [Scid , 3, 1044 (1964). 120. J. Fisher & J. Chem. Soc., 4472 (1964). 121. G. C. Buzby & s.. J. Med. Chem., 1, 755 (1964). 122. R. E. Schaub, J. H. van den Hende and M. J. Weiss, J. Org. Chem., 2234 (1965). 123. K. Nakamura, Y. Masuda, K. Nakatsuji, T. Hirooka and K. Fujimoto. J. Atherosclerosis Res., 2. 420 (1965). 124. S. Gordon, E. W. Cantrall, W. P. Cekleniak, H. J. Albers, S . Mauer, S. M. Stolar and S. Bernstein. Steroids, 4,267 (19641. 125. R. W. Robinson and R. V. Lebeau, J. Atherosclerosis Res., 2, 120 (1965). 126. (a) L. C. Powell, M. M. Guest and T. P. Bond, Am. J. Obstet. Gynecol.. 2, 167 (19651. (b) R. R. Margulis. J. L. Ambrus, I. B. Mink and J. C. Stryker, Am. J. Obstet. Gynecol., 2,161 (1965). (c) E . A. Caspary and M. Peberdy, Lancet I, 1142 (1965).
B,
-
z,
-
s, ~
a,
s..
x,
e,
Chap. 1 6
U r sp rung
Atherosclerosis
127. 128.
189 -
J. M. Thomson and L. Poller, Brit. Med. J. 11, 270 ( 1 9 6 5 ) . (a) S. D. Grant, F. Ch. Pavlatos and P. H. Forsham, J. Clin. Endocr., 3,1057 (1965). (b) 0. I. Dodek, Jr., E. J. Segre and E. L. Klaiber, Am. J. Obstet. Gynecol., 2, 173 (1965). 129. (a) K. Lifshitz and N. S. Kline, Am. J. Psychiat., 122. 329 (1965). (b) R. B. Evans and J. Marmorsten, Proc. SOC. Exptl. Biol. Med., 118,529 (1965). 130. E. Forchielli, R. I. Dorfman, S. Ichii and K. Menon, Cancer Res., 3, 1076 (19653. 131. P. J. Nestel, E. 2 . Hirsch and E. A. Cousenz, J. Clin. Invest., &. 8 9 1 (1965). 132. L. Hellman, H. L. Bradlow, B. Zumoff. D. K. Fukoshima and T. F. Gallagher, J. Clin. Endocr., B,637 (1959). 133. R. H. Furman, R. P. Howard and P. Alanpovic, J. Lab. Clin. Med., 60, 876 (1962). 134. R. E. Counsel1 and P. D. Klimstra, J. Med. Chem., 1,119 (1964). 265 (1965). 135. R. E. Ranney and S. H. Grayson, Arch. Intern. Pharmacodyn. Therapie, 136. S. Castillo, P. A. Serrano and M. Segura, Lancet 11, 1090 (1964). 137. M. Friedman, J. van den Bosch. S. 0. Byers and S. St. George, Am. J. Physiol., 208, 94 (1965). 138. W. Albrecht and W. Schuler. J. Atherosclerosis Res., 5, 353 (1965). 565 (1965). 139. P. Bjbrnstad. E. Gjone and H. N. Haugen, Acta. Med. Scand., 140. N. B. Baroody and W. G. Baroody, Am. J. Med. Sci., *,402 (1965). 141. D. Kritchevsky, Metabolism, 2, 984 (1960). 142. J. A. Azar, J. Am. Geriat. Soc., 3, 212 (1965). 143. G. S. Boyd, G. L. Montgomery and M. F. Oliver, Drugs Affecting Lipid Metabolism, S. Garattini and R. Paoletti, eds., Elsevier. Amsterdam, 1961, pp. 412-422. 144. G. S. Boyd. J. Atherosclerosis Res., 1. 26 (1961). 145. R. Hess, Advances in Lipid Research, Vol. 2, R. Paoletti and D. Kritchevsky, eds., Academic Press, N. Y.. 1964, pp. 370-381. 146. (a) G. S. Boyd and M. F. Oliver, J. Endocrinol., 21, 33 (19601. (b) E. H. Strisower, Federation Proc.. 21, 96 (1962) Fbstr.3. (c) C. Moses, J. R. Jablonski, J. H. Sunder and L. B. Katz. Am. J. Med. Sci., 244. 7 3 1 (1962). (d) J. M. Merrill and J. LemleyStone, Am. J. Physiol., 513 (1962). 147. 0. Schwarz and K. H. Kuhnstock, German Med. Monthly, lo, 53 (1965). 148. R. S. Watts, R. G. Schoenfeld, Rocky Mountain Med. J., 62, 3 4 (1965). 149. N. J. Oakley, K. Adadevesh and P. Wise, J. Endocr., 28, 225 (1964). 150. B. Blank, C. M. Greenberg and J. F. Kerwin, J. Med. Chem., 1, 53 (1964). 151. W. J. Wechter, W. A. Phillips and F. Kagan, J. Med. Chem., g, 474 (1965). 153. D. Kritchevsky and S. A. Tepper. J. Cellular Comp. Physiol.. 66, 9 1 (1965). 154. J. Fishman. L. Hellman and B. Zumoff, J. Clin. Endocr., 3,365 (1965). 155. 3. B. Duguid, Connective Tissue, Thrombosis and Atherosclerosis, I. H. Page, ed., Academic Press, N. Y., 1959, pp. 13-32. 156. T. Astrup, pp. 223-237. 157. N. Woolf and T. Crawford, J. Path. Bact., 80, 405 (1960). 158. J. F. Mustard, E. A. Murphy, H. C. Rowel1 and H. G. Downie, Am. J. Med., 2,6 2 1 (1962). (b) B. Kommerell. 159- ( a ) J. M. Waldron and G. C. Duncan, Am. J. Med.. s, 365 (1954). J. Atherosclerosis Res., 2, 233 (1962). 160. J. W. Kerr. I. MacAulay, R. Pirrie and B. Bronte-Stewart, Lancet, 1296 (1965). 161. H. W. Grieg and I. A. Runde. Lancet 11, 461 (1957)-; 162. J. F. Mustard, E. A. Murphy, H. C. Rowsell and H. G. Downie, J. Atherosclerosis Res., -4, 1 (1964). 163. Fibrinolysis, G. R. Fearnley, ed., J. Clin. Path., 305 (1964). 164. R. J. Haslam. Nature, 202, 765 (1964). 165. N. 0. Solum and H. Stormorken, Scand. J. Clin. Lab. Invest., suppl., lJ, 170 (1965). 166. J. Marr, J. J. Barboriak and S. A. Johnson, Nature, 3, 259 (1965). 167. H. Selye, B. Tuchweber and B. Rohan, Nature, 208, 900 (1965). 168. P. D. McClure, G. I. C. Ingram and R. V. Jones, Thromb. Diath. Haemorrhag., 3, 136 (1965). 169. P. J. R. B. Keelan. Brit. Med. J., I, 897 (1965). 170. P. J. D. Snow, Lancet 11, 551 (1965). 171. (a) P. A . Owen, A. Hellem and A. Odegaard, Lancet 11, 975 ( 1 9 6 4 ) . (b) A. Nordoy, Thromb. Diath. Haemorrhage, g, 543 (1965). (c) P. A. Owren, Ann. Intern. Med., &, 167 (1965).
u,
x,
a,
e.,
x,
190 172.
173*
174.
175.
Sect. I V
-
Metabolic & Endocrine
H e i n z e 1 m a n , Ed.
P . A. Owren, A. Hellem and A. Odsgaard, Lancet 11, 849 (1965). G. Bjbrck and B. Edgren, Acta Ned. Scand.. 67 (1965). P. R. Emnoris &. , Lancet 11, 603 (1965). ( a ) G. V. R . Born, R. J . Haslam, M. Goldman and R. D. Lowe, Nature, 678 (1965). ( b ) Y. I . M i s i r l i o g l u . Lancet 1 1 , 850 ( 1 9 6 5 ) . ( c ) J . W. C o n s t a n t i n e , N a t w e , 3,
m,
z,
1075 (1965). J . W. C o n s t a n t i n e , Nature, 9 1 (1965). C. W. Robinson, J r . , S. C. Kreas, R. H. Wagner and K. M. Brinkhous, Exptl. Mol. P a t h o l . , 2, 457 (1965). 178 S. V. Chandra and S. H. Z a i d i , J. A t h e r o s c l e r o s i s R e s . , 5 , 249 (1965). 5cZ (1965). ( b ) W. M. 179 * ( a ) R. B. Sawyer and J. A. Moncrief, Arch. Surg., Chadduck, W. G. C r u t c h f i e l d and M. Roberts, S w g . Gynec. O b s t e t . , 121, 491 (1965). 180. J. J . Bergan, 0. H. T r i p p e l and A. H. Kaupp, Arch. S u r g . , 338 (1965). 182. R. A. Ewald, S. W. E i c h e l b e r g e r , Jr.. A. A. Young, H. J. Weiss and W. H. Crosby, T r a n s f u s i o n , 2, 109 (1965). 183. V. Ourewich and D. P. Thomas, J . Lab. C l i n . Med., 604 (1965). 184. R. D. Williams and F. K a r a f f a , Surg. Gynec. O b s t e t . , 309 (1965). 185. I. L u s t r i n Surgery, 857 (1965). 186. G. P. McNicol and A . S. Douglas, Lancet I , 729 (1965). 187. J. F. Mustard, F. B. G i l b e r t and E. A. Murphy, Lancet I , 575 (1965). 188. E. W . Salzman, Surgery, 131 (1965). 189. C. Dufaillt, Canad. Med. Assoc. J., 2,13 (1965). 190. K. Molne and P. F. H j o r t , Acta Med. Scand., 121, 571 (1965). 191. G. A. Mayer, Capad. Med. Assoc. J . , 1151 (1965). 192. P. T. Kuo, D. R . B a s s e t t and A. M. DiGeorge, C i r c . Res., &I 2 2 1 (1965). , J. A t h e r o s c l e r o s i s Res., 5, 253 (19653. 193 * L. E. B t l t t i g e r , L. A. Carlson 194. V. A. Cooperative Study, R. V. E b e r t . c h r . , J . Am. Med. Assoc., 929 (1965). 195. D. Leak, G e r i a t r i c s , 20, 150 (1965). 196. J . D. B i l l i m o r i a , V. J. 1 - a d and N. F. Maclagan, J . A t h e r o s c l e r o s i s R e s . , 2, 9 0 , 102 (19651 198. M. I . Mamikonyan, Byul. Eksp. B i o l . Med., 1049 (1965). 199 R. R. Margulis, J. L. h b r u s , L. B. Mink and J. C . S t r y k e r , Am. J. O b s t e t . Gynecol., 2, 161 (1965). 200. D. Jewson, Minnesota Med., 4&, 1363 (1965). 201. 856 (1965). ( b ) ( a ) D. Cavanagh and E. A. Albores, Am. J . O b s t e t . Gynecol., M. C . Rozenberg, A u s t r a l i a n J. E x p t l . B i o l . Med. S c i . , 245 (1965). ( c ) C . D. Jacobsen and A. B. Chandler., Scand. J. Clin. Lab. I n v e s t . , s u p p l . . 8 , 2 2 5 (1965). ( d ) J . E. Nilehu and B. Robertson, Scand. J. Haematol., 2, 267 (1925). ( e ) L. B. Fleming and E. E. C l i p t o n , J . Surg. Res., 5, 153 (1965). 202. B. Sweet, A. P. McNicol and A. S. Douglas, Clin. S c i . , 3,375 (1965). 203. A. P. F l e t c h e r &- &., J. Lab. Clin. Med., &, 713 (1965). 731 (1965). 204. W. H. E. Roschlau and A. L. Tosoni, Can. J. Physiol. P h a r n a c o l . , 205. G. R. F e a r n l e y . R. C h a k r a b a r t i and E. D. Hocking, Lancet I, 9 (1965). 206. R. C h a k r a b a r t i , E. D. Hocking and G. R. F e a r n l e y , Lancet 11, 256 (1965). 207. S. C. S r i v a s t a v a . M. J. Smith and H. A. Dewar, J. A t h e r o s c l e r o s i s R e s . , 1. 640 t1963). 208. B. Sweet, B. M. R i f k i n d , G . P. McNicol and M. Gale, J. A t h e r o s c l e r o s i s Res.. 3, 347
a,
176. 177. I
E,
s,
&.,
66, 121,
s,
x,
s,
&.
x,
s,
5,
z,
5,
(1965 1 *
Holemans, Am. J. P h y s i o l . , 208, 511 (1965). P. McNicol and A. S. Douglas, B r i t . Med. J . . I , 1149 (1965). Friedman, G e r i a t r i c s , 2, 562 (1964). Friedman, R. H. Rosenman and V. C a r r o l , C i r c u l a t i o n , 852 (1958). Friedman and R. H. Rosenman, J. Am. Med. Assoc., 1286 (19591.' H. Rosenman and M. Friedman, C i r c u l a t i o n , 4, 1173 (1961). Friedman, S. S t . George, S. 0. Eyers and R. H. Rosenman, J . Clin. I n v e s t . ,
209. 210. 211. 212. 213. 214. 215.
R. G. M. M. M. R. M.
216.
( a ) H. S o b e l , C . E. Mondon and R . S t r a u s , C i r c . R e s . , 11,971 ( 1 9 6 2 ) . ( b ) H. L. Ratcliffe, Circulation, 481 (1963). C. S t o u t , J. Morrow, E. N. Brandt, Jr. and S. Wolf, J . Am. Med. Assoc., 845 (1964). M. Friedman. S. 0. Byers and R. H. Friedman, J . Am. Med. Assoc., B, 882 (1965).
217. 218.
a,
a,
758 (19601.
a,
188,
2,
Chapter 17. , Non-steroidal Hormones and Their Antagonists Eugene C. Jorgensen, School of Pharmacy, University California, San Francisco, Calif. INTRODUCTION The non-steroidal hormones considered in this section are composed primarily of amino acid derivatives. Structures of the simpler substances, such as the thyroid hormones and oxytocin and vasopressin have been known for some time. Recent advances center around structural variations of known hormones, structural elucidation of new hormones, and efforts of the initial syntheses of hormones whose structures have been proposed on the basis of degradation studies. The compounds selected for review are limited to those whose structures are known, or have been proposed, and in which significant recent progress has been made in the synthesis of the hormone or of its analogs. A hormone is generally considered to be a discrete chemical substance, produced in a gland, secreted into the body fluids, and producing a specific effect on the activities of other organs. The "glandular hormones" clearly belong to this class. Recently, a number of peptides with intense pharmacological activities have been found to be generated by specific enzyme catalyzed hydrolysis of plasma proteins; these have been called "tissue hormones.'' An additional miscellaneous group related by peptide nature and pharmacological properties have thus far been isolated only from non-mammalian sources.
HORMONES OF THE PANCREAS .Insulin.--Recombination experiments of synthetic and natural A and B chains of insulin have been reported from German, Chinese and American groups. The Aachen group described a synthesis of the A-chain of sheep insulin and its combination with the native B-chain to produce biological and chemical properties like those of insu1in.l Synthesis of the B-chain and condensation with the native sheep A-chain produced about 0.655; insulin activity.2 Combination of synthetic A and B chains of sheep insulin produced biological activity 0.2 to 1.0% that of native insulin.3 An improved recombination of bovine insulin was reported to produce 44% insulin-like activit using a 1:l mixture of the preoxidized A-chain and the reduced B-chain.
tr
The Shanghai-Peking groups reported combinations of synthetic B-chain with the natural A-chain of bovine insulin, and of the synthetic A-chain with the natural B-chain to give crystalline products with 2-4% of the activity of natural insulin: 5 , 6 slight biological activity was obtained initially by combining synthetic A and B chains. Improved synthesis of A and B chains,' using azide condensations at the final stages of synthesis to preclude racemization, and use of excess of the A-chain and air oxidation at pH 10.68 led to a synthetic bovine insulin with initial activity of 1.2-2.5% that of natural insulin based on the protein concentration present. Purification by solvent extraction and crystallization in a citrate buffer containing acetone and zinc acetate yielded a crystalline product identical in crystal shape and biological activity (mouse convulsion and rabbit hypoglycemia) with natural bovine insulin. Chromatographic and isotope dilution studies with C-14 labeled synthetic insulin
192 -
Sect. IV - Metabolic & Endocrine
H e i n z e l m a n , Ed.
confirmed identity with the natural protein. The Pittsburgh group has followed earlier work on the combination of s p thetic A-chain and natural B-chain of sheep insulin (0.5-1.2% activity) ,l o with synthesis of the B-chain and combination of this with the natural Achain to produce insulin-like activity equivalent to that produced by recombination of the natural A and B chains.ll Considerable activity was also found when synthetic B-chain was combined with a partially purified preparation of synthetic A-chain. The B-chain of human insulin has been prepared as the S-sulfonate and combined with the natural A-chain of bovine insulin to produce 4-8% the activity of crystalline bovine insulin.12 Synthesis of human A-chain, and combination with synthetic human B-chain and with natural bovine B-chain yielded 2% and 8% insulin activity by the mouse convulsion method.13 The combined results of the German, Chinese and American groups indicate that totally synthetic preparation of pure human insulin is possible with presently available techniques, and that the tools are available for important studies of insulin analogs. Glucagon.--The amino acid sequence of the glycogenolytic pancreatic hormone, glucagon, was determined by Bromer and co-workers in 1957. Partial syntheses of the linear peptide, which contains 29 amino acids, have been reported by Schr6der14, and by Wtinschl5 , but biological activities have not yet been reported for these glucagon-related peptides, and the complete synthesis of glucagon is not yet reported. HORMONES OF THE PITUITARY The Melanocyatimulating Hormones (M2-5) and Adrenocorticotropic Hormones JACTH).--Presence of the same amino acid sequence from 4 through 10 may account for certain common biological properties of MSH and ACTH. B-MSH from various species possess additional N-terminal amino acids, and vary in the nature of amino acids 1-3 in the a-MSH structure. Melanocyte-Stimulating Activity.--The ability to produce skin darkening in amphibia has been associated with the pentapeptide sequence 6-10, His- PheArg-Try-Gly, common to both ACTH and MSH. This requirement has now been shortened to the tetrapeptide, His-Phe-Arg-Try ( 6 - 9 ) , which has been shown to possess both melanocyte-stimulating and lipolytic activity at levels comparable to those of the pentapeptide.l6 Alteration in the (6-10) pentapeptide sequence has produced one of the few examples of inhibition by close analogs in the peptide field. The citrulline analog, His-Phe-=-Try-Gly elicits no MSH-activity, but inhibits the activity of a-MSH.I7 Substitution of D-amino acids in the pentapeptide produces compounds which range in activity from MSH-like to antagonists. The all-D isomer, D-His-D-Phe-D-Arg-D-Try-Gly showed no melanocyte-stimulating or lipolytic activity, but lightened the color of a specimen predarkened by either the all-L pentapeptide, or by synthetic a-MSH. Premixture of equal amounts of all-L and all-D isomers blocked the darkening effect on the isolated frog skin.1° The L-D-D-L and L-L-L-D (6-10) peptide sequences
Chap. 1 7
Non-ste roidal H o r m o n e s
193 -
Jorgensen
retained MSH-activity, while the D-D-D-L, L-D-D-D and D-L-L-L analogs were inactive, or weak antagonists.19 The influence of chain length on MSH-activity has been summarized by Schwyzer.20 Synthetic analogs of ACTH, lengthened from the N-terminal to the C-terminal, show initial melanocyte-stimulating activity at the decapeptide (1-101, although the nonepeptide (1-9) was not investigated. Activity increases markedly at the tridecapeptide amide stage, and activity remains constant with further elongation of the C-terminal end. Acetylation of the amino group of the N-terminal serine residue generally enhances activity 10 to 100-fold in the series.
a-MSH ACTH
Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Try-Gly-Lys-Pro-Val-~~ H-Ser-Tyr-Ser-Met-Clu-His-Phe-Arg-Tty-G1y-Lys-Pro-Val1 2 3 4 5 6 7 8 9 1 0 1 1 1 2 1 3
Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Try-Pro14 15 16 17 18 19 20 21 22 23 24 NH 1 2 [Asp-Gl y-Glu-Ala-Glu-Asp-Ser-Ala-Glu
1
Ala-Phe-Pro-Leu-Glu-Phe 34 35 36 37 38 39
F2
(Beef) (Sheep)
(Pig)
Adrenocorticotropic Activity.--The total synthesis of B-corticotropin, with the amino acid sequence characteristic of the porcine species, has now been reported in detail.21 The techniques developed have aided the synthesis of smaller fragments which have been used to relate chain length and ACTH activity.20 Corticotropin activity is associated with the presence of a free terminal amino group. From the amino end, threshold activity is found with the 1-13 tridecapeptide amide, corresponding to the free amino form of a-MSH. Four to five amino acid residues after MSH activity has reached its plateau, ACTH activity sets in strongly, reaching an almost constant value at 20-24 residues, then climbing to twice this value at the 39 residues of ACTH. The hexacosapeptide corresponding to the first 26 residues of bovine ACTH has been reported to possess adrenal- and melanocyte-stimulating activtty comparable to the native hormone on a molar basis." Ramachandran, Chung and LiZ3 have pointed out the possible significance of the concentration of all the basic amino acid residues of ACTH in the region between positions 5 and 22, with a solid core (Lys-Lys-Arg-Arg) in positions 15-18. The positive charge contributed by the basic amino acids is considered possibly to contribute to receptor binding with a negatively charged surface. The ten-fold increase in potency from the heptadecapeptide (1-17) to the nonadecapeptide (1-19) may be attributed to the additional arginine at 18, which may contribute a positive charge to receptor binding.
194
Sect. IV - Metabolic & Endocrine
H e i n z e l m a n , Ed.
Further enhancement of activity by conversion of the terminal carboxyl group to an amide in this series,24 could be due to the decrease in negative charge contributed by the carboxylate ion, which would interfere with associative interactions at a negatively charged receptor. The approximately equal activity for the octadecapaptide and nonadecapeptide amides was felt to support this concept, 23 since both contained the same core of basic amino acids. The acidic residues concentrated in the carboxyl terminal part of the molecule are suggested as playing a secondary role in enhancing receptor binding at a positively charged site. Since the amino terminal end is most sensitive to alteration, and many functional amino acid residues implicated in the active sites of proteolytic enzymes are present, this region is considered to be the active site of the hormones, oriented by the binding affinities of more distant basic and acidic centers. The importance of the basic amino acids has been further indicated by the essential loss in steroidogenic ACTH-like activit with the hexadecapeptide, cr1’14’ 17-18-Gly1-ACTH, and heptadecapeptide, cr1-T4’ 16-18-G1y1-ACTH-18-N~ in which lysine residues have been removed from the normal 1-18 sequence of ACTH analogs. 2 5 Synthesis of the active analog, 17,18-diornithyl-8-corticotropin(1-24)-tetracosapeptide adds further evidence for the important role of basic amino acids in the 15-18 region of the ACTH molecule.26 Oxytocin and Vasopressin.--BoissonnasZ7 and Lawz8 have published recent comprehensive reviews of structural analogs of these hormones of the posterior lobe of the pituitary.
The following data extends from the structure-activity correlations of Law.28 The question of the importance for hormonal activity of the 20-membered disulfide ring has been investigated further. Analogs of arginine- and lysine-vasopressin and their 1-deamino derivatives in which the ring was open and the S-atoms replaced by H-atoms (e.g , Ala1-Ala6-Arg*-vasopressin) were devoid of hormonal-like or antagonistic activity.29 Additional methylene groups in the ring eliminated activity, as shown by the inactivity of the 21-membered ring compound, 4-8-alanine-oxytocin, when compared with the moderately active 20membered ring analog 4-glycine-oxytocin, and of 1-y-mercaptobutyric acid oxytocin, compared with the highly potent deamino-oxytocin (1-6-mercaptopropionic acid oxytocin) 31 Although the intact 20-membered ring requirement has thus far been upheld, isosteric replacement of the ring atoms is possible with retention of activity. Cyclic analogs of oxytocin in which one of the S-atoms of the disulfide bridge was replaced by a methylene group,32 or by a selenium
.
.
Chap. 17
N o n - s te roidal Hormone s
Jorgensen
195 -
atom (6-seleno-oxytocin and deamino-6-seleno-oxytocin) showed significant hormonal activity. Synthesis of diseleno-oxytocin has been reported, but final purification and biological evaluation was not carried out. 34 The stereochemical relationship between the ring and the side-chain is important, as shown by the loss in oxytocic activity with both 1-hemi-D-cystine- and 6-hemi-D-cystine-oxytocin. All-D-oxytocin has been prepared and shown to lack either hormone-like or inhibiting effects.36 Replacement of L-Tyr2 by D-Tyr2 in oxytocin and its 1-deamino analog produced analogs which retained significant, although slight, oxytocin-like activities as well as an inhibiting effect on oxytocin.37 The analogs L-Dab8- and D-Dab8-vasopressin38, containing the shorter basic sidechain derived from a,y-diaminobutyric acid, showed significant pressor and antidiuretic activities. The D-analog showed selective antidiuretic activity relative to its pressor and uterotonic effects. The configuration of the basic amino acid at the 8-position seems more important for pressor, rather than antidiuretic action, as shown by the selective antidiuretic effects of D-Arg8- and D-Lys8-vasopressin. Alteration of side chains has aided the definition of structural requirements for activity, and has produced analogs with selective and prolonged effects. Both vasopressin and oxytocin show enhancement of activity in the 1-deamino derivatives.40 '41 Systematic replacement by hydrogen of other functional groups in amino acid side chains of oxytocin has shown that the phenolic hydroxyl group is not vital, but does contribute significantly to activity. The carboxamido groups are essential at 5 (asparagbe) and 9 (glycinamide), but not critical at 4 (glutamine), since glutamine may be replaced b a-aminobutyric acid with retention of significant biological a~tivity.~' Removal of the carbox terminal NH2- group alone (9-deamido oxytocin) leads to loss of activity.43 Acylation of the amino end of vasopressin (Gly-Cysl-vasopressin) resulted in a partial reduction in activity, but a three-fold prolongation of effects.43 Preparation of further extended-chain analogs of oxytocin, including Pro-Cysl-, Phe-Cysl-, D-Leu-Cysl-, Leu-Leu-Cysl-, and Gly-Gly-Cysl- oxytocins has been reported.44 The observation of oxytocin-antagonistic properties for analogs of oxytocin with 0-ethyltyrosine, p-methylphenylalanine, and p-ethylphenylalanine replacing t y r o ~ i n e ,has ~ ~ been extended by synthesis of Gly-CyslTyr (Me) 2-vasopressin. This chain-lengthened functionally modified analog showed a small but prolonged antidiuretic effect, and a relatively strong inhibition of the pressor activity of lysine-vasopressin at a molar ratio of analog to hormone of 25:l. Complete and long-lasting inhibition was produced at a ratio of 200:l. Complete inhibition of the uterotonic effect of oxytocin on the isolated rat uterus was obtained at a ratio of 300:1.43 N-Carbamyl-0carbamyl-oxytocin showed no effect alone on the isolated rat uterus, but at an analog to hormone ratio of 50:1, produced complete inhibition of oxytocin administered one minute later. The mono-acylated derivatives, N-carbamyl- and O-carbamyl-oxytocin showed slight oxytocic (0.05 and 0.1%), and no inhibitory effects on the rat uterus.46 The requirements of position 8 have been studied in detail. An aliphatic side chain is important for oxytocic activity, since Gly8-oxytocin was inactive,
196 -
Sect. IV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
while an ethyl, or even methyl group $resent in But8-oxytocin and Ala8-oxyrocin conferred a high degree of a ~ t i v i t y . ~ The importance of the basicity of the amino acid residue at position 8 and the phenolic group at position 2 for vasopressin-like activity was shown with analogs combining variations at the 2 and 8 positions. Phe2-Om8-vasopressin and Phe2-Om8-oxytocin showed selective pressor activity 48whi1e desaminol-Arg8- and desaminol-Phe2-Arg8-vaso ressins showed an enhanced antidiuretic effect. 49 Syntheses of desaminol -0rn - and desaminol-Phe2-Om8-vasopressins and oxytocins has also been described. Thialysine8-vasopressin, an isostere containing sulfur in place of a methylene group of the lysine side chain, showed antidiuretic activity greater than that of Lys8-vasopressin, with less pressor activity. Therefore, factors other than base strength appear to be involved in the role of the side chain in the 8 position.51 Reaction of oxytocin with acetone under mild conditions to produce an inactive derivative has been noted.52 Reaction is presumed,to occur with the free amino group , since deaminol-oxytocin is not deactivated under these conditions. Specific tritiation of oxytocin by catalytic deiodination has been reported. 53 HORMONES OF THE STOMACH Gastrin.--Heptadecapeptide amides gastrin I and gastrin I1 isolated in 1964 from hog antral mucosa, are believed to be related to the hormone released during digestion, which stimulates gastric secretions. On a molar basis, gastrin I1 is some 500 times more effective than histamine in stimulating gastric secretion. Gastrin I1 differs from gastrin I only in being the sulfate ester derivative of the tyrosine residue.
Pyr-Gly-Pro-Tyr-Met-(Glu)5-Ala-Tyr-Gly-Try-Met-Asp-Phe-NH2 Gastrin I Only the C-terminal tetrapeptide amide sequence, Try-Met-Asp-Phe-NH2 was found to be required to produce the full range of ghysiological effects of the natural hormones. St Structure-activity studiess5’ in the active C-terminal tetrapeptide sequence led to the following observations: (a) all N-acyl derivatives of the tetrapeptide are active, (b) substitution of all, or part of the Lamino acids by the D-isomers leads to virtual loss of activity, (c) replacement of tryptophane by other amino acids results in loss of activity, although 4-, 5-, and 6-methyl tryptophanes are highly active, (d) methionine may be replaced by norleucine or ethionine with retention of activity, byt all changes in the aspartic acid position led to inactive compounds, (e) 0-methyl tyrosine may replace phenylalanine, (f) the terminal amide cannot be converted to the methyl ester, the free acid, or a dialkylamide without loss in activity. TISSUE HORMONES Bradykinin, Kallidin and MethionyJ-ksyl-bradykinin.--Bradykinin and its N-terminal analogs are formed by enzymatic degradation of inactive precursors present in the a2-globulin fraction of plasma. R-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg 1 2 3 4 5 6 7 8 9 Bradykinin, R = H
Kallidin, R = Lys
Methionyl-lysyl-bradykinin, R = Met-Lys
Chap. 17
N o n - steroidal Hormones
197 -
Jorgensen
From a comprehensive survey of analogs in 1964,57 it was concluded that the importance of individual amino acids for biological activity was in the order, 7,8>1>9>5>4>2>3>6. The Pro7 and Phe8 residues appear to be most essential for biological activity. The terminal arginine residues (1,9) may be replaced with basic amino acids, but neutral amino acids produce a loss of activity. The aromatic residue in position 5 is essential. Exchange of Gly4 and Pro - residues causes medium loss of activity, while the Pro3 and Ser6residues are relatively insensitive to change. The importance of the free carboxyl end of bradykinin, and of other active peptides for full biological activity, has been emphasized.58 Variations in the nature and configuration of the peptide chain have led to less active or inactive analogs. Retrobrad kinin,59 containing the reverse sequence of amino acids, all-
D- bradykininx8'60, and all-D-tetrobradykinin6O showed neither bradykinin-
like nor antagonistic activity. Replacement of either or both of the L-arginine residues with D-arginine resulted in loss of activity, and no production of inhibitory effect.61 Introduction of ester in place of amide links between residues 3-4 and 5-6, in the depsipeptides glycolyl-4- and glycolyl-6-bradybinin produced analogs with 0.5 to 1% activity.62 The inactivity of the c clic decapeptide, Gly7-cyclokallidin, 3as compared with the active linear Gly -kallidin, further demonstrated the importance of conformation for biological activity.
s
A number of octa- and nonapeptide analogs containing threonine in place of serine were prepared as potential antagonist^.^^ Tests on rat uteri showed variable and unpredictable mimetic and antagonistic response; only bradykinin-like effects were seen with the isolated guinea pig ileum or rat duodenum. The solidphase synthesis of b r a d ~ k i n i nhas ~ ~ been extended to provide a number of additional bradykinin analogs. Among these, replacement of both phenylalanine residues with 0-methyl tyrosine yielded an antagonist at low concentrations, but bradykinin-like activity at higher concentrations.66 To date, no bradykinin antagonistic peptide has been reported which is free of bradykinin-like activity at high dose levels. Extension of the N-terminal end of bradykinin generally leads to little change in activity.67 Met-Lys-bradykinin is about 113 as active on isolated muscle preparations, but 2-3 times as active as bradykinin in lowering rabbit blood pressure. The methionine sulfoxide retains the activity of Met-Lys-bradykinin, while the sulfone is only about 1/10 as active. N-terminal-extended bradykinin analogs are generally highly active, with (Lys-Lys-Argl)and (Lys-Lys-Lys-Argl )-bradykinin being 8-10 times as potent as bradykinin in lowering rabbit blood pressure, while being less active in producing contractions
of isolated smooth muscle.
Dihydrochlorprothixene and a related analog have been reported to act as competitive inhibitors of bradykinin on isolated guinea pig preparations. CYPrQheptadine acted as a non-competitive inhibitor. An8iotensin.--Angiotension I, a relatively inactive decapeptide produced by the action of renin on an a2-globulin blood fraction, is converted to the active octapeptide, angiotensin-I1 by the enzymatic removal of a C-terminal dipeptide,
Sect. IV
198
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
His-Leu. Species differences provide two equiactive angiotensins, containing valine or isoleucine in the 5-position. The composition of human angiotensin is not yet established. Asp-Arg-Val-Tyr-Ile 1 2 3 4 5
(Val)-His-Pro-Phe 6 7 8
The kinetics of the renin-substrate reaction have been studied employing a synthetic tetradecapeptide renin substrate. 69 Earlier studies which provided structural relationships relative to smooth muscle-stimulating or pressor effects have been summarized by Law.28 For significant activity, the carboxyl and phenyl groups of Phe8 and phenolic hydroxyl group of Tyr4 appear to be essential. Loss of activity on photolysis and decreased activity of analogs containing 6-substituents supported the essential role of the imidazole ring of His 5 The low activity of the M a 7 analog indicated the importance of Pro7. Substitution of leucine for valine or isoleucine in the 5-position resulted in a four-fold decrease in activity, but leucine could replace Val with complete retention of activity, indicating a selective influence of side chain branching at position 5. A low degree of specificity was generally indicated for Asp1 and Arg2. Aromatic residues (4,6,8).--Using Asp (NH2)1-Val5-angiotensin-II as the parent compound, Schr6der70 has replaced the HisC residue with PhenYlalanine and lYsine+ obtaining activities of 1% and 0.1%, respectively. This provides further evidence for the importance of histidine, with aromatic character apparently being more important than base strength. A surprising loss in activity occurred when 0-methyl tyrosine replaced Tyr4 (0.2%), considering the relatively strong activity reported for the Phe4 analog (10%). Exchan e of hydroxyl groups between positions 4 and 8 with Asp (NH2) 1-Phe4-Va15-Tyr8-angiotensin-II led to inactivity. Apparently the phenolic character of Tyr4 and aromatic character of Phea are the most important features, as shown by the 10% activity of the di-tyrosyl analog, Asp (NH2) 1-Va15-Tyr8-angiotension-II. The closely related Ile5-Tyr8-angiotensinI1 has been reported as only slight1 less active than Ile5-angiotensin-II.71 Increased se aration between the Tyr' and Phe8 residues, by exchange of the Val3 and Tyr residues, led to loss of activity.70
t
r
tes+dues ( 3
~gdrbxyproline%$lace
.--Tyrosine in place of Val3 resulted in 12% activo€ Pro7 reduced activity to 7%.
-Acidic and basic residues (1,2l.--Variations of Asp1 have yielded analogs with
hei htened and prolonged activities. The isomeric a-D-? 6-L- and 6-D-Asp'Val@-angiotensins-II, by comparison with natural a-L-Aspl-Val.'-angiotensin-lI and its Asp1-B-amide, show an increase in activity of about 50%, and a two to three-fold prolongation of pressor activity in the rat. 72 This has been attributed to a decrease in the rate of degradation of the modified angiotensins by Desamino-Val5-angiotensin-I1 showed a 50% decrease, but prolonaminopeptidases ~ ~ showed that gation of activity. This series has been extended by S ~ h r t j d e rwho the D-Asp1-, Glul-, Glu (NH2)l- and Pyroglu1-Va15-angiotensin-II analogs all showed about 50% enhancement of pressor activity over that of Val5-angiotensin11.
.
Chap. 17
Non-steroidal Hormones
Jorgensen
199 -
The activities reported for the Lys2 and Val2 analogs of Asp (~~,)~-Val5angiotensin-I1 (10% and 5 % ) added to the conclusion that the arginine at position 2 is not essential for activity.74 In a study mainly involving 2-8 heptapeptide analogs, X-Val-Tyr-fle-His-Pro-Phe , Havinga’l’’7 6 has concluded that the features of the arginine moiety contributing to activity are the positive charge or the capacity to hydrogen bond of the guanidinium or ammonium groups forming part of X in active peptides. Heptapeptides with D-amino acids in the X-position were more active than the corresponding L-compounds, However, 1-8 octapeptides with D-amino acids in the 2-position were less active than their L-counterparts. All-D-Asp(N€l~~Va15-angiotensin-II has been synthesized as a potential antagonist, but showed neither angiotensin-like nor antagonistic effects in both smooth muscle-stimulation and pressor tests.7 7 97 8
The solid-phase method of peptide synthesis has been used to prepare Ile5-, Asp(NH2) ’-Ile5-, and B-Asp’-Ile5-angiotensins-I1 .79 The problem of the secondary structure of angiotensin in solution is unresolved. Thin-film dialysis studies indicate a coiled or compact form of low axial ratio.80 Biological experiments involving inhibition of smooth muscle responses to angiotensin by urea and amino acids, indicate that the simple compounds produce either randomization of an organized angiotensin structure, or produce inhibition by direct interaction with the receptor.81 MISCELLANEOUS PHYSIOLOGICALLY ACTIVE PEPTIDES
Eledoisin --- -_ .^__ and - Physa1aemg.--The powerful vasodilating hypotensive undecapeptide eledoisin was isolated in 1962 from the salivary glands of a mollusc. In 1964 the four-fold more potent related undecapeptide, physalaemin, was isolated from the skin of a South American amphibian. Eledoisin
H-Pyr-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-W2
Physalaemin H-Pyr-Ala-Asp-Pra-Asp-Lys-Phe-Tyr-Gly-Leu-Met-M2 1 2 3 4 & 6 7 8 9 1011 5 2
Studies of numerous analogs have shown that similar structure-activity relationships exist in both compounds. The C-terminal amino acids (6-11) are highly sensitive to alteration, while the N-terminal residues (1-5) are relatively insensitive.82 A minimum of five amino acid residues at the C-terminal end (7-11) is needed for appreciable activity, while activity increases sharply with the hexapepti.de (6-11) and higher analogs. The hexapeptide (6-11) related to eledoisin retains 30%;activity in lowering blood pressure in the rabbit, while the heptapeptide (5-11) is essentially as active as e l e d o i ~ i n . ~The ~ corresponding physalaemin hexapeptide (6-11) is 2-2 to 3 . 8 times as active as eledoisin, and at least half as active as physalaemin in its hypotensive effect in the d ~ g . ~ ~a Iseries n of A~p(NH~)~-eledoisinanalogs, maximal h otensive activity in the rabbit was reached in the octa to decapeptide range,T3E while maximal hypotensive activity in the dog was shown at the C-terminal nonapeptide (3-11)
200 -
Sect. IV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
related to eledoisin.86 Increased activity has been shown in eledoisin analogs with higher thioalkyl groups replacing the thiomethyl group of methionine, while alkylcysteinamide residues, with one less methylene group,or other amino acids, drastically reduce activity.87 The all-D isomer of the highly active hexapeptide analog of eledoisin (6-11) was devoid of either eledoisin-like or antagonistic activity. Systematic replacement of individual L-amino acids by D-amino acids in the active heptapeptide (5-11) resulted in essential loss in activity, except for the D-Ala6 analog, which retained 30% of the activity of the parent heptapeptide, in lowering blood pressure in the rabbit. 88 With few exceptions, both physalaemin and its close analogs are relatively inactive in producing contractions of the rat uterus as compared with eledoisin, in doses equiactive in reducing blood pressure.Q4 THYROID HORMONES Thyroxine and Triiodothyronis.--Recent contributions to studies relating structure and activity may be discussed in terms of the structure of thyroxine.
Phenolic hydroxy1.--Thyroxine-like
activity found for 4'-deoxy-3,5-diiodothyronines, and inactivity for corresponding 4'-methyl analogs was attributed to a probable metabolic introduction of the hydroxyl group to produce the active molecule.89
Outer ring substituents.--The ability of alkyl or aryl groups to replace halogen atoms on the phenolic ring with retention, or even enhancement, of biological activity, has been confirmed. Relative to L-thyroxine (loo), substituted 3,5-diiodothyronines showed the following antigoitrogenic activities in the rat: L-3'-iodo (775), DL-3l-ethyl (3401, L-3'-isopropyl (12501, L-3'-isoproBarker has noted similar potent pyl-5'-iodo (440), and L-3'-isobutyl (60). thyroxine-like effects in oxygen consumption and heart rate tests on rats for thyroxine analogs with outer ring alkyl substituents, or bearing a fused phenyl ring (3,5-diiodonaphthyr0nine).~~ In these tests, as well as a test measuring inhibition of thyrotropic hormone release,91 the 3 ' -isopropyl analog was the most potent tested. 3'-Tertiary butyl-3,5-diiodo-L-thyronine showed equal activity to L-thyroxine in the tadpole metamorphosis assay,92 and about twice the activity of L-thyroxine in the rat antigoiter assay.93 Further examples of decreased activity for outer ring 3',5'-disubstituted analogs, as compared with the correspondine 3'-monosubstituted compound were presented.89 A long standing apparent inconsistency in this regard was resolved by the demonstration that the 3'-chloro analog was more active than 3 ' ,5 '-dichloro-3,5-diiodo-L-thyronine. 94 The importance for biological activity of a distal positioning in space relative to the inner ring for the outer ring substituent has been emphasized by further examples. 89 The role of ring substituents in establishing skewed conformation for the di henyl ether nucleus has been studied on thyroxine analogs using NMR techniques.t 5
Chap. 17
N o n - 8 teroidal Hormones
Jorgensen
201 -
Ether linkage.--Three biphenyl analogs of tetra- and triiodothyroacetic acid, and of thyroxine were found to be essentially inactive in the heart rate test,89 indicating a requirement for the ether linkage. However, the biphenyl analog, 3,5-diiodo-4-(3 ,5 -dimethyl-4'-hydroxylphenyl) phenylalanine was reported to be equiactive to the corresponding diphenyl ether, and about 1.5 times as active as thyroxine in inducing metamorphosis in the immersed tadpole. g6 Iodinated 2-methyl-3-carboxy-5-hydroxybenzofurans, compounds lacking the diphenyl ether nucleus, and previously reported active in the tadpole metamorphosis assay, were inactive in the heart rate test. 89 Inner ring substituents.--The 3,5-dibromo analog of DL-thyroxine approached the activity of thyroxine in the rat oxygen consumption test,89 indicating the lack of a requirement for iodination on the alanine-bearing ring. Thyronines mono-iodinated, or lacking iodine on the inner ring were inactive in oxygen consumption tests. -Side chains.--Thyroxine analogs with alcoholic side chains of varying lengths have been prepared by reduction of the corresponding acids. 97 Among these,
3,5-diiodo-3',5'-dimethyl thyroethanol was reported to show in the rat a greater dissociation between hypocholesterolemic and calorigenic effects than either L- or D-thyroxine. A number of reports of synthesis and biological activities of a-methyl thyronines have appeared. O 0 a-Methyl-DL-thyroxinegg showed weak thyroxine-like activity in antigoitrogenic, cholesterol-lowering, and heart weight assays, and inactivity as a thyroxine antagonist in the antigoiter test. a-Methyl-DL-triiodothyronine and its D- and L-isomers were reported to be more active in the hypocholesteremic test than DL-a-methyl.thyroxine.' O 0
REFERENCES 653 (1965). 1. H. Zahn, H. Bremer, and R. Zabel, Z. Naturforsch., 3, 2. J. Meienhofer and E. Schnabel, 2. Naturforsch., x h , 661 (1965). 3. H. Zahn, 0. Brinkhoff, J . Meienhofer, E. F. Pfeiffer, H. Ditschuneit, C. Gloxhuber, Z. Naturforsch. E , 666 (1965). 4. H. Zahn, B. Gutte, E. P. Pfeiffer and J . w o n , Ann. Chem. 691, 225 (1966). 5. C. I. Niu, Y. T. Kung, W. T. Huang, L. T. Key C. C. Chen, Y. C. Chen, Y. C. Du, R. Q. Jiang, C. L. TSOU, S. C. Hu, S. Q. Chu and K. Z. Wang, 15, 231 (1966). Sci. Sinica (Peking), 14,1386 (1965); 6. Y. Wang, C. Y. Hsing, et al., Sci. Sinica, l4, 1887 (1965). 7 . T. P. Loh, C. H. Li and C. Y. Hsing, Acta Chim. Sinica, 2,509 (1965). 8. Y. C. Du, R. Q. Jiang and C. L. TSOU, Sci. Sinica (Peking), 14,229 (1965) C. A . , 6 2 , 18410 (1965). 9. Anon. The Total Synthesis of Crystalline Insulin. Kexue Tongbao, 17,241 (1966) 10. P. G. Katsoyannis, A. Tometsko and K. Fukuda, J. Am. Chem. Soc., 85, 2863 (1963). 11. P. G. Katsoyannis, K. Fukuda, A. Tometsko, K. Suzuki, and M. Tilak, J. Am. Chem. SOC., 86,930 (1964). 12. P. G. Katsoyannis, A. M. Tometsko, J. Z. Ginos and M. A. Tilak, J . Am. Chem. SOC., 88, 164 (1966). 13. P. G. Katsoyannis, A. Tometsko, and C. Zalut. J. Am. Chem. SOC., 88, 166 (1966).
m.,
.
202
Sect. I V
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
14. E. Schrtjder, Ann. Chem., fif8if, 231, 241, 250 (1965). 15. (a) E. WUnsch, Acta Chim. Hung, 4-4, 173 (1965). (b) E. Wiinsch and A. &i&, Chem. Ber., 2,101, 105 (1966). (c) E. Wtinsch and F. Drees, ibid., 9!3, 110 (1966). 16. H. Hotsuka and K. Inouye, Bull. Chem. SOC. Japan, 37, 1465 (1964). 17. M. Bodanszky, M. A. Ondetti, B. Rubin, J. J. Piala, J. Fried, J. T. Sheehan and C. A. Birkhimer, Nature, 194,485 (1962). 18. H. Yajima and K. Kubo, J. Am. Chem. SOC., 87, 2039 (1965). 19. H. Yajima and K. Kubo, Chem. and Pharm. Bull., Japan, 2, 759, 1326 (1965). 20. R. Schwyzer, Ann. Rev. Biochem., 33, 259 (1964). 21. R. Schwyzer and P. Sieber, Helv. Chim. Acta, 9, 134 (1966). 22. J. Ramachandran and C. H. Li, J. Am. Chem. SOC., 87, 2696 (1965). 23. J. Ramachandran, D. Chung, and C. H. Li, J. Am. Chem. SOC., 87, 2691 (1965). 24. H. Otsuka, K. Inouye, F. Shinozaki, and M. Kanayama, J. Biochem. (Japan), 58, 512 (1965). 25. H. Otsuka, K. Inouye, M. Kanayama and F. Shinozaki, Bull. Chem. S O C . Japan, 28, 679, 1563 (1965). 26. G. I. Tesser and R. Schwyzer, Helv. Chim. Acta, 3, 1013 (1966). 27. R. A. Boissonnas, St. Guttmann, B. Berde, and H. Konzett, Experientia, 17, 377 (1961). 28. H. D. Law, Progr. Med. Chem., 4, 86 (1965). 29. R. L. Huguenin and St. Guttmann, Helv. Chim. Acta, 48, 1885 (1965). 30. M. Manning and V. duvigneaud, Biochemistry, 4, 1884 (1965). 31. D. Jarvis, B. M. Ferrier and V. duvigneaud, J. Biol. Chem., 2%. 3553 (1965). 32. J. Rudinger and K. Jost, Experientia, 20, 570 (1964). 33. R. Walter and V. duvigneaud, J. Am. Chem. SOC., 87, 4192 (1965). 34. W. Frank, 2. Physiol. Chem.. 339, 222 (1964). 35. M. Manning and V. duvigneaud, 87, 3978 (1965). 36. G. Flouret and V. duvigneaud, J. Am. Chem. SOC., 8 7 , 3775 (1965). 37. S. Drabarek and V. duvigneaud, J. Am. Chem. SOC., 8 7 , 3974 (1965). 38. M. Zaoral and F. Sorm, Collection Czech. Chem. Commun., 31, 90, 310 (1966). 39. M. Zaoral, J. Kolc and F. Sorm, 32, 382 (1966). 40. R. L. Huguenin, E. StUrmer, R. A. Boissonnas, and B. Berde, Experientia, 2 l , 68 (1965). 41. L. A. Branda and V. duvigneaud, J. Med. Chem., 9, 169 (1966). 42. B. M. Ferrier and V. duvigneaud, J. Med. Chem., 2, 55 (1966). 43. M. Zaoral and F. Sam, Collection Czech. Chem. Commun., 30, 2812 (1965). 44. E. Kasafirek, K. Jost, J. Rudinger, and F. Sonn, w.,30, 2600 (1965). 45. A. L. Zhuze, K. Jost, E. Kasafirek, and J. Rudinger, iJbs., 29, 2648 (1964). 46. D. G. Smyth, Acta Chim. Acad. Sci. Hung., 44, 197 (1965). 47. P. A. Jaquenoud, Helv. Chim. Acta, 48, 1899 (1965). 48. R. L. Huguenin, w.,47, 1934 (1964). 49. R. L. Huguenin and R. A. Boissonnas, 49, 695 (1966). 50. R. L. Huguenin, 49, 711 (1966). 51. P. Hermann and M. Zaoral, Collection Czech. Chem. Comun., 30, 2817 (1965). 52. D. Yamashiro, H. L. Aanning, and V. duvigneaud, Proc. Nat. Acad. Sci. U.S., 54, 166 (1965). 53. Y. Agishi and J. F. Dingman, Biochem. Biophys. Res. Cow., l8, 92 (1965).
u.,
m.,
s.,
Chap. 17
54. 55. 56. 57. 58. 59. 60.
61. 62. 63. 64. 65. 66. 67. 68. 69. 70. 71. 72. 73. 74. 75. 76. 77. 78. 79. 80. 81. 82. 83. 84. 85. 86. 87. 88. 89. 90. 91. 92.
93.
Non-steroidal Hormones
Jorgensen
2 03 -
H. J. Tracy and R. A. Gregory, Nature, 204; 935 (1964). Morley, H. J. Tracy and R. A. G r e F y , Nature, 207, 1356 (1965). J. M. Davey, A. H. Laird and J. S. Morley, J . Chem. SOC. (C), 555 (1966). E. Schrbder and R. Hempel, Experientia, 20, 529 (1964). J. M. Stewart and D. W. Woolley, Nature, 206, 619, 1160 (1965). S . Lande, J. Org. Chem., 27, 4558 (1962). K. Vogler, P. Lanz, W. Lergier and W. Haefely, Helv. Chim. Acta, 49, 390 (1966). E. D. Nicoloides, D. A. McCarthy and D. E. Potter, Biochemistry, 5, 190 (1965). L. Shchukina, G. A. Ravdel, M. P. Filatova, and A. L. Zhuze, Acta Chim. Acad. Sci. Hung., 44, 205 (1965). J. M. Meienhofer, Ann. Chem., 691, 218 (1966). J. M. Stewart and D. M. Woolley, Biochemistry, 2, 700 (1964). R. B. Merrifield, Biochemistry, 2, 1385 (1964). J. M. Stewart and D. M. Woolley, Federation Proc., 24, 657 (1965). E. Schrbder, Experientia, 2l, 271 (1965). J. G. Leme and M. R. eSilva, Brit. J. Phannacol., 25, 50 (1965). D. Montague, B. Riniker, and F. Gross, Am. J . Physiol., *,599 (1966). E. Schrtjder and R. Hempel, Ann. Chem., 684,243 (1965). K. M. Sivanandaiah, R. R. Smeby and F. M. Bumpus, Biochemistry, 5, 1224 (1966). B. Riniker and R. Schwyzer, Helv. Chim. Acta, 47, 2358 (1964). E. Schrader, Ann. Chem., 232 (1966). E. Schrtjder, 680, 132 (1964). E. Havinga, C. Schattenkerk, G. H. Visser, and K.E.T. Kerling, Rec. Trav. Chim., 83, 672 (1964). C. Schattenkerk and E. Havinga, 84, 635 (1965). K. Vogler, R. 0. Studer, W. Lergier, and P. Lanz, Helv. Chim. Acta, 48, 1407 (1965). E. Schrtjder, Ann. Chem., 692, 241 (1966). G. R. Marshall and R. B. Merrifield, Biochemistry, 5, 2394 (1965). L. C. Craig, E. J . Harfenist and A. C. Paladini, Biochemistry, 2, 764 (1964). P. A. Khairallah, R. R. Smeby, I. H. Page, and F. M. Bumpus, Biochim. Biophys Acta, 104,85 (1965). E. Stunner. Ed. Sandrin, and R. A. Boissonnas, Experientia, 20, 303 (1964). E. Schrbder and K. Liibke, Experientia, 20, 19 (1964). L. Bernardi, G. Boisio, F. Chillemi, G. DeCaro, R. DeCastiglione, V. Erspamer, and 0 . Goffredo, Experientia, 22, 29 (1966). K. Liibke, R. Hempel and E. Schroder, Experientia, 21, 84 (1965). L. Bernardi, G. Bosisio, F. Chillemi, G. DeCaro, R. DeCastiglione, V. Erspamer, A. Glaesser, and 0. Goffredo, Experientia, 20, 306 (1964). L. Bernardi, G. Bosisio, F. Chillemi, G. DeCaro, R. DeCastiglione, V. Erspamer, A. Glaesser, and 0. Goffredo, Experientia, 21, 695 (1965). E. Schrbder, K. Liibke, and R. Hempel, Experientia, 21, 70 (1965). S. B. Barker, M. Shimada, and M. Makiuchi, Endocrinology, 76, 115 (1965). 78, 29 (1966). M. Wool, V. S. Fang, and H. A. Selenkow, T. Bauman, G. W. Pipes, and C. W. Turner, 76, 537 (1965). C. M. Buess, T. Giudici, N. Kharasch, W. King, D. P. Lawson, and N. N. Saha, J. Med. Chem., 8, 469 (1965). 533 (1965). E. C. Jorgensen and J. A. W. Reid, J. Med. Chem., J. S o
w.,
m,
u.,
w., w.,
2 04
Sect. IV
-
Metabolic & Endocrine
H e i n e e l m a n , Ed.
94. E. C. Jorgensen and J. A. W. Reid, Endocrinology, 76, 312 (1965). 95. P. A. Lehman and E. C. Jorgensen, Tetrahedron, 21, 363 (1965). 96. M. H. Kullk and J. F. Bester, J. Phann. Sci., 54, 494 (1965). 97. W. J. Wechter, W. A. Phillips, and F. Kagan, J. Med. Chem.,L 474 (1965). 98. DL-a-Methylthyroxlne. Chkmie Grtinenthal, Neth. Appl. 6, 503, 266, Oct. 11, 1965. C.A. 64, 9819d (1966). 99. B. Blank, E. G. Rice, F. R. Pfelffer, and C. M. Greenberg, J. Med.Chem., -9,lO (1966). 100. G. M. K. Hughes and P. F. Moore, Abstract No. 19, Div. Med. Chem., h e r . Chem. SOC. Meeting, Pittsburgh, Pa., March, 1966.
20 5 Chapter 18.
Reproduction
John C . Babcock, The Upjohn Company, Kalamazoo, Michigan Introduction There i s every reason t o b e l i e v e t h a t H i s t o r y will record t h e year 1955 a s one o f those r a r e t u r n i n g p o i n t s i n t h e L i f e o f Man f o r i t was t h e n t h a t t h e f i r s t s t e p s toward e f f e c t i v e family planning and s e l f - c o n t r o l o f population p r e s s u r e s were made; t h e elements o f o r a l contraception began t o take shape. True, it was o n l y a beginning. But it was a beginning b u i l t on a s o l i d foundation, and it o f f e r e d hope: Hope t o young couples not ready t o have children; hope t o o l d e r couples who could ill a f f o r d t o expand t h e i r f a m i l i e s ; hope t o c h i l d r e n where each new mouth t o be f e d would t h r e a t e n f u r t h e r t h e i r s l i m chance f o r s u r v i v a l . And it o f f e r e d hope t o n a t i o n s a l r e a d y s t r a i n i n g every resource i n a f u t i l e e f f o r t t o maintain an a l r e a d y inadequate l e v e l of e x i s t a n c e . A t a t i m e when the laws o f exponential growth were beginning t o t h r u s t populationsinto c r i t i c a l p e r i o d s o f s u r v i v a l , t h e developnent o f o r a l contraception was l o n g overdue. . .and almost t o o l a t e ! ~ r o g e s t e r o n (e 3 ) the hormone o f t h e corpus luteum and fundamental p r e c u r s o r o f most steroid hormones, had been known s i n c e 1 9 2 8 . ~ I t had been i s o l a t e d and synthesized by s e v e r a l research groups by 1934.3 By 1937 i t was known t o block t h e estrus 5 Eight more y e a r s cycle i n t h e r a t 4 and t o block o v u l a t i o n i n t h e r a b b i t . were t o p a s s before hormonal therapy was t o be considered s e r i o u s l y a s a means o f e f f e c t i n g b i r t h c o n t r o l “ and s t i l l t e n more y e a r s before t h e r i g h t s t e r o i d s , i n t h e hands o f some people with imagination.. ..and a plan, produced results o f e x t r a o r d i n a r y importance. Thus Rock, Pincus, and Garcia came t o r e p o r t t h a t o v u l a t i o n could be i n h i b i t e d by administering any o f 1 t h r e e 19-norsteroids o r a l l y between day 5 and day 25 o f t h e menstrual cycle. Like so many important e v e n t s i n h i s t o r y , t h e outcome may have been determined by a f o r t u n a t e coincidence. Both norethynodrel (8) and norethindrone (6b) (which were s e l e c t e d f o r f u r t h e r study) were contaminated with b i o l o g i c a l l y s i g n i f i c a n t amounts o f a n e s t r o g e n i c impurity7 while norethandrolone ( 6 a ) , a weak androgen, capable o f producing s e r i o u s l i v e r dysfunction,’ was not pursued. The corpus luteum and i t s s e c r e t o r y product progesterone, a r e generally held responsible f o r maintaining pregnancy and blocking o v u l a t i o n during t h e extended period o f g e s t a t i o n . A number o f s y n t h e t i c p r o g e s t i n s a r e a l s o recognized t o be e f f e c t i v e o v u l a t i o n i n h i b i t o r s i n animals. I t i s t h e r e f o r e not s u r p r i s i n g t h a t i n v e s t i g a t o r s i n t h e f i e l d considered t h e 19-norsteroids f i r s t s t u d i e d t o be simply “ p r o g e s t i n s . ” ? Unfortunately t h e term continues t o be a p p l i e d erroneously t o o r a l c o n t r a c e p t i v e s i n general, whether containing e s t r o g e n a s an impurity o r as t h e major i n g r e d i e n t i n terms o f b i o l o g i c a l e f f e c t . Actually most c o n t r a c e p t i v e s marketed or under study involve proestrogen, i n combination o r s e q u e n t i a l l y . gestin
-
206 -
Sect. I V
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
Available S t e r o i d Contraceptives Currently, a l l contraceptives marketed contain e i t h e r e t h i n y l e s t r a d i o l (1)o r i t s 3-methyl e t h e r , mestranol ( 2 ) . The former i s a highly potent o r a l estrogen f o r which a l a r g e body o f c l i n i c a l experience e x i s t s . The l a t t e r w a s a contaminant i n e a r l y samples of norethynodrel and norethindrone and i s generally added t o those products i n an amount required t o maint&!za f i x e d composition. I t i s believed t h a t e t h i n y l e s t r a d i o l may be s l i g h t l y more potent than mestranol since 0.05 mg. o f the former and 0.08 mg. of the l a t t e r a r e needed d a i l y t o i n h i b i t ovul a t i o n i n women.’
&- &.CECH
-CZCH
H
CH30‘ 1 Ethinylestradiol
‘ 2 Mestranol
To date, all known progestins a r e derived formally e i t h e r from t h e s t r u c t u r e o f the male hormone testosterone (4a) or from t h e female hormone progesterone (3). Among the former, e t h i s t e r o n e (4b), o r 17e t h i n y l t e s t o s t e r o n e , although t h e o n l y a v a i l a b l e o r a l progestin f o r many y e a r s , l ” has apparent1 not been used i n o r a l contraception. I t has weak androgenic properties.” The 19-nor analo norethindrone (6b), i s . a l s o and i n t h e weakly androgenic, both i n animal s t u d i e s ”jl’ I t s 17-acetate i s generally s i m i l a r i n a c t i v i t y . Norethandrolone ( 6 a ) , f i r s t marketed a s an anabolic agent t o promote weight gain and nitrogen r e t e n t i o n , a l s o e x h i b i t s androgenic p r o p e r t i e s and can produce serious hepatotoxicity over a prolonged period a t high dosage Norethynodwl (8) and norethisterone a c e t a t e a r e r e a d i l y converted t o norethindrone (6b) i n 7Jivo14, 18-21 but the former i s s a i d t o e x h i b i t more estrogenic than androHigh potency was a l s o encountered i n ethynodiol d i genic character. 16y22 a c e t a t e (10) wherein t h e 3-ketone was reduced t o an alcohol2345 and i n 26 l y n e s t r e n o l (12), an analog of 6b i n which t h e 3-ketone has been removed. Numerous r e l a t e d analogs have been prepared and studied, including haloethyriyl and t r i fluoropropynyl d e r i v a t i v e s of 19-norte s t o s t e rone ,27, 28 17chlo roe thynyl-17f3- hydroxye st r-4,9,11- t ri en- 3-one, 29 7a-me t hyl-17-e t h i nyl19-nortestosterone, &, 21-dimethyl-17-ethinyltestosterone (14, Dimethi sterone ) 31 and synthetic 13f3-ethyl-17a-ethinyl-17f3-hydroxygon-4-en-3-one.32
.’
Jd?
d
3 Progesterone
4a 4b
R = H, Testosterone R = CECH, Ethisterone
Chap. 18
Reproduction
Babcoc k
CH3
OH
CH3
6a R = C2H5 Norethandrolone 6b R = CECH Norethindrone
rogesterone 5 Medrox acetag
d
0 4&-xzcH
0’
7a
7b
8 Norethynodrel
X = C 1 Chlonadinone -OAc X = C H 3 Megestrol acetate
AcO’
9 Melengestrol a c e t a t e
&-c-czcH 0 10
Ethynodiol d i a c e t a t e
OH
{!
0
&-
- -0COC 6HL3
,C E C - C H 3
dP l3a R
13b R
05
= CH3 Hydroxyprogesterone =
H
caproat e
tH3
1 4 Dimethisterone
20 7 -
20 8
Sect. IV
-
Metabolic & Endocrine
H e i n z e l m a n , Ed.
A powerful stimulus t o t h e development o f o r a l l y e f f e c t i v e analogs o f progesterone was t h e r e c o g n i t i o n o f s u b s t a n t i a l o r a l a c t i v i t y While t h i s material was more p o t e n t t h a n i n 17~-aceto~yprogesteroone?~ e t h i s t e r o n e , it was not widely s t u d i e d because f a r more p o t e n t analogs were r a p i d l y synthesized. O f t h e s e , t h e 6a-methyl d e r i v a t i v e , (medroxyprogesterone a c e t a t e ( 5 ) ,prepared almost simultaneously i n s e v e r a l l a b o r a t o r i e s , 33--35 found wide c l i n i c a l use. Unlike t h e 19-nortestosterone derivat,iws, it has not been a s s o c i a t e d i n c l i n i c a l use with v i r i l i z a t i o n o f t h e f e t u s ( i n c o n t r a s t t o i t s e f f e c t s i n lower s p e c i e s ) nor with h e p a t i c dyso f t h e f e w p r o g e s t i n s which can be used e i t h e r f ~ n c t i o n . ~ I~t ’i s~ one ~ o r a l l y or by i n j e c t i o n . By t h e l a t t e r route, i t forms a m i c r o c r y s t a l l i n e depot from which drug i s a v a i l a b l e for prolonged a c t i v i t y 4 ’ o f up t o s i x months f r o m a s i n g l e i n j e c t i o n . 4 1 34 (n).
I n t r o d u c t i o n o f a A6-bond produces megestrol a c e t a t e i n c r e a s i n g potency s l i g h t l y a 2 and a l t e r i n g t h e metabolic pathway.43-4s i s a l s o a potent The corresponding 6-chloro analog, chlormadinone (7a) p r o g e s t i n used with mestranol i n a s e q u e n t i a l formulation. Other c l o s e l y r e l a t e d 17a-acetoxyprogesterone analogs of i n t e r e s t include t h e 16-methylene compound, melengestrol a c e t a t e (9)48 and t h e 3-desoxy compound DMAP (11).49
26’47
The 1 7 - a c e t a t e group can be replaced with a 17-alkyl roup without loss of a c t i v i t y , both i n 6,1~~-dimethyl-6-dehydroprogesteronegoandi n i t s corresponding 3-hydroxy analog .51 S i m i l a r l y , t h e acetophenonide of lh,17adihydroxyprogesterone i s an e f f e c t i v e s r o g e s t i n and has been s t u d i e d i n a parent e r a 1 contraceptive formulation. It has been estimated t h a t a t l e a s t seven m i l l i o n women i n t h e United S t a t e s a r e c u r r e n t l y using o r a l contraceptives. For most, t h e mechanism of a c t i o n appears t o be suppression of t h e mid-cycle r e l e a s e of LH, preventing ovulation. I n a s m a l l percentage of s u b j e c t s , i n d i r e c t evidence f o r ovulation has been obtained. The combined a c t i o n of estrogen and p r o g e s t i n i n t h e combination i s thought t o produce an endometrium unfavorable f o r implantation and a c e r v i c a l mucous b a r r i e r d i f f i c u l t f o r sperm t o p e n e t r a t e .53 I n t h e s e q u e n t i a l method, e f f i c a c y depends p r i n c i p a l l y on t h e i n h i b i t i o n of ovulation during the period when estrogen i s administered. Recently, l o w doses o f progesterone alane have been r e p o r t e d t o provide a measure of contraceptive efficacy.54 Further r e p o r t s w i l l be awaited with interest S i d e e f f e c t s of t h e s t e r o i d combinations v a r y w i t h t h e i n d i v i d u a l s u b j e c t and t h e p r e p a r a t i o n and may i n c l u d e , b r e a s t tenderness, weight gain, breakthrough bleeding, amenorrhea, f l a t u l e n c e , t i r e d n e s s , nausea......many of t h e symptoms of e a r l y pregnancy. Thromboembolism has not been c l e a r l y r e l a t e d t o use of o r a l contraceptives b u t occasional l i v e r dysfunction, e s p e c i a l l y i n some populations, may be r e l a t e d . 11 a d d i t i o n t o t h e s t e r o i d s used f o r contraception i n t h e female, a number o f s y n t h e t i c hormones resembling t h e s y n t h e t i c estrogens but e x h i b i t i n g a n t i e s t r o e n i c a c t i v i t y i n animals have been s t u d i e d . These i n c l u d (MRL-41), g5 which i s capable of s t i m u l a t i n g ovulation i n some women ;lymiphene U-ll100A,58 and a number of c l o s e l y related analogs.
Chap. 18
Reproduction
20 9 -
Babcock
I n the male as i n t h e female, i n h i b i t i o n of f e r t i l i t y can be produced a r t i ’ i c i a l l y a t many stages. Jackson has reviewed t h e e f f e c t s of agents i n t h e male ( e s p e c i a l l y as studied i n the male r a t ) , and has concluded t h a t while there a r e many opportunities f o r pharmacological control, interference with hormonal mechanisms has r e l a t i v e l y l i t t l e prospect f o r success Research i n t h i s f i e l d can be complicated by the r e l a t i v e l y long period of treatment and study generally required t o observe changes i n spermatogenesis. Some agents, however, l i k e methylene dimethanesulfonate (15) a f f e c t sperm i n t h e f i n a l stages of development and, when used i n experimental animals a t appropriate dosage, can produce prompt development of i n f e r t i l i t y and rapid post -treatment recovery. 6 o Related methanesulfonates i n t e r f e r e with multiple stages of spermatogenesis, suggesting t h a t s e l e c t i v e control at a most appropriate stage may be possible.61
.”
62
63
Certain b a c t e r i o s t a t i c n i t r o f i r a n s (16) and thiophenes (17) were also found t o i n t e r f e r e with spermatogenesis i n t h e male, blocking development a t t h e primary spermatocyte stage. S i m i l a r results,which were r e v e r s i b l e were a l s o obtained with b i s - (dichloroacety1)diamines (18) .64--g6 These materials, which were o r i g i n a l l y studied as amoebacidal agents, were r e l a t i v e l y well t o l e r a t e d i n man,67 e.xcept f o r an ‘Antabuse-like ’ e f f e c t . Another potent agent which blocks spermatogenesis a t t h e primary spermatocyte stage is t h e d i n i t r o p y r r o l e ORF-1616 (19)68 which i s e f f e c t i v e when given once a month.” Hormonal agents, both s t e r o i d a l and non-steroidal, have a l s o been found capable of blocking spermatogenesis. Many e x e r t t h e i r a n t i f e r t i l i t y e f f e c t s through gonadotropin i n h i b i t i o n . When used f o r t h i s purpose, e s t r o gens have the obvious drawback of producing feminization and l o s s of l i b i d o . Androgens have been l o n g k n m t e m p o r a r i l y t o suppress spermatogenesis and i n s e l e c t e d cases, t o produce a rebound i n sperm p r o d ~ c t i o n . ~ 7’ 2 A number of progestins have r e c e n t l y been evaluated i n the male, including norethandrolone (6a) and 17a-hydroxyprogesterone caproate (l3a).72 These agents i n h i b i t Leydig c e l l function and gonadal hormone production. Medroxyprogesterone a c e t a t e (5)33 a potent progestin e f f e c t i v e both o r a l l y and p a r e n t e r a l l y , was observed t o produce a marked decrease i n sperm count and m o t i l i t y l a s t i n up t o s i x months when given as a s i n g l e 1000 mg i n j e c t i o n t o male v o l ~ m t e e r s . ’ ~ The long duration of a c t i o n of t h i s progestin i s t h e r e s u l t of t h e formation of an intramuscular depot of slowly released drug when administered as a microcrystalline aqueous suspension by t h e intramuscular route.
Clomiphene (MRL-41), an agent which can induce ovulation under some conditions i n women, i n h i b i t s t e s t i c u l a r and accessory gland weights i n t h e when administered male r a t t o t h e range seen a f t e r h y p o p h y s e ~ t p m y . ’ ~ , ~However, ~ o r a l l y to7goung men i n doses of 50-200 mg/day, clomiphene stimulated Leydig c e l l A b i o l o g i c a l l y s i m i l a r dihydronaphthalene d e r i v a t i v e , U - l l l O O A (21) ,58 functior,. w a s found t o i n h i b i t spermatogenesis at a dose of 0.5 mg/kg i n t h e rabbit.75 The hydrazine d e r i v a t i v e I C I 33828 (22) a l s o i s e f f e c t i v e i n both male and female r a t s and i n other species and has been studied i n
Sect. IV
210 -
- Metabolic
& Endocrine
H e i n z e l m a n , Ed.
C12CHCONH- (CH2)8-NHCOCHCl, Win 18446
(18)
ICI
33828 (22)
CH3 O /
U-lllOOA (21)
Among n u t r i t i o n a l f a c t o r s a f f e c t i n g f e r t i l i t y , t,he r o l e of Vitamin E and A have r e c e n t l y been r e v i e ~ e d . ~ ~ J ~ ~ The r a p i d l y developing knowledge of immunological phenomena as app l i e d t o f e r t i l i t y and i n f e r t i l i t y has a l s o been reviewed79J80 and can conf i d e n t l y be expected t o provide important new approaches during t h e next decade
.
Chap. 18
Babc oc k
Reproduction
21 1
Eeferences J . Rock, 0. P i n c u s , and C. R . G a r c i a , S c i e n c e , 891 (1956). G. W. Corner i n "P